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Novel Insights Into The Genetic And Environmental Determinants Of Enteric
Nervous System Biology
Abstract
The enteric nervous system (ENS) is a complex network of neurons and glia that resides within the bowel
wall. It rivals the spinal cord in complexity and regulates crucial bowel functions like gastrointestinal
motility. Dysfunction of the ENS, also called enteric neuropathy, can cause growth failure, abdominal
distention, and, in some individuals, sepsis and early death. Hirschsprung disease, a developmental
enteric neuropathy where the ENS is missing from the distal bowel, can be treated with surgical removal
of the affected bowel segment. However, debilitating bowel problems including dysmotility persist in a
subset of patients. Treatment options of chronic intestinal pseudo-obstruction (CIPO) are even more
limited and mostly symptomatic. In CIPO, the ENS develops along the length of the bowel, but bowel
motility is compromised. Due to the dearth of options, the scientific community is actively trying to
develop effective therapeutic options to improve enteric neuropathy-related symptoms. Bowel problems
in CIPO and Hirschsprung disease post-surgery have been attributed to loss or dysfunction of subtypes of
enteric neurons. Ideally, curative treatment would involve postnatal replacement of the defective ENS or
supplementation of these missing ENS cell types. Recently developed in vitro differentiation protocols
that convert human pluripotent stem cells into enteric neurons and glia have made stem cell therapy an
enticing avenue to pursue. However, we still do not sufficiently understand the nuances of enteric neuron
subtype fate decisions to direct differentiation of enteric neuron precursors into specific neuron subtypes.
In chapter 2, I describe our work characterizing the differential expression of transcriptional regulators in
enteric neuron subtypes during embryonic development and in the adult colonic ENS. We show that the
transcription factor Tbx3 is required for the development of a normal complement of nitrergic neurons in
the neonatal ENS. In chapter 3, I describe our work towards designing a high throughput screen that will
allow us to determine whether transcriptional regulators affect differentiation into cholinergic versus
nitrergic enteric neuron subtypes. In chapter 4, I describe exciting new work that indicates that postnatal
treatment of distal colon lacking an enteric nervous system with the neurotrophic factor GDNF can regrow a normal, functional ENS in mice. This discovery may lay the foundation for the development of
adjunct, non-invasive therapeutic options for the treatment of Hirschsprung disease. Lastly, in chapter 5, I
introduce work towards understanding the function of the epigenetic regulator Bap1 in enteric nervous
system development and postnatal maintenance.
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ABSTRACT
NOVEL INSIGHTS INTO THE GENETIC AND ENVIRONMENTAL DETERMINANTS OF
ENTERIC NERVOUS SYSTEM BIOLOGY
Sabine Schneider
Robert O. Heuckeroth

The enteric nervous system (ENS) is a complex network of neurons and glia that resides
within the bowel wall. It rivals the spinal cord in complexity and regulates crucial bowel functions
like gastrointestinal motility. Dysfunction of the ENS, also called enteric neuropathy, can cause
growth failure, abdominal distention, and, in some individuals, sepsis and early death. Hirschsprung
disease, a developmental enteric neuropathy where the ENS is missing from the distal bowel, can
be treated with surgical removal of the affected bowel segment. However, debilitating bowel
problems including dysmotility persist in a subset of patients. Treatment options of chronic intestinal
pseudo-obstruction (CIPO) are even more limited and mostly symptomatic. In CIPO, the ENS
develops along the length of the bowel, but bowel motility is compromised. Due to the dearth of
options, the scientific community is actively trying to develop effective therapeutic options to
improve enteric neuropathy-related symptoms. Bowel problems in CIPO and Hirschsprung disease
post-surgery have been attributed to loss or dysfunction of subtypes of enteric neurons. Ideally,
curative treatment would involve postnatal replacement of the defective ENS or supplementation
of these missing ENS cell types. Recently developed in vitro differentiation protocols that convert
human pluripotent stem cells into enteric neurons and glia have made stem cell therapy an enticing
avenue to pursue. However, we still do not sufficiently understand the nuances of enteric neuron
subtype fate decisions to direct differentiation of enteric neuron precursors into specific neuron
subtypes. In chapter 2, I describe our work characterizing the differential expression of
transcriptional regulators in enteric neuron subtypes during embryonic development and in the adult
colonic ENS. We show that the transcription factor Tbx3 is required for the development of a normal
vii

complement of nitrergic neurons in the neonatal ENS. In chapter 3, I describe our work towards
designing a high throughput screen that will allow us to determine whether transcriptional regulators
affect differentiation into cholinergic versus nitrergic enteric neuron subtypes. In chapter 4, I
describe exciting new work that indicates that postnatal treatment of distal colon lacking an enteric
nervous system with the neurotrophic factor GDNF can re-grow a normal, functional ENS in mice.
This discovery may lay the foundation for the development of adjunct, non-invasive therapeutic
options for the treatment of Hirschsprung disease. Lastly, in chapter 5, I introduce work towards
understanding the function of the epigenetic regulator Bap1 in enteric nervous system development
and postnatal maintenance.
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1.1 Abstract
At the most fundamental level, the bowel facilitates absorption of small molecules, regulates fluid
and electrolyte flux, and eliminates waste. To successfully coordinate this complex array of
functions, the bowel relies on the enteric nervous system (ENS), an intricate network of more than
500 million neurons and supporting glia that are organized into distinct layers or plexi within the
bowel wall. Neuron and glial diversity, as well as neurotransmitter and receptor expression in the
ENS, resembles that of the central nervous system. The most carefully studied ENS functions
include control of bowel motility, epithelial secretion, and blood flow, but the ENS also interacts with
enteroendocrine cells, influences epithelial proliferation and repair, modulates the intestinal
immune system, and mediates extrinsic nerve input. Here, we review the many different cell types
that communicate with the ENS, integrating data about ENS function into a broader view of human
health and disease. In particular, we focus on exciting new literature highlighting relationships
between the ENS and its lesser-known interacting partners.
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1.2 Introduction
Digesting nutrients that fuel our survival requires complex integration of many bowel
functions and all must run smoothly to maintain a normal quality of life. Food must be broken into
small particles and chemically digested for nutrient absorption. Indigestible components must
efficiently pass through the gastrointestinal tract for elimination, while fluid and electrolyte balance
is maintained. All of these processes occur in the setting of a complex microbiome that aids nutrient
absorption, but can trigger inflammation and even infection should the system go awry. The
intestine could not coordinate these functions without the enteric nervous system (ENS), a complex
network of neurons and glia that reside in the bowel wall and send nerve fibers throughout the
bowel. Like an orchestra conductor, the ENS is a critical regulator of many processes described
above and interacts with an astounding array of cell types to facilitate bowel function.
The ENS is distributed all the way along the bowel in two layers called the myenteric and
submucosal plexus (1). Each plexus is comprised of diverse enteric neuron and glial cell types that
interact closely with each other and with other intestinal cells. Myenteric plexus cells cluster into
ganglia between the outer longitudinal and inner circular smooth muscle of the bowel. Myenteric
neurons provide the majority of direct innervation to the bowel’s motor apparatus and the final
output controlling bowel relaxation and contraction. Myenteric neurons interact closely with the
tissue-resident macrophages (muscularis macrophages) that influence motility. Submucosal plexus
ganglia reside between muscle and epithelium, where they regulate epithelial secretion and local
blood flow. Neurons in both plexi respond to input from mucosal enteroendocrine cells and the
autonomic nervous system. The ENS also interacts with immune and epithelial cells to promote
barrier function that protects the bowel from pathogens in the gut lumen. Enteric neurons are
currently classified by function, axon number, direction of axonal projections, synaptic connectivity,
neurotransmitters, receptors, and electrophysiologic signatures. Approximately 20 enteric neuron
subtypes and four glial subtypes have been characterized thus far, but a wealth of single cell
sequencing data is expected to redefine enteric neuron and glial subtypes in the next few years.
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Many excellent recent reviews detail known ENS circuitry, cell types, transmitters and functions (25) Instead of duplicating those efforts, our goal is to show how the ENS interacts with non-ENS
cell types and the implications of these interactions for human disease.
To facilitate communication, enteric neurons extend an elaborate network of neurites with
associated glia. These ENS components contact almost all bowel cells including muscle, epithelial
cells, pacemaker cells (called the interstitial cells of Cajal, (ICC)), blood vessels and immune cells.
Enteric neurons synapse on each other, but also release neurotransmitters from varicosities along
neurites to regulate smooth muscle cell (SMC) and ICC activity. The ICC act as pacemakers since
they have intrinsic slow waves of depolarization and hyperpolarization (6).
The contractile force for bowel motility is provided by SMC, which must coordinate activity
to mix luminal contents or move undigested food toward the distal bowel for eventual elimination
(7). To contract smooth muscle, myenteric plexus excitatory motor neurons project their axons
predominantly orally. In contrast, inhibitory motor neurons project axons distally and cause smooth
muscle relaxation. Simultaneous activation of excitatory and inhibitory motor neurons in a bowel
region causes proximal bowel contraction and distal relaxation, a pattern called peristalsis that is
frequently observed in the small intestine.
Additional enteric neuron types control epithelial secretion (secretomotor neurons),
epithelial secretion and blood vessel dilation (secretomotor/vasodilator neurons), epithelial
proliferation, or innervate enteroendocrine cells and lymphoid follicles. Enteric neurons also send
intestinofugal fibers to pancreas, gallbladder, prevertebral sympathetic ganglia, and the central
nervous system (CNS) (4). Finally, although the ENS can control many aspects of bowel function
autonomously, in vivo ENS activity is modulated by luminal contents (nutrients and microbes),
muscularis macrophages, parasympathetic neurons, sympathetic innervation from the celiac,
superior and inferior mesenteric ganglia, and hormonal signals (e.g., adrenaline, thyroid hormone,
corticotrophin releasing hormone, oxytocin). Many of these extrinsic signals are influenced by CNS
activity, explaining how emotional responses like anxiety and fear can alter bowel function. The
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remainder of this article will explore cell types that interact with the ENS, integrating basic science
with human disease to explore how ENS function and dysfunction impact human health.

1.3 The ENS interfaces with the SIP syncytium to regulate motility
ENS interactions with SMC, ICC, and PDGFRα+ cells are critical for bowel motility. Many
excellent manuscripts describe these interactions in detail (6-8), so here we highlight a few
important interactions and recent developments.
Gap junctions connect SMC, ICC, and fibroblast-like PDGFRα+ cells into a multicellular
syncytium commonly called the “SIP syncytium”, whose name derives from the first letter of each
cell type (Figure 1.1A) (6). The SIP syncytium receives input from excitatory and inhibitory motor
neurons whose cell bodies reside within the myenteric plexus. Although SMC were once
considered the main targets of excitatory and inhibitory ENS motor neurons, neural input onto ICC
and PDGFRα+ cells is likely also critical for mediating smooth muscle contractility and for
generating complex motility patterns necessary for life.
There are at least five types of ICC in the bowel: ICC-MY, located between the circular and
longitudinal muscle layers, ICC-IM, located within the circular muscle layer in colon and stomach,
ICC-DMP, between the inner and outer parts of the circular muscle layer of the small intestine, ICCSM, on the submucosal surface of the circular muscle layer of colon, and ICC-SS, in the subserosal
layer (Figure 1.1B). ICC-MY and ICC-SM, the “pacemaker” cells of the bowel, generate rhythmic
electrical slow waves of depolarization and hyperpolarization that propagate passively to SMC via
gap junctions and synchronize SMC contraction. This baseline electrical rhythm is present even
when the ENS is absent. ICC-IM and ICC-DMP are closely associated with nerve varicosities (8)
and electron microscopy suggests more nerve-ICC-IM contacts than nerve-SMC contacts (9). ICCIM and ICC-DMP are believed to be the primary ICC that receive input from the ENS (8).
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Figure 1.1: The SIP syncytium
(A) The SIP syncytium is composed of SMCs, ICCs, and PDGFR + cells which receive input from
ENS varicosities. (B) ICC localization and composition varies with bowel region . Abbreviations:
ICC-DMP, deep muscular plexus ICC; ICC-IM, intramuscular ICC; ICC-MY, myenteric ICC; ICCSM, submucosal ICC.

To determine how ICC contribute to neuromuscular transmission, many early studies
compared SMC recordings in wild type and ICC-IM-deficient animals during electric field stimulation
(EFS). Although some investigators observed attenuated excitatory and/or inhibitory junction
potentials in ICC-depleted smooth muscle, results were inconsistent (9-11). Possible explanations
for the disparate findings include incomplete absence of ICC in certain model organisms (e.g.,
commonly used W/WV mouse has inconsistent and incomplete ICC loss (6)), strain and species
differences, differences in level of tissue pre-contraction or pre-relaxation (12), use of nifedipine
(422), differences between bowel regions, and developmental changes in innervation or smooth
muscle reactivity in the absence of ICC. More recent studies test contributions of transduction
pathways for specific neurotransmitters, often in genetically modified conditional knockout mice
(10, 12, 13). These studies support the presence of parallel complementary pathways for signal
transduction involving smooth muscle cells, ICC, and PDGFRα+ cells (Figure 1.2A-B).
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Inhibitory signaling
Inhibitory junctional potentials (IJPs) recorded from colon smooth muscle are composed of
a fast purinergic phase that is followed by a slower nitrergic phase (13). The purinergic contribution
to the IJP is probably mediated by PDGFRα+ cells, which express high levels of the purine receptor
P2Y1. The ligand for P2Y1 receptors in the bowel was once thought to be adenosine triphosphate
(ATP), but in recent years β-nicotinamide adenine dinucleotide (β-NAD)

and adenosine 5-

diphosphate-ribose (ADPR) have emerged as more likely candidates (14). Applying β-NAD and
ADPR to PDGFRα+ cells activates apamin-sensitive small-conductance Ca2+-activated K+ (SK)
channels, leading to potassium efflux and membrane hyperpolarization (15). The change in
membrane potential spreads via gap junctions to nearby SMC. Purinergic receptors are also
expressed on SMC and ICC, but they are unlikely to mediate the strong fast hyperpolarization
associated with the IJP (14, 16).
Nitric oxide (NO) is a major signaling molecule in inhibitory motor neurons that acts on both
ICC and SMC. NO binds and activates nitric oxide-sensitive guanylyl cyclase (NO-GC). Guanylate
cyclase converts GTP to cGMP, which activates GMP-dependent protein kinase I (PRKG1).
PRKG1 in turn phosphorylates serines and threonines on many intracellular proteins, causing
hyperpolarizing via mechanisms that remain incompletely understood. Molecules downstream of
NO (e.g. NO-GC, Prkg1) have been deleted from subsets of ICC and SMC using conditional
knockout mice. Although inconsistent findings have been reported, the results suggest that both
ICC and SMC likely mediate NO signaling (10, 13). Interestingly, one study found that conditionally
deleting NO-GC from ICC in mouse colon reduced IJP amplitude in response to EFS, but
conditionally deleting NO-GC from ICC in mouse fundus completely abolished IJPs (13). This
underscores an important and underemphasized issue in the literature: regulation of ICC, SMC,
and PDGFRα+ cells by neural signaling may vary considerably depending on bowel region.
Consistent with this observation, ICC localization and receptor expression differ in various bowel
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regions (Figure 1.1B). For instance, ICC-MY in stomach do not express the NO-GC subunit
sGCβ1, whereas most ICC-MY in colon express sGCβ1, and some ICC-MY in colon express
sGCβ1 at high levels (17).
A few recent papers suggest that PRKG1-independent (but NO-GC and cGMP dependent)
NO signal transduction may occur in ICC (18, 19). Pacemaker rhythms in cultured colon ICC were
slowed by NO donors and cGMP, but not by a PRKG1 inhibitor (18). Small-molecule activation of
NO-GC decreased spontaneous calcium transients in ICC-DMP in mouse small intestine, but
PRKG1 inhibition had no effect (19). These findings are difficult to reconcile with data showing
absent NO-mediated IJPs in Prkg1 conditional knockout mice (10). Possible explanations for the
discrepancy include failure of the PRKG1 inhibitors to penetrate tissue, or differences between ICC
subtypes studied.
Although the literature on how NO affects smooth muscle and ICC are sometimes
contradictory, NO clearly has strong effects on both ICC and SMC in a guanylate cyclasedependent manner. Further research is needed to determine (a) how members of the SIP
syncytium in various bowel regions differ in receptor expression and response to signaling, (b) how
innervation of the SIP syncytium differs in each bowel region, and (c) the significance of PRKG1independent pathways in NO-mediated responses. Defining these characteristics may elucidate
molecular mechanisms that generate diverse motility in each bowel region.
In addition to NO, inhibitory enteric neurons release vasoactive intestinal peptide (VIP) and
pituitary adenylate cyclase activating peptide (PACAP). These neuropeptides likely signal through
VIP receptors VIPR1 and VIPR2 and the PACAP receptor ADCYAP1R1, which are expressed on
ICC and SMC (7). Typically, neuropeptides are released at high stimulus frequencies, so VIP and
PACAP may play less prominent roles in direct motor neurotransmission than NO (7). In SMC,
VIP/PACAP signaling is mediated via Gs which activates adenylyl cyclase, cyclic AMP (cAMP),
and protein kinase A (PKA) (20). This increases Ca2+ transients that should increase the opening
probability of Ca2+-activated K+ channels, causing membrane hyperpolarization (20). In ICC, VIP
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may act via a different pathway. VIP decreases calcium transients dramatically in some ICC, and
calcium transients increase when a VIP inhibitor is added. These calcium transients likely control
the activity of calcium-dependent chloride channels (CaCC) which regulate slow waves (19). The
mechanism behind this response is currently unknown.

Figure 1.2: Inhibitory and excitatory motor neurotransmission.
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(A) Inhibitory neurotransmission involves a combination of purine, NO, and VIP/PACAP signaling.
(B) The primary neurotransmitters involved in excitatory neuromuscular transmission are
acetylcholine and tachykinins. Abbreviations: AC, adenylate cyclase; ACh, acetylcholine;
ADCYAP1R1, pituitary adenylate cyclase-activating polypeptide type 1 receptor; ADPR, ADPRibose; β-NAD, β-Nicotinamide adenine dinucleotide; cAMP, cyclic AMP; cGMP, cyclic GMP; DAG,
diacylglycerol; GTP, guanosine triphosphate; ER, endoplasmic reticulum; ICC, interstitial cells of
Cajal; IP3, inositol triphosphate; M2, muscarinic receptor 2; M3, muscarinic receptor 3; NKA,
neurokinin A; NO, nitric oxide; PACAP, pituitary adenylate cyclase-activating peptide; PKA, protein
kinase A; PKC, protein kinase C; PRKG1, protein kinase G; PLCβ, phospholipase C beta; sGC,
soluble guanylate cyclase; SK3, small conductance calcium-activated potassium channel 3; SP,
substance P; SR, sarcoplasmic reticulum; TACR1, tachykinin receptor 1; TACR2, tachykinin
receptor 2; VIP, vasoactive intestinal peptide; VIPR, VIP receptors.

Excitatory signaling
The major excitatory neurotransmitters involved in direct motor neurotransmission are
acetylcholine (ACh) and tachykinins (neurokinin A (NKA), and substance P (SP)). ACh binds
muscarinic M2 and M3 receptors on SMC and ICC, while tachykinins bind tachykinin receptor 1
(TACR1) and tachykinin receptor 2 (TACR2) receptors on SMC and TACR1 on ICC (Figure 1.2B).
In ICC-DMP, signal transduction via M3 receptors likely occurs through Gq leading to Ca2+ release
from the endoplasmic reticulum and activation of CaCC such as anoctamin 1 (Ano1). Opening of
CaCC causes a depolarizing current predicted to enhance the likelihood of action potential
generation and increase contraction amplitude (21, 22). M2 receptors are also expressed on ICC
but may play a less important role than M3 receptors (21, 23). In contrast, evidence from knockout
mice suggests that both M3 and M2 receptors influence SMC contractility (24).
Like muscarinic signaling in ICC, tachykinin signaling via TACR1 is hypothesized to act via G q
signaling coupled to Ca2+ release and CaCC opening. Tachykinin signaling may be more important
than muscarinic signaling in ICC-DMP. Applying TACR1 receptor antagonists attenuated basal
Ca2+ transients in small intestine ICC-DMP, suggesting that ICC-DMP are tonically excited by
tachykinins (21). The same may not be true in colonic ICC, which do not express TACR1 receptor
as highly (21). In SMC, tachykinin signaling is transduced by both TACR2 and TACR1 receptors
(25). Second messenger signaling likely occurs through protein kinase C (PKC) and IP 3 (7),
although other pathways may be involved (25).
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ENS, the SIP syncytium, and bowel motility: putting it all together
When considering direct neural input to the SIP syncytium, it is important to remember that diverse
motor patterns are needed for food to be digested and absorbed, and for waste to be eliminated.
These motility patterns in human small intestine include peristalsis (waves of contraction and
relaxation that propagate down the bowel), segmentation (alternating contraction and relaxation to
mix food with digestive enzymes and bile), and the migrating motor complex (MMC) (where strong
waves of contraction and relaxation propagate down the bowel during phase III to moves luminal
contents toward distal bowel for elimination). In the colon there are high amplitude propagating
contractions (HAPC) that move stool over long distances toward the rectum and occur only
occasionally. Generation and maintenance of these motor patterns requires a complex interplay
between neural signaling, ICC, PDGFRα+ cells, and SMC. In broad strokes, ICC continually
produce oscillating electrical slow waves in the bowel that set the rhythm for many motor patterns.
Slow wave electrical activity propagates from ICC to SMC, generating rhythmic SMC depolarization
and contraction. Neural signaling onto the SIP syncytium generates and modulates ICC and SMC
activity to produce the motor patterns described above. Stimuli from the environment alter ENS
activity to determine which motor patterns should occur at specific times (7). For example,
segmentation in the small bowel occurs after meals, but phase III MMC predominates once most
nutrients are absorbed. Although the ENS is not essential for generating some motor patterns, the
ENS is probably the primary inducer of complex motility patterns needed for survival (26).
To “decide” what to do, sensory neurons of the ENS (called intrinsic primary afferent neurons,
IPANs) respond to diverse stimuli including stretch and mucosal distortion (1, 2). Stretch sensing
is mediated by mechanoreceptors located within the myenteric plexus, which fire in response to
distention (27). Historically, it has been assumed that stimulation of enterochromaffin (EC) cells in
the bowel mucosa and the resulting serotonin (5-HT) release onto IPANs play a major role in
evoking enteric neural reflexes such as the peristaltic reflex. However, recent papers question the
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importance of serotonin release from EC cells for initiation of motility since mice lacking a critical
enzyme involved in 5-HT biosynthesis in EC cells (tryptophan hydroxylase 1, or TPH1) survive to
adulthood and have a normal gastrointestinal transit time (28). Further research has shown these
mice have larger fecal pellets and aberrant colonic migrating motor complexes (29) suggesting that
in the absence of 5-HT from EC cells, a higher degree of stretch is required to trigger contractions
(30).
We have focused thus far on neurotransmission to the SIP syncytium, but enteric glia also influence
bowel motility. Female mice lacking enteric glia have reduced gastrointestinal transit time and
increased CMMC frequency compared to controls. Intriguingly, the same effect was not seen in
males, suggesting potential glia-intrinsic sex-dependent differences, or sexual dimorphism in glial
interacting partners (31). Other studies also suggest enteric glia influence bowel motility; for
instance, mice lacking the glial-specific hemichannel connexin-43 had prolonged colonic transit,
increased stool water content, and diminished contraction and relaxation amplitude (32).
Mechanisms behind glial control of motility are not well understood. One hypothesis is that trophic
factors produced by glia may prevent ENS dysfunction. Another possibility is that enteric glia
directly modulate ICC slow wave activity (33).

Clinical relevance
Human bowel motility disorders include life threatening problems like Hirschsprung and
chronic intestinal pseudo-obstruction (CIPO) syndrome. In these disorders, ENS or SIP syncytium
function is so disrupted that surgical intervention or intravenous nutrition is often needed for survival

Hirschsprung disease. The ENS forms from neural crest-derived precursor cells (ENCDC) that
colonize the bowel during first trimester fetal development. In about 1:5000 children, ENCDC never
reach the distal bowel resulting in a region where the ENS is completely absent. This problem is
called Hirschsprung disease. In children with Hirschsprung disease, the region of bowel that lacks
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enteric ganglia (i.e. aganglionic bowel) is tonically contracted and does not have propagated
motility, leading to functional obstruction. Because aganglionic bowel does not efficiently pass stool
or air, Hirschsprung disease symptoms include distension, constipation, vomiting, abdominal pain,
growth failure, and a predisposition to bowel inflammation (called enterocolitis) that may lead to
death from sepsis. Hirschsprung disease provides absolute proof that the ENS is essential for life,
since even a small region of aganglionosis can cause serious illness and premature death. Our
recent review provides more detailed information about Hirschsprung disease symptoms and
molecular mechanisms (34).

Chronic intestinal pseudo-obstruction syndrome (CIPO). When the ENS is present throughout
the bowel, but bowel motility does not consistently support survival or growth without at least
intermittent intravenous nutrition, CIPO is the likely diagnosis. Symptoms of CIPO include repetitive
episodes of abdominal distension and pain, vomiting, growth failure, and weight loss (89). CIPO
may occur as a primary disorder, or it may be secondary to complications of another disease. CIPO
should not be confused with transient bowel motility defects such as ileus (the absence of bowel
contractions) that commonly accompanies abdominal surgery, pancreatitis, appendicitis or sepsis.
The etiology of CIPO remains poorly understood, although clues are emerging from human
and mouse genetics. Because so many cell types, transmitters, and signaling molecules impact
ENS development and intestinal function, there are likely many underlying causes of CIPO,
potentially including dysfunction of ENS, SMC, ICC, and/or PDGFRα+ cells. Unfortunately, even
with advanced genetic tools like whole exome sequencing, causative genetic variants remain poorly
defined. Only a few genetic causes of CIPO have been identified. These include mutations in the
genes encoding filamin A (FLNA), DNA polymerase gamma (POLG), and gamma smooth muscle
actin (ACTG2), leiomodin 1 (LMOD1), myosin heavy chain 11 (MYH11) and myosin light chain
kinase (MYLK) (35, 36). Identifying more genetic causes of CIPO is critical as it will undoubtedly
aid diagnosis. New medicines to treat CIPO are also desperately needed. Available prokinetic
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medications prevent ACh degradation (e.g. Pyridostigmine), activate 5-HT4 receptors (enhancing
ACh release from excitatory motor neurons and increasing bowel motility; e.g. Cisapride,
Tegeserod, Prucalopride), inhibit dopamine receptors (Metoclopramide, Domperidone), activate
somatostatin receptors (Octreotide) or activate receptors for motilin, a peptide that increases GI
motility (e.g. Erythromycin). Unfortunately, many of these medicines have serious side effects or
are only minimally effective at enhancing small bowel motility and resolving symptoms for people
with serious motility disorders like CIPO (35, 37).

1.4 The ENS and vascular endothelium
During digestion, blood flow to intestinal mucosa increases as much as 2-fold owing in part
to dilation of submucosal arterioles. Vasodilation and resulting hyperemia are needed to meet the
high metabolic demands of the mucosa and to exchange nutrients, water, and solutes across bowel
epithelium. Neurogenic vasodilation of submucosal arterioles is mediated by extrinsic and intrinsic
(ENS) innervation. In contrast, vasoconstriction of bowel arterioles is wholly under control of
extrinsic sympathetic innervation. Here we briefly review ENS control of vasodilation, which has
been extensively characterized.
Most studies of submucosal arteriole vasodilation evaluated guinea pig small intestine,
using varied preparations including isolated submucosa and full thickness intact bowel. These
studies suggest many triggers for ENS-mediated vasodilation, including gently stroking bowel
mucosa, distorting the mucosa with puffs of gas, and distending smooth muscle with a balloon.
Small distortions of the mucosa (stroking, puffing gas) cause EC cells to release 5-HT onto enteric
nerve terminals expressing 5-HT3 [myenteric IPANS (38)] and 5-HT4, and/or 5-HT1P [submucosal
IPANs (39)]. Stimulation of these IPANs by 5-HT activates short (1–2 mm) reflex pathways within
the submucosa, as well as longer reflex pathways that span submucosal and myenteric plexus
(39). Stretching the bowel activates 5-HT3 and 5-HT4-insensitive mechanotransducers in the
myenteric plexus (40) and possibly submucosal plexus (41) leading to vasodilation. Mechanical
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deformation of the gut activates neurites and soma of a large number of mechanosensitive enteric
neurons within the myenteric plexus (27). These mechanosensitive neurons are multifunctional (i.e.
they may be afferents, interneurons, or efferents) and their responses to mechanical stimulation
may be rapid-adapting, slow-adapting, or ultra-slow-adapting (42).
A final common pathway for ENS-mediated vasodilation in guinea pig small intestine is
release of ACh onto endothelial cells which activates muscarinic M 3 receptors, leading to NO
release and vasodilation (43). In guinea pig distal colon, substance P and/or VIP release from
submucosal plexus neurons may contribute to vasodilation (44). The ENS may also stimulate mast
cells to release the vasodilator histamine directly onto submucosal blood vessels (45) via SP and/or
calcitonin gene-related peptide (CGRP) (45).

Clinical relevance
Impaired vascular control has been implicated in a number of inflammatory conditions,
including necrotizing enterocolitis (NEC) and inflammatory bowel disease (IBD). NEC is a
dangerous bowel disease in premature neonates, characterized by severe inflammation, ischemic
necrosis, and sometimes bowel perforation. It is tempting to hypothesize that neuron dysfunction
may contribute to development of necrotizing enterocolitis, for instance through dysregulation of
vasodilation that occurs in response to feeding. Indeed, altered microcirculation involving
constricted arterioles has been demonstrated in NEC (47) and damage to the ENS also occurs with
NEC (47). However, there is not yet convincing evidence that ENS dysfunction is the primary cause
of altered blood circulation in babies with NEC. Arguing against this hypothesis, vessel endothelial
cells from bowel with NEC failed to generate NO in response to ACh, but vessels dilated in
response to exogenous NO administration, suggesting dysfunction of endothelial cells may be
paramount (48). This is similar to IBD, where vessel endothelium does not appropriately produce
NO even when stimulated by ACh (49). Unfortunately, because defects seem intrinsic to endothelial
cells, neuromodulators (e.g. AChE inhibitors) are unlikely to have therapeutic value in these
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disorders, although gut derived neural stem cells do appear to prevent NEC-like injury in a rodent
model (47).

1.5 Epithelial secretion and the ENS
5-HT released from enteroendocrine cells in response to mucosal stroking not only elicits
peristalsis and supports vasodilation, but also activates fluid and electrolyte secretion into the gut
lumen to facilitate digestion. 5-HT activates IPANS that in turn synapse on secretomotor neurons
that release ACh or VIP. ACh acts via muscarinic receptors and VIP via VIPR1 receptors on crypt
epithelial cells to increase intracellular Ca2+ (via phospholipase C and IP3) and cAMP (via Gs)
respectively. Cyclic AMP activates the cystic fibrosis transmembrane regulator (CFTR) chloride
channel. Calcium activates the HCLCA1 chloride channel inducing more transient chloride flux.
Movement of chloride into the gut lumen is accompanied by sodium and water. The details of these
circuits are much better understood than this brief description suggests, and they are beautifully
described in reviews (50, 51).
Interestingly, a recent publication has also defined a role for enteric glia in the regulation
of epithelial ion transport. When glial cells lack the glial-specific hemichannel connexin-43 neuronregulated electrogenic ion transport was reduced while transmural conductance and epithelial
permeability were not significantly changed. Activation of GFAP-expressing glial cells stimulated
electrogenic ion transport similar to that observed with direct neuronal stimulation. Inhibiting
neuronal activation with tetrodotoxin only partially reduced glial-induced electrogenic ion transport,
indicating that the enteric glia interactions with the epithelium do not require neuronal activity (52).

Clinical relevance
Dysfunctional regulation of epithelial secretion may lead to increased stool water content.
VIP-producing tumors and SSRI-induced serotonin syndrome cause diarrhea by directly increasing
neurotransmitters in the ENS circuit that controls epithelial secretion (53). Cholera, Rotavirus,
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Clostridium difficile, Cryptosporidium, and enterotoxin producing Escherichia coli all cause profuse
watery diarrhea at least in part by activating ENS circuits (54, 55).

1.6 The ENS, epithelial proliferation and repair
Bowel epithelium is replaced every few days via proliferation of stem cells and transitamplifying cells in the crypt. Newly-generated cells differentiate into absorptive epithelial cells,
goblet cells, and EC (among other cells types) before being lost via apoptosis. Regulation of
epithelial proliferation and differentiation is carefully controlled since too little epithelial replacement
reduces absorptive capacity and too much epithelial proliferation causes cancer. Among other
regulatory mechanisms, accumulating data suggest the ENS influences epithelial proliferation and
repair, as well as epithelial barrier function, but that effects of the ENS on bowel epithelium are
complex.
For example, chemical ablation of the myenteric plexus with benzalkonium chloride increases
epithelial proliferation, crypt depth and villus height (56) suggesting inhibitory effects of the ENS on
epithelial renewal. Consistent with the hypothesis that ENS components reduce epithelial
proliferation, mice with a hypomorphic ENS because of mutations in the tyrosine kinase receptor
Ret have enhanced small bowel epithelial proliferation after small bowel resection during the
adaptive response (57). In contrast, loss of the hepatocyte growth factor receptor Met within the
ENS leads to reduced epithelial proliferation after dextran sodium sulfate (DSS)-induced bowel
injury (58). Because Met and Ret are expressed in different subsets of myenteric neurons, these
observations suggest some enteric neurons enhance and others suppress bowel epithelial
proliferation depending on context.
Consistent with this hypothesis, ACh activates muscarinic receptors on intestinal stem or progenitor
cells to enhance epithelial proliferation (59-62). Neuron-derived serotonin activates 5-HT(2A)
receptors on cholinergic neurons, enhancing ACh release (63) and also enhancing epithelial
proliferation. Interestingly, glucagon-like peptide 2 (GLP-2), a potent stimulant for epithelial
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proliferation, might also work via the ENS since GLP-2 receptors are expressed by enteric neurons,
but not intestinal epithelium (64). Alternatively, GLP-2 might support epithelial proliferation via
subepithelial myofibroblasts that express GLP-2 receptor and release IGF-1 in response to GLP-2.
In support of this hypothesis, IGF-1 is required for GLP-2 intestinotrophic effects and this
mechanism could bypass the ENS (65).
In addition to regulating epithelial cell proliferation, enteric neurons appear to enhance
epithelial barrier function. Co-culture of primary enteric neurons with primary intestinal epithelial
stem cells, increases expression of tight junction associated protein zona occludens 1 (ZO-1),
increases transepithelial resistance across the monolayer, and reduces apical to basolateral
dextran permeability (66). Parallel studies suggest enteric glia may also influence intestinal
epithelial barrier function (67-70). For these studies, enteric glia were eliminated using a transgenic
GFAP-Cre driver to induce expression of HSV-TK or using the GFAP promoter to drive expression
of the neoantigen haemagglutinin. In the former case, treatment with gancyclovir induced cell death
in any cell that expressed the transgene by conversion of the antiviral agent to a toxic nucleotide
analog. In the latter case, neoantigen expression led to CD8+-mediated cell death of any
neoantigen-expressing cell. Eliminating glia in these ways led to massive bowel inflammation. Coculture of epithelial cells and glia also changed gene expression (71) in epithelial cells, increasing
tight junction proteins (like ZO1 and occludin) and decreasing transepithelial permeability in
cultured epithelial monolayers (69-71). S-nitrosoglutathione was identified as a soluble glial-derived
factor that increased epithelial barrier function in vitro. This compound drastically reduced the
development of enterocolitis in vivo after HSV-TK-mediated damage to ENS and epithelium (69).
Another study found that mucosal glia strongly upregulate their expression of GDNF in states of
inflammation (72, 73). GDNF reduced epithelial apoptosis in vitro (74, 75) and in a mouse model
of DSS-colitis, GDNF overexpression increased tight junction protein expression and decreased
epithelial permeability (76). Collectively these studies provided substantial support for the
hypothesis that enteric glia enhance epithelial barrier function. Interestingly, enteric glial cell17

derived GDNF also activates RET on type 3 innate lymphoid cells (ILC3) to induce release of IL22, which enhances epithelial expression of genes that reduce bacterial translocation (77).
Collectively these studies provided substantial support for the hypothesis that enteric glia enhance
epithelial barrier function.
Surprisingly, an elegant set of experiments showed that enteric glial cells are not required
for maintenance of epithelial integrity in mice. The authors eliminated all enteric glia by inducing
cholera toxin subunit A expression under the control of the PLP1 promoter. In this system, no
enterocolitis developed, and epithelial cell ultrastructure, proliferation and permeability were
unaffected despite a dramatic loss of enteric glia. The absence of glia in the setting of DSS-induced
colitis did not worsen symptom severity or specifically affect transepithelial permeability. Lastly, the
authors showed that the discrepancy between their study and the previous in vivo studies could be
explained by the aberrant GFAP-Cre transgene expression in a small number of epithelial cells
which caused direct injury to the epithelial cell layer after ganciclovir treatment or induction of
neoantigen expression (31).
Overall, it is clear the ENS influences intestinal barrier function in a normal physiologic
state and during inflammation. The exact contributions of the different enteric neuron subtypes and
of enteric glia have not yet been conclusively elucidated.

1.7 The ENS and macrophages
Two broad classes of tissue-resident macrophages contribute to intestinal immune
function. The most abundant macrophage (Mφ) class resides in the lamina propria (LpMφ) directly
beneath bowel epithelium (78) and are surrounded by dense submucosal neuron projections that
innervate the epithelial layer. Direct functional interactions between ENS and LpMφ have not yet
been document, but seem plausible. The second, relatively understudied group called muscularis
macrophages (MMφ) are very closely associated with the myenteric plexus and emerging literature
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suggests significant cross-talk and even developmental interdependence between these cell types
(Figure 1.3).

Figure 1.3: Interaction between muscularis macrophages and enteric neurons.
(A) Muscularis macrophages support enteric neurons through BMP2 signaling and possibly
synaptic pruning and clearing of debris. (B) Enteric neurons are a key part of the cholinergic antiinflammatory pathway (CAIP) reducing the activation of macrophages through vagal stimulation.
(C) Activation of muscularis macrophages by ACh decreases macrophage activation and
decreases production of TNFα. Abbreviations: α7nAChR, α7 nicotinic acetylcholine receptor; ACh,
acetylcholine; ATP, adenosine triphosphate; BMP2, bone morphogenetic protein 2; CSF-1, colony
stimulating factor 1; JAK, Janus kinase; NF-κB, nuclear factor kappa-light-chain-enhancer of
activated B cells; STAT, signal transducer and activation of stimulation; TNFα, tumor necrosis factor
alpha; Transcr., transcription.

1.8 The ENS depends on MMφ for normal structure and function
MMφ produce bone morphogenetic protein 2 (BMP2), a morphogen that binds its receptor
BMPRII on neurons and influences ENS precursor differentiation, neurite fasciculation, and
ganglion formation (79, 80). Mice lacking MMφ during development have increased numbers of
enteric neurons and a disorganized ENS. Interestingly, this phenotype is similar what occurs when
the BMP antagonist noggin is over-expressed in vivo (79, 81). Acute depletion of MMφ from the
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bowel in adulthood enhanced colon contractility in response to stretch ex vivo, but delayed
expulsion of a bead by the colon in vivo, suggesting problems with coordinating muscle activity.
The motility changes were not limited to the colon since gastric emptying was also accelerated two
days after acute MMφ depletion. The effects of MMφ depletion on ex vivo colon contractility could
be mimicked by dorsomorphin (a BMP signaling inhibitor) or rescued by adding BMP2. Consistent
with these observations, nuclear localization of pSMAD1/5/8 (a downstream effector complex for
BMP signaling) was reduced in enteric neurons from MMφ-depleted bowel. Interestingly, antibiotic
treatment to reduce luminal microbes reduced bowel MMφ, BMP2 levels, and nuclear pSMAD1/5/8
in enteric neurons. Antibiotics increased whole-bowel transit time and enhanced colon contractility
ex vivo, suggesting dysfunctional bowel motility (81).
Taken together, these results offer strong evidence that enteric neurons rely on BMP2
produced by MMφ for normal morphology and function. These observations also suggest that
postnatal acquisition of intestinal microbes critically shapes neuroimmune interactions in the bowel.
Some authors have suggested that MMφ also contribute to normal ENS morphology by
phagocytosing neuronal debris (82). This function of MMφ would be similar to that of microglia, the
tissue-resident macrophages of the brain, which clear apoptotic neurons and eliminate
unnecessary axons and synaptic connections (i.e. synaptic pruning). Further research is needed
to determine the extent to which phagocytosis by MMφ shapes the ENS.

1.9 Activated MMφ regulate enteric neuron excitability during inflammation
Activated murine MMφ release chemokines, cytokines (interleukin 1, monocyte
chemoattractant protein 1, interleukin 6, tumor necrosis factor alpha (TNFα)) and other bioactive
compounds (NO, prostaglandins) (83, 84). NO regulates neuron excitability and directly relaxes
SMC, so it is not surprising that increased NO reduces bowel contractility. Some enteric neurons
also produce TNFα receptors, and TNFα activates neuropeptide Y (NPY) expression. NPY
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increases bowel epithelial permeability during inflammation (85), suggesting a neuro-immune
interaction that might be modulated to reduce intestinal inflammation.

1.10 The ENS modulates MMφ activation, and may affect MMφ survival
Macrophages

express

many

neurotransmitter

receptors,

including

α7

nicotinic

acetylcholine (α7nAChR), tachykinin, glycine, and P2 purine receptors, all of which may alter MMφ
function (84). The most well-characterized example of ENS modulation of MMφ is the cholinergic
anti-inflammatory pathway (CAIP), a circuit involving the vagus, ENS, and MMφ. Stimulating the
vagus nerve activates cholinergic enteric neurons near MMφ, leading to release of ACh and
stimulation of α7nAChR on MMφ. This reduces inflammation by decreasing the ATP-induced
calcium transients in MMφ, decreasing macrophage activation (86) and reducing TNFα production
by macrophages (87). α7nAChR also activates the Jak2-STAT3 signaling pathway, which likely
plays a role in attenuating macrophage activation (88). ENS-MMφ signaling is likely not limited to
ACh-α7nAChR interactions given the large number of neurotransmitter receptors expressed by
macrophages. Extrinsic nerves also modulate MMφ activation directly through norepinephrine
signaling onto adrenoreceptor β2, but this pathway is probably independent of the ENS (78).
Intriguingly, adult enteric neurons express colony stimulating factor 1 (CSF-1), the primary
survival factor for MMφ (450). Since other CSF-1 expressing cell types had not been identified in
the bowel, we hypothesized that MMφ rely on CSF-1 produced by enteric neurons for normal
development. Surprisingly, MMφ appear normal in neonatal bowel even in the absence of an ENS.
Other intestinal cell types (endothelial cells, ICC) produce CSF-1 perinatally and may be the main
cells supplying MMφ with CSF-1 in early life (89). Since a considerable ENS development occurs
after birth, ENS-MMφ interactions likely mature postnatally, and it remains possible that CSF-1
expressed by neurons is critical for MMφ survival in adulthood. Global knockout models of CSF-1
(i.e. Csf1op/op mice) lack all MMφ, but thus far conditional depletion of CSF-1 from enteric neurons
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has not been reported. This experiment would be needed to confirm that ENS-derived CSF-1
influences adult MMφ number or function.

Clinical relevance
Post-operative paralytic ileus is a common condition characterized by transiently impaired
bowel motility after abdominal surgery. Post-operative ileus may be partially mediated by low-grade
inflammation leading to impairment of muscle contractility. Supporting a role for MMφ in postoperative ileus, depletion of MMφ by clodronate or genetic MMφ loss in Csf1op/op mice protects
against post-operative ileus (90). Intriguingly, vagal nerve stimulation reduced inflammation and
improved post-operative ileus (91). This is likely mediated by the vagal-ENS-MMφ antiinflammatory pathway described previously (86). MMφ activation has also been implicated in other
gastrointestinal motility disorders such as gastroparesis, which also may be helped by vagal
stimulation. This topic is summarized in a number of excellent recent reviews (83, 84).

1.11 ENS interactions with the microbiome
After birth, the bowel must grapple with drastic changes as it is exposed to a diverse array
of microbes seeking to establish themselves within the gut lumen. Microbial colonization occurs
while the ENS is still maturing, and we now believe these microbes substantially affect ENS
development. At least two studies have shown reductions in neuron density in the small intestine
and/or colon of young germ-free (GF) mice compared to age-matched gnotobiotic controls (92, 93).
Oddly, one study reported an increased proportion of nitrergic myenteric neurons in their 3-day-old
GF mice (93), while the other study, which used 4-week old GF mice, reported decreased nitrergic
neuron numbers (92). The cause of this difference is unclear.
A few mechanisms for microbial effects on ENS development have been proposed.
Interestingly, enteric neurons and glia express toll-like receptors (TLR), pattern recognition
receptors that are activated by pathogen associated molecular patterns (PAMPs) as part of the
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innate immune system. TLRs 3, 4, and 7 are expressed in enteric neurons and glia (94).
Additionally, TLR2 may be expressed in ENS and in surrounding cells including SMC (95). Global
deletion of TLR2 reduced the number of nitrergic neurons in colon, and accelerated gastrointestinal
transit (95). Mice with a global deletion of TLR4, which detects lipopolysaccharide (LPS; a major
component of gram-negative bacteria) had reduced numbers of nitrergic neurons, slow bowel
motility, and reduced bowel relaxation in response to EFS. Conditional knockout mice missing
Myd88 selectively in neurons and glia also had delayed colon transit and reduced nitrergic neurons
(92) MYD88 is a mediator of TLR4 activity. Finally, a high fat diet, which causes dysbiosis, also
reduced NO-producing myenteric neuron number and slowed bowel motility in a TLR4-dependent
fashion (96).
One possible explanation for these findings is that microbes could activate TLRs on enteric
glia or mesenchymal cells, leading to release of the RET ligand glial cell line-derived neurotrophic
factor (GDNF). GDNF provides trophic support for enteric neurons expressing RET and its coreceptor GDNF Family Receptor alpha 1 (GFRα1) during ENS development (97). In addition, GDNF
contributes to motility by stimulating the ascending limb of the peristaltic response (98). In support
of this theory, mice lacking TLR2 had significantly reduced GDNF in muscle. Administering
recombinant GDNF to these mice subcutaneously for seven days restored neuron numbers and
reversed dysmotility (95). Some evidence suggests enteric glia produce GDNF in response to
inflammation (72), making them a plausible intermediary in this pathway, although SMCs or other
mesenchymal cells could also be involved.
In addition to developmental effects, the microbiome can affect the ENS in adult life.
Microbiome composition directly affects mature ENS function by altering electrophysiologic
properties of neuron subtypes (99) and leading to changes in intestinal motility and neurallymediated secretion (100, 101). Furthermore, giving mice antibiotics reduces neuron numbers and
slows gastrointestinal transit (92). The ENS can also influence the composition of the microbiome.
In a zebrafish model of HSCR, the pathogenic over-abundance of pro-inflammatory bacterial strains
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could be corrected simply by restoring ENS function (102). These observations highlight just a few
of the complex interactions between gut microbes and the ENS; a more detailed description of
ENS-microbiome interactions can be found in recent reviews (103, 104).

1.12 ENS interactions with the adaptive immune system
Enteric neuron projections can be found within mucosal lymphoid follicles (Peyer’s
patches) (105, 106). When lymphocytes from Peyer’s patches were exposed to neuropeptides,
they significantly increased their proliferation rate and immunoglobulin synthesis (107). This
suggests the exciting possibility that enteric neurons can directly influence the adaptive immune
system. For example, the Y1 receptor that binds neuropeptide Y is expressed on monocytes,
macrophages, lymphocytes, and granulocytes (108). Y1-deficient mice have reduced antigen
presenting cell function, reduced effector T cells, and reduced production of TNFα and IL-12 by
macrophages. Similarly, Npy-/- mice have lower TNFα levels and Y1-/- mice resist colitis that
occurs after epithelial injury with dextran sodium sulfate (DSS) (109). VIP is produced by inhibitory
motor neurons, descending interneurons and secretomotor neurons of the ENS to control motility
and epithelial function. The VIP receptor is also expressed by T-cells, where VIP promotes a T-reg
phenotype (110), by dendritic cells where VIP induces a tolerogenic phenotype (111, 112), and by
macrophages where VIP inhibits production of TNFα, IL-6 and IL-12p40 (110). These antiinflammatory effects of VIP in vitro contrast with the observation that VIP-/- mice are resistant to
TNBS-induced colitis (113) and LPS-induced endotoxemia (114). The reason for this discrepancy
is not known.

1.13 ENS interaction with enteroendocrine cells
Enteroendocrine cells (EEC) are a diverse group of neuroendocrine cells in the bowel
epithelium that produce hormones and neuropeptides in response to stimulation from the gut
lumen. The molecules produced by EEC act locally on cells within the mucosa, as well as
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systemically via the bloodstream (115). Significant cross-talk occurs between EEC and the ENS to
modulate vasodilation, motility and epithelial secretion. We already alluded to one mechanism by
which enterochromaffin cells (EC), a subtype of EEC, signal enteric neurons through release of 5HT onto nerve terminals. The triggers for 5-HT release are incredibly diverse and include
mechanical deformation of the mucosa, macromolecules (e.g. glucose, fatty acids, amino acids),
chemical irritants (e.g. allyl isothiocyanate), injury or stress (e.g. norepinephrine), and changes in
the bacterial milieu (e.g. butyrate and other short chain fatty acids) (115, 116). In response to
stimulation, EC activate neurons through the release of 5-HT onto nerve terminals. In addition to
5-HT, EEC produce neuropeptides such as somatostatin, motilin, VIP, glucagon-like peptide-1
(GLP-1) and cholecystokinin (CCK), which modulate ENS activity (117-119). It has traditionally
been assumed that these neuroactive peptides signal in a paracrine manner. However, presynaptic
and postsynaptic markers have been identified on EC, suggesting that EC communicate with
nerves via synapse-like structures (116, 120). Even more compelling, monosynaptic transmission
of modified rabies virus confirms the presence of functional efferent synapses (120). Unfortunately,
the in vivo data does not address the question of whether the EC form synapses with enteric or
extrinsic neurons (120). There is a paucity of research regarding EEC-ENS connections and
particularly efferent ENS signaling onto hormone-producing EEC. Given the similarity in signaling
molecules and receptors between EECs and the ENS, it seems highly likely that these cells
communicate through additional pathways that remain to be discovered.

1.14 The ENS, CNS and the autonomic nervous system
A variety of extrinsic nerves innervate the bowel, including sympathetic nerves, the
parasympathetic vagus and sacral plexus nerves, and the dorsal root ganglia. Some of these
nerves interact directly with their targets in the bowel, but they may also mediate their effects
indirectly by synapsing on enteric neurons. We already mentioned the cholinergic anti-inflammatory
(CAIP) pathway, where vagal nerve fibers signal ENS intermediaries that then signal macrophages
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to reduce inflammation. Here we provide a brief overview of other important ENS interactions with
the autonomic nervous system. Please see the following reviews for a more in-depth discussion of
this topic (4, 121),

1.15 Sympathetic neuron-ENS interactions
Sympathetic nerve endings contact the vast majority of enteric neurons (122), and may
also activate enteric glia via ATP release (123). Sympathetic nerves indirectly regulate epithelial
secretion by inhibiting secretomotor neurons in the submucosal plexus. This inhibition is likely tonic
since transepithelial secretion is greatly enhanced after sympathectomy (122), and acute
sympathetic inhibition effects on secretion are most apparent when the secretomotor reflex has
been activated (124, 125).
The sympathetic nervous system coordinates motility across large segments of bowel. The
changes in motility are mediated by reflex arcs that involve afferent sensory neurons of the ENS
and efferent inhibition of enteric neurotransmission by the sympathetic nervous system. These
reflex arcs may include or bypass the CNS, depending on context. Sympathetic reflexes have been
worked out in detail and are well described elsewhere (122).

1.16 Parasympathetic-ENS interactions
Parasympathetic innervation of the upper gastrointestinal tract is exclusively provided by
the vagus nerve and vagal projections are known to reach as far as the colon. Whether the entire
bowel is innervated by the vagus nerve is still contested. Evidence suggests that the innervation
includes the distal colon at least in some animal models (126). The pelvic nerves may provide
additional parasympathetic innervation to the lower gastrointestinal tract. However, a recent study
argues that these nerves are actually part of the sympathetic nervous system (127).
Most enteric ganglia in the small intestine and stomach are innervated by vagal nerve fibers
(128). The vast majority of vagal nerve fibers are sensory and transmit afferent input to the CNS. It
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is unclear if afferent vagal signaling to the CNS is directly influenced by the ENS. Vagal-enteric
(efferent) neurotransmission is predominantly cholinergic, although additional neurotransmitters
have been identified in preganglionic vagal neurons (catecholamines and NO) and could have an
auxiliary role (129, 130). Efferent vagal input affects all functions of the ENS, including the
regulation of bowel motility, epithelial secretion, and vasoconstriction (4). Additionally, the vagus
nerve mediates anti-inflammatory effects on the bowel through enteric neurons as part of the CAIP
as described earlier (86).

1.16 Clinical relevance
The pathways described above confirm bidirectional communication between the ENS and
CNS that has important effects on bowel function, but the gut also influence the brain, an interaction
referred to as the “Gut-Brain Axis” (131). An additional intriguing hypothesis is that these pathways
may lead to CNS disease since protein misfolding events that occur in the ENS could be initiators
for certain CNS diseases such as Parkinson’s disease (PD). PD involves the prion-like misfolding
of α-synuclein which aggregates into deposits called Lewy bodies, leading to neurodegeneration
and dementia. Genetic changes or ingested toxins like the pesticide rotenone could first cause αsynuclein aggregation in the ENS (132), which then travels to the CNS via the vagus, where they
induce misfolding of additional α-synuclein to cause the characteristic Lewy body pathology.
Support for this hypothesis includes the observation that Lewy body-type pathology is found within
enteric neurons of people with PD (133), bowel symptoms often precede CNS symptoms and
correlate with disease severity (134), and that α-synuclein aggregates can travel from the bowel to
the brain via the vagus nerve (135, 136). In humans, truncal vagotomy may reduce PD risk (137,
138). Similar transit of misfolded protein from the bowel to the brain could also explain the spread
of prion diseases like kuru, variant Creutzfeldt-Jakob, scrapie, chronic wasting disease and
spongiform encephalopathy where ingestion of misfolded prion proteins initiates disease
pathogenesis (139). More details are provided in excellent reviews (140-142).
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1.17 ENS and the CNS
Since the ENS shares many neurotransmitters, receptors, and transcription factors with
the CNS, it is not surprising that many people with CNS disease also have problems with bowel
function. People with autism spectrum disorder (ASD) are 3-4 times more likely to have
gastrointestinal symptoms than unaffected individuals; intriguingly, mutations in chromodomainhelicase-DNA binding protein 8 (CDH8), haploinsufficiency for the transcription factor TCF4, an
activating mutation in the sodium-dependent 5-HT transporter (SERT/SLC6A4), and MET
mutations are all directly linked to ASD and GI motility disorders (58,143-146). Mice expressing
mutant forms of amyloid precursor protein associated with familial Alzheimer disease accumulate
amyloid beta in enteric neurons, have a reduced enteric neuron number, dysmotility and increased
vulnerability to bowel inflammation (147, 148). Mutations in TAR DNA-binding protein 43 (TDP-43)
that cause familial amyotrophic lateral sclerosis (ALS), may also cause ENS defects, including
intestinal obstruction in the Prp-TDP43Ala315Thr mouse model (149, 150). There is much more to
learn about links between ENS and CNS disease.

1.18 Summary
The enteric neurons and glia richly integrate sensory stimuli to control bowel motility,
epithelial function, blood flow, and immune system activity. To do this, almost every cell of the
bowel wall closely interacts with the ENS including smooth muscle, ICC, PDGFRα+ cells, EEC,
epithelial cells, blood vessels, and many hematopoietic lineages. The ENS also interacts with
extrinsic sympathetic, parasympathetic and sensory nerves, and is influenced by hormonal signals
to modulate bowel function to meet systemic needs. Mechanisms and cell types that impact ENS
activity remain under-investigated. Defining molecular and cellular mechanisms of ENS activity
promises new approaches to dangerous bowel motility disorders (Hirschsprung disease, CIPO,
gastroparesis), common and less dangerous motility problems (irritable bowel syndrome, chronic
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constipation, functional dyspepsia), inflammatory bowel disease, necrotizing enterocolitis, and
ischemic bowel disease. Given links between gut microbes, bowel motility, epithelial function and
CNS activity, ENS biology may also provide new approaches to addressing complex problems like
anxiety, depression, autism, Parkinson’s and ALS, and Alzheimer’s disease as we begin to define
the interplay along the gut brain axis.
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2.1 Abstract
Bowel function requires coordinated activity of many enteric neuron subtypes. Clear
definition of subtype-specific gene expression may facilitate molecular diagnoses for bowel motility
disorders. Using adult mouse colon RNAseq data from 635 myenteric neurons and 707 E17.5
neurons, we defined seven adult myenteric neuron subtypes, eight E17.5 neuron subtypes and
hundreds of differentially- expressed genes. Manually dissected human colon myenteric plexus
yielded data from 48 neurons, 3798 glia, 5568 smooth muscle, 377 interstitial cells, and 2153
macrophages. Immunohistochemistry demonstrated differential protein abundance for BNC2,
PBX3, RBFOX1, TBX2, and TBX3 in enteric neuron subtypes. Conditional Tbx3 loss reduced
NOS1-expressing myenteric neurons. Differential Gfra1 and Gfra2 expression coupled with calcium
imaging revealed that GDNF and neurturin acutely and differentially regulate activity of ~50% of
myenteric neurons with distinct effects on smooth muscle contractions. This insight into enteric
nervous system biology provides a foundation for future studies of bowel motility disorders.
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2.2 Introduction
The enteric nervous system (ENS) is a network of neurons and glia within the bowel wall
that controls gut motility, mucosal immunity, epithelial function and proliferation, along with
vasodilation in response to local and extrinsic stimuli (1–3). Thus, ENS defects can cause
debilitating bowel dysfunction. Defects include developmental anomalies like Hirschsprung disease
(HSCR) and primary chronic intestinal pseudo-obstruction. Acquired ENS defects occur in
achalasia, Parkinson’s disease, Chagas, and probably gastroparesis and irritable bowel syndrome.
Unfortunately, we currently have limited ability to identify missing or defective ENS cell populations
in people with bowel dysmotility and available therapies are often ineffective. Even if missing cells
were identified, neurotransmitters, receptors, and signaling pathways that may be therapeutic
targets in the ENS are poorly defined. Potential new therapies include stem cell replacement (4),
trophic factor-induced regeneration (5) and repurposing medicines based on genetic
polymorphisms that underlie symptoms. Each strategy would benefit from detailed data about ENS
gene expression.
Our goal was to use single cell RNAseq in mouse and human enteric neurons to gain new
insight into enteric neuron subtype identity, regional neuron identity, and to learn more about how
RET ligands impact neural activity and motility in adult mice. As our studies proceeded, other
groups described single cell ENS RNAseq data from P21 mouse small bowel (6) and adult mouse
bowel with or without gut microbes (7). New bioRxiv papers also provide single cell RNAseq data
from adult mouse and human colon (8), and from E15.5, E18.5, and P21 mouse small bowel (9).
Each manuscript has a unique focus. These data, along with our analyses, provide the rich tapestry
of ENS gene expression information needed for progress in diagnosing and treating bowel motility
disorders.
The RNA-seq data collectively define 8-12 myenteric neuron types and >20 total enteric
neuron types, plus 4-7 types of enteric glia, consistent with anatomic and functional analyses over
decades (2,10–13). Here we focus on distinctions between myenteric nitrergic (nitric oxide
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producing) and cholinergic (acetylcholine producing) neurons, which comprise >89% of human and
>95% of mouse myenteric neurons (14,15). We found many cell type-specific ion channels,
neurotransmitters, adhesion proteins, and signaling pathways supporting functional connectivity,
and identified >40 differentially expressed transcriptional regulators, including Tbx3, which is
preferentially expressed in neuronal nitric oxide synthase (NOS1)-producing myenteric neurons.
Tbx3-/- mice had a 30% reduction in NOS1 neurons. We also found that Pbx3 is preferentially
expressed in cholinergic neurons, consistent with a report that Pbx3-/- mice have fewer CALB1+
cholinergic neurons (9). Further, Pou3f3 marks colon, but not small bowel, neurons from early
development to adulthood, consistent with distinct ENS organization and function in colon versus
small bowel.
An additional major distinction is that nitrergic neurons predominantly express Gfra1, but
cholinergic neurons express Gfra2 in adult and E17.5 mouse myenteric plexus. GFRA1 and GFRA2
are cell surface receptors that bind preferentially to glial cell line-derived neurotrophic factor
(GDNF) and neurturin (NRTN), respectively, and this binding activates RET kinase. RET impacts
many signaling pathways and has clear trophic effects (16), but if the only purpose of
GDNF/GFRA1 and of NRTN/GFRA2 signaling was to activate RET, it is unclear why distinct trophic
factors and co-receptors would be advantageous once development is complete. We thus used
calcium imaging to test the hypothesis that GDNF and NRTN acutely affect ENS function and bowel
motility. We discovered strikingly different effects of these trophic factors on GCaMP6s activity in
enteric neurons. Collectively, our single cell RNAseq data provide highly validated information
about gene expression in mouse and human ENS and a new foundation for ENS cell classification.
Our novel observations about TBX3, GDNF/GFRA1, NRTN/GFRA2, POU3F3, and many other
genes also offer distinct new insights that could facilitate stem cell or trophic factor based therapies
for human bowel motility disorders.
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2.3 Results
Single nucleus RNA-sequencing defines mouse distal colon enteric neuron subpopulations
Isolating ENS cells from adult mouse distal colon was challenging. Many approaches did
not work well (Supplementary Table 2.1). Ultimately, myenteric plexus nuclei were isolated from
47-52 day old Wnt1-CreCre/wt; R26R-LSL-H2B-mCherry mice that express the fluorescent nuclear
protein Histone 2B-mCherry (Supplementary Figure 2.1A-D). Cryosectioning disrupted muscle,
improving yield. Dounce homogenization released nuclei (Figure 2.1A). 10x Genomics platform
generated data from 1,520 mCherry+ neuronal (Figure 2.1B) and glial nuclei. Because of low read
depth we included intronic reads, yielding a mean of 2,970 unique molecular identifiers (UMI,
number of unique RNA molecules sequenced) and 1,549 genes per cell.
Using CellRanger and Seurat (17,18), we identified 12 clusters: 4 glial (Plp1+ and Sox10+),
4 neuronal (Elavl4+), and several non-ENS (6.5% of total), including Pdgfra+ (PDGFRα+ cells),
Kit+ (interstitial cells of Cajal, ICC), and Actg2+ (smooth muscle cells (SMC); Supplementary
Figure 2.1E-J). Mean UMI and gene counts were higher for neurons than glia (Neurons: 4,629 UMI
and 2,217 genes; Glia: 1,780 UMI, 1,069 genes; Figure 2.1C). To refine analyses, we re-clustered
neuronal groups (Figure 2.1B) and identified 7 clusters (635 neurons total).
Two neuron groups (Nos1 and Nos2) express Nos1, Vip, and Gal, consistent with known
co-expression in inhibitory motor neurons and interneurons that have NOS1+/VIP+ nerve terminals
within circular smooth muscle and myenteric ganglia respectively (13,19). Chat1 cells express
choline acetyl-transferase (Chat) and preprotachykinin (substance P precursor, Tac1), but not
proenkephalin (Penk), consistent with excitatory motor neurons or intrinsic sensory neurons
(20,21). Chat2 cells express Chat, Tac1 and Penk, a combination marking guinea pig ileum
excitatory motor neurons and ascending interneurons. Chat3 cells express Chat, Tac1, Penk, and
hepatocyte growth factor receptor Met (Figure 2.1D, E, Supplementary Figure 2.2E). We tested
if Tac1

and Penk expression could differentiate between motor- and interneurons.

Immunohistochemistry showed that in circular smooth muscle, 55.3± 8.4% of varicosities
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containing substance P (SP) do not contain enkephalin (ENK; Supplementary Figure 2.1K-M, S),
but in myenteric ganglia, ~25% of SP terminals lack ENK and vice versa (Supplementary Figure
2.1N-P, S). An additional clustered neuron group appeared heterogeneous. We manually divided
these neurons into Chat4 that express Chat, Penk, and Slc17a6 (encodingVGLUT2) and Calcb that
express Calcb (Calcitonin Related Polypeptide Beta), Grp (Gastrin releasing peptide) and Nmu
(Neuromedin U)). We hypothesize that Chat4 are interneurons since VAChT+/VGLUT2+ terminals
were reported in mouse distal colon myenteric ganglia, but not muscle (22) Chat/Penk/Vglut2
neurons also express Calb1, a calcium-binding protein in mouse interneurons (13,23,24). To further
validate Vglut2/Chat co-expression, we bred Vglut2-IRES-Cre;TdTomato x ChAT-L10A-EGFP and
found 95.9 ± 0.9% of TDTOMATO+ neurons in myenteric plexus co-expressed EGFP
(Supplementary Figure 2.1T-V).
Many neurotransmitters (Figure 2.1E; Supplementary Figure 2.2A) and neurotransmitter
receptors (Figure 2.1F; Supplementary Figure 2.2B) were differentially expressed between
neuron subgroups, including receptors for acetylcholine, glutamate, serotonin, opioids, and
purines. Neuron groups also differentially expressed ion channels (Supplementary Figure
2.2C,D), signaling molecules (Supplementary Figure 2.2E,F), axon guidance molecules,
adhesion proteins, and survival factors and receptors.
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Figure 2.1: Adult mouse distal colon myenteric plexus RNAseq defines neuron and glia
subtypes.
(A) Single nucleus RNAseq workflow. (B) T-SNE plot of enteric neuron and glial clusters. (C) Violin
plots for neuron and glia clusters. (D) Feature plots for selected markers highlight neuron subtypes.
Color shows loge(normalized gene expression). (E, F) Heatmaps show expression of commonly
used enteric neuron markers with >0 detected reads (E) and neurotransmitter receptors (F). (E-F)
Colors show loge(normalized mean gene expression).

Single-nucleus sequencing reveals distinct roles for GDNF and NRTN in mouse distal colon.
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We were particularly intrigued that Gfra1 and Gfra2, preferred receptors for GDNF and
NRTN respectively, were abundant in glia but differentially expressed in neuron subsets. Gfra2 was
primarily in Chat+ neurons (Figure 2. 2A-B), consistent with prior studies (25,26). Gfra1 was
primarily in Nos/Vip/Gal+ neurons. We could not find prior reports of Gfra1-restricted expression in
adult mouse ENS, so we tested if NOS1 colocalized with GFP in distal colon of Gfrα1Gfp/wt mice that
express GFP from a Gfra1 locus (27). GFP was in 88.9±1.8% of NOS1+ neurons, 8.8±5.7% of
NOS1-negative neurons (Figure 2.2D-E), and in S100β+ glia (Supplementary Figure 2.3A)
consistent with RNAseq. Coupled with the observation that GDNF acts acutely in the ascending
peristaltic response (28), our data suggest GDNF and NRTN have opposing acute effects on bowel
contractility, although both activate RET.
To test this, we recorded myenteric neuron calcium transients in GDNF or NRTN-treated
full-thickness colon of E2a-Cre;R26R-GCaMP6s mice that express the calcium indicator GCaMP6s
in all cells (Figure 2.2F-G). We also simultaneously monitored colon movement, an indirect
measure of muscle tension (29). GDNF and NRTN increased or decreased spontaneous GCaMP6s
activity in 50% (260/523) of all myenteric neurons (Figure 2.2H-J). Only 8.3% responded to both
GDNF and NRTN (Figure 2.2I) suggesting most effects are via their preferred receptors, GFRA1
and GFRA2 respectively. To test this, we identified nitrergic neurons post-hoc in 3 fields. 63%
(29/48) of neurons responding only to GDNF were nitrergic, while 25% (17/68) NRTN-only
responders were nitrergic (Supplementary Figure 2.3B-G). The high percentage of non-nitrergic
neurons responding to GDNF suggested some changes in GCaMP6s activity were due to synaptic
connectivity. Remarkably, when we added the voltage-gated sodium channel blocker, tetrodotoxin
(TTX), only 3-4% of myenteric neurons were GDNF- or NRTN-responsive, and only 7-8%
responded in the presence of the nicotinic acetylcholine receptor antagonist, hexamethonium, with
almost no overlap between GDNF- and NRTN-influenced cells (Figure 2.2K-L and
Supplementary Figure 2.3H-I). This suggests that GDNF and NRTN have direct and indirect
effects on GCaMP6s activity in distinct myenteric neurons.
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GDNF also increased myenteric neurons responding to oral electrical field stimulation
(EFS) by 71.3 ± 17.5% (p=0.0068), but did not affect responses to EFS applied aboral to recorded
ganglia (p=0.49; Suppl. Fig. 3J-K). In contrast, NRTN did not affect the percentage of EFSresponsive myenteric neurons, regardless of stimulus location (p=0.116 aboral, p=0.188 oral;
Supplementary Figure 2.3L-M). GDNF and NRTN both altered which neurons responded to oral
and/or aboral EFS (data not shown). Further, GDNF robustly increased spontaneous and oral
EFS-induced movement in the imaging field (p=0.0230, Supplementary Figure 2.3J,N). NRTN
decreased movement in 3 of 5 preparations, but this was not statistically significant (Figure 2.2MO). These observations suggest that GDNF and NRTN influence distinct myenteric neurons and
that GDNF acutely enhances colon contractility.
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Figure 2.2: GDNF and NRTN acutely influence GCaMP activity of largely non-overlapping
adult distal colon myenteric neuron populations.
(A-C) Feature plots show Gfra1 is primarily in Nos1/Vip/Gal neurons (A), Gfra2 is in Chat neurons
(B), and Ret is in almost all neurons except Chat 3 (C). (D) Whole mount immunohistochemistry
shows GFP (green) in most NOS1+ (red) neurons of Gfra1Gfp/wt distal colon. White arrowheads,
GFP+, NOS1+ neurons. Yellow arrowhead, GFP-, NOS1+ neuron. (E) Most NOS1+ neurons are
GFP+. Most NOS1- neurons are GFP-, consistent with RNAseq (p<0.0001, Student’s t-test, n=3
mice (Gfra1Gfp/wt)). (F-G) Time-lapse images (top; pixels assigned color based on timing of
transients; i.e., color=activity) and traces (bottom) of GCaMP6s activity from ROIs on myenteric
neurons during baseline (left) and after addition of 10 nM GDNF (F) or NRTN (G) (right). (H) Sample
traces from neurons with activity increased (top) or decreased (bottom) by GDNF (red) or NRTN
(blue). Baseline (gray) and percent neurons (in parentheses) with increased or decreased activity
(>2 standard deviation change). (I) Percent neurons responding only to GDNF (red), only to NRTN
(blue), or both (gray) (P<0.05, one-way ANOVA with Tukey’s multiple comparisons test). (J) Iris
plot of GDNF and NRTN responsive myenteric neurons (49.7% of total neurons, 260 of 523 total
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neurons). GDNF (outer circle, red). NRTN (inner circle, blue) (n=5 mice). White, no ligand-induced
activity change. Light shades indicate decreased activity after ligand addition. Most responsive
neurons are affected by either GDNF or NRTN, but not both. (K-L) Heatmaps of GCaMP6s activity
before and after adding the voltage-gated sodium channel blocker tetrodotoxin (TTX) and during
sequential addition of GDNF and NRTN. Colors indicate GCaMP signal amplitude (red, no activity).
(K) Heatmap of all neurons (n=301 neurons, 4 independent colon sections, 1 mouse). Dotted box
shows GDNF- and NRTN-responsive neurons. (L) Expanded heatmap of 13 neurons that were
only GDNF-responsive, 11 neurons only NRTN-responsive, and 3 neurons that responded to both.
(M, N) Sample traces (left) and graph (right) of tissue displacement at baseline and after GDNF (M)
(P=0.022, ratio paired t-test) or NRTN (N) (P=0.1583, ratio paired t-test). (O) GDNF, but not NRTN,
enhanced tissue movement (P<0.01, unpaired t-test). (E,I,O) Mean +/- SEM. (D,F,G) Scale
bar=100 microns. *p<0.05, **<0.01, ****p<0.0001.

Sequencing suggests combinatorial transcription factor codes define neuron subtypes.
To gain insight into neuronal subtype identity, we examined transcription and splicing
factors ('regulatory genes') in adult colon myenteric neurons. Some genes that affect ENS subtype
ratios (e.g. Ascl1, Hand2, and Sox6) were not differentially expressed in adults, but others not yet
known to affect subtype specification were differentially expressed (e.g. Tbx3, Tlx2, and Zeb2; (30–
32); Figure 2.3A; Supplementary Figure 2.2G). Many other transcription factors had distinct
expression patterns in neuron subgroups including Pbx3, Etv1, Casz1, Bnc2, and Zfhx3. Consistent
with data from other nervous system regions (33), few transcription factors were expressed in only
one neuron subpopulation, suggesting combinatorial codes regulate enteric neuron phenotype
(Figure 2.3A; Supplementary Figure 2.2G).
We focused on regulatory genes differentially expressed in cholinergic or nitrergic neurons,
as most myenteric neurons express Chat or Nos1, but not both. We used ChAT-EGFP-L10A mice
that reliably express EGFP at high levels in CHAT+ cells, since antibody staining is often weak
(34). Consistent with RNAseq, SATB1, RBFOX1, and PBX3 immunoreactivity was preferentially in
Chat-EGFP+ neurons, and TBX3 was primarily in NOS1+ neurons (Figure 2.3B-F; I-L). RNAseq
also suggested Etv1 enrichment in NOS1+ neurons. To validate this, we treated Etv1CreERT2Cre/wt;R26R-TdTomato mice with high-dose tamoxifen to induce TDTOMATO from Etv1+
regulatory elements. TDTOMATO was in 56.4±3.6% of NOS1+ and 5.6±0.9% of NOS1- myenteric
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neurons (Figure 2.3B,H, N). Also consistent with RNAseq, PHOX2B protein had similar abundance
in Chat-EGFP+ and Chat-EGFP- myenteric neurons (Figure 2.3B,G, M). Distribution of these
transcription factors between Chat-EGFP+ and NOS1+ neurons is summarized in Figure 2.3O-P.
These quantitative analyses show substantial correlation between protein and single-nucleus
RNAseq data (Figure 2.3A).

Figure 2.3: Regulatory genes in distinct adult ENS subsets.
(A) Transcription and splicing factors with known roles in ENS development (top). Differentially
expressed factors newly identified in this study (bottom). n.s. = not significantly differentially
expressed between neuron clusters. Color key shows loge(normalized mean gene expression
within each cluster). (B) Feature plots of select regulatory genes. Color key shows log e(normalized
gene expression). (C-G) Myenteric plexus wholemount immunohistochemistry in young adult
ChAT-EGFP-L10A distal colon shows expression in neuron subsets. (H) Wholemount myenteric
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plexus immunohistochemistry in distal colon from tamoxifen-treated Etv1-CreErt2;R26R-TdTomato
mice. TDTOMATO is in many NOS1+ neurons and some non-neuronal cells with ICC morphology.
(I-M) Quantification of immunohistochemistry. TBX3 is mostly in nitrergic (NOS1+) neurons (I,
p<0.0001, n=3). SATB1 (J, p=0.013, n=3), PBX3 (K, p<0.0001, n=3), and RBFOX1 (L, p=0.0006,
n=3) are mostly in cholinergic (EGFP+) neurons, consistent with single-cell data. PHOX2B is
equally abundant in Chat-EGFP+ and Chat-EGFP- cells (M, p=0.2193, n=4). (N) Quantification of
(H) shows 56.4±3.6% of NOS1+ neurons are TDTOMATO+. Only 5.6±0.9% of NOS1- neurons are
TDTOMATO+ (p=0.0002, n=3). (O-P) Cholinergic (Chat-EGFP+, O) and nitrergic (NOS1+, P)
identity for cells expressing select factors. SATB1 (p=0.0022), PBX3 (p=0.0026), and RBFOX1
(p=0.019) are largely restricted to cholinergic (Chat-GFP+) neurons. PHOX2B is in both cholinergic
and
non-cholinergic
neurons
(p=0.370)
(P
values
compare
Transcription
factor+EGFP+/Transcription factor+ versus EGFP+/Total neuron ratios). TBX3 (p<0.0001) and
ETV1 (p<0.0001) are primarily in nitrergic (NOS1+) neurons (P values compare Transcription
factor+NOS1+/Transcription factor+ versus NOS1+/Total neuron ratios). (J-P) Student’s t-test. (I)
ANOVA with Tukey’s post-hoc test. Scale bar = 100 microns. ChAT-EGFP-L10A = Chat-EGFP.
*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.

Adult neuron subtype transcription factor patterns are largely established by E17.5
In mice, CHAT+ and NOS1+ enteric neurons are identifiable by late gestation and appear
lineage committed (35,36). To identify lineage specific transcription factors at E17.5, we performed
RNAseq using whole bowel from ChAT-L10a-EGFP

wt/wt;

Nos1-CreERT2Cre/wt;TdTomato+ and

ChAT-L10a-EGFP+; Nos1-CreERT2wt/wt;TdTomato+ littermates after E15.5 tamoxifen treatment. In
these mice, EGFP marks CHAT-lineage and TDTOMATO identifies NOS1-lineage neurons (Figure
2.4A). 1005 cells were sequenced at 83% saturation. We normalized after removing outliers,
leaving 707 neurons (Elavl4+), 179 epithelial (Epcam+), and 67 smooth muscle cells (Actg2+)
(Supplementary Figure 2.4A-B). Reclustering without epithelia and muscle yielded 8 neuron
clusters (Figure 2.4B), which all had high Ret expression, but were still Dcx+, a marker of immature
neurons (37). Enteric glia were rare based on Plp1 and Sox10 (Supplementary Figure 2.4E).
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Figure 2.4: Single-cell RNAseq of E17.5 ChAT-EGFP-L10A+ and Nos1-CreERT2Cre/wt;R26RTdTomato+ neurons show distinct nitrergic and cholinergic clusters.
(A) Workflow for RNAseq. (B) T-SNE plot shows neuron subpopulations. (C) Violin plots show
subgroups had 25,319.7±5562.2 unique RNA transcripts (UMI) and 5291.6±558.8 detected genes
(nGene) per cell. (D-F) Heatmaps show commonly used enteric neuron markers with > 0 detected
reads (E), neurotransmitter receptors (F), and ion channels. Color shows log e(normalized mean
gene expression). (D) *Indicates differential expression across neuron subtypes. (E-F) Genes listed
are differentially expressed across subtypes.
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Chat transcripts were rare as others reported (8,9), but vesicular acetylcholine transporter Slc18a3
was highly expressed in neuron clusters with low Nos1 (Supplementary Figure 2.4C-D). Three
clusters appeared less mature, prominently expressing neurite projection and cytoskeleton
reorganization genes, based on Gene Ontology (GO) term analysis. Other clusters expressed
synaptogenesis and maintenance genes suggesting more mature neurons (Supplementary
Figure 2.4F-G). As in adults, many neurotransmitters, receptors, ion channel subunits, and
signaling molecules were differentially expressed between subgroups (Figure 2.4D-F and
Supplementary Figure 2.5A-E), including Gfra1 and Gfra2 (Supplementary Figure 2.5D-E).
Many differentially expressed regulatory genes identified in adult mouse ENS were also
differentially expressed in neuron subsets at E17.5, including Casz1, Bnc2, Etv1, Pbx3, Tbx2, Tbx3,
and Rbfox1 (Figure 2.5 and Supplementary Figure 2.5F-G), suggesting they could influence
subtype identity.
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Figure 2.5: Many differentially expressed regulatory genes at E17.5 are also differentially
expressed in adult distal colon.
(A) Transcription and splicing factors with known roles in ENS development (top), and newlyidentified in this study (bottom). n.s. = not significantly differentially expressed between clusters.
(B) Feature plots. (A,B) Colors show loge (normalized mean gene expression). (C-G) Whole-mount
immunohistochemistry of E17.5 ChAT-EGFP-L10A mid-small intestine. (H-L) Quantification of
immunohistochemistry. BNC2 (H, p=0.0005, n=3), PBX3 (I, p=0.0119, n=3), RBFOX1 (J, p=0.0012,
n=3), and TBX2 (K, p<0.001, n=3) are primarily in cholinergic (Chat-GFP+) neurons. TBX3 (L,
p<0.0001, n=3, ANOVA with Tukey’s post-hoc test) is primarily in NOS1+ neurons. (M-N)
Quantification of cholinergic (Chat-EGFP+, M) and nitrergic (NOS1+, N) identity. Neurons
expressing BNC2 (p=0.0018), PBX3 (p=0.0165), RBFOX1 (p<0.0001), and TBX2 (p=0.0016) are
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primarily
cholinergic
(Chat-GFP+)
neurons
(P
values
compare
Transcription
factor+EGFP+/Transcription factor+ versus EGFP+/Total neuron ratios). TBX3+ neurons (p=0.003)
are primarily nitrergic neurons (P values compare Transcription factor+NOS1+/Transcription
factor+ versus NOS1+/Total neuron ratios). (H-L) Mean +/- SEM. (C-P) ChAT-EGFP-L10A reporter
= Chat-EGFP. (H-K,M-N) Student’s t-test. (L) ANOVA with Tukey’s post-hoc test. Scale bar = 50
µm. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.

Conditional Tbx3 loss reduced NOS1+ myenteric neuron density, but Etv1 and Rbfox1 loss
did not alter CHAT/NOS1 subtype ratios
For several differentially expressed regulatory genes we determined if mutations altered
nitrergic or cholinergic enteric neuron abundance. We found that P0 Wnt1-Cre;Tbx3fl/fl;R26RTdtomato mice lacking TBX3 in ENS had a ~30% lower NOS1+ neuron density in small bowel,
despite normal total neuron density (Figure 2.6A-D). In contrast, P0 mice lacking Etv1 (Etv1-CreERT2cre/cre;ChAT-L10A-EGFP), which is enriched in nitrergic neurons, had normal NOS1+ to ChatEGFP+ enteric neuron ratios (Figure 2.6E-H). Chat-EGFP+ neuron density was also normal in
Rbfox1 mutants (Wnt1-Cre;Rbfox1fl/fl;Chat-EGFP-L10A) despite Rbfox1 enrichment in cholinergic
neurons (Figure 2.6J-M). Colonic bead expulsion latency tests were also normal in adult Etv1
(Figure 2.6I) and Rbfox1 (Figure 2.6N) mutant mice, suggesting intact ENS-mediated distal colon
motility. Collectively, these findings suggest TBX3 impacts NOS1+ neurons, but ETV1 and
RBFOX1 mutations do not alter CHAT/NOS1 neuron numbers.
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Figure 2.6: Tbx3 loss in ENS reduces NOS1+ myenteric neurons, but NOS1+ or Chat-EGFP+
neuron abundance and colon bead expulsion was normal in Etv1 and Rbfox1 mutants.
POU3F3 is restricted to colon ENS.
(A-B) Confocal maximum-intensity projections of NOS1+ (green) and total HuC/D (magenta)
neurons in Tbx3 mutant and control P0 small bowel. (C-D) Quantification shows 30% reduction in
NOS1+/Total neuron ratio in Wnt1-CreCre/wt;Tbx3fl/fl P0 small bowel (C; p=0.041, n=3 per group)
despite normal total neuron density (D; p=0.601, n=3 per group). (E-F) Confocal maximum-intensity
projections of P0 small bowel. (E) Control and (F) Etv1-CreERT2Cre/Cre bred to Chat-EGFP-L10A
and stained for EGFP (green), NOS1 (red), and HuC/D (blue). (G) Quantification shows normal
NOS1+ and Chat-EGFP+ neuron ratios (p=0.797, two-way ANOVA, n=4 in each group) and normal
neuron density (H; p=0.117, n=4 in each group) in Etv1 mutant P0 small bowel. (I) Colonic bead
expulsion latency is normal in Etv1-CreERT2Cre/Cre mice (p=0.429, n=6 control, M=3/F=3, P45-50
at start of assay), n=5(Etv1-CreERT2Cre/Cre, M=3/F=2, P49-58 at start of assay)). (J-K) Single
confocal planes in P0 small bowel of control (J) and Wnt1-CreCre/wt;Rbfox1fl/fl (K) bred to ChatEGFP-L10A and stained for EGFP (green) and HuC/D (magenta). (L,M) Quantification shows that
proportion of EGFP+ neurons (p=0.162, n=4 per group) and total neuron density (p=0.470, n=4 per
group) are normal in Rbfox1 mutants. (N) Colon bead expulsion latency is normal in Wnt1CreCre/wt;Rbfox1fl/fl mice (N; p=0.2677, n=5(control, M=2/F=3, P44-46 at start of assay), n=6(Wnt1CreCre/wt;Rbfox1fl/fl, M=2/F=4, P46-58 at start of assay)). (O-P) Whole mount shows POU3F3 in
colon and cecum but not ileum at E14.5 (O) and E17.5 (P). (O) Epifluorescence, unstitched. (P)
Flattened, stitched confocal Z-stack. (Q) Representative RT-PCR for flow sorted TDTOMATO+
ENS cells from Wnt1-Cre;R26R-TdTomato mice confirms Pou3f3 in fetal colon but not small
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intestine (SI). (C-D, G-I, L-N) Mean +/- SEM. (C-D,H,K-L) Student’s t-test. (I,N) Mann-Whitney. (AB,E-F,J-K) Scale bar=100 µm. (O) Scale bar = 500 µm. (P) Scale bar = 1 mm. ChAT-EGFP-L10A
= Chat-EGFP. *p<0.05.

Pou3f3 is expressed in colon, but not small intestine ENS
In addition to subtype identity, regional differences in neurons could promote different
motility patterns. We were intrigued by the observation that Pou3f3 (a.k.a. Brn1), a transcription
factor important for CNS development (38), was mostly restricted to E17.5 immature Chat2 and
immature Nos1 clusters (Supplementary Figure 2.6A-B). Since colon ENS matures after small
bowel, this could be explained by Pou3f3 enrichment in colon ENS, a hypothesis confirmed by RTPCR (Figure 2.6Q). Immunohistochemistry using two antibodies showed POU3F3 marks all
immature and mature colon neurons, but no small bowel neurons (Figure 2.6O-P, Supplementary
Figure 2.6C-X), as recently reported by others (7). Human colon also showed POU3F3 in the
nucleus of all submucosal and myenteric neurons. Human small bowel submucosal neurons lacked
POU3F3, but some small bowel myenteric neurons had cytoplasmic POU3F3 immunoreactivity of
uncertain significance (Supplementary Figure 2.6Y-V’). These data significantly extend recent
reports that colon, but not small bowel, enteric neurons express POU3F3.
Using Pou3f3 to mark E17.5 colon neurons (Supplementary Figure 2.6W’) and restricting
comparisons to only mature or immature clusters based on GO terms, we identified 5 genes
differentially expressed in Pou3f3+ versus Pou3f3- enteric neurons of immature clusters (Slc18a3,
Klhl1, Dpysl3, Gna14, and Itm2a, Supplementary Figure 2.6X’) and 3 genes differentially
expressed in Pou3f3+ versus Pou3f3- enteric neurons of mature clusters (Ahr, Pantr1, Zfhx3,
Supplementary Figure 2.66Y’). Ahr, Pantr1, and Zfhx3 patterns resemble Pou3f3 (Pearson
Correlation, compare Supplementary Figure 2.6B to Supplementary Figure 2.6A’’) and others
recently reported Ahr enrichment in colon ENS (7). Differentially expressed genes in immature
clusters seem less likely to be colon restricted since patterns (Supplementary Figure 2.6Z’) are
distinct from Pou3f3 (Supplementary Figure 2.6B). Instead, differential expression of Slc18a3
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(vesicular acetylcholine transporter) and Klhl1 (P/Q-type calcium current density modulator) may
reflect neuron maturation (39). Dpysl3, a cytoskeletal regulator, was in all groups, but 32% more
abundant in Pou3f3+ cells (Supplementary Figure 2.6Z’). Gna14, and Itm2a are underinvestigated, but at the highest levels in immature Chat clusters.

Adult human myenteric plexus
From human colon we sequenced single nuclei of the myenteric plexus region. Human
enteric neurons comprise <1/10,000 cells and separating ENS from surrounding muscle was
difficult. To identify ENS and aid microdissection of the myenteric plexus layer, we stained live
colon with 4-Di-2-Asp (Supplementary Figure 2.7A), a dye taken up by mitochondria in
presynaptic nerve terminals. We unsuccessfully attempted single cell RNAseq after ENS
microdissection. Isolating neuronal nuclei using NeuN (40) or PHOX2B antibody staining was
likewise unsuccessful. Ultimately, we obtained data from a limited number of human colon
myenteric neuron nuclei by microdissecting using 4-Di-2-Asp, freezing in O.C.T., sectioning,
Dounce homogenizing, and flow sorting Hoechst+ single nuclei from cell debris. 10x Genomics
(Figure 2.7A) yielded RNAseq data from 20,167 nuclei of 16 adult colons (Supplementary Table
2.4) with a mean of 1,455 UMI and 894 genes per nucleus (Supplementary Table 2.5). Our data
included many smooth muscle, ICC, PDGFRα+ cells, enteric glia, muscularis macrophage,
vascular endothelial and hematopoietic cells (Figure 2.7B; Supplementary Figure 2.7B-J; i.e.,
most cells that impact bowel motility). One cluster of 48 cells was strongly positive for neuronal
genes like ELAVL4, SNAP25, and UCHL1 (Supplementary Figure 2.7N-R). Because of small cell
numbers, we used hierarchical Euclidean clustering based on the top 50 markers distinguishing
neurons from other cells. This gave two distinct clusters (Figure 2.7C) that differ in
NOS1/VIP/GAL+ expression. CHAT and SLC18A3 (VAChT) transcripts were not detected in either
neuron subgroup, probably due to low read depth, as low CHAT was also noted by other groups
(8,9). We next asked if any of the 41 transcription or splicing factors differentially expressed in
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mouse Nos1+ versus Chat+ myenteric neurons were also differentially expressed in human enteric
neuron subtypes. Consistent with mouse data, ETV1 was most abundant in NOS1+ neurons, while
RBFOX1 and BNC2 were enriched in NOS1- neurons (Figure 2.7D) after multiple comparison
testing. Immunohistochemistry confirmed BNC2 (Figure 2.7E-H,Y), PBX3 (Figure 2.7I-L,Z),
RBFOX1 (Figure 2.7M-P,A’), TBX2 (Figure 2.7Q-T,B’), and TBX3 (Figure 2.7U-X,C’) were
differentially expressed in human enteric neuron subtypes, with patterns similar to mouse (i.e. most
RBFOX1+, PBX3+, BNC2+, and TBX2+ cells are CHAT+; most TBX3+ cells are NOS+; Figure
2.7D’-E’).
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Figure 2.7: Human myenteric plexus NOS1/VIP/GAL+ and NOS1/VIP/GAL- neurons
differentially express many regulatory genes also differentially expressed in mouse ENS.
(A) Workflow for single-nucleus RNAseq of adult human colon myenteric plexus. (B) T-SNE plot of
20,167 nuclei shows glia, ICC, muscularis macrophages, Pdgfrα+ cells, smooth muscle, T cells,
endothelium, and unknown groups. Neurons comprise one small cluster (~48 cells). (C) Heatmap
shows 50 genes with the highest fold difference between neurons and other cells. Hierarchical
clustering suggests 2 subgroups: NOS1+/VIP+/GAL+ (17 neurons) and NOS1-/VIP-/GAL- (31
neurons). (D) Heatmap shows transcription and splicing factors differentially expressed in mouse
colon that were in >10% of human myenteric neurons. RBFOX1, ETV1, and BNC2 were
differentially expressed between NOS1/VIP/GAL+ and NOS1/VIP/GAL- human neurons (Wilcoxon
rank-sum test with Bonferroni correction). (E-X) Maximum intensity projections of confocal Z-stacks
show adult human colonic ENS. BNC2 (E-H). PBX3 (I-L, white arrowheads indicate nuclear PBX3
in neurons.), RBFOX1 (M-P), TBX2 (Q-T) and TBX3 (U-X) are present in subsets of human
myenteric neurons. (Y-C’) Quantification of immunohistochemistry shows BNC2 (Y, p=0.0001,
n=3), PBX3 (Z, p=0.0021, n=3), RBFOX1 (A’, p=0.0007, n=3), and TBX2 (B’, p=0.0089, n=3) are
primarily in CHAT+ neurons. TBX3 (C’, p=0.0004, n=3) is primarily expressed in NOS1+ neurons.
(Z-A’) Quantification of CHAT+ (D’) and NOS1+ (E’ cells reveals BNC2 (p=0.0102), PBX3
(p=0.0021), RBFOX1 (p=0.0016), and TBX2 (p=0.0162) are largely restricted to CHAT+ neurons
in adult human ENS (P values compare Transcription factor+EGFP+/Transcription factor+ versus
EGFP+/Total neuron ratios). TBX3 (p=0.0073) is primarily in NOS1+ neurons (P values compare
Transcription factor+NOS1+/Transcription factor+ versus NOS1+/Total neuron ratios). (Y-E’) Mean
+/- SEM and Student’s t-test. *p<0.05, **p<0.01, ***p<0.001.

2.4 Discussion
Life-threatening bowel motility disorders like HSCR and chronic intestinal pseudoobstruction (41) are challenging to treat and difficult to diagnose. To facilitate molecular diagnostics,
enhance understanding of ENS function, and advance new strategies like stem cell therapy (42,43),
we used single-cell transcriptomics to identify a vast array of neurotransmitters, receptors, ion
channels, signaling molecules, and mRNA regulatory genes. These data identified 7 mouse
myenteric neuron subclasses in adult distal colon and 8 neuron groups at E17.5.
Immunohistochemistry in mouse and human validated RNAseq, and functional studies identified
new ENS roles for TBX3, GDNF and NRTN. Our analyses complement recent data from others
examining different ages and bowel regions (6–9), providing a foundation for novel diagnostics and
disease management.
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Several transcription factors were differentially expressed in nitrergic versus cholinergic
neurons. We therefore tested if gene loss altered Chat or Nos1 subtype abundance. We found that
Tbx3 loss in Wnt1-lineage cells reduced NOS1+ myenteric neuron density, but not total neuron
density. Interestingly, Tbx3 expression in limb bud is induced by the transcription factor HAND2
(44), and Hand2 mutations cause complete loss of NOS1+/VIP+ enteric neurons (45), suggesting
TBX3 also acts downstream of HAND2 in the ENS. In contrast, NOS1+ and Chat-EGFP+ neuron
density was normal in Etv1 mutant mice although most adult NOS1+ myenteric neurons express
Etv1 and ETV1 regulates CNS neuron subtype differentiation (46). Similarly, while the splicing and
mRNA binding protein RBFOX1 (47,48) is present in most ENS cholinergic neurons and RBFOX1
regulates CNS neuron subtype differentiation (49), the percentage of Chat-EGFP+ myenteric
neurons was normal in Wnt1-CreCre/wt; Rbfox1fl/fl mice. Normal colonic bead expulsion latency in
Etv1 and Rbfox1 mutant mice suggests redundant mechanisms in the ENS prevent obvious
anatomic or functional defects.
Another striking observation is that the transcription factor POU3F3 is found in the nucleus
of all mouse and human colon enteric neurons, but not in small bowel neurons as another group
recently confirmed (7). POU3F3 function in colon ENS is not known, but POU3F3 regulates cortical
neuron migration and neurogenesis (50,51). Human mutations cause intellectual disability, speech
delay, autism, epilepsy, craniofacial anomalies and cryptorchidism (52), but effects of POU3F3
mutation on bowel function were not reported. Restricted colon expression is interesting because
colon motility and ENS structure differ between colon and small bowel (13,19,23,24,53), but we
know little about underlying developmental mechanisms. The observation that there are colonrestricted ENS transcription factors suggests more intense investigation of regional gene
expression in the ENS may be valuable.
Human RNAseq yielded data from 17 NOS1+ and 31 NOS1- myenteric neurons as well as
from many other cells that impact bowel motility. Guided by RNAseq, we found ETV1 was more
abundant in human nitrergic neurons, while RBFOX1 and BNC2 were enriched in non-nitrergic
67

neurons, suggesting subtype-specific genes may be conserved between humans and mice.
Immunohistochemistry confirmed TBX3, PBX3, and TBX2 are also present in subsets of human
enteric neurons as predicted by mouse data.
Many other genes differentially expressed in enteric neuron subclasses may merit investigation.
For example, ZEB2 mutations cause Mowat-Wilson syndrome, characterized by Hirschsprung
disease (HSCR), intellectual disability and distinctive facial features. Post-surgical outcomes in
Mowat-Wilson syndrome are worse than for isolated HSCR and ZEB2 mutations cause chronic
constipation without HSCR (54,55) suggesting Zeb2 might have roles beyond bowel colonization
by ENS precursors. Zfhx3, another HSCR-associated gene (56) drives neuronal differentiation in
other regions, but roles in ENS subtype specification are unexplored.

Integrating new and old data about ENS subtypes
Using neurotransmitter-associated markers in adults (Supplementary Table 2.2) and at
E17.5 (Supplementary Table 2.3), we correlated our RNAseq data with known ENS subtype
markers. Subtype designations at E17.5 include small bowel and colon neurons (distinguished by
Pou3f3) and immature clusters defined by Gene Ontology (GO) Term modules (Supplementary
Figure 2.4F, G). The similarities between E17.5 small bowel and adult colon suggest that some
aspects of neuron differentiation are similar across bowel regions and completed by E17.5. Many
newly identified differentially expressed genes are highlighted in Supplementary Tables 2.2 and
2.3. Some genes known to be expressed in enteric neuron subtypes were not detected (see
Supplementary Table 2.2), but lack of expression is uninterpretable, because of limited read depth
in adult colon nuclei. In adults, Calcb neurons appear to be AH/Dogiel type II intrinsic sensory
neurons that express neurofilament M (Nefm), Nav1.9 (Scn11.1a), calretinin (Calb2), NK1
tachykinin receptor (Tacr1), serotonin receptors Htr3A and Htr3b, and purine receptor P2rx2
(19,57,58). Chat1 neurons express the mechanosensitive channel Piezo1 suggesting these cells
are stretch sensitive intrinsic sensory neurons, but other sensory neuron markers are absent. There
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are reports of mechanosensitive interneurons and motor neurons (59), so Chat1 neurons may
correspond to these. Tac1 and Penk co-expression make Chat2 and Chat3 clusters excitatory
motor neurons or interneurons (19), Supplementary Figure 2.1K-S). Unexpectedly, however,
Chat3 neurons also express hepatocyte growth factor receptor Met and do not express CGRP
(Calcb), suggesting Met+ colonic neurons may differ from small bowel where MET and CGRP were
found in the same neurons by immunohistochemistry (60). Finally, Chat4 cells appear to be
interneurons based on co-expression of Slc18a3, Chat, Nos1, Vip, and Calb1. Thus, many findings
fit well with known neuron subtypes, and immunohistochemistry correlates well with RNAseq,
providing high confidence in our results. We point out unexpected findings to suggest there is more
to learn and that future studies based on our RNAseq are needed to fully define adult enteric neuron
subtypes.
Defining neuron subtypes at E17.5 presents an added challenge because differentiation is
incomplete. Supplementary Table 2.3 highlights some markers differentially expressed in neuron
subtypes. Since almost all cholinergic and nitrergic neurons at E17.5 remain cholinergic or nitrergic
respectively in adults (35,36), we extrapolate from adult data. Assessment of maturity is based on
GO Term analysis. Colon neurons were identified by Pou3f3 expression. Chat cluster 1 and Chat
cluster 2 markers suggest small bowel excitatory motor neurons and intrinsic sensory neurons,
respectively. Chat cluster 2 also expresses BMP and TGFβ signaling antagonists (Nog, Bambi,
Smad7), which may provide new insights into ENS development. Immature Chat cluster 1 appears
to be developing myenteric interneurons that express Slc17a6, similar to the adult Chat4 cluster.
Nos1 clusters 1 and 3 are most likely inhibitory motor neurons, but could also be interneurons.
Nos1 cluster 2 represents possible inhibitory interneurons based on the expression of the
transcription factor Neurod6 (9). Interestingly, Nos1 cluster 1 differentially expresses Ednrb, but the
role of Ednrb/EDN3 signaling at this time is not known. We highlight these observations to
emphasize how mining our data might provide new insight into development.
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GDNF and NRTN acutely affect calcium signaling in distinct adult enteric neuron
populations
Our data also provide new insight into adult gene function. We knew already that
GDNF/GFRA1/RET signaling is essential during gestation for ENS precursor survival, proliferation,
and bowel colonization (61). As the ENS matures, GDNF/GFRA1/RET signaling enhances
neuronal differentiation, increases neurite growth, and alters axon trajectories for NOS1+ enteric
neurons (62). Then, in adults, GDNF increases the strength of bowel contraction in the ascending
limb of the peristaltic response (28). We were therefore unsurprised that GDNF altered calcium
signaling in some enteric neurons and that GDNF acutely enhanced basal and EFS-evoked motor
patterns. In contrast, although NRTN/GFRA2/RET are known to influence bowel motility and
support acetylcholinesterase+ and substance P+ neurites (25,26), acute effects of NRTN on the
ENS or bowel motility had not been demonstrated. Our data confirm and extend prior observations.
Gfra1 and Gfra2, preferred co-receptors for GDNF and NRTN respectively, are expressed in largely
non-overlapping populations of Ret+ E17.5 and adult myenteric neurons. GFRA1 is in ~90% of
NOS1+ myenteric neurons, but in very few NOS1- neurons, so we anticipated GDNF effects
primarily in NOS1+ neurons. However, 44% (33/75) of GDNF influenced neurons were nonnitrergic. This might occur because GDNF activates RET via GFRA2 (NRTN’s preferred coreceptor) at high (pharmacologic) concentrations (63–65), but this seems unlikely since GCaMP6s
signaling was altered by both GDNF and NRTN in only 8% of myenteric neurons. Instead, the
observation that some neurons had increased and others decreased GCaMP activity in response
to each trophic factor suggests both direct and indirect effects were measured and that responses
may depend on synaptic inputs, as confirmed by TTX/hexamethonium data. The hypothesis that
GDNF and NRTN sensitize responsive neurons to incoming stimuli is also supported by our prior
studies of dorsal root ganglion neurons where these factors acutely potentiate TRPV1-induced
calcium signals and induce hyperalgesia when injected into hindpaw (66). Although we do not know
the source of calcium (e.g., intra- or extracellular) or whether evoked GCaMP signals were activity70

dependent, our data collectively show that NRTN and GDNF acutely influence non-overlapping
sets of myenteric neurons and differentially regulate bowel motility.

Summary
Bowel motility disorders remain poorly defined in part because the ENS is complicated and
under-investigated. As we move into an era of advanced genetic testing for people with lifethreatening medical problems like chronic intestinal pseudo-obstruction, we remain hampered by
inadequate data about enteric neuron subtypes that support normal bowel function. In addition to
defining many subtype specific molecules, we demonstrated new roles for Tbx3, GDNF and NRTN,
and showed colon- specific POU3F3 expression in enteric neurons at many ages, combining data
from mouse and human myenteric plexus. Many additional studies will build on this work.

2.5 Methods
Study approval
Studies adhere to ARRIVE (Animals in Research: Reporting In Vivo Experiments)
guidelines (69). Mouse experiments were performed in accordance with Institutional Animal Care
and Use Committee (IACUC) approval from Children’s Hospital of Philadelphia (IACUC#19001041) and University of Pittsburgh (IACUC#IS00013297) or University of Melbourne Animal
Experimentation Ethics Committee (project number 1714308.2). Human colon was acquired with
Institutional Review Board approval from Perelman School of Medicine at University of
Pennsylvania (IRB#804376) and from Children’s Hospital of Philadelphia (IRB#13-010357).

Animals
B6.FVB(Cg)-Tg(Chat-EGFP/Rpl10a,Slc18a3)DW167Htz/J mice (referred to as ChATEGFP-L10a (RRID:IMSR_JAX:030250; C57BL/6J) were a kind gift from Dr. Joseph Dougherty at
Washington University School of Medicine in St. Louis. Tbx3tm3.1Moon mice (referred to as Tbx3;
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RRID:MGI:5538564; described previously (22); mixed background) were a kind gift from Dr. Anne
Moon at Geisinger Commonwealth School of Medicine. B6.129S2-Rbfox1tm1.1Dblk/J mice
(referred to as Rbfox1; RRID:IMSR_JAX:014089; C57BL6/J) were a kind gift from Dr. Douglas
Black at the University of California Los Angeles. Gfra1tm2.1Jmi mice (referred to as Gfra1-Gfp;
RRID:MGI:3715157, C57BL/6) were a kind gift of Dr. Sanjay Jain at Washington University School
of Medicine in St. Louis. C57BL/6J mice (RRID:IMSR_JAX:000664), H2az2(Tg(Wnt1cre)11Rth
mice (referred to as Wnt1-Cre; RRID:IMSR_JAX:003829), B6;129S6-Gt(ROSA)26Sortm1(CAGtdTomato*,-EGFP*)Ees/J mice (referred to as ROSAnT-nG; RRID:IMSR_JAX:023035), B6;129SGt(ROSA)26Sortm1.1Ksvo/J mice (referred to as R26R-H2b-mCherry; RRID:IMSR_JAX:023139),
B6(Cg)-Etv1tm1.1(cre/ERT2)Zjh/J

mice

(referred

to

as

Etv1-CreERT2

mice;

RRID:IMSR_JAX:013048), Slc17a6tm2(cre)Lowl/J mice (referred to as Vglut2-IRES-Cre mice;
RRID:IMSR_JAX:016963), B6;129S-Nos1tm1.1(cre/ERT2)Zjh/J mice (referred to as Nos1CreERT2; RRID:IMSR_JAX:014541), Gt(ROSA)26Sortm9(CAGtdTomato)Hze mice (referred to as
R26R-TdTomato; RRID:IMSR_JAX:007909), B6.FVB-Tg(EIIa-cre)C5379Lmgd/J (referred to as
E2a-Cre

RRID:IMSR_JAX:003724;

C57BL/6),

and

B6J.Cg-Gt(ROSA)26Sortm96(CAG-

GCaMP6s)Hze/MwarJ (referred to R26R-Gcamp6s; RRID:IMSR_JAX:028866; C57BL/6) were
obtained from The Jackson Laboratory (Bar Harbor, ME). Wnt1-Cre mice on a mixed C57BL/6J x
CBA/J)F1 background were bred into R26R-H2b-mCherry mice on a mixed 129S4/SvJaeSor x
C57BL/6J background and maintained on a mixed C57BL/6J x 129S4/SvJaeSor x CBA/J)F1
background. Etv1-CreERT2 mice were bred to R26R-TdTomato mice and ChAT-EGFP-L10a mice
to generate Etv1-CreERT2;R26R-TdTomato;ChAT-EGFP-L10a mice on a C57BL/6J background.
Vglut2-IRES-Cre mice on a C57BL/6;FVB;129S6 background were bred to R26R-TdTomato on a
C57BL/6J background and maintained on a mixed C57BL/6;FVB;129S6 background. Nos1CreERT2 mice were crossed with R26R-TdTomato mice and ChAT-EGFP-L10a mice to generate
ChAT-EGFP-L10a; Nos1-CreERT2; R26R-TdTomato mice and maintained on a C57BL/6
background. Rbfox1;Wnt1-Cre;R26R-TdTomato;ChAT-EGFP-L10a mice were generated by
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crossing Rbfox1 mice to Wnt1-Cre mice, ChAT-EGFP-L10a mice, and R26R-TdTomato mice and
were maintained on a mixed background. Wnt1-Cre;Tbx3 mice were generated by crossing Wnt1Cre mice to Tbx3 mice and were maintained on a mixed background. E2a-Cre mice were crossed
with R26R-Gcamp6s mice to generate mice that express GCaMP6s (a genetically encoded calcium
indicator) in all cells. E2a-Cre;R26R-GCaMP6s mice were maintained on a pure C57BL/6
background. Genotyping was performed using previously published and novel primers
(Supplementary Table 2.9) and by Transnetyx (Cordova, TN). Vaginal plug day was considered
day E0.5. Experimental animals of the correct strain, genotype, and age were randomly selected
from the total pool of mice available. General animal husbandry information for the mice used in
this study is provided in Supplementary Table 2.10.

Human colon
Colon tissue was acquired with Institutional Review Board approval from Perelman School
of Medicine at University of Pennsylvania (IRB #804376) and the Children’s Hospital of Philadelphia
Institutional Review Board (IRB#13-010357) using the Abramson Cancer Center Tumor Bank.
Colon was de-identified, providing limited clinical data. Resected colons were maintained at
ambient temperature until arrival in pathology, where they were transferred to ice-cold Dulbeccomodified PBS (DPBS) 1-4 hours after resection. Pathologists selected regions of colon without
gross abnormalities, and colon specimens were transferred to the laboratory in DPBS on ice.

Tamoxifen treatment
Tamoxifen (10mg/mL or 20mg/mL; Sigma, Cat#T5648) was prepared by first adding 200
uL ethanol and then 1800 uL sunflower oil (Sigma, Cat#S5007). Tamoxifen was dissolved by
alternately vortexing and incubating in a 37ºC water bath. Nos1-creERT2;Chat-EGFP-L10A;R26TdTomato E15.5 dams were injected once with 200mg/kg tamoxifen at 10mg/mL concentration.
Etv1-CreERT2;Chat-EGFP-L10A;R26-TdTomato E15.5 dams were gavaged once with tamoxifen
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at 200mg/kg concentration at 20mg/mL concentration and pups were dissected at E17.5. Adult
Etv1-CreERT2;R26-TdTomato adult mice were gavaged twice (two days apart) with 233mg/kg
tamoxifen at 20mg/mL concentration three weeks prior to dissection.

Preparing young adult mouse colon for nuclei isolation
Wnt1-CreCre/wt;R26R-H2b-mCherry+ 47-52-day-old mice (8 females, 1 male) were
euthanized with CO2. Colon was removed, flushed with cold, sterile Dulbecco’s phosphate buffered
saline (DPBS) using a 20 mL syringe to remove luminal contents, and placed in fresh cold, sterile
DPBS. Colon was carefully cut along the mesentery, pinned mucosal side down on dishes treated
with Sylgard Elastomer 184 (Sylgard Elastomer 184 Silicone Encapsulant Clear, Dow Corning,
Midland, MI). Muscularis was carefully peeled from the mucosa and placed in cold O.C.T.
compound (Fisher Healthcare Tissue-Plus O.C.T. Compound; Thermo Fisher Scientific, Hampton,
NH; Cat#23-730-571) in a biopsy specimen cryomold (VWR, Radnor, PA; Cat#4565), frozen in
methylbutane on dry ice, and stored at -80°C.

Preparing adult human colon for nuclei isolation
Using insect pins (Fine Science Tools, Cat# 26002-20), colons were maximally stretched
and pinned serosa side up on 30 mm dishes treated with Sylgard Elastomer 184 (Sylgard
Elastomer 184 Silicone Encapsulant Clear, Dow Corning, Midland, MI). Tissue was incubated in 9
parts carboxygenated (95% oxygen, 5% CO2) Krebs-Ringer solution (118 mM NaCl (Sigma,
Cat#S6191), 4.6 mM KCl (Thermo Fisher Scientific, Cat#BP366-500), 2.5 mM CaCl2 (Cat# C7902),
1.2 mM MgSO4 (Sigma, Cat#M-7506), 1 mM NaH2PO4 (Sigma, Cat#S0751), 11 mM D-(+)-Glucose
(Sigma, Cat#G-7021), 25 mM NaHCO3 (Thermo Fisher Scientific, Cat#BP328-500), pH 7.4) and 1
part 4-(4-(Dimethylamino)styryl) -N-Methylpyridinium Iodide (4-Di-2-Asp; Abcam, Cambridge, U.K,
Cat# ab145266) at room temperature in sterile DPBS. After 10 minutes, the tissue was transferred
to ice-cold carboxygenated Krebs-Ringers solution under a SteREO Discovery.V20 fluorescence
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dissecting scope (ZEISS, Oberkochen, Germany, 488 nm filter). Fluorescent ENS was carefully
dissected from muscularis by peeling away longitudinal muscle strips with Dumont #5 forceps (Fine
Science Tools, Cat#11251-30), placed in cold O.C.T. compound (Fisher Healthcare Tissue-Plus
O.C.T. Compound; Thermo Fisher Scientific, Hampton, NH; Cat#23-730-571) in a biopsy specimen
cryomold (VWR, Radnor, PA; Cat#4565), frozen in methylbutane (Thermo Fisher Scientific
Cat#O3551-4) on dry ice, and stored at -80°C.

RNA extraction for RIN assessment prior to sequencing
One to three days before sequencing, frozen mouse or human tissues were sectioned on
a Microm HM 505 E Cryostat (GMI, Ramsey, MN; 100 µM sections, -20°C). RNA was extracted
from several (1-5) 100 µM sections using the Qiagen RNeasy Plus Micro kit (Qiagen, Hilden,
Germany; Cat# 74034) and using Qiagen's RNase Free DNase Set (Qiagen, Cat# 79254).
Samples were run on an 2100 Agilent Bioanalyzer using an RNA 6000 Pico Kit (Agilent, Santa
Clara, CA, Cat#5067-1513), and tissue was used if RNA Integrity Number (RIN) was > 7.0.

Nuclei isolation and sorting
To isolate nuclei, frozen colon sections (100 µm) in ice-cold lysis buffer (10mM Tris HCl
pH 7.5 (Cat# 15567-027), 10 mM NaCl (Sigma, Cat#S6191), 3 mM MgCl2 (Cat# BP214-500),
0.005% Nonidet P40 Substitute (Thermo Fisher Scientific, Cat#AM9010; Sigma, Cat#74385) were
chopped rapidly with iridectomy scissors (1 minute), transferred to a pre-cooled Dounce
homogenizer (VWR, Cat#357538) on ice, homogenized 15 strokes with the loose pestle and 40
strokes with the tight pestle, filtered through MACS SmartStrainer (Miltenyi Biotec, Cat#130-098458), centrifuged (590xg, 8 minutes, 4°C), and resuspended in staining buffer (1x phosphatebuffered saline (PBS), 1% w/v Ultrapure BSA (Life Technologies, Cat#AM2618), 0.2U/mL Protector
RNase inhibitor, (Sigma, Cat#3335399001)), 2.5µg/mL Hoechst 33342 Trihydrochloride Trihydrate
(Thermo Fisher Scientific, Cat# H3570) was added to a final concentration of 2.5 µg/mL before
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filtering (FlowMi strainer, VWR, Cat#H13680-0040) and flow sorting (MoFlo Astrios) into 5µL
staining buffer using a 70µm nozzle to isolate Hoechst+/mCherry+ nuclei (mouse) or Hoechst+
nuclei (human).

Whole cell isolation from E17.5 mice
An E17.5 Nos1-CreERT2;ChAT-L10A-EGFP;R26R-TdTomato dams, tamoxifen treated
(200 mg/kg) at E15.5 was euthanized, and pups were rapidly dissected on ice (2 TdTomato+, 3
GFP+). For RNA-seq, full-length small intestines and colon dissociated together were used for
RNA-seq. For RT-PCR, TdTomato+ E14.5 and E17.5 small intestine and colon from Wnt1Cre+;R26-TdTomato+ mice were analyzed separately. Tissue in carboxygenated 1x Hanks’
Balanced Salt Solution (HBSS, Thermo Fisher Scientific, Cat#14025092) was cut into small pieces
with insulin needles, and dissociated with Liberase (Sigma, Cat#5401135001) plus DNase I
(0.02U/µL, Roche, Basel, Switzerland; Cat#04716728001), MgCl 2 (6mM, Cat# BP214-500) and
CaCl2 (1mM, Cat# C7902) in HBSS (37oC, 40 minutes) with repeated trituration (P1000).
Dissociated cells were, passed 2-3x through 35 µm filters (Falcon, Cat#352235), pelleted (170xg,
3 minutes, 4°C) in 10% fetal bovine serum (FBS)/Iscove's DMEM (Corning, Cat#10-016-CM),
resuspended in FACS buffer (0.04% w/v BSA (Thermo Fisher Scientifics, Cat#AM2618) in HBSS
(Thermo Fisher Scientific, Cat#14025092)), filtered again, and sorted (BD FACSJazz, 100µm
nozzle) into 300μL FACS buffer for sequencing. For RT-PCR, tdTomato+ cells were collected in
1mL Iscove's DMEM/10% FBS, centrifuged (600xg, 5 minutes, 4°C) and resuspended in Buffer
RLT plus (Qiagen, Cat#74034).

Library generation, sequencing, and data processing
Libraries prepared with Chromium Single Cell 3’ Reagent Kits v2, (Cat#120237, 10X
Genomics, Pleasanton, CA) were sequenced on an Illumina HiSeq 2500. Cell Ranger pipeline (10x
Genomics) was used to convert BCL files into FASTQ files, perform STAR alignment (70), filter,
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count UMI, and generate gene-barcode matrices. Cell Ranger Aggr pipeline (10x genomics, v.
3.0.0) was used to aggregate multiple samples, normalize outputs, and re-compute gene-barcode
matrices on combined data.

Analysis of murine single-nucleus and single cell sequencing data
Using Seurat (17,18), gene-barcode matrices were imported into R, filtered to remove lowexpressors or doublets (nGene=200-5000 for adult distal colon, nGene = 1000-9000 for E17.5
whole bowel) and mitochondrial contaminants (percent mitochondria <10% for adult distal colon,
percent mitochondria <5% for E17.5 whole bowel), normalized, scaled to regress out UMI and
percent mitochondria. Cells were clustered using the most statistically significant principal
components. To cluster the E17.5 mouse data, we excluded genes located on the X- and YChromosomes from the principal components and included principal components up to the point
where either any additional principal component contributed less than 5% of standard deviation
and the principal components cumulatively contributed to 90% of the standard deviation or when
the variation changes by less than 0.1% between consecutive principal components (71). This
turned out to be 15 principal components. For adult mouse distal colon data, we found that taking
all of the recommended statistically significant principal components resulted in difficult-to-interpret
clustering, possibly due to batch effects in our dataset, and that the first ~11 components were
sufficient to cluster our data in a biologically meaningful way. When reclustering was performed on
subsets of data (i.e., to filter out contaminants), subsetted data was rescaled and reclustered using
the same method described above, minus the normalization step. To identify genes that were
differentially- expressed between clusters, clusters were compared one at a time to all other cells
in the dataset using a Wilcoxon Rank Sum test with Bonferroni multiple testing correction (Seurat's
FindAllMarkers command). A cutoff of at least 10% of cells in a group expressing a gene of interest
was required for genes to be tested, and only genes with loge(fold change) > 0.25 were included in
the analysis. Heatmaps (Figures 2.1, 2.3-2.5, Suppl. Figures 2.2, 2.5) were generated by taking
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the mean of the log-normalized data scaled by Seurat for cells within each cluster. Except where
indicated, only genes that were differentially expressed between neuronal clusters are shown.
Hierarchical clustering (Figure 2.7C) was performed using the complete linkage method. For the
GO Term analysis, we combined the three putative immature clusters into one and compared gene
expression for these three clusters with the gene expression of all other clusters using a Wilcoxon
Rank Sum test with Bonferroni multiple testing correction (Seurat's FindMarkers command). We
performed GO Enrichment Analysis for GO biological processes (PANTHER Overrepresentation
Test, GO Ontology database released 2020-02-21) using Fisher's exact test with FDR correction.
We submitted differentially expressed genes for the immature clusters (immature Chat cluster1,
immature Chat cluster 2, immature Nos1 cluster) and compared these to the reference gene list for
mus musculus (22265 genes). We also submitted differentially expressed genes for the more
mature cluster (Chat cluster 1, Chat cluster 2, Nos1 cluster 1, Nos1 cluster 2, Nos1 cluster 3) and
compared these to the reference gene list for mus musculus (22265 genes). We reported the 20
most enriched GO Terms. To identify genes differentially expressed between colon and small
intestine, we defined colonic neurons as all cells with detectable Pou3f3 expression. We compared
gene expression using a Wilcoxon Rank Sum test with Bonferroni multiple testing correction
(Seurat's FindMarkers command) for neurons within the immature clusters (Immature Chat cluster
1, Immature Chat cluster 2, Immature Nos1 cluster) or within the mature clusters (Chat cluster 1,
Chat cluster 2, Nos1 cluster 1, Nos1 cluster 2, and Nos1 cluster 3) to normalize for the relatively
more immature state of development of the majority of Pou3f3-expressing cells (40 mature Pou3f3expressing neurons versus 503 other mature neurons and 94 immature Pou3f3-expressing
neurons versus 62 other immature neurons). We followed up the identification of potentially colonspecific genes by correlating the gene expression of the gene in question with Pou3f3 expression
in all neurons (pairwise Pearson Correlation).
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Analysis of human single-nucleus sequencing data
Using Seurat (17,18), gene-barcode matrices were imported into R, filtered to remove lowexpressors or doublets (nGene=200-5000) and mitochondrial contaminants (percent mitochondria
<10%), normalized, and scaled to regress out UMI and percent mitochondria. Nuclei were clustered
using the most statistically significant principal components identified by elbow plot (11 principle
components). Since unbiased clustering initially did not detect the small group of neurons as a
distinct group, we identified 48 neurons by isolating all nuclei expressing any copies of ELAVL4,
UCHL1, or SNAP25 (Supplementary Figure 2.7N-P). These nuclei were reclustered. We saw 7
subgroups that we believe are doublets containing neuronal and non-neuronal nuclei based on coexpression of genes like ACTG2, PLP1, KIT 9 (Supplementary Figure 2.7Q-R). One subgroup
appeared to be pure single neuron data based on high expression of other neuronal markers like
SYT1 and DSCAM and the absence of markers for other well-defined cell populations
(Supplementary Figure 2.7Q-R). The strongly-positive cluster (48 neurons) was mapped back
onto the t-SNE plot. To identify neuron-specific genes, we compared this cluster of neurons against
all other cell populations using a Wilcoxon Rank Sum test with Bonferroni multiple testing correction
(Seurat’s FindMarkers command). A cutoff of at least 25% of cells in a group with expression > 0
was required for genes to be tested. Neuron gene expression for the top 50 neuron-specific genes
was graphed and neurons were clustered using the Euclidean distance method (Figure 2.7C). This
revealed two groups of neurons, one which was NOS1+, and another that was NOS1-. We imported
a list of 36 transcription and splice factors identified as significantly different in mouse adult colon
Nos1 and Chat expressing neurons. Using this list and Seurat’s FindMarkers command, we
compared expression for these genes between NOS1+ and NOS1- neurons and found differential
expression for a subset of transcription factors (Figure 2.7D).
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Preparing bowel for whole mount immunochemistry
E17.5 bowel was washed in PBS, straightened with stainless steel insect pins (Fine
Science Tools, 26002-20) on Sylgard® Elastomer 184 (Silicone Encapsulant Clear, Dow Corning,
Midland, MI), and fixed (4% paraformaldehyde (PFA), 20 min, room temperature (RT)). P0 small
intestine in ice-cold PBS was opened along mesenteric border, pinned with insect pins serosal side
up without stretching onto Sylgard® Elastomer 184 (Sylgard Elastomer 184 Silicone Encapsulant
Clear, Dow Corning, Midland, MI), before fixing (4% PFA, 20-30 minutes, RT) and peeling
muscularis from mucosa/submucosa. Adult distal colon flushed with ice-cold PBS, was opened
along the mesenteric border. Muscle layers were peeled from mucosa/submucosa using Dumont
#5 forceps (Fine Science Tools, Cat# 11251-30), maximally stretched, pinned (insect pins) to
Sylgard® Elastomer 184, fixed (4% PFA, 20-30 minutes, RT), briefly washed (1x PBS), equilibrated
in 50% glycerol/50% PBS (30 minutes, RT or overnight, 4ºC) before storage (-20°C). For high
magnification anti-enkephalin and anti-substance P staining, colon opened along mesenteric
border was stretched, pinned, and fixed (4% PFA, overnight, 4°C), rinsed in 1x PBS (3 x 10min),
and the dissected with fine forceps to remove mucosa, submucosa, and circular muscle from
myenteric plexus attached to longitudinal muscle.
Anti-enkephalin and anti-substance P antibodies studies used C57BL6 wild-type mice.
Proximal, mid and distal-colon tissue was removed, opened along the mesenteric border, cleaned
of fecal matter, stretched and pinned to Sylgard Elastomer 184 and post-fixed (4% PFA, overnight,
4°C). After rinsing 3 times (10-minute/rinse) in 1x phosphate-buffered saline, mucosa, submucous
plexus and circular muscle were removed with fine forceps, leaving preparations of myenteric
plexus attached to longitudinal muscle.

Whole mount immunohistochemistry
Bowel stored at -20oC in 50% glycerol/50% PBS was rinsed in PBS, blocked (2 hours, PBS
+ 0.5% Triton X-100 (Sigma, Cat# T8787) (PBST) with 5% Normal Donkey Serum (NDS; Jackson
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ImmunoResearch Laboratory, West Grove, PA, RRID: AB_2337258), incubated in primary
antibody (Supplementary Table 2.7) with gentle rocking (4°C, 2 days) except for ANNA-1 which
was incubated overnight (4°C). After washing (3 x 5 minutes, 0.5% PBST) and secondary antibody
(Supplementary Table 2.7) incubation in blocking solution with gentle rocking (1 hour, RT), tissue
was washed (3 x 5 minutes, PBS), and mounted in 50% glycerol/50% PBS.
For high magnification imaging, longitudinal muscle with exposed myenteric plexus was placed in
10% Casblock (Thermo Fisher Scientific, Cat# 008120) with 0.1% Triton X-100 (ProSciTech,
Thuringowa, QLD) in PBS (30 minutes, RT), then in primary antisera (Supplementary Table 2.7)
(24-48 hours, 4°C) before rinsing (PBS, 3x 10min), and secondary antisera staining
(Supplementary Table 2.7) (2 hours, RT). After rinsing (PBS, 3x 10min), preparations were
mounted using fluorescence mounting medium (DAKO, Carpenteria, CA).

NADPH diaphorase staining
Bowel was pinned flat and fixed (4% PFA, 20min, RT), briefly washed (1xPBS), incubated
in 0.1M phosphate buffer, pH7.4 with 1mg/mL beta-nicotinamide adenine dinucleotide phosphate
(beta-NADPH, Sigma, Cat# N750), 0.1mg/mL nitroblue tetrazolium (Sigma, Cat#11383213001),
0.3% Triton-X 100 (1 hour, 37oC), washed in PBS, and imaged immediately in a custom-made
holding chamber.

Preparing human colon for whole mount immunochemistry
Human colon with fat trimmed was pinned serosa side up on Sylgard® Elastomer 184
plates in ice-cold PBS using stainless steel insect pins. Tissue was maximally stretched during
pinning to make the colon as thin as possible. Pinned tissue was fixed overnight (4ºC, 4% PFA),
washed in DPBS, and stored at 4ºC in 50% PBS/50% glycerol/0.05% sodium azide until staining.
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Immunofluorescence staining of human colon whole mount
Following our new protocol (14), 0.7-1cm x 0.7-1cm colon pieces were washed (1x PBS,
RT), incubated in 100% methanol on ice (1 hour), treated with Dent's bleach (1 mL 30% hydrogen
peroxide (Thermo Fisher Scientific, Cat #H1009), 1 mL dimethyl sulfoxide (Sigma, Cat#D2650), 4
mL 100% methanol (72)) at room temperature (2 hours), washed again (1x PBS, 3x5 minutes, room
temperature), blocked (0.5% Triton X-100, 5% NDS in PBS, 3 days) and then incubated 14 days
in blocking solution with primary antibodies (Supplementary Table 2.7, 37oC, 40-100 rpm).
Following PBS washing (1 day, 3 washes, gentle rocker, RT), colon was incubated in secondary
antibodies 3 days, 37ºC, 40-100 rpm), washed in PBS over 1 day, dehydrated in a methanol series,
placed in Murray's clear (2:1 benzyl benzoate:benzyl alcohol, gentle rocking, RT) until translucent
(30-60 min). Transparent colon mounted on glass slides in Murray's clear was imaged within 1 day.
For details see (dx.doi.org/10.17504/protocols.io.wyeffte).

Microscopy
Images were acquired with a Zeiss LSM 710 confocal microscope with 20x/0.8 air or
63x/1.4 oil DIC M27 Plan-Apochromat objectives and Zeiss Zen software version 2.3 14.0.14.201
(Zeiss, Oberkochen, Germany) or upright fluorescent Olympus BX60 microscope with Axiocam
CCD camera and Axiovision software. ImageJ (NIH) and Photoshop CS6 (Adobe, San Jose, CA)
were used to crop and uniformly adjust color. High magnification myenteric plexus images were
acquired with a Zeiss LSM 880 Airyscan microscope with a Plan-Apochromat 63x1.40 Oil DIC M27
objective (Carl Zeiss Microscopy, North Ryde, NSW, Cat#420782-990-799) at the Biological Optical
Microscopy Platform (BOMP), University of Melbourne.

Image analysis
Counting for adult mouse distal colon and human colon was performed on >5 randomlyselected x20 fields per animal in each region using ImageJ's CellCounter module (NIH). Because
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of high cell density at E17.5, only half of each 20X field was counted. Investigators were blinded to
genotype when comparing knockout to control mice. High magnification myenteric plexus images
were processed to quantify substance P and enkephalin colocalization using Imaris 9.0.0 (Bitplane)
(22).

RNA extraction and RT-PCR for Pou3f3 expression analysis
Wnt1-Cre;R26-TdTomato E14.5 and E17.5 dams were euthanized with 5% CO2, and pups
were removed from the mother. For each litter, all TdTomato+ small intestines and colons were
combined to increase cell count. Small intestines and colons were dissected in ice-cold Dulbeccomodified PBS, transferred to HBSS (Thermo Fisher Scientific, Cat No: 14025092), separated,
divided into small pieces using insulin needles (Beckton Dickerson, Cat#08290-3284-18), and
dissociated for 30 minutes at 37°C in Liberase (Sigma, Cat#5401135001) supplemented with
DNase I (Roche, Basel, Switzerland; Cat#04716728001), MgCl2 (6 mM) and CaCl2 (1 mM) in HBSS
with P1000 trituration. Cells were filtered, washed with Iscove's DMEM (Corning, Cat#10-016-CM),
and resuspended in FACS buffer (10mM HEPES, 1mg/mL BSA, 1% penicillin and streptomycin
(Thermo Fisher Scientific, Cat#15140122) in HBSS). Fluorescent TdTomato+ cells were sorted on
a BD FACSJazz and collected in Iscove's DMEM with 10% FBS. Cells were spun down at 600xg,
resuspended in Buffer RLT plus, and RNA was isolated using the Qiagen RNeasy Plus Micro Kit
(Qiagen, Hilden, Germany; Cat# 74034) with DNase treatment (Qiagen, Cat#79254).
RNA integrity and concentrations were measured on a 2100 Agilent Bioanalyzer using an
RNA 6000 Pico Kit (Agilent, Santa Clara, CA, Cat#5067-1513). All samples used had RIN ≥ 7.
cDNA was generated using Superscript II RNase H (Thermo Fisher Scientific, Cat#18064022). RTPCR was performed using KAPA mixture (KAPA biosystems, Cat#KK7352) and previouslydescribed primers (Supplementary Table 2.8). Three replicates were run for all experiments.
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Colon Bead Expulsion studies
Young adult mice (P44-58 at begin of assay, P49-64 at end of assay) were anesthetized
with 2L/min carbogen with 2.5% (v/v) isoflurane (Piramal, Cat#NDC 66794-017-10) for 1.5 minutes
before the start of the experiment, anesthesia was continued until completed bead insertion. A
glass bead (3 mm, Sigma, Cat#Z143928) lubricated with sunflower seed oil (Sigma, Cat#S5007)
was inserted 2 cm into the colon using a custom-made 3-mm rounded glass rod. Glass rod was
removed, isoflurane stopped, mice were placed in empty cages, and time to bead expulsion was
recorded. If a mouse regained consciousness before bead insertion, mice were anesthetized for
an additional 2-4min. Assay was repeated 3 times per mouse (48-96 hours between procedures).
Mice had free access to food and water prior to the experiment.

Calcium imaging full thickness colon
Colons from E2a-Cre;R26R-Gcamp6s mice aged 12-16 weeks were cut longitudinally and
pinned (mucosa facing down) in a Sylgard-lined dish superfused with carbogenated (95% O2, 5%
CO2) artificial cerebrospinal fluid (ACSF) (29), freshly prepared, maintained at 35ºC. Nifedipine
(1µM, Sigma, Cat# N7634) in ACSF improved stability for calcium imaging analyses. GCaMP6s in
myenteric neurons was imaged with an upright DM6000FS Leica fluorescence microscope (Leica,
Buffalo Grove, IL) and EMCCD camera (Photometrics; Roper Scientific, Tucson, AZ) using a x20
objective. Images were collected with Metamorph software (Molecular Devices, San Jose, CA) at
10 Hz sampling rate. For each field, spontaneous activity was imaged 2 min, before two 30s movies
were collected in response to electrical field stimulation (EFS; 100 µs pulse, 20 Hz, 1 s) using
concentric electrodes 5 mm oral or aboral to imaging fields (order randomized). Recombinant rat
GDNF (Cat. #512-GF, R&D Systems) or NRTN (Cat. #450-11, PeproTech) were added at 10nM
final concentration (order of presentation randomized). We recorded spontaneous activity in 2-min
movies collected intermittently while ligands continuously superfused circulating ACSF for 10 min.
Responses to oral and aboral stimulation were then re-imaged. Colon was washed for 30 min and
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baseline activity and responses were re-imaged before the next receptor ligand was applied. In a
subset of experiments, the addition of tetrodotoxin (TTX, 0.5µM, Cat. #T8024, Sigma) or
hexamethonium (HEX, 300µM, Cat. #H0879, Sigma) blocked all neural transmission or excitatory
synaptic transmission, respectively, allowing for identification of myenteric neurons directly
activated by GDNF or NRTN. Spontaneous activity was recorded (three 2-min movies) at baseline,
10 min following TTX or HEX, and during application of GDNF or NRTN (in the presence of either
TTX or HEX; order of presentation of GDNF/NRTN was randomized). Colon tissue was then
“washed” with the particular blocker, activity was re-imaged, and the next receptor ligand was
applied while imaging responses.

Analysis of live GCaMP6s imaging
Metamorph (Molecular Devices, Downington, PA) image files exported to ImageJ (NIH)
were coded for blind analysis. Circular ROIs were drawn on all myenteric neurons in each field.
Amplitude of GCaMP6s signals were analyzed and quantified as described (Smith-Edwards et al.
2016). We calculated ΔF/F0 [% = ((F − F0)/F0) x 100], where F is peak fluorescence and F0 is
baseline mean fluorescence; ΔF/F0 of 4SD > baseline was considered a response. Time control
studies, in which GCaMP6s activity from individual neurons was measured over time, were used
to determine whether changes in activity were significantly altered due to GDNF or NRTN
application. Tissue movement along x- and y-axes was measured using ImageJ TemplateMatching plugin. Time-lapse color-coded images created in ImageJ use pixel color to indicate when
pixels reached maximum F, providing spatial and temporal information about activity.

Statistics
We used Prism 7.03 (GraphPad Software, San Diego, CA) software. A cutoff of p < 0.05
was considered significant. Data represent mean ± standard error of the mean (SEM).
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2.8 Supplementary Materials
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Supplementary Figure 2.1: Initial processing of single nucleus RNA-seq data from young
adult Wnt1-crecre/wt; R26R-H2B-mCherrych/wt mouse colon with validation of enkephalin and
substance P co-expression.
(A-D) H2B-mCherry fluorescence (red) in 50 day old Wnt1-crecre/wt; R26R-H2B-mCherrych/wt mice
colocalizes with HuC/D+ neurons (green) and S100β+ glia (blue) in the ENS. ~73% of HuC/D+
neurons were H2B-mCherry+. (E) T-SNE plot of all cell groups from distal colon of Wnt1-crecre/wt;
R26R-H2B-mCherrych/wt mice. (F-J) Feature plots for Actg2 (F), Pdgfrα (G), Kit (H), Elavl4 (I), and
Plp1 (J) indicate the locations of SMC, Pdgfrα+ cells, ICC, neurons, and glia respectively. Color
key represents loge(normalized gene expression). Scale bar 100μm. (K-M) Enkephalin (green)
colocalizes with substance P (red) in myenteric neuron cell bodies in proximal (K), mid (L), and
distal colon (M). (N-P) Most myenteric intraganglionic neuron varicosities in proximal (N), mid (O),
and distal colon (P) express both enkephalin (green) and substance P (red). (Q-R) Most
enkephalin+ (green) neuron varicosities in circular smooth muscle in mid-colon (Q) and distal colon
(R) also express substance P (red), but only a subset of substance P-expressing neuron
varicosities in circular smooth muscle express enkephalin. (K-R) Images representative of n=3
preparations per colon region and n=3 images per preparation. (S) Quantification of colocalization
of enkephalin and substance P in varicosities within mid-colon myenteric ganglia and within circular
smooth muscle. (T) EGFP (green) fluorescence signal colocalizes with TDTOMATO+ (red) neurons
(blue) in Vglut2-IRES-Cre; R26R-TdTomato; ChAT-EGFP-L10A mice. (U) In a small subset of
HuC/D+ neurons (blue), TDTOMATO+ (red) does not colocalize with EGFP fluorescence signal in
Vglut2-IRES-Cre; R26R-TdTomato; ChAT-EGFP-L10A mice. (V) Quantification of the
colocalization of EGFP fluorescence with TDTOMATO fluorescence in Vglut2-IRES-Cre; R26RTdTomato mice. (K-M) Scale bar = 10μm. (N-R) Scale bar 5μm. (K-R) White arrows point towards
cells and varicosities that express both enkephalin and substance P. (N-R) White arrowheads point
towards varicosities that express enkephalin only. Empty arrowheads point towards varicosities
that express substance P only. (S, V) Mean +/- SEM.
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Supplementary Figure 2.2: Percent of cells per cluster with detectable levels of differentially
expressed neurotransmitters, commonly used enteric neuron immunohistochemical
markers, neurotransmitter receptors, and regulatory factors in adult distal mouse colon.
Average expression per cluster and percent of cells per cluster with detectable levels of
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differentially expressed ion channels and signaling pathway molecules in adult distal mouse
colon.
(A-B) Proportion of cells per cluster with expression values >0 for differentially expressed
neurotransmitters, immunohistochemical markers (A) and neurotransmitter receptors (B). Color bar
applies to both panels. (C) Average expression of differentially expressed ion channel (subunit)
genes for different neuron and glial groups. (D) Proportion of cells per cluster with expression
values >0 for differentially expressed ion channels. (E) Average expression for selected ligands
(left) and receptors (right) that were differentially expressed between different neuron and glial
subclasses. (F) Proportion of cells per cluster with expression values >0 for differential expressed
ligands (left) and receptors (right). (G) Proportion of cells per cluster with expression values >0 for
transcription and splicing factors with known roles in ENS development(top), and regulatory genes
(transcription factors and splicing factors) newly-identified in the ENS in this study (bottom). n.s. =
not significantly differentially expressed between neuron clusters. (C-E) Color key represents
loge(normalized average gene expression within each cluster).
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Supplementary Figure 2.3: Gfra1 is expressed in adult enteric neurons and glia. GDNF
modulates activity in some myenteric neurons and enhances colon muscularis movement.
(A) Whole mount immunohistochemistry using Gfra1Gfp/wt distal colon shows colocalization of GFP
(green) with S100B+ (red) glia and HuC/C (blue) neurons. Scale bar = 100 microns. (B) NADPH
diaphorase stained colon identifies nitric oxide producing neurons. (C) Corresponding GCaMP6s
imaging field. (D) GCaMP6s imaging field in (C) where yellow arrowheads identify putative nitrergic
myenteric neurons and asterisks indicate putative NADPH diaphorase positive neurons with low
GCaMP6s signal. (E) Quantification of GDNF- and NRTN-responsive nitrergic neurons (n=3 fields
from separate experiments, p=0.0298, Fisher Exact test, 2x2 contingency table (NOS+/NOS- and
GDNF response/NRTN response)). (F, G) Quantitative data for GCaMP6s imaging fields stained
post-hoc for NADPH diaphorase, indicating response to GDNF and NRTN. (F) Responsive nitrergic
neurons. (G) Responsive non-nitrergic neurons. (H) Heatmap illustrating GCaMP6s activity before
and after addition of the nicotinic acetylcholine receptor antagonist hexamethonium (HEX) and
during the sequential application of GDNF and NRTN. Each row represents a single neuron and
colors represent the magnitude of the change in GCaMP6s activity (red = no activity change).
Dotted line shows GDNF and NRTN responsive neurons. Activity was assessed for 352 total
neurons in 4 independent colon sections from 1 mouse. (I) Heatmap focusing only on GDNF- and
NRTN-responsive neurons illustrating GCaMP6s activity before and after hexamethonium (HEX)
addition and during the sequential application of GDNF and NRTN. 28 neurons were only GDNFresponsive, 24 neurons only NRTN-responsive, and 9 neurons responded to both GDNF and
NRTN. Each row represents a single neuron and colors represent the magnitude of the change in
GCaMP6s activity (red = no activity change). (J-M) Percent of total observed neurons per
GCaMP6s imaging field with increased activity after electrical field stimulation (EFS) applied 5 mm
oral (J, L) or aboral (K,M) relative to the imaging field at baseline (vehicle) and in the presence of
GDNF (J, K) and NRTN (L, M). GDNF increases the percent of activated neurons after orally
applied EFS (J, p=0.0068, ratio paired t-test). (N-Q) Tissue displacement (micrometers) after EFS
applied 5 mm oral (N, P) or aboral (O,Q) relative to the imaging field at baseline (vehicle) and in
the presence of GDNF (N, O) and NRTN (P-Q). Tissue displacement is increased in the presence
of GDNF after orally applied EFS (N, p=0.0230, ratio paired t-test). (B-G) n=3 fields of view from
separate mice. *p<0.05 **p<0.01
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Supplementary Figure 2.4: Single-cell sequencing of E17.5 ChAT-EGFP-L10A+ and Nos1CreERT2Cre/wt;R26R-TdTomato+ cells reveals several neuron clusters at different stages of
maturity.
(A) T-SNE plot of all cell groups isolated from E17.5 bowel. (B) Feature plots of Acta2 as smooth
muscle marker, Epcam as an intestinal epithelial marker, and Elavl4 as a pan-neuronal marker.
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Color key represents loge(normalized gene expression). (C) After removing the epithelial and
smooth muscle cells from the dataset and reclustering, T-SNE plot reveals multiple neuron
subpopulations. (D) Expression of Nos1 and the cholinergic marker Slc18a3/VachT verifies the
presence of the expected cholinergic and nitergic neuronal subpopulations. Chat expression was
low throughout, but overlapped with Slc18a3 expression. Color key represents loge(normalized
gene expression). (E) All neurons have high expression of pan-neuronal markers Tubb3 and Elavl4.
There is minimal contamination with glial cells based on the expression of enteric glial marker Plp1.
Sox10, which marks enteric glia and enteric neural crest precursors was also low, but Ret, which
is expressed in ENS precursors and many neurons, was present in all clusters. This suggests that
these cells are lineage-restricted neurons, however, all neurons still express the immature panneuronal marker Dcx. (F) GO Term analysis of differentially expressed genes in the three more
immature neuron clusters (immature chat cluster 1, immature chat cluster 2, immature Nos1
cluster) compared to all other clusters indicates that these neurons are actively involved in
cytoskeletal reorganization and neurite extension. (G) GO Term analysis of differentially expressed
genes in the five more mature neuron clusters (Chat cluster 1, Chat cluster 2, Nos1 cluster 1, Nos1
cluster 2, and Nos1 cluster 3) compared to the immature clusters (Immature Chat cluster 1,
Immature Chat cluster 2, and Immature Nos1 cluster) indicates that these neurons are actively
involved in synapse formation.
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Supplementary Figure 2.5: Cholinergic and nitrergic neuron subsets at E17.5 differentially
express ion channels and signaling pathway molecules as well as many regulatory genes
found in adult distal colon ENS.
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(A) Neurotransmitter and commonly used enteric neuron immunohistochemical markers with > 0
detected reads. Asterisks mark genes differentially expressed across the distinct neuron
subclasses. Color key represents proportion of cells per cluster with expression values >0. (B-C)
Neurotransmitter receptor (B) and ion channel (C) genes differentially expressed across distinct
neuron subclasses. Color key represents proportion of cells per cluster with expression values >0.
(D-E) Genes involved in extracellular signaling pathways differentially expressed across neuron
subclasses. (D) Color key represents loge(normalized average gene expression within each
cluster). (E) Color key represents proportion of cells per cluster with expression values >0. (F)
Transcription and splicing factors with known roles in ENS development (top), and newly-identified
in the ENS in this study (bottom). n.s. = not significantly differentially expressed between neuron
clusters. Color key represents proportion of cells per cluster with expression values >0. (G-K)
Whole-mount immunohistochemistry of select regulatory genes in E17.5 ChAT-EGFP-L10A
reporter mouse mid-colon shows gene localization in neuron subsets. BNC2 (G), PBX3 (H), and
RBFOX1 (I) are predominantly expressed in cholinergic (EGFP+) neurons. (B-D) White arrowheads
indicate neurons that express the regulatory gene in question, but are not cholinergic. (J) TBX2
does not have nuclear or diffuse cytoplasmic staining in the E17.5 colon. Instead, TBX2
immunoreactive cytoplasmic aggregates were detected in a subset of cholinergic (EGFP+) neurons
(notched white arrowheads). (K) TBX3 is expressed in some cholinergic (EGFP+, white arrows)
and most nitrergic (NOS1+, empty arrowheads) neurons. (G-K) ChAT-EGFP-L10A reporter = ChatEGFP. Scale bar = 20µm (B-G).
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Supplemental Figure 2.6: Pou3f3 is expressed in mouse colon but not small intestine ENS.
(A) Feature plot shows scattered E17.5 enteric neurons expressing Pou3f3 throughout the neuron
clusters. Color key represents loge(normalized gene expression). (B) Violin plot of Pou3f3
expression in E17.5 enteric neurons indicates that Pou3f3 is predominantly expressed in Immature
Chat cluster 2 and Immature Nos1 cluster. (C-X) Whole mount immunohistochemistry confirms that
POU3F3 immunoreactivity (green) is not detected in most of the small bowel at E12.5 (C), E14.5
(E), E17.5 (H), or in adulthood (N,T). POU3F3 immunoreactivity is easily detected in proximal colon
(D) at E12.5 (arrows) and throughout the colon at E14.5 (F), E17.5 (K), and in adulthood (Q,W).
(L,R,X) At E17.5 and in adulthood, colonic POU3F3 co-localizes with the enteric neuron marker
HuC/D. (Y-V’) Confocal z-stack maximum intensity projections at lower magnification (Y-J’) and
high magnification (K’-V’) of whole mount immunohistochemistry for POU3F3 in adult human small
intestine (Y-A’, E’-G’, K’-M’, Q’-S’) and adult human colon (B’-D’, H’-J’, N’-P’, T’-V’) shows nuclear
POU3F3 localization only in colonic neurons. No POU3F3 staining was detectable in human small
intestine submucosal plexus (Y-A’, K’-M’), whereas clear nuclear POU3F3 staining could be seen
in human colon submucosal neurons (B’-D’, N’-P’). Cytoplasmic POU3F3 antibody staining was
present in a subpopulation of human small intestine myenteric neurons (E’-G’, Q’-S’). In the human
colon myenteric plexus all neurons showed clear nuclear POU3F3 localization (H’-J’, T’-V’). (W’)
Feature plot showing scattered E17.5 enteric colonic neurons. Cells expressing Pou3f3 were
assigned colonic identity. Red circle marks immature clusters: immature Chat cluster 1, immature
Chat cluster 2, and immature Nos1 cluster. (X’) Genes differentially expressed by cells assigned
colon identity compared to cells assigned small intestine identity within the three immature clusters
(immature Chat cluster 1, immature Chat cluster 2, immature Nos1 cluster). (Y’) Genes differentially
expressed by cells assigned colon identity compared to cells assigned small intestine identity within
the three mature clusters (Chat cluster 1 and 2 and Nos1 cluster 1, 2, and 3). (Z’) Violin plots
showing expression of the differentially expressed genes across all E17.5 neuron clusters indicate
that the genes identified in (X’) are specific to immature Chat cluster 1 and not colon or small
intestine (Pearson Correlation between the expression of the identified gene and Pou3f3 supports
this conclusion: p>0.1 for all, except Dpysl3, corr. coeff.=0.0819, p=0.0294) (A’’) Violin plots
showing expression of the differentially expressed genes across all E17.5 neuron clusters suggest
that the expression of genes Ahr and Pantr1 and possibly Zfhx3 are specific to colon myenteric
neurons (Pearson Correlation between the expression of the identified gene and Pou3f3 supports
this conclusion: Ahr, corr. coeff.= 0.3581, p<2.2x10-6; Pantr1, corr.coeff.=0.5640, p<2.2x10-6;
Zfhx3, 0.4034, p<2.2x10-6). SP = submucosal plexus, MP = myenteric plexus. Images are
representative of 3 independent biological replicates. Scale bar = 100 µM (C, E-J’), 200 µM (D), 20
µM (K’-V’).
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Supplementary Figure 2.7: Human single nucleus RNA-seq analysis from 20,167 cells
yielded data from 48 definitive neurons and many other cells that impact bowel motility
including SMC, ICC, PDGFRA+ cells, muscularis macrophage, and glia.
(A) Human myenteric plexus after incubation with 4-Di-2-Asp, with muscle layers partially peeled
away. (B-J) Feature plots showing genes expressed highly in adult human smooth muscle (B, C;
ACTG2, MYH11), glial cells (D, E; PLP1, SOX10), ICC (F; ANO1), PDGFRA+ cells (G; PDGFRA),
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vessel endothelial cells (H; VWF), muscularis macrophages (I; CD14), and T cells (J; CD2). Color
key represents loge(normalized gene expression). Scale bar = 50µm. (K-M) T-SNE plots of human
nuclei colored by sample number (K), colon location (right versus sigmoid; L), and sex (M). Cells
from different colon regions and different sexes largely form the same t-SNE clusters. (N-P) Feature
plots show location of ELAVL4 (N), UCHL1 (O), and SNAP25 (P) expression suggest that a small
population of neurons expressing all three is present in this dataset, but most of the 20,000 nuclei
are not ELAVL4, SNAP25, or UCHL1-positive. Color key represents loge(normalized gene
expression). (Q) T-SNE plot of all human nuclei expressing ELAVL4, UCHL1, or SNAP25 (inclusive
or) reveals many populations that may be doublets because they cluster with nuclei expressing
non-neuronal cell markers. For this manuscript, we only describe in detail expression data for the
tight cluster of cells we believe are single neurons based on high expression of ELAVL4, SNAP25,
UCHL1, SYT1, and DSCAM (highlighted with red circle) (R) Feature plots of neuronal markers
(ELAVL4, SNAP25, UCHL1, SYT1, and DSCAM), SMC markers (ACTG2), glial cell markers
(PLP1), ICC markers (KIT), and PDGFRA+ cell markers (PDGFRA) suggest that other populations
are not neurons. Color key represents loge(normalized gene expression).
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Supplementary Table 2.1: Methods used to isolate cells or nuclei for RNA-seq.
Genotype

Whole cells,
or nuclei?

Description

Wnt1-Cre;R26R-EGFP

Cells

The EGFP signal in Wnt1-Cre;R26R-EGFP animals
was too weak to flow sort effectively given the high
degree of background in the 488 channel.

Wnt1-Cre;R26RtdTomato

Cells

The localization of tdTomato to neurites in our Wnt1Cre;R26R-Tdtomato line was problematic, since we
desired clean separation of single cells. Sorting
myenteric plexus from this mouse line often resulted in
preps with neurites attached to tdTomato- cells. We
tried dissociating with different proteases (cold active
protease, dispase and collagenase), different
incubation times (15 minutes, 30 minutes), multiple
methods of trituration (pipette-based, needle-based),
and different bowel layers, with little improvement in
outcome

Wnt1-Cre;ROSANT-NG

Nuclei

Wnt1-Cre;RosaNT-NG mice had tdTomato in their nuclei
at baseline; with CRE-induced recombination, they
accumulated EGFP in their nuclei instead of tdTomato.
Unfortunately, these mice lost fluorescent signal
during the Dounce homogenization procedure. We
hypothesize that membrane damage associated with
homogenization led to diffusion of GFP and loss of
signal.

Nuclei

Successful and used to generate data in Figures 1
through 4.

Nuclei

We attempted to use directly-conjugated NeuN and
PHOX2B antibodies to isolate mouse ENS nuclei with
flow sorting, since some neuronal nuclei in mouse
stain
with
this
NeuN
antibody
by
immunohistochemistry. We were unsuccessful.

Wnt1-Cre;Rosa26
H2B mCherry

Wild type
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Supplementary Table 2.2: Predicted adult enteric neuron subtype classification based on
RNA-seq

Cluster name
(Adult Colon)

Chat 1

Chat 2

Chat 3 (Met)

Suggested
neuron type

Intrinsic sensory
neurons,
interneurons (with
mechanosensitive
properties)

Interneurons
or excitatory
motor
neurons

Interneurons
or excitatory
motor
neurons

Chat*, Slc18a3,
Tac1, (Piezo1*)

Calcb*,
Nefm,
Slc18a3*,
Scn11a*
Chat, Nos1,
Chat, Tac1*, Chat, Met*,
, Calb2*, Nos1*, Vip*,
Vip, Calb1*,
Penk*
Penk*, Tac1*
Tacr1*, Gal*, Npy*
Penk*,
Htr3a*,
Nefm*
Htr3b*,
P2rx2*

Expressed
markers
supporting
conclusion
(differential
expression
marked by *)

Other genes of
note
Calb2*
differentially
expressed
Corresponding
neuron
subtype
designations
PEMN 1, 3, 4, 6
from
(based on Chat,
Drokhlyansky Tac1, Piezo1)
et al., 2019,
BioXRIV (Adult
Mouse Colon)

PEMN 2, or
PIN1, PIN2
(based on
Chat, Penk,
Tac1, and
absent
Piezo1)

Corresponding
neuron
subtype
designations
ENC1,7 (Chat,
in Morarach et
Tac1, absent
al, 2020 (P21
Penk)
mouse Small
Intestine)- very
limited data
available

ENC4 (Chat,
ENC2-4
Tac1, Penk,
(Chat, Tac1,
Fut9,
Penk)
Nfatc1),
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PIN1, PIN2 or
PEMN 2
(based on
Chat, Penk,
Tac1, Calcrl,
Ramp1)

Chat 4
(Vglut2)

Calcb

Interneuron

Inhibitory
Intrinsic
motor
Sensory
neurons +/Neuron
interneurons?

Nos 1

Nos 2

Inhibitory
motor
neurons +/interneurons?

Nos1*, Vip,
Gal, Npy

Slc17a6*

Nmu*,
Grp*,
Avil*

Htr3a*,
P2rx2*

PIN3 or
PSN3
(based on
Chat,
Slc17a6,
Nxph2)

PSN_1
(based
on Nmu,
Grp,
Calcb)

PIMN_1-7
(based on
Nos1, Vip,
Gal)

PIMN_1-7
(based on
Nos1, Vip,
Gal)

ENC12 >
ENC7
(Slc17a6,
Penk,
Nxph2,
Nefm)

ENC6 >
ENC5
ENC8-10
(Calcb,
(Nos, Vip,
Nmu,
Gal)
Nog,
Sst)

ENC8-10
(Nos, Vip,
Gal)

Cluster name
(Adult Colon)

Chat 1

Chat 2

Chat 3 (Met)

Chat 4
(Vglut2)

Calcb

Nos 1

Nos 2

ENT9
(Nmu,
Myl1,
P2rx2)

ENT2 >
ENT1, EN3
(Cartpt, Nos1,
Ass1, Bglap)

ENT1,3 >
ENT2 (Nos1,
Ass1, Cox8b,
Gal, Moxd1)

10,19

10,19

No
equivalent
cluster in
this small
intestine
dataset.
Corresponding
neuron
subtype
designations
from Zeisel et ENT5 (Chat, Tac1,
al 2018 (P21
Dmkn, Hoxb5,
mouse Small
absent Penk)
Intestine) http://mousebr
ain.org/genese
arch.html?

No equivalent
cluster in this
Penk is only small
expressed in intestine
ENT7
ENT6 and
dataset.
(based on
ENT7, but
Chat, Penk,
neither of
Slc17a6,
ENT6 is
these
closest (Chat, Calb1,
clusters are
Tac1, Penk, Nxph2,
a good
Fut9, Nfatc1, Phox2a)
match due
but ENT6 is
to Slc17a6
missing Met
expression
expression)
and lack of
Fut9 and
Nfatc1
expression
in this
cluster.

Markers
missing

Citations
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Kcnn4,
Piezo1

20,21,59,67

20,21

60

9,23,58
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Supplementary Table 2.3: Predicted E17.5 enteric neuron subtype classification based on
RNA-seq
Cluster
Name
(E17.5
whole
bowel)

Immature
Chat
cluster 1

Chat
cluster 1

Chat
cluster 2

Nos1
cluster 1

Nos1
cluster 2

Nos1
cluster 3

Immature
Chat
cluster 2

Immature
Nos1
cluster

Suggested
neuron
type

Small
intestine
interneurons

Small
intestine
excitator
y motor
neurons

Small
intestine
intrinsic
sensory
neurons

Small
intestine
inhibitory
motor
neurons
or interneurons

Small
intestine
interneurons

Small
intestine
inhibitory
motor
neurons
or interneurons

Colon (+/some
small
intestine)
cholinergic
neurons

Colon (+/some
small
intestine)
nitrergic
neurons

Slc18a3,
Chat,
Penk,
Calb1

Slc18a3,
Chat,
Penk,
Tac1

Calca,
Calcb,
Htr3b,
Nmu

Nos1,
Vip, Gal

Nos1,
Vip, Gal,
Neurod6

Nos1,
Vip, Gal

Slc18a3

Nos1,
Pou3f3

Slc17a6,
Npy1r,
Avpr1a

Tgfb2,
Htr2b

Nmu,
Nog,
Bambi,
Smad7,
Adra2a,
Ntrk3,
Npy2r

Ednrb,
C1ql1,
P2ry6,
Htr3a,
Cartpt,
Npy2r

Dbh,
Sstr1,
Sstr2,
Cartpt,
Htr3a,
Npy2r

Sstr1,
Sstr2,
Cartpt,
Prokr1,
Npy2r

Htr2b,
Npy1r,
Ramp1

Npy1r,
Ramp3

+/- Npy

+/- Npy

+/- Npy

Differential
ly
Expressed
markers
supporting
conclusion
Other
genes of
note
differential
ly
expressed

Markers
missing
Correspon
ding P21
small
intestine
neuron
subtype
designatio
ns from
Morarach
et al., 2020,
BioXRIV
Correspon
ding P21
small
intestine
neuron
subtype
designatio
ns from
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ENC12
(based on
Chat,
Slc18a3,
Slc17a6,
Calb1,
Penk)

ENC2 >
ENC3
(based
on Chat,
Slc18a3,
Penk,
Tac1,
Gda,
Ndufa4l2
)

ENC6
(based
on Calcb,
Nmu)

ENC8 or
ENC9
(based
on Nos1,
Vip, Gal,
C1ql1)

ENC10
(based
on Nos1,
Vip, Gal,
Neurod6)

ENC8 or
ENC9
(based
on Nos1,
Vip, Gal)

N/A

N/A

ENT7
(based on
Chat,
Slc18a3,
Slc17a6,
Calb1,
Penk)

ENT6 >
ENT6
and
ENT4
(based
on Chat,
Slc18a3,
Penk,

ENT9
(based
on Calcb,
Nmu,
Nog)

ENT3 >
ENT2
(based
on Nos1,
Vip, Gal,
Cartpt)

ENT1
(based
on Nos1,
Vip, Gal,
Cartpt,
Neurod6)

ENT2 >
ENT3
(based
on Nos1,
Vip, Gal,
Cartpt,
Ltk)

N/A

N/A

Cluster
Name
(E17.5
whole
bowel)

Immature
Chat
cluster 1

Zeisel et
al., 2018,
Cell

Citations
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Chat
cluster 1

Chat
cluster 2

Nos1
cluster 1

Nos1
cluster 2

Nos1
cluster 3

Immature
Chat
cluster 2

Immature
Nos1
cluster

9,19,58

13,23,68

9,68

13,23,68

Our own
data

Our own
data

Tac1,
Gda,
Ndufa4l2
)
9,13,23,24
,58)

13,19,24
Our own
data

Supplementary Table 2.4: Characteristics of colon resection samples

4579

54

M

Cecal polyp

Right colon

RNA
Integrity #:
Plexus
7.6

4602

75

M

Hx of cecal lesion

Right colon

7.5

6.9

4683
4695

38
77

M
F

Goblet
cell
carcinoma
Colonic mass

7.9
7.4

8
7.4

4701

78

M

Rectal cancer

Right colon
Right colon
Sigmoid
colon

6.3

4950

78

M

Bowel obstruction

Sigmoid
colon

8.2
6.50, 6.90,
and 7.10 (3
pieces)

4969
4966

83
71

M
F

Adenocarcinoma
Bowel obstruction

Right colon
Right colon

4988

65

F

Colon polyp

Right colon

4992
5031

47
70

M
M

Rectal carcinoma
Colon polyp

5035
5040

24
44

M
M

Volvulus
Colonic mass

Sigmoid
colon
Right colon
Sigmoid
colon
Right colon

5047
5054
5059

65
36
59

M
F
F

Rectal
adenocarcinoma
Bowel adhesions
Adenocarcinoma

Sigmoid
colon
Right colon
Right colon

Sample ID
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Age

Sex

History

Colon
region

6.5
7.2
5.20 and
2.90 (RNA
conc. v low)*

RNA Integrity #:
Surrounding
muscle
7.9

7.6
7.90, 5.80 (2
pieces)
8.1, 7.9 (2 pieces)
7.5 and 7.4 (2
pieces)

4.4 (RNA
conc v. low)*
7.8

7.1
7.4 and 7.2

8
7.7

6.6 and 7.2
7.5 and 7.8

6.6
7.6
7.2

7.4
7.20 and 7.70
7.50 and 6.40

Supplementary Table 2.5: UMI and gene counts from colon resection samples
Avg gene
count with
intronic
reads
mapped

Sample ID

4579
4602
4683
4695

4000
6900
6300
4000

680
2,316
2,081
833

0.17
0.3356522
0.3303175
0.20825

2,474
2,004
1,397
1,487

1,559
1,268
876
974

4701
4950
4969
4966
4988
4992

12300
5200
5300
2100
1200
673

4,414
1,237
653
432
237
60

0.3588618
0.2378846
0.1232075
0.2057143
0.1975
0.089153

1,296
1,415
1,262
1,856
2,354
3,939

780
910
1,262
1,193
1554
2336

5031
5035
5040
5047
5054
5059

5200
7100
2300
5000
3100
1200

1728
2524
755
957
1219
338

0.3323077
0.355493
0.3282609
0.1914
0.3932258
0.2816667

1,538
1,886
1,941
1,701
2,071
2470

967
1119
1212
1013
1216
1474
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# of Cells
with RNAseq data

Ratio of
sequenced
cells to
loaded cells

Avg UMI
count with
intronic
reads
mapped

Cells or nuclei
loaded
(predicted
from FACS)

Supplementary Table 2.6: Numbers of Biological Replicates and Numbers of Cells/Terminals
Counted
Experiment

Biological
replicate
number

Total
neurons
or nerve
terminals
counted

Statistical
tests used

Descriptive Statistics:
Mean ± standard deviation // Median
(range if n=3, interquartile range if
n>3)

Figure 1 Enkephalin and
substance P
staining
quantification

3

11628
(myenteric
ganglia)

Unpaired ttest

Varicosities within myenteric ganglia:
% of Enk+ varicosities that were SP+:
74.5 ± 23.6 // 86.9 (41.9)
% of SP+ varicosities that were Enk+:
81.2 ± 8.7 // 78.0 (16.5)

2918(circul
ar muscle)

Varicosities in circular muscle:
% of Enk+ varicosities that were SP+:
76.5 ± 5.0 // 78.7 (9.3)
% of SP+ varicosities that were Enk+:
44.7 ± 8.4 // 41.9 (16.0)

Figure 2 - Gfra1GFP quantification
(mouse adult distal
colon)

3

614

Student’s ttest

% of NOS1+ that were GFP+: 88.9 ±
1.8 //89.1 (3.7)
% of NOS- neurons that were GFP+:
8.8 ± 5.7 //7.7 (11.2)

Figure 2 - NADPH
diaphorase
staining

5

340

Fisher Exact
Test (2x2
contingency
table)

N/A

Figure 3 - Etv1CreERT2;TdTomat
o x NOS1
quantification
(mouse adult distal
colon)

3

1101

Student’s ttest

% of NOS+ neurons that were TDT+:
56.4 ± 6.3 // 59.7 (11.3)
% of NOS- neurons that were TDT+:
5.6 ± 1.5 // 5.6 (3.0)

Figure 3 - PBX3 x
Chat-EGFP
quantification
(mouse adult distal
colon)

4

108

% of TDTOMATO+ neurons that were
NOS+: 85.0 ± 5.8 // 85.7 (11.6)
% of TDTOMATO neurons that were
NOS-: 15.0 ± 5.8 // 14.3 (11.6)
2684

Student’s ttest

% of EGFP- neurons that were
RBFOX1+: 31.4 ± 6.0 // 29.5 (10.9)
% of EGFP+ neurons that were
RBFOX1+: 72.7 ± 5.4 // 74.2 (9.8)

Experiment

Biological
replicate
number

Total
neurons
or nerve
terminals
counted

Statistical
tests used

Descriptive Statistics:
Mean ± standard deviation // Median
(range if n=3, interquartile range if
n>3)

% of PBX3+ neurons that were EGFP+:
79.2 ± 5.3 // 79.4 (12.3)
% of PBX3+ neurons that were EGFP-:
20.8 ± 5.3 // 20.6 (10.2)
Figure 3 PHOX2B x ChatEGFP
quantification
(mouse adult distal
colon)

4

Figure 3 RBFOX1 x ChatEGFP
quantification
(mouse adult distal
colon)

3

Figure 3 - SATB1
x Chat-EGFP
quantification
(mouse adult distal
colon)

3

2136

Student’s ttest

% of EGFP- neurons that were
PHOX2B+: 69.9 ± 7.3 // 72.0 (13.5)
% of EGFP+ neurons that were
PHOX2B+: 76.1 ± 5.1 // 76.3 (9.5)
% of PHOX2B+ neurons that were
EGFP+: 60.8 ± 2.9 // 62.1 (4.9)
% of PHOX2B+ neurons that were
EGFP-: 39.2 ± 2.9 // 37.9 (4.9)

993

Student’s ttest

% of EGFP- neurons that were
RBFOX1+: 39.4 ± 3.8 // 38.7 (7.6)
% of EGFP+ neurons that were
RBFOX1+: 82.5 ± 6.7 // 78.8 (11.8)
% of RBFOX1+ neurons that were
EGFP+: 74.2 ± 5.8 // 76.9 (10.7)
% of RBFOX1+ neurons that were
EGFP-: 25.8 ± 5.8 // 23.1 (10.7)

1028

Student’s ttest

% of EGFP- neurons that were
SATB1+: 7.9 ± 12.3 // 1.6 (22.1)
% of EGFP+ neurons that were
SATB1+: 50.0 ± 12.0 // 45.3 (22.5)
% of SATB1+ neurons that were
EGFP+: 94.8 ± 7.9 // 98.8 (14.3)
% of SATB1+ neurons that were EGFP: 5.2 ± 7.9 // 1.2 (14.3)

Figure 3 - TBX3 x
NOS1
quantification
(mouse adult distal
109

4

1033

Student’s ttest

% of NOS+/EGFP- neurons that were
TBX3+: 90.9 ± 8.2 // 92.0 (15.7)
% of NOS+/EGFP+ neurons that were
TBX3+: 86.5 ± 12.1 // 85.6 (22.6)

Experiment

Biological
replicate
number

Total
neurons
or nerve
terminals
counted

Statistical
tests used

colon)

Descriptive Statistics:
Mean ± standard deviation // Median
(range if n=3, interquartile range if
n>3)

% of NOS-/EGFP+ neurons that were
TBX3+: 23.4 ± 7.7 // 26.3 (13.1)
% of TBX3+ neurons that were EGFP+:
31.0 ± 7.0 // 34.5 (10.6)
% of TBX3+ neurons that were EGFP-:
69.0 ± 7.0 // 65.5 (10.6)
% of TBX3+ neurons that were NOS+:
66.0 ± 5.6 // 64.5 (10.0)
% of TBX3+ neurons that were NOS-:
34.0 ± 5.6 // 35.5 (10.0)

Figure 3 - All
neurons (mouse
adult distal colon)

3 (EGFP)

N/A

7 (NOS)

% of total neurons that were
EGFP+:58.1 ± 4.4 // 58.8 (8.8)
% of total neurons that were EGFP-:
41.9 ± 4.4 // 41.2 (8.8)
% of total neurons that were NOS+:
38.1 ± 4.5 // 39.2 (7.9)
% of total neurons that were NOS-:
61.9 ± 4.5 // 60.8 (7.9)

Supplementary
Figure 1 - VglutIres-Cre;TdTomato
x Chat-EGFP
quantification
(mouse adult distal
colon)

3

Figure 5 - BNC2 x
Chat-EGFP
quantification
(mouse E17.5 midsmall intestine)

3
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114

N/A

% TDTOMATO+/EGFP+/HUC+:
4.1 ± 1.5 // 3.5 (2.7)
% TDTOMATO+/EGFP-/HUC+:
95.9 ± 1.5 // 96.5 (2.7)

6186

Student’s ttest

BNC2+EGFP+/EGFP+:
54.8 ± 5.2 // 52.3 (9.5)
BNC2+EGFP-/EGFP-:
21.6 ± 1.5 // 21.3 (2.94)
BNC2+EGFP+/BNC2+:
78.7 ± 1.1 // 78.7 (2.1)
EGFP+HUC+/HUC+:
59.2 ± 4.4 // 57.0 (8.0)

Experiment

Biological
replicate
number

Total
neurons
or nerve
terminals
counted

Statistical
tests used

Descriptive Statistics:
Mean ± standard deviation // Median
(range if n=3, interquartile range if
n>3)

Figure 5 - PBX3 x
Chat-EGFP
quantification
(mouse E17.5 midsmall intestine)

3

10259

Student’s ttest

PBX3+EGFP+/EGFP+:
53.4 ± 13.3 // 60.6 (23.4)
PBX3+EGFP-/EGFP-:
12.1 ± 9.5 // 9.7 (18.6)
PBX3+EGFP+/PBX3+:
85.7 ± 8.6 // 84.5 (17.1)
EGFP+HUC+/HUC+:
56.2 ± 9.6 // 55.8 (19.1)

Figure 5 RBFOX1 x ChatEGFP
quantification
(mouse E17.5 midsmall intestine)

3

11522

Student’s ttest

RBFOX1+EGFP+/EGFP+:
49.7 ± 9.4 // 48.3 (18.7)
RBFOX1+EGFP-/EGFP-:
3.7 ± 2.1 // 4.0 (4.2)
RBFOX1+EGFP+/RBFOX1+:
95.3 ± 2.1 // 95.7 (4.1)
EGFP+HUC+/HUC+:
59.7 ± 2.8 // 60.6 (5.3)

Figure 5 - TBX2 x
Chat-EGFP
quantification
(mouse E17.5 midsmall intestine)

3

8369

Student’s ttest

TBX2+EGFP+/EGFP+:
51.5 ± 4.3 // 51.4 (8.5)
TBX2+EGFP-/EGFP-:
7.8 ± 7.3 // 3.7 (12.7)
TBX2+EGFP+/TBX2+:
92.3 ± 5.1 // 94.7 (9.3)
EGFP+HUC+/HUC+:
60.9 ± 5.1 // 63.3 (9.4)

Figure 5 - TBX3 x
Chat-EGFP x
NOS1
quantification
(mouse E17.5 midsmall intestine)

3

4235

ANOVA with
Tukey’s
post-hoc
test

TBX3+EGFP+/EGFP+:
49.1 ± 6.3 // 48.1 (12.5)
TBX3+NOS1+/NOS1+:
95.2 ± 1.7 // 94.6 (3.4)
TBX3+NOS1+EGFP+/NOS1+EGFP+:
91.2 ± 3.9 // 91.4 (7.8)
TBX3+EGFP+/TBX3+:
60.9 ± 5.1 // 0.5 (0.1)
TBX3+NOS1+/TBX3+:
44.6 ± 3.2 // 43.9 (6.3)
TBX3+EGFP+NOS1+/TBX3+:
5.6 ± 0.9 // 5.4 (1.7)
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Experiment

Biological
replicate
number

Total
neurons
or nerve
terminals
counted

Statistical
tests used

Descriptive Statistics:
Mean ± standard deviation // Median
(range if n=3, interquartile range if
n>3)

EGFP+/(sum of
EGFP+,NOS1+,NOS1+EGFP+):
68.3 ± 1.6 // 67.5 (3.0)
NOS1+/(sum of
EGFP+,NOS1+,NOS1+EGFP+):
31.1 ± 1.7 // 32.0 (3.0)
EGFP+NOS1+/(sum of
EGFP+,NOS1+,NOS1+EGFP+):
0.8 ± 0.0 // 0.8 (0.1)
Figure 6 - Etv1CreERT2;
TdTomato neuron
numbers (mouse
P0 mid-small
intestine)

4 (control),
4 (KO)

5620
(control),
5157 (KO)

ANOVA with
Tukey’s
post-hoc
test

% Chat-EGFP+ neurons:
KO: 39.5 ± 6.6 // 41.03 (12.4)
Control: 40.0 ± 2.9 // 39.6 (5.5)
% NOS1+ neurons:
KO: 14.5 ± 3.2 // 15.8 (5.4)
Control: 12.9 ± 2.7 // 12.6 (5.2)
% Chat-EGFP+/NOS1+ neurons:
KO: 2.4 ± 0.5 // 2.5 (0.9)
Control: 1.6 ± 0.6 // 1.5 (1.1)
% Chat-EGFP-/NOS1- neurons:
KO: 43.6 ± 5.7 // 43.1 (10.5)
Control: 45.5 ± 2.6 // 45.4 (4.9)
Total Neuron Density:
KO: 3530 ± 563.3 // 3334 (980)
Control: 4241 ± 535.6 // 4144 (1009)

Figure 6 - Wnt1Cre;Tbx3 flox
neuron numbers
(mouse P0 midsmall intestine)

3 (control),
3 (KO)

Figure 6 - Wnt1-

4 (control),

112

8618
(control),
3983 (KO)

Student’s ttest

% NOS1+ neurons:
KO: 18.2 ± 3.3 // 17.4 (6.6)
Control: 26.0 ± 3.0 // 26.4 (6.0)
Total Neuron Density:
KO: 2180 ± 403.2 // 2075 (786)
Control: 2337 ± 260.6 // 2302 (517)

6871

Student’s t-

% Chat-EGFP+ neurons:

Experiment

Biological
replicate
number

Total
neurons
or nerve
terminals
counted

Statistical
tests used

Descriptive Statistics:
Mean ± standard deviation // Median
(range if n=3, interquartile range if
n>3)

Cre;Rbfox1 flox
neuron numbers
(mouse P0 midsmall intestine)

4 (KO)

(control),
5348 (KO)

test

KO: 47.4 ± 2.9 // 47.3 (5.1)
Control: 53.6 ± 7.3 // 53.6 (14.1)
Total Neuron Density:
KO: 1603 ± 352.2 //1589 (674)
Control: 1789 ± 364.6 // 1903 (665)

Figure 7 - BNC2 x
CHAT
quantification
(human colon)

3

2675

Student’s ttest

BNC2+CHAT+/CHAT+:
36.6 ± 4.1 // 34.3 (7.1)
BNC2+CHAT-/CHAT-:
1.6 ± 1.3 // 0.8 (2.3)
BNC2+CHAT+/BNC2+:
97.9 ± 1.3 // 97.9 (2.7)
CHAT+HUC+/HUC+:
66.6 ± 11.8 // 60.0 (20.6)

Figure 7 - PBX3 x
CHAT
quantification
(human colon)

3

2439

Student’s ttest

PBX3+CHAT+/CHAT+:
19.0 ± 4.3 // 19.9 (8.6)
PBX3+CHAT-/CHAT-:
1.1 ± 0.3 // 1.1 (0.6)
PBX3+CHAT+/PBX3+:
97.5 ± 1.1 // 97.2 (2.2)
CHAT+HUC+/HUC+:
68.7 ± 6.9 // 67.7 (13.8)

Figure 7 RBFOX1 x CHAT
quantification
(human colon)

3

2825

Student’s ttest

RBFOX1+CHAT+/CHAT+:
44.4 ± 7.7 // 41.4 (14.4)
RBFOX1+CHAT-/CHAT-:
1.5 ± 1.4 // 1.6 (2.8)
RBFOX1+CHAT+/RBFOX+:
99.4 ± 0.5 // 99.3 (1.0)
CHAT+HUC+/HUC+:
87.4 ± 2.7 // 86.9 (5.3)

Figure 7 - TBX2 x
CHAT
quantification
(human colon)

3

3427

Student’s ttest

TBX2+CHAT+/CHAT+:
7.8 ± 2.8 // 6.2 (4.8)
TBX2+CHAT-/CHAT-:
0.1 ± 0.1 // 0.1 (0.2)
TBX2+CHAT+/TBX2+:
99.4 ± 0.5 // 99.3 (1.0)
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Experiment

Biological
replicate
number

Total
neurons
or nerve
terminals
counted

Statistical
tests used

Descriptive Statistics:
Mean ± standard deviation // Median
(range if n=3, interquartile range if
n>3)

CHAT+HUC+/HUC+:
69.6 ± 12.9 // 72.5 (25.3)
Figure 7 - TBX3 x
NOS1
quantification
(human colon)

114

3

972

Student’s ttest

TBX2+NOS1+/NOS1+:
90.0 ± 9.7 // 92.4 (19.0)
TBX2+NOS1-/NOS1-:
16.4 ± 6.5 // 14.9 (12.8)
TBX3+NOS1+/TBX3+:
83.5 ± 8.9 // 83.3 (17.7)
NOS1+HUC+/HUC+:
49.1 ± 7.8 // 47.3 (15.3)

Supplementary Table 2.7: List of Antibodies
Antibody

Concentration

Rabbit anti-NOS1
Goat anti-CHAT
ANNA-1 (HuC/D)

1:200 (mouse),
1:100 (human)
1:100 (human)
N/A (mouse)

Mouse anti-HuC/D

1:200 (human)

A21271

Goat anti-TBX3

AF4509-SP

Goat anti-PHOX2B

1:100 (human and
mouse)
1:100 (mouse)

Rabbit anti-SATB1

1:100 (mouse)

ab109122

Chicken anti-GFP

1:500 (mouse)

#GFP-1020

Rabbit anti-S100B
Rabbit anti-PBX3

1:200 (mouse)
1:100 (human and
mouse)
1:100 (human and
mouse)
1:100 (human and
mouse)
1:100 (human and
mouse)
1:100 (mouse)

Ab52642
12571-1-AP

1:100 (human and
mouse)
1:500 (mouse)

HPA018525
AB5026

Sigma;
RRID:AB_1845402
Sigma; RRID:AB_91644

1:800 (mouse)

AB150349

Abcam

1:400 (mouse and
human)
1:400 (mouse and
human)
1:400 (mouse and
human)

A21445

Thermo Fisher Scientific;
RRID:AB_2535862
Thermo Fisher Scientific;
RRID:AB_2535792
Thermo Fisher Scientific;
RRID:AB_141637

Rabbit anti-TBX2
Rabbit anti-POU3F3
Rabbit anti-RBFOX1
Goat anti-BRN1 (also
called POU3F3
protein)
Rabbit anti-BNC2
Rabbit anti-Met
Enkephalin
Rat anti-Substance P
(NC1/34)
Alexa Fluor goat antihuman 647
AlexaFluor donkey
anti-rabbit 488
AlexaFluor donkey
anti-rabbit 594
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Catalog
number
AB5380

Source

AB144P
N/A

22346-1-AP

Sigma, RRID:AB_2079751
Kind gift from Dr. V. Lennon,
Mayo Clinic
Thermo Fisher Scientific,
RRID:AB_221448
R&D Systems,
RRID:AB_2240328
R&D Systems,
RRID:AB_10889846
Abcam,
RRID:AB_10862207
Aves Labs,
RRID:AB_10000240
Abcam; RRID:AB_882426
Proteintech Group;
RRID:AB_2160469
Proteintech Group

HPA067151

Sigma; RRID:AB_2685790

HPA040809

Sigma; RRID:AB_10796228

AF4940-SP

Sigma, RRID:AB_91824

Santa Cruz; no longer sold

A21206
A21207

Antibody

Concentration

AlexaFluor donkey
anti-rabbit 647
AlexaFluor goat antirat 594
AlexaFluor donkey
anti-goat 594
AlexaFluor goat antichicken 488
AlexaFluor donkey
anti-goat 647
AlexaFluor donkey
anti-goat 488
AlexaFluor goat antirabbit 488

1:400 (mouse and
human)
1:500 (mouse)
1:400 (mouse and
human)
1:400 (mouse and
human)
1:400 (mouse and
human)
1:400 (mouse and
human)
1:400 (mouse and
human)

Catalog
number
A31573
A11007
A11058
A11039
A21447
A11055
A31556

Source
Thermo Fisher Scientific;
RRID:AB_2536183
Thermo Fisher Scientific;
RRID:AB_10561522
Thermo Fisher Scientific;
RRID:AB_2534105
Thermo Fisher Scientific;
RRID:AB_142924
Thermo Fisher Scientific;
RRID:AB_141844
Thermo Fisher Scientific;
RRID:AB_2534102
Thermo Fisher Scientific;
RRID:AB_221605

Supplementary Table 2.8: List of RT-PCR primers
Gene

Primer Sequence

Band size

Genotyping
solution

Pou3f3
(mouse)

5'-CAACAGCCACGACCCTCACT-3'
5'-CAGAACCAGACCCGCACGAC-3'

450 bp

KAPA (KAPA
(74)
Biosystems, Cat
#KK7352)

Actb
(mouse)

5'-GAGAGGGAAATCGTGCGTGAC3'
5'-AGCTCAGTAACAGTCCGCCTA-3'

534 bp

KAPA ((KAPA (75)
Biosystems, Cat
#KK7352)
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Reference

Supplementary Table 2.9: List of PCR primers for mouse genotyping
Gene
(Strain)

Primer Sequence

Band size

Tbx3

F: 5'-GTG TGA GAC AGA
GAA ATC AGT GG-'3
R: 5’-5' CCA ACT GGT
ATC TTG ATA AAC CTC-'3

Mut: 480bp KAPA (KAPA
(30)
WT: 320bp Biosystems, Cat
#KK7352), Taq
(NEB, Cat
#M0271L)

Gfp (ChATEGFP-L10a)

F: 5'-TCA TAG AGG CGC
AGA GTT CC-3'
R: 5'-CTG AAC TTG TGG
CCG TTT AC-3'

Mut: 250bp KAPA (KAPA
JAX genotyping
Biosystems, Cat protocol (Stock
#KK7352)
No: 030250)

Rbfox1

F: 5ATGCCCATGCAGTGAAA
AAT-3’
R: 5’TGCAGCACATTGAAACCT
TC-3’

Mut: 397bp KAPA (KAPA
(76)
WT: 294bp Biosystems, Cat
#KK7352)

Gfra1-Gfp

Common F: 5’CTTCCAGGTTGGGTCGG
AACTGAACCC-3’
Mut R: 5’GCCGTTTACGTCGCCGT
CCAGCTCGACCAG-3’
WT R: 5’AGAGAGCTCAGCGTGCA
GAGATC-3’

WT:
~200bp
Mut:
~300bp

KAPA (KAPA
(27) and personal
Biosystems, Cat correspondence
#KK7352)
with Dr. Sanjay
Jain’s laboratory

Cre (Wnt1Cre)

F: 5’- GCA TTA CCG GTC
GAT GCA ACG AGT GAT
GAG-3’
R: 5’-GAG TGA ACG AAC
CTG GTC GAA ATC AGT
GCG-3’

408bp

KAPA (KAPA
Biosystems, Cat
#KK7352), Taq
(NEB)

R26RmCherry
(R26R-H2bmCherry)

Common F: 5’-AAA GTC
GCT CTG AGT TGT TAT-3’
Mutant R: 5’-TTA TGT AAC
GCG GAA CTC CA-3’
WT R: 5’GGA GCG GGA
GAA ATG GAT ATG-3’

Mut: 309bp KAPA (KAPA
JAX genotyping
WT: 603bp Biosystems, Cat protocol (Stock
#KK7352)
No: 023139)

117

Genotyping
solution

Reference

https://mgc.wustl.e
du/protocols/pcr_g
enotyping_primer_
pairs

Gene
(Strain)

Primer Sequence

Band size

Genotyping
solution

Reference

Cre (Vglut2IRES-Cre)

F: 5’-GCA TTA CCG GTC
GAT GCA ACG AGT GAT
GAG-3’
R: 5’-GAG TGA ACG AAC
CTG GTC GAA ATC AGT
GCG-3’

408bp

KAPA (KAPA
Biosystems, Cat
#KK7352), Taq
(NEB, Cat
#M0271L)

https://mgc.wustl.e
du/protocols/pcr_g
enotyping_primer_
pairs

Cre (Nos1CreERT2)

F: 5’-GCA TTA CCG GTC
GAT GCA ACG AGT GAT
GAG-3’
R: 5’-GAG TGA ACG AAC
CTG GTC GAA ATC AGT
GCG-3’

408bp

KAPA (KAPA
Biosystems, Cat
#KK7352), Taq
(NEB, Cat
#M0271L)

https://mgc.wustl.e
du/protocols/pcr_g
enotyping_primer_
pairs

R26RTdTomato

Common F: 5'AAAGTCGCTCTGAGTTGT
TAT-3'Mut R: 5’GCGAAGAGTTTGTCCTCA
ACC-3’
WT R:
5'GGAGCGGGAGAAATGGA
TATG-3'

Mut:
~350bp
WT:
~600bp

KAPA (KAPA
JAX genotyping
Biosystems, Cat protocol (Stock
#KK7352), Taq No: 007900)
(NEB, Cat
#M0271L)

Etv1CreERT2

WT F: 5’-CCC TCC CCT
CTC ATT TTC TC-3’
Mut F: 5’-TGG TTT GTC
CAA ACT CAT CAA-3’
Common R: 5’-ACA GTT
TCT CCC ACG CTG AC-3’

Mut: 170bp KAPA ((KAPA
JAX genotyping
WT:
Biosystems, Cat protocol (Stock
459bp
#KK7352)
No: 013048)

Cre (E2aCre)

F: 5’-GCG GTC TGG CAG
TAA AAA CTA TC-3’
R: 5’-GTG AAA CAG CAT
TGC TGT CAC TT-3’

100bp

R26RGCaMP6s

Mut F: 5’-ACG AGT CGG
ATC TCC CTT TG-3’
Mut R: 5’-AGA CTG CCT
TGG GAA AAG CG-3’
WT F: 5’-AAG GGA GCT
GCA GTG GAG TA-3’

Mut: 356bp KAPA (KAPA
JAX genotyping
WT: 297bp Biosystems, Cat protocol (Stock
#KK7352)
No: 028866)
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HotStar Taq Kit
(Qiagen, Cat#
203443)

JAX genotyping
protocol (Stock
No: 003724)

Gene
(Strain)

Primer Sequence

WT R: 5’-CCG AAA ATC
TGT GGG AAG TC-3’
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Band size

Genotyping
solution

Reference

Supplementary Table 2.10: ARRIVE Guidelines - General animal husbandry information
Location of Animal
facility (types of
experiments)

CHOP (all experiments,
except listed
elsewhere)

University of
Pittsburgh (Live
calcium imaging
experiments)

University of
Melbourne (High
magnification images
of myenteric plexus
stained with
substance P and
enkephalin)

Facility Type

Conventional: cages are
opened at room air, face
masks are not required
when handling mice

Barrier housing and
maintained with caging
opened under Animal
Transfer
Station/Biosafety
Cabinets

Individually Ventilated
Cages (IVC,
Tecniplast): cages
opened under Animal
Transfer Station

Facility Type

Specific pathogen free,
Pathogens detected in
room within the past 2
years: MNV (mouse
norovirus), Helicobacter
not tested but likely
present

Specific pathogen free;
sentinel testing for
excluded pathogens
and MNV

Specific pathogen free;
sentinel testing for
excluded pathogens
and MNV

Animal welfare
assessment

Daily

Daily

Daily (food and water)
Weekly (health check)

Bedding

¼ inch corn cob (The
Andersons, Product 4B)

P.J Murphy Coarse
Certified Aspen Sanichip

Compressed paperbased bedding

Cage type

Lab Products (Seaford,
DE) 75 sq. in. Ventilated.

Allentown mouse IVC
caging

Tecniplast IVC caging
(Green line)
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Location of Animal
facility (types of
experiments)

CHOP (all experiments,
except listed
elsewhere)

University of
Pittsburgh (Live
calcium imaging
experiments)

University of
Melbourne (High
magnification images
of myenteric plexus
stained with
substance P and
enkephalin)

Cage
cleaning/sterilization

Standard tunnel washer

Standard tunnel
washer, boxes
autoclaved before use

Rack washer
(Tecniplast), steam
sterilisation

Mouse diet

Mouse Diet 5015 (Lab
Diet), direct from
manufacturer: not
autoclaved, not
irradiated

Prolab Isopro RMH
3000 (5P75) irradiated

Jackson labs: LabDiet®
5K52 formulation (6%
fat).

Light-dark cycle

12/12

12/12

12/12

Temperature

72°F +/- 2°F

72°F +/- 4°F

18-24°C +/- 1°C

Humidity

30-70% depending on
the day/season

30-70% depending on
the day/season

30-70% depending on
the day/season

Water pH and quality

Reverse Osmosis,
pH~7, Edstrom
automatic watering
system

Reverse Osmosis,
pH~7, Edstrom
automatic watering
system

Filtered water bottles
(down to 0.2 microns),
pH~7
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Animal Facility:
Barastoc WEHI Mice
Cubes, irradiated

Location of Animal
facility (types of
experiments)

CHOP (all experiments,
except listed
elsewhere)

University of
Pittsburgh (Live
calcium imaging
experiments)

University of
Melbourne (High
magnification images
of myenteric plexus
stained with
substance P and
enkephalin)

Access to food and
water

Continuous

Continuous

Continuous

Number of mice per
cage

1-5 (20-30g)

1- 4 males, 1-5 females

1-5

Cage Enrichment

house/dome (Bioserve,
S3174) and nestlet
(Ancare)

house/dome (Bioserve,
S3174) and nestlet
(Ancare)

house/dome, tissues,
chewing wooden block
for single-housed mice

Mating strategy

Continuous

Continuous

not applicable in this
study

Age at weaning

19-20 days

19-28 days

19-21 days (not
applicable for this
study)
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CHAPTER 3: Development of a screening platform to identify transcription factors
directing enteric neuron subtype specification and differentiation

This manuscript is being prepared for publication. This chapter details progress towards
establishing a high-throughput screening system to test the effect of transcription factor
overexpression on enteric neuron subtype differentiation. Authors: Sabine Schneider, Sohaib K
Hashmi, Chinmay Kalluraya, Paul Gadue, Deborah L. French, Robert O. Heuckeroth. (2020)

3.1 Abstract
Enteric neuropathies, dysfunction of the enteric nervous system (ENS), can cause
devastating disease in affected individuals. The symptoms include abdominal pain, diarrhea,
vomiting, distention and in severe cases sepsis and death. Our current treatment options remain
limited to supportive treatment and surgical resection of the most severely affected bowel regions.
The underlying cause of enteric neuropathy is loss or dysfunction of one or more enteric neuron
subtypes. One enticing way to study these disorders and develop new therapy takes advantage of
recently developed in vitro differentiation protocols for human pluripotent stem cells (hPSCs). Stem
cell therapies aim to replace or supplement missing or defective ENS cell types to re-establish
functioning neural circuits. However, in vitro differentiation protocols are not yet sophisticated
enough to direct differentiation into specific neuronal subtype fates. My hypothesis was that a better
understanding of the extracellular signals and transcriptional regulation that controls subtype
specification and differentiation would facilitate protocol development for directed differentiation of
stem cells to specific ENS subtype fates. Here, we present progress towards the goal of testing the
effects of select transcriptional regulators on stem cell differentiation into cholinergic versus
nitrergic enteric neuron fates. To pursue this work we established an in vitro ENS differentiation
protocol in our lab and created a small library of doxycycline-inducible lentiviral vectors that express
transcriptional regulators differentially expressed in developing enteric neuron subtypes. We are
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currently validating CHAT and NOS1 fluorescent reporter hPSC lines to facilitate future screening
of the transcriptional regulator library.

3.2 Introduction
The enteric nervous system (ENS) is a complex network of 500 million neurons and glia
that spans the entire length of the bowel. More than 20 specialized enteric neuron subtypes form
repeating neural circuits that coordinate vital functions like muscle contraction and epithelial ion
transport (1–4). For this reason, congenital and acquired imbalances in enteric neuron subtypes
may cause debilitating and potentially life-threatening gastrointestinal motility disorders (5–7).
Symptoms include constipation, nausea, vomiting, abdominal pain and distention, and in some
cases sepsis and early death (5, 7). For all of these ENS disorders, quality of life can be poor and
few effective treatments exist (7–9). If an obvious ENS abnormality is regionally restricted, surgical
removal of the affected bowel region is routine. An example is Hirschsprung disease where the
ENS is completely missing in the distal bowel and surgical resection of the abnormal region can be
curative. However, in many children, debilitating symptoms persist after Hirschsprung disease
surgery (10–12). One explanation for post-surgical problems appears to be dysfunctional ENS
circuitry in areas of the bowel where the ENS looks grossly normal (13–17). When bowel motility is
abnormal in many regions, the problem is called chronic intestinal pseudo-obstruction (CIPO). For
CIPO, treatment options are particularly limited (8, 9). Neuropathic CIPO is presumed to be caused
by altered enteric neuron subtype ratios and neuron subtype dysfunction, but exact genetic
mutations and the mechanisms of disease are still only rarely identified (see our work in chapter 2
to address this problem).
For both Hirschsprung disease and CIPO, an ideal therapy would replace the missing or
defective ENS cell types (18). Recent advances in stem cell biology have made stem cell therapy
an enticing possibility. Patient-derived human pluripotent stem cells (hPSCs) can now be robustly
generated. hPSCs can be cultured long-term in serum-free, chemically-defined, and xeno-free
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culture media without loss of pluripotency (19) and innovations in genome-editing technology (20)
have dramatically simplified the process of correcting gene defects. Even more excitingly, several
differentiation protocols have been developed to convert human pluripotent stem cells into enteric
nervous system cells (21–26). However, no differentiation protocol is optimized to generate specific
ENS subtypes. This is not surprising since only limited mouse (27, 28) and human (28) gene
expression data sets were available to guide hypothesis-driven protocol development. Most
importantly, only a few extracellular signaling molecules (BMP2/4 and Noggin (29–31), NRTN (32,
33), 5-HT (34), and GDNF (35)), extracellular matrix components (laminin-I, heparan sulfate,
collagen-I, and collagen-IV (36)), and transcription factors (Ascl1/Mash1 (37), Sox6 (28), Hand2
(38, 39), Dlx1/Dlx2 (40), and Smad1 (31)) have been shown to affect specification or differentiation
of enteric neuron subtypes in experimental models. Our work (Chapter 2) and that of others (41–
44) now provide exciting new gene expression data defining extracellular factors and transcriptional
regulatory networks that could facilitate directed enteric neuron subtype differentiation. Using our
own data, I decided to explore a fundamental question of enteric nervous system development: Is
the expression of a defined number of transcription factors sufficient to direct differentiation of a
multipotent enteric neural precursor into a cholinergic versus a nitrergic enteric neuron fate?
Cholinergic and nitrergic cell types make up the vast majority of enteric myenteric neurons
and include excitatory and inhibitory motor neurons respectively. In mouse small intestine
myenteric plexus, ~30% of all neurons are nitrergic, ~60% cholinergic, and ~3% both cholinergic
and nitrergic (45, 46). In human colon myenteric plexus, 43-51% of all neurons are nitrergic only,
28-52% cholinergic only, and 4-10% both nitrergic and cholinergic (see Chapter 6 Supplemental
Table 6.4 and 6.5 for a more in depth discussion of human myenteric plexus staining). These
cholinergic and nitrergic neurons are derived from a common enteric neuron precursor and the
subtype fate decision is made at or after the penultimate cell division (27). The observation that
enteric neuron subtypes diverge from a common precursor late in differentiation supports the
hypothesis that a few transcriptional regulators could control enteric neuron subtype differentiation.
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Even more compellingly, one myenteric interneuron subtype appears to differentiate postmitotically from a common precursor that also produces inhibitory motor neurons in a Pbx3dependent manner (42). To more broadly investigate the transcriptional regulation of cholinergic
versus nitrergic enteric neuron subtype fate, we established an hPSC differentiation protocol that
generates enteric neuron and glial subtypes. We are currently developing fluorescent reporter
hPSC lines to facilitate identification of nitrergic and cholinergic enteric neurons and we have
generated doxycycline-inducible lentiviruses that express selected transcriptional regulators. We
are now poised to use this system to test the hypothesis that specific transcription factors can direct
enteric neuron subtype differentiation into either cholinergic or nitrergic fate. This system can also
be easily adapted to systematically study extracellular signaling pathways regulating cholinergic
and nitrergic neuron subtype differentiation.

3.3 Results
Reproducible differentiation of human pluripotent stem cell-derived into enteric neuron and
glial subtypes
We used the differentiation protocol developed by Fattahi et al. (22), as well as the feederfree version of the protocol by Barber et al. (25) to reproducibly differentiate human pluripotent stem
cells (hPSCs) into enteric neurons and glia (called Enteric Neural Crest-derived Cells or ENC). On
day 11/12 of ENC differentiation, we were able to verify the presence of CD49D+/p75+ enteric
neuron precursors (Figure 3.1A-B) (22, 47). Cells expressing high levels of CD49D were isolated
via FACS and ENC differentiation was continued with purified enteric neuron precursors. By day
17 of differentiation, enteric neuron precursors had a mesenchymal appearance (flat, low
nucleus:cytoplasm ratio), were highly migratory (data not shown) and individual cells were often
connected to neighboring cells by thin neurites (Figure 3.1C), similar to migrating enteric neuron
precursors in mouse (48, 49). Around day 25 of differentiation, cells adopted a more rounded
appearance with longer, more robust neurites (Figure 3.1D). Immature enteric neurons and glia
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then started aggregating after day 30 (Figure 3.1E). These cell body aggregates connected by
fasciculated neurites closely resemble enteric ganglia, the clusters of neurons and glia that are
characteristic of a normal mature ENS (50). By day 36, tubulin 3 beta (TuJ1+)- expressing neuron
cell bodies and a dense network of long TuJ1+ axons were interspersed with S100B+ glial cells
(Figure 3.1F). After day 60 of differentiation, the cultures were dominated by small, tight “ganglion”like cell aggregates (Figure 3.1G) and larger, dense cell accumulations (Figure 3.1H) connected
to each other by thick strands of fasciculated neurites (Figure 3.1G-H).
The “mature” ENC differentiation cultures after day 60 contained enteric neurons that
expressed a wide variety of important enteric neuron subtype markers: CALB2 (calretinin), GABA
(gamma butyric acid), NPY (neuropeptide Y), NOS1 (nitric oxide synthase I), RET(REarranged
during Transformation proto-oncogene), SST (somatostatin), TAC1 (substance P), TH (tyrosine
hydroxylase), TPH2 (tryptophan hydroxylase 2), and VIP (vasoactive intestinal peptide) (Figure
3.1I). “Mature” ENC cultures included large numbers of p75+ enteric glia (Figure 3.1I) coexpressing combinations of the glial markers S100B, GFAP, and SOX10 (Figure 3.1J-K) (51). We
detected the pan-enteric neuron marker PHOX2B (52) in most of the enteric neurons within our
culture, including TH+ neurons (Figure 3.1L). We also assessed co-expression of some neuron
subtype marker combinations in our cultures. As expected based on immunohistochemical
characterization of mouse enteric neuron subtypes (45, 53), NOS1 and CALB2 were generally not
expressed by the same neurons (Figure 3.1M) while many neurons co-expressed calretinin
(CALB2) and vesicular acetylcholine transporter (SLC18A3), a combination present in most
cholinergic neurons (Figure 3.1N) (46, 53). A small subset of neurons co-expressed vasoactive
intestinal peptide (VIP) and somatostatin (SST, Figure 3.1O), a neuropeptide combination that
marks interneurons and submucosal secretomotor neurons in guinea pig (54). These observations
extend previous immunohistochemical characterizations of the enteric neuron and glial subtypes
found in “mature” ENC cultures (22, 24–26). The presence of all expected enteric neuron subtype
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markers indicates that these two ENC differentiation protocols allow for the differentiation of many
important categories of enteric neuron subtypes.

Figure 3.1: Reproducible differentiation of hPSC-derived enteric neuron and glia
A) Fluorescence activated cell sorting at day 11 of differentiation shows robust generation of
CD49D (α4 integrin)-expressing enteric nervous system precursor cells. Compare unstained cells
(left) to CD49D-stained cells (right). (B) CD49D-expressing cells also express the enteric nervous
system precursor marker p75 (LNFR, low-affinity nerve growth factor receptor) by fluorescence
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activated cell sorting at day 11 of differentiation. Compare unstained cells (left) with p75/CD49Dstained cells (right). (C) At day 17 of differentiation, the enteric neural precursor cells have a
mesenchymal appearance and extend thin neurites. (D-E) The cells gain a more rounded
appearance up by day 28 of differentiation (D) and start aggregating into “ganglia”-like structures
by day 33 (E). (F) By day 36 of differentiation, expression of the pan-neuronal marker TuJ1 (tubulin
3 beta) and the glial marker S100B can be appreciated in distinct cell populations. (G-H) Extensive
networks of fasciculated neurites connect tight “ganglia”-like cell clusters and looser cell aggregates
after day 60 of differentiation. (I) The expected wide variety of enteric glial markers and enteric
neuron subtype markers can be detected in mature cultures after day 60 of differentiation. TPH2
(tryptophan hydroxylase 2), NOS1 (nitric oxide synthase 1), CALB2 (calretinin), p75 (LNFR, lowaffinity nerve growth factor receptor), TH (tyrosine hydroxylase), GABA (gamma aminobutyric acid),
CGRP (calcitonin gene-related peptide), NPY (neuropeptide Y), RET (rearranged during
transfection proto-oncogene), SST (somatostatin), TAC1 (substance P), and VIP (vasoactive
intestinal peptide). Pan-neuronal marker TUJ1 (tubulin 3 beta) is shown for context in a subset of
panels. (J-O) Coexpression was assessed from a limited number of glial and neuron subtype
markers: (J) S100B and GFAP as well as (K) S100B and SOX10 are coexpressed by subsets of
enteric glia. (L) Pan-enteric neuron marker PHOX2B is expressed in differentiated neurons
(including TH-expressing neurons). (M) NOS1 and CALB2 are not expressed in the same neurons.
(N) CALB2+ neurons co-express the pan-cholinergic neuron marker SLC18A3 (vesicular
acetylcholine transporter and lastly, (O) VIP and SST are coexpressed in a subset of neurons.
(F,I,J) Blue pan-nuclear marker is Hoechst. (C-E, G-H) Scale bar = 100 μm. (F) Scale bar = 50
μm. (I-O) Scale bar = 20 μm.

Generating a NOS1 and CHAT fluorescent reporter H9-hESC cell line to facilitate
identification of nitrergic and cholinergic enteric neurons
Quantification of cholinergic and nitrergic neurons in mature ENC cultures is necessary to
determine if transcription factor overexpression enhances enteric neuron differentiation into
cholinergic or nitrergic neurons. However, commonly used immunohistochemical markers choline
acetyltransferase (CHAT), vesicular acteylchine transporter (SLC18A3), and neuronal nitric oxide
synthase (NOS1) are in neuron cell bodies and their extensive neurites (45) making it difficult to
count individual cell bodies in dense neuron aggregates. To address this problem, I decided to
generate fluorescent reporter H9-hESC lines that label cholinergic and nitrergic neurons. Using
CRISPR/CAS9, we generated two independent reporter lines with a nuclear localized tandem dimer
red fluorescent protein (tdRFP) knocked into the 3’ untranslated region (3’ UTR) of either the
endogenous NOS1 locus or the endogenous CHAT locus. An internal ribosome entry site (IRES)
sequence after the NOS1 and CHAT stop codons permits expression of nuclear tdRFP from the
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same mRNA as the endogenous NOS1 and CHAT transcripts, respectively. Thus, tdRFP
expression can serve as a proxy for NOS1 or CHAT expression. We included a floxed puromycin
selection cassette at the 3’ end of the CRISPR insertion template (Figure 3.2A) and screened ~300
clones by PCR for correct genomic insertion of the IRES-NLS-tdRFP-puromycin selection cassette
(Figure 3.2B-E). We expanded one morphologically healthy hPSC clone for each of NOS1 or
CHAT fluorescent reporter genomic insertion. Chromosomal G band analysis for the CHAT reporter
line confirmed the absence of chromosomal aberrations (Supplementary Figure 3.1). The NOS1
reporter line has not yet been karyotyped.
Both reporter clones were subsequently transfected with pCAG-Cre-GFP to excise the
floxed puromycin selection cassette, which was verified by PCR (Figure 3.2G-J). We attempted
differentiations with NOS1 and CHAT fluorescent reporter lines, but unfortunately saw only faint
cytoplasmic tdRFP with no nuclear-localized tdRFP (data not shown). Upon re-examination of the
repair template, we found a 10 bp spacer between the NLS and tdRFP sequences that introduced
a frameshift preventing production of normal protein. However, the tdRFP sequence itself has an
ATG start codon that could explain the faint cytoplasmic tdRFP signal.
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Figure 3.2: Development of CHAT and NOS1 3’UTR fluorescent reporter knock-in h9-hESC
cell lines
A) Schematic of the CRISPR repair template integrated into the genomic CHAT and NOS1 loci. An
internal ribosomal entry site (IRES), the coding sequence for tandem-dimer RFP (TdRFP) with a
nuclear localization sequence (NLS), and a purmycin selection cassette were introduced into the
3’UTR of the CHAT and NOS1 loci. The dsDNA repair template homology arms extend 1kb both
upstream (5’) and downstream (3’) from the Cas9 cut site within the CHAT and NOS1 3’UTRs. (BE) Four sets of primers were used to verify a complete insertion of the repair template into the
correct genomic location (see Supplementary Table 3.3). (F) Schematic of the genomic locus with
inserted repair template. The approximate location of the primer pairs (B-D) are marked by colored
arrows. (G) Transient expression of CRE removed the puromycin selection cassette from the NOS1
clone with correct insertion of the repair template (see B-D) and allowed us to select 3 clones (1,3
and 8) with retained correct genomic insertion (see Supplementary Table 3.3). (H) Schematic of
the NOS1 genomic locus with inserted repair template. The approximate location of the primer pair
(G) is marked by arrows. (I) Transient expression of CRE removed the puromycin selection
cassette from the CHAT clone with correct insertion of the repair template (see B-D) and allowed
us to select 2 clones (3 and 7) with retained correct genomic insertion (see Supplementary Table
3.3). (J) Schematic of the CHAT genomic locus with inserted repair template. The approximate
location of the primer pair (G) is marked by arrows.

Lentiviral overexpression of transcription factors specific to enteric neuron subtypes
I chose nine transcription factors to overexpress in differentiating ENC cultures. These
transcription factors were selected based on differential expression in myenteric cholinergic or
nitrergic enteric neuron subtypes as defined by single cell RNA-sequencing data at embryonic day
17.5 (E17.5) and single nucleus sequencing in adult mouse colon (see Chapter 2 and Figure 3.3AB). Some selected transcription factors are expressed in all cholinergic neuron clusters, but few
nitrergic neuron clusters in E17.5 mouse ENS (Casz1 and Meis1), some are only detected in
specific cholinergic clusters (Bnc2, Tbx2, and Pbx3), and some are primarily restricted to nitrergic
neuron clusters (Creb5, Etv1, Ebf1) (Figure 3.3B and Chapter 2).
I decided to introduce the transcription factors into enteric neural precursors via lentiviral
infection. Transcription factor expression was controlled by a doxycycline-inducible cis regulatory
element for tight temporal control (see Supplementary Figure 3.2A). As proof-of-principle, I
infected enteric neural precursors at day 22 of differentiation with high titer lentiviral particles
carrying the cDNA sequence for doxycycline-responsive transcriptional activator, reverse
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tetracycline-controlled transactivator (rtTA), and EBF1 cDNA with added V5 and His tag
sequences. Differentiating ENC cultures were treated with doxycycline from day 24 to day 27 and
analyzed for EBF1 expression at day 27 of differentiation. Enteric neuron precursors were identified
by SOX10 expression and nuclear expression of both V5 and His protein tags verified efficient
EBF1 expression in the vast majority of cells (Figure 3.3C).

Figure 3.3: Successful generation of lentiviral overexpression vectors for select
transcription factors to be used in overexpression screen
(A) TSNE plot of embryonic day 17.5 (E17.5) mouse enteric neuron single cell sequencing data
shows 4 clusters of nitrergic neurons (1 immature and 3 mature clusters) and 4 clusters of
cholinergic neurons (2 immature and 2 mature clusters) (see chapter 2). (B) Dot plot with nine
transcription factors differentially expressed in cholinergic or nitrergic E17.5 enteric neuron
cluster(s). The transcription factors were selected for the overexpression screen and cloned into
the FU-tetO-Gateway lentiviral expression vector under control of a tetracycline response element
(see Supplementary Table 3.4 and Supplementary Figure 3.2). Dot plot illustrates both the fold
change in transcription factor differential expression per cluster (denoted by color shades ranging
from blue to red) and percent of cells per cluster expressing the transcription factor (denoted by
circle diameter). (C) Transcription factor EBF1 is successfully expressed in enteric neuron
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precursors (SOX10+) at day 27 of differentiation. Enteric neuron precursors at day 22 of
differentiation were infected with lentiviral expression vector carrying the EBF1 coding sequence
and expression of the HIS and V5 tag can be verified. Hoechst is used to mark all nuclei in the field
of view. (A-B) Imm.= immature. (B) Color legend denotes fold change (average normalized gene
expression level in cluster of interest/ average normalized gene expression level in all other
clusters). (C) Scale bar = 50 μm.

3.4 Discussion and Future Directions
The future of targeted stem cell therapies for enteric neuropathies like CIPO depends on
understanding the transcriptional regulation of enteric neuron subtype specification and
differentiation. Some studies using conditional knockout mouse models studies have already
implicated transcription factors in enteric neuron subtype differentiation (28, 31, 37–40, 42, 55).
However, conditional knockout mouse models are a low-throughput tool to identify transcription
factors that critically influence differentiation. In contrast, high-throughput screening in pluripotent
cells could rapidly identify transcriptional regulators that alter enteric neuron subtype
differentiation.
An important consideration is that redundancy in transcription factor regulatory networks
frequently obscures regulatory functions of single transcription factors in loss-of-function studies
(56, 57). Gain-of-function studies thus may have a higher chance of revealing a regulatory role for
a given transcription factor. However, only rare transcription factors can induce the expression of
genes in transcriptionally silent chromatin regions (58, 59) which may encompass gene loci with
cell type or cell subtype-specific expression. Limited combinations of pioneer factors are able to
initiate gene regulatory networks that can convert one distantly related mature cell type to another
(60–62) or, rarely, single-handedly establish a specific cell fate (63). Therefore, the overexpression
system I established may increase the likelihood of elucidating regulatory functions of specific
transcription factors in differentiating enteric neurons. Candidate transcription factors can be
expressed in immature enteric neurons. These cells have already established enteric neuronspecific transcriptional regulatory networks, and may express required transcriptional coregulators
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for subtype specific gene modules. Most importantly, subtype-specific gene loci may already be
accessible to transcription factor binding due to permissive chromatin modifications (64).
My selection of transcription factors was based on my newly generated mouse single cell
and single nucleus data. Mouse models well-recapitulate a number of human enteric neuropathies
(65–67) and regulatory relationships between specific genes and transcription factors appear to be
largely conserved between mammals (68). However, there are interspecies differences in enteric
neuron subtype neurotransmitter expression (45) and enteric neuron subtype ratios (52). It is
possible that transcriptional regulation of enteric neuron subtype differentiation is altered in subtle
but important ways when comparing mouse and human. This makes it even more important that
the role of candidate transcriptional regulators is assessed in human cells.
We chose transcription factors based on their differential expression in fetal and adult
cholinergic versus nitrergic myenteric neuron subsets. Most selected transcription factors also have
roles in CNS neuron subtype differentiation (Supplementary Table 3.4). Our novel data shows
that Tbx3 is required for normal perinatal numbers of myenteric nitrergic neurons (Chapter 2) and
others reported Pbx3 is required for differentiation of a subset of myenteric interneurons (Pbx3,
(42)). This makes these transcription factors perfect candidates to test and validate the transcription
factor overexpression screen as we differentiate hESC into enteric neurons.
To facilitate the identification of cholinergic and nitrergic neurons in dense enteric nervous
system cultures (after day 60 of ENC differentiation), I decided to generate fluorescent reporter
lines that will label any nitrergic (NOS1-expressing) or cholinergic (CHAT-expressing) cells.
Addition of a nuclear localization sequence to the tdRFP protein should further simplify
quantification of these neurons since dense networks of neurites will not contain tdRFP. I decided
to introduce the tdRFP sequence into the 3’UTR to avoid having to select for heterozygous insertion
of the construct into hPSC. Homozygous loss of Chat (69) and Nos1 leads to structural ENS defects
(70) and beyond that, we wanted to minimize changes in endogenous gene expression as much
as possible. One drawback of this design decision is the dependence of tdRFP translation efficiency
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on the transcription rate of the endogenous CHAT and NOS1 transcripts. Recent data we and
others generated shows that in both mouse and human, NOS1 transcripts are abundant in nitrergic
neurons, however, CHAT transcripts are rare (Chapter 2 and (42, 43)). This may reflect low CHAT
RNA transcript stability or possibly predominantly local CHAT protein translation at pre-synaptic
terminals (71, 72). Since the tdRFP has been introduced into the 3’UTR after an IRES sequence,
translation of tdRFP will likely be less efficient than that of the endogenous CHAT and NOS1
transcripts (73) and thus tdRFP signal could be very low even in unambiguously cholinergic
neurons. However, the half-life of RFP proteins is around 20-26 hours (74–76), so even a low
translation rate may be sufficient to detect tdRFP fluorescence.
Unfortunately, we detected a frameshift in both the CHAT and NOS1 fluorescent lines,
which likely explains the lack of nuclear tdRFP signal and low tdRFP signal overall. We will continue
the characterization of the lines we generated to see if the reporters can be used despite the design
error. However, it is likely that we will have to repeat the reporter line CRISPR screen with a correct
CRISPR repair template without the frame-shift. At this point, we do not predict this to take very
long since all tools have already been generated and validated in our hands.
Our screen currently only focuses on cholinergic versus nitrergic fate decisions, but could
be extended to look at other functionally relevant neuron subtypes like intrinsic sensory neurons or
motor neurons (1). We have already extended the previously published characterization of enteric
neuron subtypes that spontaneously arise in ENC differentiation cultures (22, 25) by staining for
known mouse and human enteric neuron subtype markers. We were able to verify the presence of
many important markers and the expected co-expression patterns for a much smaller subset. To
better understand the possibilities and limitations of the current ENC differentiation protocols, we
plan on quantifying the proportions of total neurons co-expressing unique combinations subtype
markers using single cell/nucleus RNA sequencing data that has only recently been generated
(Chapter 2 and (42–44)).
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Since at least some subtype fate decisions are made late in the enteric neuron
differentiation timeline (27, 42) and may require tight temporal control of transcriptional regulator
expression, we chose a lentiviral vector with a doxycycline-responsive cis regulatory element (TRE)
5’ to the transcription factor sequences (Supplementary Figure 3.2A) (77, 78). Introduction of
doxycycline in the cell culture medium for differentiating enteric neuron precursors would then
permit us to control the timing of transcription factor gene expression. Stable genomic insertion of
the construct allows us to infect differentiating enteric neural precursors before they form tight
aggregates (compare Figure 3.1C to Figure 3.1F), thereby maximizing infection efficiency.
Differentiating cells are thus infected days to weeks before “mature” enteric neuron subtypes are
observed in culture. We currently plan to infect enteric neural precursors at day 20-22 of
differentiation and to start transcription factor overexpression by day 25 (concurrent with the change
in enteric neural precursor morphology to a rounded cell shape and shortly before first detection of
pan-neuronal marker tubulin III beta (Figure 3.1D-F). Cultures will be monitored closely for the
appearance of cholinergic/nitrergic neurons (nuclear RFP+ neurons) and mature ENC cultures will
be quantified for the absolute numbers and cholinergic/nitrergic to total neuron ratio
(Supplementary Figure 3.2B).
We are now poised to use this system to study the effects of select transcription factors on
enteric neuron subtype differentiation into either cholinergic or nitrergic fate. Furthermore, this
system can easily be expanded to study fate decisions for functionally important sub-categories of
cholinergic and nitrergic neurons (e.g. intrinsic sensory neurons or inhibitory motor neurons) as
well as the effects of extracellular signaling pathway modulation (e.g. addition of trophic factors and
small molecule inhibitors) on neuron subtype differentiation.
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3.5 Methods
Cell Culture
Maintenance of pluripotent stem cells on a feeder layer
Human pluripotent stem cells (hPSCs, H9-hESCs; WA09, WiCell, Madison, WI; NIH
Registration Number 0062) were maintained in HES medium (see Reagents and Solutions in
Supplementary Data) on a layer of irradiated mouse embryonic fibroblasts (MEFs) plated on
gelatin-coated tissue culture dishes. HPSCs were examined daily by brightfield microscopy to verify
normal morphology and passaged once colonies were compact, rounded, and almost touching
(every 3-4 days) without being raised. 1-4 days before passaging hPSCs, irradiated MEFs were
plated on 6-well plates coated with 0.1% gelatin (Sigma-Aldrich; Cat# G1890) in MEF medium (see
Reagents and Solutions in Supplementary Data). Before plating PSCs on the MEF feeder-layer,
the wells were washed 1x with Iscove’s Modified Dulbecco’s Eagle Medium (IMDM, ThermoFisher,
Cat#12440053). To passage one well of a 6-well plate of hPSCs, 1 mL of TrypLE Express
(Invitrogen, Cat#12605010) was added to the hPSC plate and incubated at room temperature (RT)
for 3 minutes. The well was then gently agitated and inspected by brightfield microscopy. Once
most of the MEFs had detached and the edges of the hPSC colonies had lifted off while the center
remained firmly attached, TrypLE was aspirated and the well was washed once with IMDM. IMDM
was then aspirated and 1 mL of HES medium was added to the well. The hPSC colonies were
gently removed from the bottom of the well using a rubber cell scraper (Fisher Scientific, Cat#50809-208). Cells were triturated three times with a P1000 pipet tip and a subset of cells (1:10
passaging ratio for maintenance culture) was transferred to a 14 mL Falcon tube (Corning,
Cat#352059) containing HES medium supplemented with 10 μM Rho-associated kinase inhibitor
(ROCKi) (Y-27632 dihydrochloride, R&D Systems, Cat#1254/1). 2 mL of cell suspension was
plated per well and cultured at 37°C in 5% carbon dioxide, 5% oxygen, and 90% nitrogen. HES
medium with ROCKi was replaced with normal HES medium after allowing cells to attach overnight
and replaced daily until cells were ready for their next passage. To freeze cells, the normal
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passaging protocol was followed (as above), but cells were scraped into IMDM after dissociation
with TrypLE. PSCs were triturated, and the cell suspension was transferred to a 15 mL Falcon tube,
and centrifuged at 270 xg for 3 minutes. The media was aspirated and the cell pellet was
resuspended in 50% FBS, 40% HES media, and 10% dimethyl sulfoxide (DMSO) (Sigma,
Cat#2650-100ml). Resuspended cells were transferred into labeled cryovials and placed into
freezing containers containing isopropanol at -80°C for 24 hours before being transferred to liquid
nitrogen for long-term storage.

Maintenance of pluripotent stem cells in feeder-free conditions
To transition hPSCs from MEF feeders to feeder-free conditions, tissue culture plates were
coated with Corning® Matrigel® hESC-Qualified Matrix, LDEV-free (Corning, Cat#354277). The
Matrigel was diluted 1:100 in DMEM/F12 (Dulbecco's Modified Eagle Medium: Nutrient Mixture F12, ThermoFisher, Cat#11320033) and incubated at room temperature for 45 min to 1 hour.
Matrigel was then aspirated and replaced with IMDM and used right away or stored at 37°C in 5%
carbon dioxide for up to 1 week. HPSCs on a MEF feeder layer were dissociated with TrypLE as
previously described and plated on the Matrigel-coated plates at a ratio of 1:6 in Essential 8 (E8)
Flex medium (Gibco, Cat#A2858501). Cells were cultured at 37 oC in 5% carbon dioxide. Cells were
fed every day with 2 mL/well (6-well plate) of fresh E8 medium. HPSCs were adapted to feederfree conditions after 2-3 passages. To passage feeder-free hPSCs, colonies were observed by
brightfield microscopy daily. Once colonies were large but still tightly formed and covered close to
75% of the well, the well was washed once with 1x Dulbecco’s Phosphate Buffered Saline (DPBS)
without calcium and magnesium (Cat#21-031-CV), and 0.5 mM EDTA (EDTA Buffer, pH 8, 0.5 M,
Invitrogen, Cat#15575020) diluted in 1x DPBS (EDTA-PBS) (pre-warmed to 37°C) was added.
Cells were incubated with EDTA-PBS for 4 minutes while closely observing the well under a
brightfield microscope. When the cells in the colonies appeared rounded and cells at the center
began to separate from each other, EDTA-PBS was gently removed and 1 mL E8 Flex medium
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was added to the well followed by gentle agitation to lift off cell aggregates. A P10 pipet tip was
used to gently draw up the cell aggregates into a 14 mL Falcon tube with E8 media and cells were
plated at a passaging ratio of 1:3-1:5 on a new plate coated with 1:100 Matrigel. For cryopreserving
feeder-free PSCs, cells were passaged with 0.5 mM EDTA-PBS as previously described. After
removing EDTA-PBS, 1 mL/well of STEM-CellBanker-GMP Grade (Amsbio LLC, Cat#NC0400932)
was added and cell aggregates were lifted off by gentle agitation. After triturating once,
resuspended cells were transferred into labeled cryovials and placed into freezing containers with
isopropanol at -80°C for 24 hours before being transferred to liquid nitrogen for long-term storage.

Differentiation of pluripotent stem cells into enteric neural crest precursor cells
Differentiation of hPSCs into enteric neurons and glia starting from hPSCs maintained on a
MEF feeder-cell layer (22)
Up to a week before starting a differentiation, 6-well plates were prepared for differentiation
by coating with Matrigel (Corning Matrigel Basement Membrane Matrix, Corning, Cat#354234). The
Matrigel was thawed on ice and diluted 1:20 with DMEM/F12 medium (Dulbecco's Modified Eagle
Medium: Nutrient Mixture F-12, ThermoFisher, Cat#11320033). The diluted Matrigel was added to
the wells and allowed to incubate at 37°C for 1-2 hours. The plates were monitored carefully under
a brightfield microscope to identify the ideal Matrigel layer thickness at which regular, elongated,
feathery aggregates were visible on the well bottom (79).
One to three days before the start of differentiation, hPSCs were passaged onto 1:20
Matrigel. Differentiations were carried out in tissue culture-treated 6-well plates. For passaging, the
wells were washed briefly with Iscove’s Modified DMEM (IMDM). 0.05% Trypsin-EDTA (Mediatech,
Cat#MT25-052-CI) was added to each well (1 mL/well). During the incubation with Trypsin at room
temperature for 1-2 minutes, the plate was continuously agitated with vigorous side-to-side motions
across the cell culture hood surface. This allowed the MEF feeder layer cells to detach very quickly
while the hPSC stayed firmly attached to the bottom of the well. Once most of the MEF had
150

detached, the trypsin was carefully aspirated from the side of the well and the dish was left without
any medium for another 1-2 minutes at room temperature. At this point, HES medium was added
to the wells (1mL/well) and the cells were triturated 2-3 times with a P100 pipet before they were
counted and replated on 1:20 Matrigel at a cell density of 100,000 cells/cm 2. Differentiation was
started 1 to 3 days after plating on 1:20 Matrigel once hPSCs reached a 70-80% confluent
monolayer (see Fattahi et al. 2015 for images denoting the optimal cell density at the start of
differentiation (79)).
On day 0 of differentiation, HES medium was replaced with 2 mL/well KSR medium for
differentiation day 0-1 (see Supplementary Materials - Reagents and Solutions). Differentiating
cultures were maintained in 37°C in 5% carbon dioxide. On day 2 of differentiation, KSR medium
for differentiation day 0-1 was replaced with 2 mL/well KSR medium for differentiation day 2-11
(see Reagents and Solutions in Supplementary Data). On day 4 of differentiation, the medium was
replaced with 2 mL/well 75% (v/v) KSR medium for differentiation day 2-11 and 25% (v/v) N2
medium (see Reagents and Solutions in Supplementary Data). On day 6 of differentiation, the
medium was replaced with 4 mL/well 50% (v/v) KSR medium for differentiation day 2-11 and 50%
(v/v) N2 medium plus the addition of 1 µM retinoic acid (100mM, Sigma, Cat#R2625). On day 8 of
differentiation, the medium was replaced with 4 mL/well 25% (v/v) KSR medium for differentiation
day 2-11, 75% (v/v) N2 medium, and 1 µM retinoic acid (100mM, Sigma, Cat#R2625). On day 10
of differentiation, the medium was replaced with 4 mL/well N2 medium with 1 µM retinoic acid.
CD49D-expressing enteric neural precursors were purified via fluorescence activated cell sorting
on day 11 of differentiation.
Differentiation of hPSCs into enteric neurons and glia starting from hPSCs maintained in
feeder-free conditions (25)
Two days before start of differentiation, hPSCs in feeder-free conditions were passaged
according to the methods specified above, but with a passaging ratio of 5:6 (cell aggregates from
5x wells of a 6-well plate are seeded in 6x wells of a 6-well plate) on a plate coated with 1:100
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Matrigel (Corning, Cat#354234). Culture medium is replaced with fresh Essential 8 Flex medium
(Gibco, Cat#A2858501) the next day. Two days after plating, differentiation was started if the hPSC
cultures had proliferated to a confluent monolayer. This was considered day 0 of differentiation and
the maintenance medium (Essential 8 Flex medium) was switched to 2mL/well differentiation
medium A (see Reagents and Solutions in Supplementary Data). Whenever medium was
aspirated, care was taken to slowly aspirate from the edge of the wells in order to not disrupt the
cell layer in the wells. On day 4 of differentiation, differentiation medium A was replaced with
differentiation medium B (see Reagents and Solutions in Supplementary Data) at 2mL/well. On day
6, the medium in the wells was replaced with fresh differentiation medium B at 4mL/well. On day 8,
differentiation medium B was replaced with differentiation medium C (see Reagents and Solutions
in Supplementary Data) at 4mL/well. On day 10 of differentiation, the medium in the wells was
replaced with 6mL/well fresh differentiation medium C. CD49D-expressing enteric neural
precursors were purified via fluorescence activated cell sorting on day 12 of differentiation.

Differentiation of enteric neural crest precursor cells into enteric neurons and glia
ENC spheroid phase (differentiation days 11/ 12 to 15)
After FACS-mediated purification of CD49D+ enteric neural crest precursor cells on day
11/12 of differentiation, the sorted cells were resuspended in NC medium (see Reagents and
Solutions in Supplementary Data) at a concentration of 2.5 million cells/mL NC medium and plated
at 2mL/well in a 6-well plate (Costar® 6-well Clear Flat Bottom Ultra-Low Attachment 6-Well Plate;
Corning, Cat#3471). During these 3-4 days, the cells aggregated into and proliferated as floating
spheroids. Two days after plating (differentiation day 13/14), the old NC medium was removed by
gently swirling the plate with the ENC spheroids so that they group at the center of the well. This
allowed careful aspiration of the old NC medium with a P1000 pipet from the edge of the well while
actively avoiding the removal of any ENC spheroids. 2 mL/well fresh NC medium was added.
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Enteric Neuron Induction (differentiation days 15 to >60)
On day 15 of differentiation, the ENC spheroids are grouped at the center of their wells by
gently swirling the plate and the NC medium was carefully aspirated from the edge of the well with
a P1000 pipet. 1 mL/well accutase was added to the wells and the plate was incubated at 37°C for
30 minutes to dissociate the ENC spheroids. The spheroids were then mechanically dissociated
with a P1000 pipet and cells were pelleted (270xg, 3 min). The cells were resuspended in EN
medium (see Reagents and Solutions in Supplementary Data) and plated on poly-Lornithine/laminin/fibronectin-coated glass coverslips in 12-well plates at a cell density of 100,000
cells/cm2. EN medium was replaced every 2 days until day 50 of differentiation. After that EN
medium was supplemented with 2 μg/mL laminin-I (L, R&D Systems, Cat#3400-010-01) and 2
μg/mL fibronectin (FN, BD Biosciences, Cat#356008) and replaced weekly.
Preparation of poly-L-ornithine/laminin/fibronectin-treated long-term ENC culture plates
Two to seven days before ENC spheroids were plated for enteric neuron induction
(between day 6 and 13 of differentiation), the plates used for long-term ENC culture were prepared
for seeding. Glass coverslips were placed into each well (18mm glass coverslips (Fisherbrand,
Cat#12-546) were used for 12-well plates) and 15 μg/mL poly-L-ornithine hydrobromide (Sigma,
Cat#P3655) in 1xPBS was added. The plate was then incubated overnight at 37°C. The next day,
the poly-L-ornithine hydrobromide solution was replaced with 2 μg/mL laminin-I (R&D Systems,
Cat#3400-010-01) and 2 μg/mL fibronectin (BD Biosciences, Cat#356008) in 1x PBS and the plate
was incubated overnight at 37°C and used the next day or left at 37°C until needed (up to 6 days).
Before cell seeding, the laminin/fibronectin solution was aspirated and replaced with EN medium.

Flow cytometry to confirm maintenance of pluripotency
To confirm pluripotency, hPSCs were assessed by flow cytometry for expression of cell
surface markers associated with the pluripotent state. One well of PSCs was washed once with 1x
Dulbecco’s Phosphate Buffered Saline (DPPBS) (Invitrogen, Cat#14190136), treated with 1 mL
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0.25% Trypsin-EDTA (Invitrogen, Cat#25200056) for 5 minutes at 37°C to dissociate colonies into
single cells, neutralized with 0.5 mL Fetal Bovine Serum (FBS) (Tissue Culture Biologicals,
Cat#101), and centrifuged at 270 xg for three minutes. The pellet was resuspended in 500 μL FACS
Buffer (see Reagents and Solutions in Supplementary Data) and 100 μl each was pipetted into 4x
wells of a 96-well plate. The plate was spun down for two minutes at 750xg. The pellets were
resuspended once more in 100 μL of FACS buffer and spun down for two minutes at 750 xg. Each
well was resuspended in fluorophore-conjugated antibody mixtures as follows: 1 - Unstained control
(100 μl FACS buffer), 2 - SSEA3 (1:50)/SSEA4 (1:400) in 100 μl FACS buffer, 3 - Tra 1-60
(1:50)/Tra 1-81 (1:50) in 100 μL FACS buffer, and 4 - SSEA1 (1:50)/SSEA5 (1:200) in 100 μL FACS
buffer. Antibody catalog numbers are in Supplementary Table 3.1. Cells were incubated with the
antibodies for 15 minutes in the dark at room temperature. 80 μL of FACS buffer was added to
each well and the plate is spun down at 750 xg for 2 minutes. The pellet was resuspended in 200
μL FACS buffer and spun down once more at 750 xg for 2 minutes. Finally, the cells were
resuspended in 100 μL of FACS buffer and analyzed for cell surface marker expression using the
Cytoflex LX (Beckman Coulter).

Purification of enteric neural precursors via FACS at day 11/ 12 of differentiation
On day 11 of differentiation (if hPSCs were maintained on a feeder layer) or day 12 of
differentiation (if PSC were maintained in feeder-free conditions), all wells were washed once with
2 mL/well sterile 1x DPBS before dissociation with 1mL/well Accutase (Innovative Cell
Technologies, Cat#AT104) at 37°C for 20-30 min. After gentle agitation of the plate, all cells were
collected with a P1000 pipet, titrated 2-3 times, and transferred into one 14 mL Falcon tube per 6well plate. The cells were pelleted (270 xg, 3 min) after addition of 4 mL 10% FBS in IMDM. The
cell pellet was then resuspended in 600µL IMDM supplemented with 10% FBS, 10 uL/mL DNaseI
(EMD Millipore; Cat#260913), and 3 μL/mL monothioglycerol (MTG, Sigma Aldrich; Cat#M6145)
plus anti-CD49D antibody (see Supplementary Table 3.1). The cells were incubated on ice for 15
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min protected from light exposure with periodic agitation. The cells were subsequently washed
twice by the addition of 5 mL IMDM supplemented with 10% FBS and subsequent pelleting (270
xg, 3 min). After the second wash, the cells were resuspended in IMDM supplemented with 10%
FBS, 10 uL/mL DNaseI (EMD Millipore; Cat#260913), and 3 μL/mL monothioglycerol (MTG, Sigma
Aldrich; Cat#M6145), passed through a mesh strainer (Falcon, Cat#352235), and sorted on a BD
FACSJazz (BD Biosciences), MoFlo Astrios (Beckman-Coulter), or BD FACSAria Fusion (BD
Biosciences) to isolate CD49D-expressing cells. Cells were sorted into IMDM supplemented with
10% FBS, 10 μL/mL DNaseI, and 3 μL/mL MTG (Sigma Aldrich; Cat#M6145), centrifuged (270 xg,
3 min), and resuspended in NC medium (see Reagents and Solutions in Supplementary Data) for
plating.

Immunofluorescence staining
Cells on glass coverslips were washed with phosphate-buffered saline (PBS), fixed (4%
paraformaldehyde, 20 minutes, RT), washed twice with PBS, blocked (5% normal donkey serum
(NDS), 0.5% Triton X-100 in PBS (0.5% PBST)) (1 hour, RT), incubated in primary antibodies (5%
NDS, 0.5% PBST 1 hour, RT) (see Supplementary Table 3.1, washed 3 x 5 minutes (0.5% PBST),
and then incubated in secondary antibodies (see Supplementary Table 3.1) (0.5% PBST, 30
minutes, dark, RT). Cells washed three times in PBS, incubated in Hoechst 3342 nuclear dye
(1:1000, Invitrogen, Cat#H3570) (30 minutes, RT) were washed two times in PBS, mounted in
Prolong Gold AntiFade Mountant (Life Technologies; Cat#P36934) and allowed to set (overnight,
dark, RT) before long-term storage at 4°C.

Microscopy
Immunofluorescence images were acquired on a Zeiss LSM 710 laser scanning confocal
microscope and Zeiss ZEN 2.3 SP1 FP3 (black) (Version 14.0.18.201; Zeiss, Oberkochen,
Germany) software with a 20x/0.8 air or 63x/1.4 oil DIC M27 Plan-Apochromat objective. The Zeiss
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LSM 710 condenser numerical aperture is 0.55. Confocal images were processed in ImageJ to
crop, scale, and uniformly color adjust. Brightfield images were acquired on a Leica DFC340 FX
camera attached to a Leica DMI4000B microscope with Leica Application Suite X version
1.5.1.13187 (Leica Microsystems, Wetzlar, Germany).

Generating NOS1 3’UTR and CHAT 3’UTR fluorescent reporter human embryonic stem cells
(hESCs)
Guide RNA design
The genomic sequence for human NOS1 (Transcript ID ENST00000618760.4, NOS1-202,
Location

Chromosome

12:

117,208,142-117,452,170)

and

CHAT

ITranscript

ID

ENST00000395562.2, CHAT-205, Chromosome 10:49,609,095-49,665,104) were obtained from
the Ensembl Genome Browser (NOS1: Ensembl 87 December 2016 release, CHAT: Ensembl 89
May 2017) (80). A region of 150 bp within the 3’UTR of NOS1 starting from 30bp 3’ of the STOP
codon was analyzed for suitable CRISPR/Cas9 guide RNAs (gRNAs) using the Broad Institute
software crispr.mit.edu (Feb. 2017) (81). A 150bp region encompassing the entire CHAT 3’UTR
and a short region upstream from the STOP codon was analyzed for suitable gRNAs using the
software http://crispor.tefor.net/ (July 2017) (82) and genome version “UCSC Feb. 2009
(GRCh37/hg19) + SNPs: 1000 Genomes, ExaC”. Four gRNAs were chosen for testing based on
the best combinations of specificity/quality scores (see Supplementary Table 3.2). Each gRNA
has a 20 bp sequence with a NGG protospacer adjacent motif (PAM) sequence at the 3’ end. The
sequences were edited in the following way for cloning into the empty gRNA cloning vector
(Addgene Plasmid #41824; RRID:Addgene_41824; gRNA_Cloning Vector was a gift from George
Church) (83): 1) The PAM sequence was removed. 2) The nucleotide at the 5’ end was changed
to a G if it was not already a G. 3) Homology arms were added as follows:
5’- TTTCTTGGCTTTATATATCTTGTGGAAAGGACGAAACACC- add gRNA sequence here -3’
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5’- GACTAGCCTTATTTTAACTTGCTATTTCTAGCTCTAAAAC- add reverse complement of
gRNA sequence here -3’
The 60 bp oligos (sequence and reverse complement of sequence) were ordered as 25 nmole
oligos (Purification: Standard desalting) (Integrated DNA Technologies, IDT) and annealed in a 1:1
ratio (95°C for 5 minutes, cool at RT for 10 minutes). The annealed product was amplified using
Phusion High-Fidelity DNA Polymerase (New England Biolabs Catalog#M0530S) (98oC for 30s, 30
cycles (98°C for 10s, 55°C for 20s, 72°C for 30s), 72°C for 5 min, 4°C hold). The PCR product was
visualized by agarose gel electrophoresis using a 1.5% agarose gel. The product band was excised
under ultraviolet light and purified using the NucleoSpin Gel and PCR Clean-Up kit (MacheryNagel,PA, USA; Cat#740609).
The gRNA empty cloning vector was digested using the AflII restriction enzyme and Gibson
Assembly (Gibson Assembly Master Mix; New England Biolabs, Catalog#E2611) was used to clone
the PCR-amplified gRNA sequences into the vector. The assembled gRNA vectors were
transformed into NEB 5-alpha Competent E. coli (High Efficiency) (New England Biolabs,
Catalog#C2987H), colonies were picked and amplified by miniprep, and plasmids were purified
using the QIAprep Spin Miniprep Kit (QIAGEN, Catalog#27106). Sequences were verified by
Sanger sequencing.
Guide RNA testing
H9-hESCs (H9-hESCs; WA09, WiCell, Madison, WI; NIH Registration Number 0062) were
plated in a 6-well dish on a feeder layer of irradiated MEFs to reach 30-60% confluency after 24
hours. Media was changed 4 hours before transfection. H9-hESCS were transfected with the
identified gRNAs and pCas9_GFP (pCas9_GFP was a gift from Kiran Musunuru (Addgene
plasmid#44719; http://n2t.net/addgene:44719; RRID:Addgene_44719)) (84) using 0.104 μg of
plasmid/cm2 of plate surface area and Lipofectamine Stem Transfection Reagent (ThermoFisher
Scientific, Cat#STEM00003) following manufacturer instructions. Transfected cells were incubated
for 48 hours in 5% oxygen, 5% carbon dioxide, and 90% nitrogen at 37°C and sorted for GFP
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positive cells. Sorted hESCs were plated in conditioned HES medium (see Reagents and Solutions
in Supplementary Data) at 5000 cells/plate on 100 mm dishes coated with Corning® Matrigel®
hESC-Qualified Matrix, LDEV-free (Corning, Cat#354277) (diluted 1:3 in DMEM/F12). Up to 20
colonies were manually picked using a 200 μL pipet tip after 10-15 days when they reached ~1 mm
in diameter and transferred into PCR strip tubes. After triturating 3-4 times, the colonies in PCR
strip tubes were pelleted at 10,000 x g for 5 minutes and the supernatant was removed. 20 μL
Proteinase K buffer (see Reagents and Solutions in Supplementary Data) was added to each tube
followed by incubation at 55°C for 1 hour and inactivation at 94°C for 10 minutes. The digest was
vortexed and centrifuged at 10,000 x g for 5 minutes and 5 μL of digest was used in a PCR reaction
using primers specified in Supplementary Table 3. The PCR products were analyzed by agarose
gel electrophoresis using a 2.5% agarose gel. Size changes and presence of doublets was used
to determine cutting efficiency and gRNAs CHAT-1 and NOS1-2 were chosen.
NOS1 3’UTR and CHAT 3’UTR fluorescent reporter cell line creation
NOS1 3’UTR and CHAT 3’UTR fluorescent reporter cell lines were created using H9
human embryonic stem cells (H9-hESCs; WA09) (WiCell, Madison, WI; NIH Registration Number
0062). A tandem dimer red fluorescent protein (tdRFP) reporter was introduced in separate screens
into the 3’ untranslated regions (3’UTRs) of NOS1 and CHAT in H9-hESCs. gRNA binding
sequences in the CHAT and NOS1 3’UTR were identified. A gRNA screen was performed (see
methods above and gRNA sequences in Supplementary Table 3.2) and gRNAs CHAT-1 and
NOS1-2 were chosen for subsequent gene editing. A plasmid was created to serve as the
homology-directed repair template after the Cas9-induced double-stranded DNA break. The repair
template consisted of an internal ribosome entry site (IRES) followed by tdRFP with a 5’ nuclear
localization signal (NLS) (repair constructs are referred to as NOS1 3’UTR IRES-NLS-tdRFP and
CHAT 3’UTR IRES-NLS-tdRFP). 1 kb homology arms were added at the 5’ and 3’ ends of the
repair template. The repair template also included a loxP-flanked puromycin selection cassette.
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However, this was not utilized due to the unavailability of puromycin-resistant MEFs at the time of
the experiment.
H9-hESCS were transfected with the identified gRNAs and pCas9_GFP (pCas9_GFP was
a

gift

from

Kiran

Musunuru

(Addgene

plasmid#44719;

http://n2t.net/addgene:44719;

RRID:Addgene_44719)) (84) using 0.104 μg of plasmid/cm2 of plate surface area and
Lipofectamine Stem Transfection Reagent (ThermoFisher Scientific, Cat#STEM00003) following
manufacturer instructions. Transfected cells were incubated for 48 hours in 5% oxygen, 5% carbon
dioxide, and 90% nitrogen at 37°C and sorted for GFP positive cells. Sorted hESCs were plated in
conditioned HES medium (see Reagents and Solutions in Supplementary Data) at 5000 cells/plate
on 100 mm dishes coated with Corning® Matrigel® hESC-Qualified Matrix, LDEV-free (Corning,
Cat#354277) (diluted 1:3 in DMEM/F12). All healthy-looking colonies were manually picked using
a 200 μL pipet tip after 10-15 days when they reached ~1 mm in diameter and transferred into PCR
strip tubes. After triturating 3-4 times, half of the volume was plated in HES medium on 48-well
plates coated with Corning® Matrigel® hESC-Qualified Matrix, LDEV-free (Corning, Cat#354277)
(diluted 1:3 in DMEM/F12) and seeded with irradiated MEFs 24 hours prior to seeding of the picked
colonies.The other half of the cell suspension was pelleted at 10,000 x g for 5 minutes and the
supernatant was removed. 20 μL Proteinase K buffer (see Reagents and Solutions in
Supplementary Data) was added to each tube followed by incubation at 55°C for 1 hour and
inactivation at 94°C for 10 minutes. The digest was vortexed and centrifuged at 10,000 x g for 5
minutes and 5 μL of digest was used in a PCR reaction. Primers for PCR screening of CRISPR
clones are listed in Supplementary Table 3.3. The PCR products were analyzed by agarose gel
electrophoresis. Any colonies that showed a correct insertion of the repair template were expanded
into progressively larger wells with MEF feeder cells plated on 0.1% gelatin (Sigma-Aldrich; Cat#
G1890) until they could be maintained as normal (see above) and stocks of the cell line clone could
be frozen for long-term storage.
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To excise the puromycin selection cassette, clones with the correct insertion were
expanded and transfected with pCAG-Cre-GFP (pCAG-Cre:GFP was a gift from Connie Cepko
(Addgene plasmid # 13776; http://n2t.net/addgene:13776 ; RRID:Addgene_13776)) (85) using
Lipofectamine Stem. GFP positive cells were FAC-sorted after 48 hours and plated at 5000 cells
per 100 mm dish, and individual colonies were manually picked, as previously described. Colonies
were screened for excision of the puromycin selection cassette using the primers outside of the
inserted sequence including the 1kb homology arms (sequences in Supplementary Table 3.3).

Transcription factor cloning into lentiviral expression vector
Transcription factor cDNA sequences (see Supplemental Table 3.4) were amplified using primers
that added the Gateway recombination sequence attB1 flanking the ORF: attB1 Fwd: 5’GGGGACAAGTTTGTACAAAAAAGCAGGCT-3’

and

attB1

Rev:

5’-

GGGGACCACTTTGTACAAGAAAGCTGGGTA-3’. The PCR reaction was run on a 0.7% agarose
gel and the product band was excised under ultraviolet light and purified using the NucleoSpin Gel
and PCR Clean-Up kit (Machery-Nagel,PA, USA; Cat#740609). The amplified transcription factor
sequences were then inserted into the FU-tetO-Gateway lentiviral expression vector (kind gift from
John Gearhart, Addgene plasmid # 43914 ; http://n2t.net/addgene:43914 ; RRID:Addgene_43914)
(77) using a One Tube Gateway cloning reaction (86). 100 fM (315 ng) of Gateway pDONR221
Vector (ThermoFisher, Cat#12536017) and 300 fM of the amplified transcription factor sequences
were combined with 3 μL BP Clonase II enzyme mix (ThermoFisher, Cat#11789100) and TE buffer
pH 8.0 was added up to a final volume of 15 μL. The reaction mixture was incubated at room
temperature overnight. To assess the efficiency of the first step of the reaction (BP reaction), 0.5
µl of proteinase K solution (ThermoFisher, Cat#11789100) was added to 5 μL of the BP reaction
mixture and incubated at 37°C for 10min and then transformed into OneShot TOP10 Competent
Cells (ThermoFisher, Cat#C404003). 100 fM (678 ng) of FU-tetO-Gateway lentiviral expression
vector and 3 μL LR Clonase II enzyme mix (ThermoFisher, Cat#11791100) were added to the
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remaining 10 μL of BP reaction and TE buffer pH 8.0 was added up to a final volume of 15 μL. The
reaction mixture was incubated at room temperature overnight and to stop the reaction, the reaction
was incubated at 37°C for 10 minutes in the presence of 2 µl of proteinase K solution
(ThermoFisher, Cat#11791100). 2 µl of LR clonase reaction was subsequently transformed into
OneShot TOP10 Competent Cells (ThermoFisher, Cat#C404003), colonies were picked, amplified
by miniprep, and plasmids were purified using the QIAprep Spin Miniprep Kit (QIAGEN,
Catalog#27106). Sequences were verified by Sanger sequencing.

Lentivirus production
This protocol closely follows the recommendations made by Wang et al. (87). HEK293T
cells (ATCC, Cat#CRL-3216) were seeded at a cell density of 3.5x106 cells/plate on 2x 10 cm plates
per transcription factor lentiviral expression vector in HEK293T culture medium (see Reagents and
Solutions in Supplementary Data). The next day, the culture medium was exchanged and the cells
were transfected: Per 10 cm plate, 48 µL FuGENE transfection reagent (Promega, Cat#E2311)
was added to 600 µL IMDM (ThermoFisher, Cat#12440053) without touching the side of the well
or microcentrifuge tube. The FuGENE/IMDM mixture was left at room temperature for 5 minutes. 4
µg of each lentiviral packaging vector pVSV-G (88), pMDLg/pRRE (89), and pRSVREV (89) and 4
µg of the FU-tetO-Gateway lentiviral expression vector were combined separately before addition
to the FuGENE/IMDM mixture. The FuGENE/IMDM/DNA mixture was gently mixed (several
inversions of microcentrifuge tube) and left undisturbed at room temperature for 20 minutes. The
transfection mix was then slowly added to the culture medium on the HEK293T culture plate and
the plate was tilted several times to mix the contents. The plates were left undisturbed for 3 days
at 37°C in 5% carbon dioxide before the media was collected and passed through a Millex-HV
Syringe Filter Unit, 0.45 µm, PVDF, 33 mm (Sigma, Cat#SLHV033RS) using a 20mL syringe
(Becton Dickinson, Cat#302830) into ultraclear centrifuge tubes (Beckman Coulter, Cat#344058)
and the viral particles were pelleted at 24,000 rpm for 90 minutes (no breaking at the end of the
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spin) in a SW-28 Ti rotor (Beckman Coulter, SW 28 Ti Swinging-Bucket Aluminum Rotor Package,
Cat#342204). The ultracentrifuge tubes were then inverted to remove the supernatant and added
100uL of 1x Dulbecco’s Phosphate Buffered Saline (DPBS, Cat#21-031-CV). After 1 hour at 4°C,
the virus was aliquoted into 10 µL aliquots and frozen at -80oC for long-term storage.
To facilitate titering of the FU-tetO-Gateway lentiviral expression vector that only expresses
the gene product of interest in the presence of doxycycline hyclate (doxycycline, Sigma,
Cat#D9891-25G) and a reverse tetracycline-controlled transactivator (rtTA), a polyclonal HEK293T
cell line stably expressing rtTA was created. Briefly, HEK293T cells were infected with FUdeltaGWrtTA

vector

(kind

gift

from

Konrad

Hochedlinger,

Addgene

plasmid

#

19780

;

http://n2t.net/addgene:19780 ; RRID:Addgene_19780) (90) and maintained in the presence of 0.5
µg/mL doxycycline for 14 days. 0.5 µg/mL doxycycline, which had been empirically determined to
be the lowest concentration of doxycycline to kill 100% of HEK293T cells within 48 hours.
For titering, this polyclonal rtTA-expressing cell line was passaged into a 48-well plate at a
cell density of 60,000 cells/well. The next day, a subset of the wells was infected with FUdeltaGWrtTA-lentivirus. The virus was serially diluted (1:2 serial dilution from 1:250 to 1:16,000) in the
presence of 1:2000 protamine sulfate (Fresenius Kai, Cat#C22905, NDC 63323-229-05) and 0.5
µg/mL doxycycline. The virus-containing culture medium was replaced 24 hours after infection with
fresh HEK293T culture medium with 0.5 µg/mL doxycycline and the virus was titered 48 hours after
infection using intracellular flow cytometry.

Intracellular Flow Cytometry for virus titering
The wells with infected HEK293T were washed once with 1x Dulbecco’s Phosphate
Buffered Saline (DPBS) (Invitrogen, Cat#14190136), treated with 1 mL 0.25% Trypsin-EDTA
(Invitrogen, Cat#25200056) for 5 minutes at 37oC to dissociate colonies into single cells,
neutralized with 0.5 mL Fetal Bovine Serum (FBS) (Tissue Culture Biologicals, Cat#101), and
centrifuged at 270 xg for three minutes. The cells were resuspended in IMDM and centrifuged at
162

270 xg for three minutes. The cells were then fixed for 30 minutes at 37°C in 1.6% (v/v) PFA in
Dulbecco’s Phosphate Buffered Saline (DPBS, Cat#21-031-CV) and then centrifuged (700 xg two
minutes). The cells were then resuspended in DPBS and centrifuged at 700 xg for two minutes.
For permeabilization, the cells were washed twice in 1x Intracellular Staining Permeabilization
Wash Buffer (10x stock, BioLegend, Cat#421002) in DPBS and centrifuged at 700 xg for two
minutes. The cells were then resuspended in anti-His or anti-V5 primary antibody (details in
Supplementary Table 3.3) in 1x Intracellular Staining Permeabilization Wash Buffer in DPBS with
and incubated for 30 minutes at room temperature. The cells were washed twice with 1x
Intracellular Staining Permeabilization Wash Buffer in DPBS, centrifuged (700 xg, 2 min), and
supernatant was aspirated. The cells were then resuspended in Alexa Fluor 488-conjugated
secondary antibody (details in Supplementary Table 3) in 1x Intracellular Staining Permeabilization
Wash Buffer in DPBS with and incubated for 30 minutes at room temperature. The cells were
subsequently washed twice with 1x Intracellular Staining Permeabilization Wash Buffer in DPBS,
centrifuged (700 xg, 2 min), the supernatant was aspirated, and cells were resuspended in FACS
Buffer (see Reagents and Solutions in Supplementary Data) for analysis on a Cytoflex LX
(Beckman Coulter).

Lentiviral infection of ENC differentiations
Differentiating enteric neuron precursors were infected with EBF1-FU-tetO-Gateway-lentivirus and
FUdeltaGW-rtTA-lentivirus on day 22 of differentiation: EN medium was aspirated from the wells
and replaced with EN medium supplemented with EBF1-FU-tetO-Gateway-lentivirus (1:1000
dilution of concentrated virus stock, ~2x108 viral particles/mL), FUdeltaGW-rtTA-lentivirus (1:1000
dilution of concentrated virus stock, viral titer unknown), and 1:2000 protamine sulfate (Fresenius
Kai, Cat#C22905, NDC 63323-229-05). The EN medium was replaced the next morning and on
day 24 of differentiation, EN medium was supplemented with 0.5 μg/mL doxycycline hyclate
(Sigma, Cat#D9891-25G) to start expression of the EBF1 coding sequence. On day 27 of
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differentiation, the wells were briefly washed with phosphate-buffered saline (PBS), fixed with 4%
paraformaldehyde, and then immunofluorescence stained for V5- and His-tag expression.
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3.7 Supplementary Data

Supplementary Figures and Tables

Supplementary Figure 3.1: Chromosomal G-band analysis (karyotyping) of CHAT 3’ UTR
IRES-NLS-tdRFP fluorescent reporter iPSC line
Cre recombinase overexpression was used to excise the puromycin selection cassette from one
clone with the correctly inserted full-length CRISPR repair template, CHAT#59. Chromosomal GBand analysis of one clone (#7) was normal.
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Supplementary Figure 3.2: Looking ahead - the candidate transcription factor
overexpression screen
A) Plasmid map of the FU-tetO-Gateway lentiviral expression vector used for this screen (77). The
Gateway recombination sites (attR1 and attR2) allow for efficient insertion of coding sequences
into the expression vector “Gateway cassette” under control of a tetracycline response element and
a T7 promoter. The coding sequence is tagged with a V5 and HIS tag, simplifying verification of
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infection and expression. (B) Schematic of the planned transcription factor overexpression screen.
Differentiating enteric neural precursors will be transfected at day 20-22 when the cells are
transitioning from a mesenchymal phenotype (image on the bottom left, Day 17) to a more rounded
cell type (image on the bottom middle, Day 25). Doxycycline treatment to turn on transcription factor
expression is started on day 25, before the cells start aggregating into “ganglia”-like structures
(image on the bottom right, Day 33). The cells will then be monitored for the appearance of RFP+
nuclei, indicating the emergence of NOS1+ or CHAT+ neurons, and the proportion of RFP+
neurons will be quantified in mature cultures at or beyond day 60.
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Supplementary Table 3.1: Antibodies
Antibody Name
(species)

Application
(Concentration)

Manufacturer

Catalog

Hoechst 33342,
Trihydrochloride,
Trihydrate

Immunofluorescence
(1:1000)

Invitrogen

Cat#:H3570

SOX10 (goat)

Immunofluorescence
(1:200)

Santa Cruz

Cat#:sc-17342,
RRID:AB_2195374

SOX10 (goat)

Immunofluorescence
(1:200)

R&D Systems

Cat#:AF2864,
RRID:AB_442208

TUJ1 (rabbit)

Immunofluorescence
(1:5000)

Covance,
BioLegend

Cat#:PRB-435P
(Covance), Cat#:802001
(BioLegend),
RRID:AB_2564645

TUJ1 (chicken)

Immunofluorescence
(1:400)

Aves Labs

Cat#:TUJ,
RRID:AB_2313564

HUC/D (clone
16A11, mouse)

Immunofluorescence
(1:200)

Invitrogen

Cat#:A21271,
RRID:AB_221448

NOS1 (rabbit)

Immunofluorescence
(1:100)

Millipore

Cat#:AB5380,
RRID:AB_91824

Tyrosine
hydroxylase (TH,
sheep)

Immunofluorescence
(1:800)

Chemicon
(Millipore)

Cat#:AB1542,
RRID:AB_90755

CGRP (goat)

Immunofluorescence
(1:500)

Abcam

Cat#:Ab36001,
RRID:AB_725807
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Antibody Name
(species)

Application
(Concentration)

Manufacturer

Catalog

TAC1 (N-18, goat)

Immunofluorescence
(1:500)

Santa Cruz

Cat#:Sc-9758,
RRID:AB_661439

CALB2 (rabbit)

Immunofluorescence
(1:1000)

Chemicon
(Millipore)

Cat#:AB5054,
RRID:AB_2068506

TPH2 (sheep)

Immunofluorescence
(1:400)

Chemicon
(Millipore)

Cat#:AB1541,
RRID:AB_90754

VACHT (rabbit)

Immunofluorescence
(1:1000)

Synaptic
Systems

Cat#:139103,
RRID:AB_887864

GABA (rabbit)

Immunofluorescence
(1:1000)

Sigma

Cat#:A2052,
RRID:AB_477652

NPY

Immunofluorescence
(1:500)

Peninsula
Laboratories
International

Unknown

SST (YC7, rat)

Immunofluorescence
(1:500)

Millipore

Cat#:MAB354,
RRID:AB_2255365

RET (rabbit)

Immunofluorescence
(1:400)

ImmunoBiological
Laboratories

Cat#:18121,
RRID:AB_2301042

VIP (rabbit)

Immunofluorescence
(1:250)

Abcam

Cat#:ab78536,
RRID:AB_1604043
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Antibody Name
(species)

Application
(Concentration)

Manufacturer

Catalog

GFAP (chicken)

Immunofluorescence
(1:500)

BioLegend

Cat#:PCK-591P
(Covance), Cat#:829401
(BioLegend),
RRID:AB_2564929

P75 (rabbit)

Immunofluorescence
(1:400)

Chemicon
(Millipore)

Cat#:AB1554,
RRID:AB_90760

S100B (rabbit)

Immunofluorescence
(1:100)

abcam

Cat#:Ab52642,
RRID:AB_882426

RFP (5F8, Rat)

Immunofluorescence
(1:150)

Chromotek

Cat#:5F8-100,
RRID:AB_2336064

V5 tag (rabbit)

Immunofluorescence
(1:200) and Intracellular
flow Cytometry (1:100)

Cell Signaling
Technology

Cat#:D3H8Q,
RRID:AB_2687461

HIS tag (ad1.1.10,
mouse)

Immunofluorescence and
Intracellular Flow
cytometry (1:200)

R&D Systems

Cat#:MAB050,
RRID:AB_357353

Goat anti-Chicken
IgG (H+L) Highly
Cross-Adsorbed
Secondary
Antibody, Alexa
Fluor 488

Immunofluorescence
(1:400)

Life
Technologies

Cat#:A11039,
RRID:AB_142924

Goat anti-Chicken
IgG (H+L) Highly
Cross-Adsorbed
Secondary
Antibody, Alexa
Fluor 594

Immunofluorescence
(1:400)

Life
Technologies

Cat#:A11042,
RRID:AB_2534099
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Antibody Name
(species)

Application
(Concentration)

Manufacturer

Catalog

Goat anti-Chicken
IgG (H+L) Highly
Cross-Adsorbed
Secondary
Antibody, Alexa
Fluor 647

Immunofluorescence
(1:400)

Life
Technologies

Cat#:A21449,
RRID:AB_1500594

Donkey anti-Goat
IgG (H+L) Highly
Cross-Adsorbed
Secondary
Antibody, Alexa
Fluor 488

Immunofluorescence
(1:400)

Life
Technologies

Cat#:A11055,
RRID:AB_2534102

Donkey anti-Goat
IgG (H+L) Highly
Cross-Adsorbed
Secondary
Antibody, Alexa
Fluor 647

Immunofluorescence
(1:400)

Life
Technologies

Cat#:A21447,
RRID:AB_141844

Donkey anti-Mouse
IgG (H+L) Highly
Cross-Adsorbed
Secondary
Antibody, Alexa
Fluor 488

Immunofluorescence and
Intracellular Flow
cytometry (1:400)

Life
Technologies

Cat#:A21202,
RRID:AB_141607

Donkey anti-Mouse
IgG (H+L) Highly
Cross-Adsorbed
Secondary
Antibody, Alexa
Fluor 647

Immunofluorescence
(1:400)

Life
Technologies

Cat#:A31571,
RRID:AB_162542

Donkey anti-Rabbit
IgG (H+L) Highly
Cross-Adsorbed
Secondary
Antibody, Alexa
Fluor 488

Immunofluorescence and
Intracellular Flow
cytometry (1:400)

Life
Technologies

Cat#:A21206,
RRID:AB_2535792
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Antibody Name
(species)

Application
(Concentration)

Manufacturer

Catalog

Donkey anti-Rabbit
IgG (H+L) Highly
Cross-Adsorbed
Secondary
Antibody, Alexa
Fluor 594

Immunofluorescence
(1:400)

Life
Technologies

Cat#:A21207,
RRID:AB_141637

Donkey anti-Rabbit
IgG (H+L) Highly
Cross-Adsorbed
Secondary
Antibody, Alexa
Fluor 647

Immunofluorescence
(1:400)

Life
Technologies

Cat#:A31573,
RRID:AB_2536183

Donkey anti-Rat
IgG (H+L) Highly
Cross-Adsorbed
Secondary
Antibody, Alexa
Fluor 488

Immunofluorescence
(1:400)

Life
Technologies

Cat#:A21208,
RRID:AB_141709

Donkey anti-Rat
IgG (H+L) Highly
Cross-Adsorbed
Secondary
Antibody, Alexa
Fluor 594

Immunofluorescence
(1:400)

Life
Technologies

Cat#:A21209,
RRID:AB_2535795

Donkey anti-Sheep
IgG (H+L) Highly
Cross-Adsorbed
Secondary
Antibody, Alexa
Fluor 488

Immunofluorescence
(1:400)

Life
Technologies

Cat#:A11015,
RRID:AB_141362

Donkey anti-Sheep
IgG (H+L) Highly
Cross-Adsorbed
Secondary
Antibody, Alexa
Fluor 594

Immunofluorescence
(1:400)

Life
Technologies

Cat#:A11016,
RRID:AB_10562537
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Antibody Name
(species)

Application
(Concentration)

Manufacturer

Catalog

Alexa Fluor® 488
anti-human SSEA3 Antibody

Flow cytometry (1:50)

BioLegend

Cat#:330305
RRID:AB_1279441

Alexa Fluor® 647
anti-human SSEA4 Antibody

Flow cytometry (1:400)

BioLegend

Cat#:330407
RRID:AB_1089201

Alexa Fluor® 488
anti-human TRA-160-R Antibody

Flow cytometry (1:50)

BioLegend

Cat#:330613
RRID:AB_2295395

Alexa Fluor® 647
anti-human TRA-181 Antibody

Flow cytometry (1:50)

BioLegend

Cat#:330705
RRID:AB_1089245

Alexa Fluor® 488
anti-mouse/human
CD15 (SSEA-1)
Antibody

Flow cytometry (1:50)

BioLegend

Cat#:125609,
RRID:AB_1089191

APC anti-human
SSEA-5 Antibody

Flow Cytometry (1:200)

BioLegend

Cat#:355209,
RRID:AB_2562012

FITC anti-human
CD271
(LNGFR/p75)
Antibody

Flow Cytometry (1:200)

Miltenyi Biotec

Cat#:130-098-103,
RRID:AB_2661083

PE/Cy7 antihuman
CD49D Antibody

Flow Cytometry (1:200)

BioLegend

Cat#:304313,
RRID:AB_10642817
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Supplementary Table 3.2: Candidate gRNAs identified using CRISPR Guide RNA Design
tools for NOS1 3’UTR IRES-NLS-tdRFP (http://crispr.mit.edu) and CHAT 3’UTR IRES-NLStdRFP (http://crispor.tefor.net/). Selected gRNAs are highlighted in grey.
gRNA

NOS1-1

NOS1-2

NOS1-3

NOS1-4
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Cut in Sense
or Antisense
Strand

Sequence
(5’ → 3’)

Sequence with
homology arms

Software annotation of
gRNA sequence

antisense

TTTCTTGGCTTTATATA
ACTGAGGG
Quality Score: 77,
TCTTGTGGAAAGGACG
GCGAGAAG
Predicted off-target
AAACACCGCTGAGGG
CCCGAGG
sites: 129 (31 in genes)
GCGAGAAGCCCG

sense

GACTAGCCTTATTTTAA
CCTCGGGC
CTTGCTATTTCTAGCT
TTCTCGCC
CTAAAACCGGGCTTCT
CCTCAGT
CGCCCCTCAGC

sense

TCGGGCTT
CTCGCCCC
TCAGTGG

antisense

GACTAGCCTTATTTTAA
CCACTGAG
CTTGCTATTTCTAGCT
GGGCGAGA
CTAAAACCTGAGGGGC
AGCCCGA
GAGAAGCCCGC

sense

TTTCTTGGCTTTATATA
AGTGGTTT
Quality Score: 71,
TCTTGTGGAAAGGACG
CCTCGGCC
Predicted off-target
AAACACCGGTGGTTTC
CTCCTGG
sites: 183 (29 in genes)
CTCGGCCCTCC

antisense

GACTAGCCTTATTTTAA
CCAGGAGG
CTTGCTATTTCTAGCT
GCCGAGGA
CTAAAACGGAGGGCC
AACCACT
GAGGAAACCACC

antisense

TTTCTTGGCTTTATATA
GAAACCAG
Quality Score: 70,
TCTTGTGGAAAGGACG
GGCACAGC
Predicted off-target
AAACACCGAAACCAGG
GACAAGG
sites: 265 (37 in genes)
GCACAGCGACA

sense

CCTTGTCG
CTGTGCCC
TGGTTTC

TTTCTTGGCTTTATATA
Quality Score: 76,
TCTTGTGGAAAGGACG
Predicted off-target
AAACACCGCGGGCTTC
sites: 96 (21 in genes)
TCGCCCCTCAG

GACTAGCCTTATTTTAA
CTTGCTATTTCTAGCT
CTAAAACTGTCGCTGT
GCCCTGGTTTC

gRNA

CHAT-1

CHAT-2

CHAT-3

CHAT-4

Cut in Sense
or Antisense
Strand

antisense

sense

antisense

antisense

Sequence
(5’ → 3’)

Software annotation of
gRNA sequence

TTTCTTGGCTTTATATA Specificity score: 82,
GCAGGGTC
TCTTGTGGAAAGGACG Predicted efficiency: 53
TGGCTGTT
AAACACCGCAGGGTCT (Doench ‘16)/
CTAG AGG
GGCTGTTCTAG
52 (Mor.-Mateos)
CCTCTAGA
ACAGCCAG
ACCCTGC

GACTAGCCTTATTTTAA
CTTGCTATTTCTAGCT
CTAAAACAGTGGCAGG
AGTCAAGGTTC

CAACCTTG
ACTCCTGC
CACT AGG

TTTCTTGGCTTTATATA
TCTTGTGGAAAGGACG
AAACACCGAACCTTGA
CTCCTGCCACT

CCTAGTGG
CAGGAGTC
AAGGTTG

GACTAGCCTTATTTTAA
CTTGCTATTTCTAGCT
CTAAAACAGTGGCAGG
AGTCAAGGTTC

GTTTGGGA
GGTGAAAC
CTAG TGG

TTTCTTGGCTTTATATA
TCTTGTGGAAAGGACG
AAACACCGTTTGGGAG
GTGAAACCTAG

CCACTAGG
TTTCACCT
CCCAAAC

GACTAGCCTTATTTTAA
CTTGCTATTTCTAGCT
CTAAAACCTAGGTTTC
ACCTCCCAAAC

Specificity score: 71,
Predicted efficiency: 54
(Doench ‘16)/
26 (Mor.-Mateos)

Specificity score: 69,
Predicted efficiency:
56 (Doench ‘16)/
50 (Mor.-Mateos)

TTTCTTGGCTTTATATA Specificity score: 60,
CTGTTCTA
TCTTGTGGAAAGGACG Predicted efficiency:
GAGGCTGG
AAACACCGTGTTCTAG 67 (Doench ‘16)/
GTTT GGG
AGGCTGGGTTT
48 (Mor.-Mateos)
CCCAAACC
CAGCCTCT
AGAACAG
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Sequence with
homology arms

GACTAGCCTTATTTTAA
CTTGCTATTTCTAGCT
CTAAAACAAACCCAGC
CTCTAGAACAC

Supplementary Table 3.3: PCR primers for screening CHAT and NOS1 3’UTR NLS-tdRFP
reporter CRISPR clones
Forward
Primer

Sequence
(5’ → 3’)

Tm (°C)

Reverse
Primer

Sequence
(5’ → 3’)

Tm (°C)

PCR Product
Size (kb)

CHAT
Fwd

AGTCTGC
TGCCGCC
TACTGAG
A

64

CHAT
Rev

GCTGTGG
AAAGCTG
GGGTAAG
G

61

176 - gRNA
screen

NOS1
Fwd

CTGAGCC
CAGAGCA
TGGGTGA
TTT

63

NOS1
Rev

GGAGTGG
GAACAGA
GTTTTGTA
AGAGCC

63

364 - gRNA
screen

tdRFP
unique
internal
Fwd

GCATGGC
ACCGGCA
GCACCG

68

CHAT
3’UTR
genomic
Rev

ACATCTC
AACTCTG
CCTCTGC
TG

60

1790 - after
puromycin
selection cassette
removal

tdRFP
unique
internal
Fwd

GCATGGC
ACCGGCA
GCACCG

68

NOS1
3’UTR
genomic
Rev

GCAACTC
TTTCCAA
CCTCATC
CAC

60

2147 - after
puromycin
selection cassette
removal

PGK Prom
Fwd

CTGTCCA
TCTGCAC
GAGACTA
GTG

61

CHAT
3’UTR
genomic
Rev

CTGCCTC
ATAGGGT
TGTGGTG
AG

61

1434

PGK Prom
Fwd

CTGTCCA
TCTGCAC
GAGACTA
GTG

61

NOS1
3’UTR
genomic
Rev

GCAACTC
TTTCCAA
CCTCATC
CAC

60

1415

CHAT
3’UTR
Fwd

CTCAGCA
CACAGCA
CCAGAAA
C

60

IRES_R

CAGTTCC
TCTGGAA
GCTTCTT
GA

58

1.321

NOS1
3’UTR
Fwd

GAAGCAA
GAGGATG
GCCTGAT
C

59

IRES_R

CAGTTCC
TCTGGAA
GCTTCTT
GA

58

1.559
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Forward
Primer

Sequence
(5’ → 3’)

Tm (°C)

Reverse
Primer

Sequence
(5’ → 3’)

Tm (°C)

PCR Product
Size (kb)

IRES Fwd

TGGCTCT
CCTCAAG
CGTATTC
AACAAGG
GG

67

tdRFP
unique
internal
rev

CGGTGCT
GCCGGTG
CCATGC

68

0.927

PGK Fwd

TGGCAAA
ACAATAC
TGAGAAT
GAAGTG

58

Puro
Rev

AACCTCC
CCTTCTA
CGAGCG

60

0.589

Supplementary Table 3.4: Transcription factor coding sequences cloned into FUdeltaGWrtTA lentiviral expression vector
Transcription
Factor

RefSeq
Accession
Number

Source,
Catalog
Number

Literature supporting a
possible role in neuronal
subtype differentiation

Citations

Homo sapiens
basonuclin 2
(BNC2),
transcript variant
1, mRNA

NM_017637

Genscript,
Cat#:
OHu25354

Expressed in subset of
dorsal horn neurons in
mouse, Loss causes neural
crest- derived craniofacial
abnormalities

(91–93)

Homo sapiens
castor zinc finger
1 (CASZ1),
transcript variant
2, mRNA

NM_017766

Genscript,
Cat#:
OHu12480

Loss causes reduced CNS
axonal network and aberrant
gene expression in D.
melanogaster CNS,
Expression restricted to a
subset of CNS neurons,
Possibly regulates
differentiation of dorsal horn
neurons

(94, 95)

Homo sapiens
cAMP
responsive
element binding

NM_182898.
3

Genscript,
Cat#:
OHu31208D

Differentially expressed in
spinal motor neurons

(96)
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Transcription
Factor

RefSeq
Accession
Number

Source,
Catalog
Number

Literature supporting a
possible role in neuronal
subtype differentiation

Citations

Homo sapiens
early B cell
factor 1 (EBF1),
transcript variant
1, mRNA

NM_0012903
60

Genscript,
Cat#:
OHu23556

Required for coupling to cell
cycle exit to neuronal
differentiation during mouse
hindbrain development

(97)

Homo sapiens
ETS variant 1
(ETV1),
transcript variant
1, mRNA

NM_004956

Genscript,
Cat#:
OHu14889

Required for cerebellar
granule cell differentiation in
mouse

(98)

Homo sapiens
Meis homeobox
1 (MEIS1),
mRNA

NM_002398

Genscript,
Cat#:
OHu19435

Expressed in specific murine
CNS neuron subtypes,
Regulates mouse cerebellar
granule development,
Required for murine
sympathetic neuron survival

(99–101)

Homo sapiens
PBX homeobox
3 (PBX3),
transcript variant
1, mRNA

NM_006195

Genscript,
Cat#:
OHu10595

Regulates post-mitotic
differentiation of putative
enteric interneurons in
mouse, Regulates segmentspecific neuron subtype
specification in D.
melanogaster, Required for
medullary respiratory control
center development and
dorsal horn interneuron
differentiation in mouse

(42, 102,
103)

protein 5
(CREB5),
transcript variant
1, mRNA
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Transcription
Factor

RefSeq
Accession
Number

Source,
Catalog
Number

Literature supporting a
possible role in neuronal
subtype differentiation

Citations

Homo sapiens Tbox 2 (TBX2),
mRNA

NM_005994

Genscript,
Cat#:
OHu11986

Required for UV
photoreceptor specification
in zebrafish retina, regulates
anterior neural specification
in xenopus

(104, 105)

Homo sapiens Tbox transcription
factor 3 (TBX3),
transcript variant
1, mRNA

NM_005996.
3

Genscript,
Cat#:
OHu17127

Reduced numbers of
nitrergic enteric neurons in
ENS conditional knockout in
mouse
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Reagents and Solutions
Proteinase K Buffer
10x buffer stock of 50 mM Tris·HCl (pH 7.4), 15 mM ammonium sulfate (pH 9.3), 2.5 mM MgCl 2,
0.1% (v/v) Tween 20, 100 μg/ml Proteinase K (QIAGEN, Catalog#19133).

HES Medium
Combine DMEM/F12 medium (Dulbecco's Modified Eagle Medium: Nutrient Mixture F-12,
ThermoFisher, Cat#11320033), 15% (v/v) knockout serum replacement (ThermoFisher,
Cat#A3181502), 100 μM nonessential amino acids (NEAA, 100x stock, Thermofisher, Cat#11140050), 2 mM GlutaMAX (100x stock, ThermoFisher, Cat#35050061), 1x Penicillin-Streptomycin
(100x stock, ThermoFisher, Cat#15140122), 0.1 mM β-mercaptoethanol (ThermoFisher,
Cat#21985-023), and 10 ng/ml human bFGF (can vary from 5-10 ng/μL depending on the cell line,
R&D Systems, Cat# 233-FB). Store at 4°C for no longer than 1 month.

Conditioned HES medium
Wash 0.1% gelatin-coated wells with MEF at least 24 hours after plating (see methods above) with
IMDM to remove traces of FBS. Add HES medium with 15 ng/mL bFGF (R&D Systems, Cat# 233FB)) at 200 µL/cm2 to the wells and incubate the medium with the MEF feeder layer at 37°C in 5%
carbon dioxide. Collect the medium after 48 hours and remove any cellular debris by passing the
medium through a vacuum filter.

MEF medium
Iscove’s Modified Dulbecco’s Medium (IMDM, ThermoFisher, Cat#12440053), 15% Fetal bovine
serum (Tissue Culture Biologicals, Cat#101), 100 μL monothioglycerol (MTG, Sigma Aldrich;
Cat#M6145) per 100 mL total media volume (from stock diluted 13 µL/mL in IMDM; make fresh
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daily), 1x Penicillin-Streptomycin (100x stock, ThermoFisher, Cat#15140122). Store at 4°C for no
longer than 1 month.

KSR medium for differentiation day 0-1
Add 10 µM SB431542 (10 mM stock; R&D Systems, Cat#1614), 100nM LDN1931189 (500 µM
stock, Stemgent, Cat#04-0074-02), 15% (v/v) knockout serum replacement (ThermoFisher,
Cat#A3181502), 2 mM L-Glutamine (100x stock, ThermoFisher, Cat#25030081), 100 μM
nonessential amino acids (NEAA, 100x stock, Thermofisher, Cat#11140-050), 1x PenicillinStreptomycin

(100x

stock,

ThermoFisher,

Cat#15140122),

0.1

mM

β-mercaptoethanol

(ThermoFisher, Cat#21985-023) to KnockOut DMEM (ThermoFisher, Cat#10829018). Store at 4°C
for no longer than 2 weeks.

KSR medium for differentiation day 2-11
Add 10 µM SB431542 (10 mM stock; R&D Systems, Cat#1614), 100nM LDN1931189 (500 µM
stock, Stemgent, Cat#04-0074-02), 3 µM CHIR99021 (6 mM stock; R&D Systems, Cat#4423), 15%
(v/v) knockout serum replacement (ThermoFisher, Cat#A3181502), 2 mM L-Glutamine (100x
stock, ThermoFisher, Cat#25030081), 100 μM nonessential amino acids (NEAA, 100x stock,
Thermofisher,

Cat#11140-050),

1x

Penicillin-Streptomycin

(100x

stock,

ThermoFisher,

Cat#15140122), 0.1 mM β-mercaptoethanol (ThermoFisher, Cat#21985-023) to KnockOut DMEM
(ThermoFisher, Cat#10829018). Store at 4°C for no longer than 2 weeks. Starting with day 6 of
differentiation, add 1 µM retinoic acid (100mM, Sigma, Cat#R2625) to the culture medium the day
of use.

N2 medium
Add 3 µM CHIR99021 (6 mM stock; R&D Systems, Cat#4423), 10 µM SB431542 (10 mM stock;
R&D Systems, Cat#1614), 100nM LDN1931189 (500 µM stock, Stemgent, Cat#04-0074-02), 1%
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(v/v) N2 supplement (Stemcell Technologies, Cat#07156), 2 mM L-Glutamine (100x stock,
ThermoFisher,

Cat#25030081),

1x

Penicillin-Streptomycin

(100x

stock,

ThermoFisher,

Cat#15140122), to Neurobasal medium (ThermoFisher, Cat#21103049). Store at 4°C for no longer
than 2 weeks. Starting with day 6 of differentiation, add 1 µM retinoic acid (100mM, Sigma,
Cat#R2625) to the culture medium the day of use.

Differentiation medium A
Add 1 ng/mL BMP4 (100 μg/mL stock; R&D Systems, Cat#314-BP), 600 nM CHIR99021 (6 mM
stock; R&D Systems, Cat#4423), and 10 µM SB431542 (10 mM stock; R&D Systems, Cat#1614)
to Essential 6 medium (ThermoFisher, Cat#A1516401). Store at 4°C for no longer than 2 weeks.

Differentiation medium B
Add 1.5 µM CHIR99021 (6 mM stock; R&D Systems, Cat#4423) and 10 µM SB431542 (10 mM
stock; R&D Systems, Cat#1614) to Essential 6 medium (ThermoFisher, Cat#A1516401). Store at
4°C for no longer than 2 weeks.

Differentiation medium C
Add 1.5 µM CHIR99021 (6 mM stock; R&D Systems, Cat#4423), 10 µM SB431542 (10 mM stock;
R&D Systems, Cat#1614), and 1 µM retinoic acid (100mM, Sigma, Cat#R2625) to Essential 6
medium (ThermoFisher, Cat#A1516401). Store at 4°C for no longer than 2 weeks.

NC medium
Combine Neurobasal medium (ThermoFisher, Cat#21103049) with 2% (v/v) B27 supplement
(ThermoFisher, Cat#17504044), 1% (v/v) N2 supplement (Stemcell Technologies, Cat#07156), 2
mM GlutaMAX (100x stock, ThermoFisher, Cat#35050061), 1x Penicillin-Streptomycin (100x stock,
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ThermoFisher, Cat#15140122), 10 ng/mL FGF2 (R&D Systems, Cat# 233-FB), and 3 µM
CHIR99021 (6 mM stock; R&D Systems, Cat#4423). Store at 4°C for no longer than 2 weeks.

EN medium
Combine Neurobasal medium (ThermoFisher, Cat#21103049) with 2% (v/v) B27 supplement
(ThermoFisher, Cat#17504044), 1% (v/v) N2 supplement (Stemcell Technologies, Cat#07156), 2
mM GlutaMAX (100x stock, ThermoFisher, Cat#35050061), 1x Penicillin-Streptomycin (100x stock,
ThermoFisher, Cat#15140122), and 10 ng/mL GDNF (Peprotech, Cat#450-10). Store at 4°C for no
longer than 2 weeks. The day of use, add 100 µM ascorbic acid (Sigma, Cat#A8960).

HEK293T culture medium
Add 10% FBS (Tissue Culture Biologicals, Cat#101) and 1x Penicillin-Streptomycin (100x stock,
ThermoFisher, Cat#15140122) to Dulbecco’s Modified Eagle Medium (DMEM, Corning, Cat#10013-CV).

FACS Buffer
Combine phosphate-buffered saline (PBS), 2% fetal bovine serum, 1 mM EDTA, and 0.1% sodium
azide.

184

3.8 References

1. Fung C, Vanden Berghe P. Functional circuits and signal processing in the enteric
nervous system [Internet]. Cell. Mol. Life Sci. [published online ahead of print: May 18,
2020]; doi:10.1007/s00018-020-03543-6

2. Schneider S, Wright CM, Heuckeroth RO. Unexpected Roles for the Second Brain:
Enteric Nervous System as Master Regulator of Bowel Function [Internet]. Annu. Rev.
Physiol. [published online ahead of print: October 31, 2018]; doi:10.1146/annurevphysiol-021317-121515

3. Furness JB, Callaghan BP, Rivera LR, Cho H-J. The enteric nervous system and
gastrointestinal innervation: integrated local and central control. Adv. Exp. Med. Biol.
2014;817:39–71.

4. Furness JB. The Enteric Nervous System. Malden, Mass: Wiley; 2006:
5. Knowles CH, Lindberg G, Panza E, De Giorgio R. New perspectives in the diagnosis and
management of enteric neuropathies. Nat. Rev. Gastroenterol. Hepatol. 2013;10(4):206–
218.

6. Rivera LR, Poole DP, Thacker M, Furness JB. The involvement of nitric oxide synthase
neurons in enteric neuropathies. Neurogastroenterol. Motil. 2011;23(11):980–988.

7. Heuckeroth RO. Hirschsprung disease - integrating basic science and clinical medicine to
improve outcomes. Nat. Rev. Gastroenterol. Hepatol. 2018;15(3):152–167.

8. Antonucci A et al. Chronic intestinal pseudo-obstruction. World J. Gastroenterol.
2008;14(19):2953–2961.

185

9. Nardo GD et al. Chronic intestinal pseudo-obstruction in children and adults: diagnosis
and therapeutic options [Internet]. Neurogastroenterology & Motility 2017;29(1):e12945.

10. Yanchar NL, Soucy P. Long-term outcome after Hirschsprung’s disease: patients'
perspectives. J. Pediatr. Surg. 1999;34(7):1152–1160.

11. Jarvi K, Laitakari EM, Koivusalo A, Rintala RJ, Pakarinen MP. Bowel function and
gastrointestinal quality of life among adults operated for Hirschsprung disease during
childhood: a population-based study. Ann. Surg. 2010;252(6):977–981.

12. Neuvonen MI, Kyrklund K, Rintala RJ, Pakarinen MP. Bowel Function and Quality of Life
After Transanal Endorectal Pull-through for Hirschsprung Disease: Controlled Outcomes
up to Adulthood. Ann. Surg. 2017;265(3):622–629.

13. Musser MA, Correa H, Southard-Smith EM. Enteric neuron imbalance and proximal
dysmotility in ganglionated intestine of the Sox10(Dom/+) Hirschsprung mouse model.
Cell Mol Gastroenterol Hepatol 2015;1(1):87–101.

14. Roberts RR, Bornstein JC, Bergner AJ, Young HM. Disturbances of colonic motility in
mouse models of Hirschsprung’s disease. Am. J. Physiol. Gastrointest. Liver Physiol.
2008;294(4):G996–G1008.

15. Zaitoun I et al. Altered neuronal density and neurotransmitter expression in the
ganglionated region of Ednrb null mice: implications for Hirschsprung’s disease.
Neurogastroenterol. Motil. 2013;25(3):e233–44.

16. Coyle D, O’Donnell AM, Gillick J, Puri P. Altered neurotransmitter expression profile in
the ganglionic bowel in Hirschsprung’s disease. J. Pediatr. Surg. 2016;51(5):762–769.

186

17. Cheng LS, Schwartz DM, Hotta R, Graham HK, Goldstein AM. Bowel dysfunction
following pullthrough surgery is associated with an overabundance of nitrergic neurons in
Hirschsprung disease. J. Pediatr. Surg. 2016;51(11):1834–1838.

18. Burns AJ et al. White paper on guidelines concerning enteric nervous system stem cell
therapy for enteric neuropathies. Dev. Biol. 2016;417(2):229–251.

19. Fan Y, Wu J, Ashok P, Hsiung M, Tzanakakis ES. Production of human pluripotent stem
cell therapeutics under defined xeno-free conditions: progress and challenges. Stem Cell
Rev Rep 2015;11(1):96–109.

20. Hockemeyer D, Jaenisch R. Induced Pluripotent Stem Cells Meet Genome Editing. Cell
Stem Cell 2016;18(5):573–586.

21. Li W et al. Characterization and transplantation of enteric neural crest cells from human
induced pluripotent stem cells [Internet]. Mol. Psychiatry [published online ahead of print:
October 25, 2016]; doi:10.1038/mp.2016.191

22. Fattahi F et al. Deriving human ENS lineages for cell therapy and drug discovery in
Hirschsprung disease [Internet]. Nature [published online ahead of print: February 10,
2016]; doi:10.1038/nature16951

23. Workman MJ et al. Engineered human pluripotent-stem-cell-derived intestinal tissues
with a functional enteric nervous system [Internet]. Nat. Med. [published online ahead of
print: November 21, 2016]; doi:10.1038/nm.4233

24. Lai FP-L et al. Correction of Hirschsprung-Associated Mutations in Human Induced
Pluripotent Stem Cells Via Clustered Regularly Interspaced Short Palindromic
Repeats/Cas9, Restores Neural Crest Cell Function [Internet]. Gastroenterology
[published online ahead of print: March 23, 2017]; doi:10.1053/j.gastro.2017.03.014
187

25. Barber K, Studer L, Fattahi F. Derivation of enteric neuron lineages from human
pluripotent stem cells [Internet]. Nat. Protoc. [published online ahead of print: March 25,
2019]; doi:10.1038/s41596-019-0141-y

26. Lau S-T et al. Activation of Hedgehog Signaling Promotes Development of Mouse and
Human Enteric Neural Crest Cells, Based on Single-Cell Transcriptome Analyses.
Gastroenterology 2019;157(6):1556–1571.e5.

27. Lasrado R et al. Lineage-dependent spatial and functional organization of the mammalian
enteric nervous system. Science 2017;356(6339):722–726.

28. Memic F et al. Transcription and Signaling Regulators in Developing Neuronal Subtypes
of Mouse and Human Enteric Nervous System. Gastroenterology 2018;154(3):624–636.

29. Chalazonitis A et al. Bone morphogenetic protein regulation of enteric neuronal
phenotypic diversity: relationship to timing of cell cycle exit. J. Comp. Neurol.
2008;509(5):474–492.

30. Chalazonitis A et al. Bone morphogenetic protein-2 and -4 limit the number of enteric
neurons but promote development of a TrkC-expressing neurotrophin-3-dependent
subset. J. Neurosci. 2004;24(17):4266–4282.

31. Liu X, Liu S, Xu Y, Liu X, Sun D. Bone morphogenetic protein 2 regulates the
differentiation of nitrergic enteric neurons by modulating Smad1 signaling in slow transit
constipation. Mol. Med. Rep. 2015;12(5):6547–6554.

32. Chalazonitis A et al. Neurotrophin-3 Is Required for the Survival–Differentiation of
Subsets of Developing Enteric Neurons. J. Neurosci. 2001;21(15):5620–5636.

188

33. Rossi J et al. Retarded Growth and Deficits in the Enteric and Parasympathetic Nervous
System in Mice Lacking GFRa2, a Functional Neurturin Receptor. Neuron 1999;22:243–
252.

34. Li Z et al. Essential roles of enteric neuronal serotonin in gastrointestinal motility and the
development/survival of enteric dopaminergic neurons. J. Neurosci. 2011;31(24):8998–
9009.

35. Wang H et al. The timing and location of glial cell line-derived neurotrophic factor
expression determine enteric nervous system structure and function. J. Neurosci.
2010;30(4):1523–1538.

36. Raghavan S, Bitar KN. The influence of extracellular matrix composition on the
differentiation of neuronal subtypes in tissue engineered innervated intestinal smooth
muscle sheets. Biomaterials 2014;35(26):7429–7440.

37. Memic F et al. Ascl1 Is Required for the Development of Specific Neuronal Subtypes in
the Enteric Nervous System. J. Neurosci. 2016;36(15):4339–4350.

38. Blaugrund E et al. Distinct subpopulations of enteric neuronal progenitors defined by time
of development, sympathoadrenal lineage markers and Mash-1-dependence.
Development 1996;122(1):309–320.

39. Hendershot TJ et al. Expression of Hand2 is sufficient for neurogenesis and cell typespecific gene expression in the enteric nervous system. Dev. Dyn. 2007;236(1):93–105.

40. Wright CM et al. Dlx1/2 mice have abnormal enteric nervous system function [Internet].
JCI Insight 2020;5(4). doi:10.1172/jci.insight.131494

189

41. Zeisel A et al. Molecular Architecture of the Mouse Nervous System. Cell
2018;174(4):999–1014.e22.

42. Morarach K, Mikhailova A, Knoflach V, Memic F. Diversification of molecularly defined
myenteric neuron classes revealed by single cell RNA-sequencing [Internet]. bioRxiv
[published online ahead of print:
2020];https://www.biorxiv.org/content/10.1101/2020.03.02.955757v1.abstract. cited

43. Drokhlyansky E et al. The enteric nervous system of the human and mouse colon at a
single-cell resolution [Internet]. bioRxiv 2019;746743.

44. May-Zhang AA et al. Combinatorial transcriptional profiling of mouse and human enteric
neurons identifies shared and disparate subtypes in situ
[Internet]2020;2020.07.03.187211.

45. Qu Z-D et al. Immunohistochemical analysis of neuron types in the mouse small
intestine. Cell Tissue Res. 2008;334(2):147–161.

46. Sang Q, Young HM. The identification and chemical coding of cholinergic neurons in the
small and large intestine of the mouse. Anat. Rec. 1998;251(2):185–199.

47. Hao MM, Young HM. Development of enteric neuron diversity. J. Cell. Mol. Med.
2009;13(7):1193–1210.

48. Young HM et al. Dynamics of neural crest-derived cell migration in the embryonic mouse
gut. Dev. Biol. 2004;270(2):455–473.

49. Druckenbrod NR, Epstein ML. The pattern of neural crest advance in the cecum and
colon. Dev. Biol. 2005;287(1):125–133.

190

50. Fu M, Vohra BPS, Wind D, Heuckeroth RO. BMP signaling regulates murine enteric
nervous system precursor migration, neurite fasciculation, and patterning via altered
Ncam1 polysialic acid addition. Dev. Biol. 2006;299(1):137–150.

51. Boesmans W, Lasrado R, Vanden Berghe P, Pachnis V. Heterogeneity and phenotypic
plasticity of glial cells in the mammalian enteric nervous system. Glia 2015;63(2):229–
241.

52. Graham KD et al. Robust, 3-Dimensional Visualization of Human Colon Enteric Nervous
System Without Tissue Sectioning [Internet]. Gastroenterology [published online ahead of
print: February 26, 2020]; doi:10.1053/j.gastro.2020.02.035

53. Sang Q, Young HM. Chemical coding of neurons in the myenteric plexus and external
muscle of the small and large intestine of the mouse. Cell Tissue Res. 1996;284(1):39–
53.

54. Hansen MB. The enteric nervous system I: organisation and classification. Pharmacol.
Toxicol. 2003;92(3):105–113.

55. Lei J, Howard MJ. Targeted deletion of Hand2 in enteric neural precursor cells affects its
functions in neurogenesis, neurotransmitter specification and gangliogenesis, causing
functional aganglionosis. Development 2011;138(21):4789–4800.

56. Niwa H. The principles that govern transcription factor network functions in stem cells
[Internet]. Development 2018;145(6). doi:10.1242/dev.157420

57. Jiang J et al. A core Klf circuitry regulates self-renewal of embryonic stem cells. Nat. Cell
Biol. 2008;10(3):353–360.

191

58. Zaret KS, Carroll JS. Pioneer transcription factors: establishing competence for gene
expression. Genes Dev. 2011;25(21):2227–2241.

59. Iwafuchi-Doi M, Zaret KS. Cell fate control by pioneer transcription factors. Development
2016;143(11):1833–1837.

60. Ieda M et al. Direct reprogramming of fibroblasts into functional cardiomyocytes by
defined factors. Cell 2010;142(3):375–386.

61. Son EY et al. Conversion of mouse and human fibroblasts into functional spinal motor
neurons. Cell Stem Cell 2011;9(3):205–218.

62. Morris SA. Direct lineage reprogramming via pioneer factors; a detour through
developmental gene regulatory networks. Development 2016;143(15):2696–2705.

63. Davis RL, Weintraub H, Lassar AB. Expression of a single transfected cDNA converts
fibroblasts to myoblasts. Cell 1987;51(6):987–1000.

64. Minoux M et al. Gene bivalency at Polycomb domains regulates cranial neural crest
positional identity [Internet]. Science 2017;355(6332). doi:10.1126/science.aal2913

65. Hosoda K et al. Targeted and Natural (Piebald-Lethal) Mutations f Endothelin-B Receptor
Gene Produce Megacolon Associated with Spotted Coat Color in Mice. Ceil, Voi.
1994;79:1267–1276.

66. Fujimoto T. Natural history and pathophysiology of enterocolitis in the piebald lethal
mouse model of Hirschsprung’s disease. J. Pediatr. Surg. 1988;23(3):237–242.

192

67. Cantrell VA et al. Interactions between Sox10 and EdnrB modulate penetrance and
severity of aganglionosis in the Sox10Dom mouse model of Hirschsprung disease. Hum.
Mol. Genet. 2004;13(19):2289–2301.

68. Stergachis AB et al. Conservation of trans-acting circuitry during mammalian regulatory
evolution. Nature 2014;515(7527):365–370.

69. Johnson CD et al. Deletion of choline acetyltransferase in enteric neurons results in
postnatal intestinal dysmotility and dysbiosis. FASEB J. 2018;32(9):4744–4752.

70. McCann CJ et al. Transplantation of enteric nervous system stem cells rescues nitric
oxide synthase deficient mouse colon. Nat. Commun. 2017;8:15937.

71. Holt CE, Martin KC, Schuman EM. Local translation in neurons: visualization and
function. Nat. Struct. Mol. Biol. 2019;26(7):557–566.

72. Koenig E. Synthetic mechanisms in the axon—I. Local axonal synthesis of
acetylcholinesterase. J. Neurochem. 1965;12(5):343–355.

73. Mizuguchi H, Xu Z, Ishii-Watabe A, Uchida E, Hayakawa T. IRES-dependent second
gene expression is significantly lower than cap-dependent first gene expression in a
bicistronic vector. Mol. Ther. 2000;1(4):376–382.

74. Corish P, Tyler-Smith C. Attenuation of green fluorescent protein half-life in mammalian
cells. Protein Eng. 1999;12(12):1035–1040.

75. Khmelinskii A et al. Tandem fluorescent protein timers for in vivo analysis of protein
dynamics. Nat. Biotechnol. 2012;30(7):708–714.

193

76. Lo C-A et al. Quantification of Protein Levels in Single Living Cells. Cell Rep.
2019;26(11):3172.

77. Addis RC et al. Efficient conversion of astrocytes to functional midbrain dopaminergic
neurons using a single polycistronic vector. PLoS One 2011;6(12):e28719.

78. Das AT, Tenenbaum L, Berkhout B. Tet-On Systems For Doxycycline-inducible Gene
Expression. Curr. Gene Ther. 2016;16(3):156–167.

79. Fattahi F, Studer L, Tomishima MJ. Neural Crest Cells from Dual SMAD Inhibition. Curr.
Protoc. Stem Cell Biol. 2015;33:1H.9.1–9.

80. Yates AD et al. Ensembl 2020. Nucleic Acids Res. 2020;48(D1):D682–D688.
81. Hsu PD et al. DNA targeting specificity of RNA-guided Cas9 nucleases. Nat. Biotechnol.
2013;31(9):827–832.

82. Concordet J-P, Haeussler M. CRISPOR: intuitive guide selection for CRISPR/Cas9
genome editing experiments and screens. Nucleic Acids Res. 2018;46(W1):W242–W245.

83. Mali P et al. RNA-guided human genome engineering via Cas9. Science
2013;339(6121):823–826.

84. Ding Q et al. Enhanced efficiency of human pluripotent stem cell genome editing through
replacing TALENs with CRISPRs. Cell Stem Cell 2013;12(4):393–394.

85. Matsuda T, Cepko CL. Controlled expression of transgenes introduced by in vivo
electroporation. Proc. Natl. Acad. Sci. U. S. A. 2007;104(3):1027–1032.

86. Gateway Cloning Protocols - US [Internet]https://www.thermofisher.com/us/en/home/lifescience/cloning/gateway-cloning/protocols.html. cited August 19, 2020
194

87. Wang X, McManus M. Lentivirus production [Internet]. J. Vis. Exp. [published online
ahead of print: October 2, 2009];(32). doi:10.3791/1499

88. Qin X-F, An DS, Chen ISY, Baltimore D. Inhibiting HIV-1 infection in human T cells by
lentiviral-mediated delivery of small interfering RNA against CCR5. Proc. Natl. Acad. Sci.
U. S. A. 2003;100(1):183–188.

89. Dull T et al. A third-generation lentivirus vector with a conditional packaging system. J.
Virol. 1998;72(11):8463–8471.

90. Maherali N et al. A high-efficiency system for the generation and study of human induced
pluripotent stem cells. Cell Stem Cell 2008;3(3):340–345.

91. Bhoj EJ et al. Human balanced translocation and mouse gene inactivation implicate
Basonuclin 2 in distal urethral development. Eur. J. Hum. Genet. 2011;19(5):540–546.

92. Chamessian A et al. Transcriptional Profiling of Somatostatin Interneurons in the Spinal
Dorsal Horn. Sci. Rep. 2018;8(1):6809.

93. Vanhoutteghem A et al. The importance of basonuclin 2 in adult mice and its relation to
basonuclin 1. Mech. Dev. 2016;140:53–73.

94. Mellerick DM, Kassis JA, Zhang SD, Odenwald WF. castor encodes a novel zinc finger
protein required for the development of a subset of CNS neurons in Drosophila. Neuron
1992;9(5):789–803.

95. Monteiro CB et al. Zinc finger transcription factor Casz1 expression is regulated by
homeodomain transcription factor Prrxl1 in embryonic spinal dorsal horn late-born
excitatory interneurons [Internet]. European Journal of Neuroscience 2016;43(11):1449–
1459.
195

96. Delile J et al. Single cell transcriptomics reveals spatial and temporal dynamics of gene
expression in the developing mouse spinal cord [Internet]. Development
2019;146(12):dev173807.

97. Garcia-Dominguez M, Poquet C, Garel S, Charnay P. Ebf gene function is required for
coupling neuronal differentiation and cell cycle exit. Development 2003;130(24):6013–
6025.

98. Abe H, Okazawa M, Nakanishi S. The Etv1/Er81 transcription factor orchestrates activitydependent gene regulation in the terminal maturation program of cerebellar granule cells.
Proc. Natl. Acad. Sci. U. S. A. 2011;108(30):12497–12502.

99. Barber BA et al. Dynamic expression of MEIS1 homeoprotein in E14.5 forebrain and
differentiated forebrain-derived neural stem cells. Ann. Anat. 2013;195(5):431–440.

100.

Bouilloux F et al. Loss of the transcription factor Meis1 prevents sympathetic

neurons target-field innervation and increases susceptibility to sudden cardiac death
[Internet]. Elife 2016;5. doi:10.7554/eLife.11627

101.

Owa T et al. Meis1 Coordinates Cerebellar Granule Cell Development by

Regulating Pax6 Transcription, BMP Signaling and Atoh1 Degradation. J. Neurosci.
2018;38(5):1277–1294.

102.

Rhee JW et al. Pbx3 deficiency results in central hypoventilation. Am. J. Pathol.

2004;165(4):1343–1350.

103.

Rottkamp CA, Lobur KJ, Wladyka CL, Lucky AK, O’Gorman S. Pbx3 is required

for normal locomotion and dorsal horn development. Dev. Biol. 2008;314(1):23–39.

196

104.

Alvarez-Delfin K et al. Tbx2b is required for ultraviolet photoreceptor cell

specification during zebrafish retinal development. Proc. Natl. Acad. Sci. U. S. A.
2009;106(6):2023–2028.

105.

Cho G-S, Park D-S, Choi S-C, Han J-K. Tbx2 regulates anterior neural

specification by repressing FGF signaling pathway. Dev. Biol. 2017;421(2):183–193.

197

CHAPTER 4: A MOLECULAR-BASED REGENERATIVE MEDICINE APPROACH FOR
THE TREATMENT OF HIRSCHSPRUNG DISEAS
This manuscript is in press at Gastroenterology (September 2020) and reprinted here with
permission. Authors: Rodolphe Soret, Sabine Schneider, Guillaume Bernas, Briana Christophers,
Ouliana Souchkova, Baptiste Charrier, Franziska Righini-Grunder, Ann Aspirot, Mathieu Landry,
Steven W. Kembel, Christophe Faure, Robert O. Heuckeroth, Nicolas Pilon. Copyright©2020 the
authors.

4.1 Abstract
BACKGROUND & AIMS: Hirschsprung disease (HSCR) is a life-threatening birth defect where
distal colon is devoid of enteric neural ganglia. Current HSCR treatment is surgical removal of
aganglionic bowel, but many children continue to have severe problems after surgery. Here, we
tested a non-surgical therapy based on the hypothesis that post-natal administration of Glial cell
line-Derived Neurotrophic Factor (GDNF) might induce enteric nervous system regeneration.
METHODS: GDNF was administered via rectal enema to several HSCR mouse models from
postnatal day (P) 4 to P8. We assessed survival, ENS structure and regeneration, colon bead
expulsion, colon epithelial permeability, muscle thickness, neutrophil infiltration, and stool
microbiome in GDNF-treated and untreated mice. Time-lapse imaging and genetic cell lineage
tracing were used to identify a source of GDNF-targeted enteric neural progenitors. Human
aganglionic colon explants from children with HSCR were also cultured with GDNF and evaluated
for enteric neurogenesis.
RESULTS: Three different HSCR-model mice had prolonged survival after GDNF enema
treatment. GDNF-treated mice developed enteric neurons and glia in distal bowel that should have
been aganglionic, had enhanced colon motility, reduced distal colon epithelial permeability,
reduced muscle thickness, reduced neutrophil infiltration and partial normalization of
aganglionosis-induced dysbiosis.
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Exogenous luminal GDNF penetrated aganglionic colon epithelium, triggering production of
endogenous GDNF. Some new enteric neurons appear to arise from Dhh-Cre+ lineage Schwann
cells within extrinsic nerves. Ex vivo cultured explants of human aganglionic bowel also respond to
GDNF.
CONCLUSIONS: This study provides hope that GDNF-based regenerative therapy might
supplement or replace current HSCR treatment.

4.2 Introduction
The enteric nervous system (ENS) extends along the entire gastrointestinal tract to control
bowel motility and epithelial activity in response to sensory stimuli (1). Interconnected enteric
ganglia containing neurons and glia develop from neural crest-derived progenitors before birth.
Incomplete colonization of distal colon by these ENS progenitors causes Hirschsprung disease
(HSCR), a condition affecting 1 in 5000 newborns (2). In HSCR, distal colon without ganglia (i.e.,
aganglionic colon) remains tonically contracted, causing functional intestinal obstruction.
Symptoms also include bowel inflammation and a high risk of sepsis and premature death (2).
HSCR is subdivided into short-segment (S-HSCR) and long-segment forms (L-HSCR) (2).
In S-HSCR (>80% of cases), the ENS is absent from rectum and sigmoid colon only. L-HSCR
means longer regions of distal bowel are aganglionic. Many genes influence HSCR risk (2), and
genetic risk variants may combine with non-genetic factors (3). The major HSCR-associated gene
is RET, a transmembrane tyrosine kinase activated when GDNF binds the co-receptor GFRα1.
GDNF-GFRα1-RET signaling is needed for survival, proliferation, and migration of ENS progenitors
(4-6). Accordingly, >90% of children with S-HSCR bear non-coding variants that reduce RET
expression (7). Protein altering RET variants are not common in S-HSCR, but occur in ~35% of
people with L-HSCR (8, 9). Other genes influencing HSCR risk encode EDNRB signaling pathway
molecules, transcription factors, guidance and extra-cellular matrix molecules, and diverse
additional factors (7, 9-11). Male sex also increases HSCR risk ~4-fold, while Down syndrome
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increases HSCR risk ~100-fold (2). Collectively, these observations mean that most children with
HSCR have reduced, but not absent RET signaling, and that diverse additional factors impact
HSCR occurrence.
Since 1948, surgical removal of aganglionic bowel has been life-saving for most children
with HSCR (12). However, post-surgical complications are common and can be long-lasting,
impacting survival and/or quality of life (2). One ideal alternative approach would be to rebuild the
ENS and reduce the need for surgery. This idea prompted many groups to develop cell
transplantation-based HSCR therapies (13). However, despite many encouraging results, some
difficulties remain (14). The optimal source of stem cells, ideal amplification and/or differentiation
strategies prior to transplantation, methods of cell delivery, and cell fate after transplantation are
not yet well defined.
Here we tested the hypothesis that endogenous ENS progenitors could be activated after
birth and generate enteric neurons de novo. Our cell-free strategy is based on the idea that HSCR
is due to incomplete rostrocaudal colonization of distal bowel by the main subpopulation of ENS
progenitors, namely neural crest cells of vagal origin (15). Since extracellular matrix in colon
becomes refractory to migration after a certain developmental window (16), reactivating vagalderived ENS progenitor migration seemed unlikely after birth. However, it seemed possible that
ENS progenitors of sacral (17) or Schwann cell lineage (18) origin, which are already present in
aganglionic colon, could be induced to proliferate and differentiate into functioning neurons.
Schwann cells in particular are abundant in hypertrophic extrinsic nerve tracts that populate both
muscular and submucosal layers of distal aganglionic bowel (19). GDNF appeared as a primary
candidate for postnatal reactivation of ENS progenitors in the aganglionic zone notably because of
its ability to stimulate migration and proliferation of Schwann cells in a RET-independent but
GFRα1-dependent manner through its alternative receptor NCAM (20, 21).
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4.3 Materials and Methods
Mice
Details about all mouse lines used are in Supp. Methods. Enema treatments of most
mouse lines were performed at Université du Québec à Montréal, except for Ret9/- that were
treated with mycophenolate (22) and GDNF at the Children’s Hospital of Philadelphia Research
Institute (as detailed in Supplementary Methods). Where indicated, some HolTg/Tg and Ednrbs-l/s-l
were also GDNF-treated at the Children’s Hospital of Philadelphia Research Institute after
reciprocal exchange of mice between Philadelphia and Montreal. Unless specified otherwise (see
Supplementary Figure 4.1), 10 µl enemas consisting of a 1 µg/µl solution of human recombinant
GDNF (Peprotech, Cat# 450-10) diluted in PBS were administered daily between P4 to P8 (see
Supp. Methods for more detail). Clinical grade GDNF (Medgenesis Therapeutix Inc., Canada) and
a previously described 6XHis-tagged version (23) used for some experiments had similar efficiency
(see Supp. Methods for other tested molecules). For EdU incorporation assays, mouse pups
received 10 µl intraperitoneal injections of a 10 mM EdU solution (ThermoFisher Scientific, Cat#
C10337) once a day during the 5-day (P4 to P8) GDNF enema treatment.

Tissue processing, immunohistochemistry, and imaging
Bowel was cut longitudinally along the mesentery, washed in PBS, pinned onto Sylgardcoated petri dishes, fixed with 4% PFA at 4°C overnight, and finally microdissected to separate
longitudinal/circular muscles from the submucosa/mucosa layer. For ex vivo analyses of living
tissues, unfixed tissues were microdissected in ice-cold oxygenated Krebs solution. For histological
analyses, fixed full-thickness bowel segments were embedded in paraffin and transversally
sectioned at 10 µm. For Western blotting, unfixed organs were weighed and dissolved in RIPA
buffer, using 1 mL for every 100 mg of tissue (further details are provided in Supplementary
Methods). Details about immunohistochemistry and imaging can be found in Supplementary
Methods.
201

Analysis of colonic motility and permeability. In vivo analysis of distal colonic motility in P20 mice
was performed using the bead latency test, as detailed in Supplementary Methods. For ex vivo
analysis of colonic motility, strips of living muscles from most distal colon (1 cm from the anus) of
P20 mice were prepared as described above, and attached in the longitudinal direction in a Schuler
organ bath (Harvard apparatus) filled with oxygenated Krebs solution. Contraction/relaxation of
longitudinal muscles was then recorded as detailed in Supplementary Methods. For ex vivo
analysis of mucosal barrier function, segments of living mucosa from most distal colon of P20 mice
were prepared as described above, mounted in Ussing chambers with 0.5 cm² exposed surface
area (Warner Instruments, Model U-9926), and evaluated for paracellular permeability as described
in Supplementary Methods.

Microbiome analysis
Stool isolation, microbiome sequencing and data analysis were performed as previously
described (details are provided in Supplementary Methods) (24).

Ex vivo time-lapse imaging and culture of murine aganglionic colon
For time-lapse imaging, strips of living muscles from the last cm of distal colon from P4
HolTg/Tg;G4-RFP double transgenic pups were prepared as described above, and pinned onto
Sylgard-coated 35mm ibidi µ-dishes (ibidi, Cat# 81156). Muscle strips were then cultured in
suspension as detailed in Supplementary Methods. For ex vivo induction of neurogenesis, strips of
living muscles from the last cm of distal colon from P4 HolTg/Tg pups were cultured as for time-lapse
imaging in presence of 0.5 µM EdU. After 96h of culture, tissues were fixed with PFA and processed
for immunofluorescence and EdU labelling.
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Culture of human aganglionic colon tissues
Human sigmoid colon tissue was obtained from 12 HSCR patients undergoing Swenson-type
surgical resection of the aganglionic zone. Nine patients (7 boys and 2 girls; aged between 28 and
1638 days at the time of surgery) were recruited at the Centre hospitalier universitaire SainteJustine (Montreal, Canada) while 3 patients were recruited at the Children’s Hospital of Philadelphia
(2 boys and 1 girl; aged between 300 and 1177 days at the time of surgery). After the surgery, fullthickness colon tissues were placed in ice-cold Krebs solution or Belzer UW Cold Storage Solution
(Bridge to Life Ltd.) and immediately brought to the relevant research laboratory. Muscle strips
were then prepared as described above and cut in smaller pieces of 0.5 cm X 0.5 cm. One piece
was kept aside for validation of aganglionosis via immunofluorescence, while the others were
cultured for 96h as described above for inducing neurogenesis in mouse tissues. Samples from
two patients (86 and 1638 days of age at surgery) were in addition cultured for 7 days, under the
same conditions. At the end of culture period, all tissues were fixed with PFA and processed for
immunofluorescence and EdU labelling.

Study approval
All experiments with mice were approved by animal research ethics committees of the
Université du Québec à Montréal (CIPA reference # 878) and the Children's Hospital of
Philadelphia Research Institute (IAC reference # 16-001041). Likewise, experiments with human
samples were approved by human research ethics committees of the Université du Québec à
Montréal (CIEREH protocol # 491), the Centre hospitalier universitaire Sainte-Justine (CER
protocol # 4172) and the Children’s Hospital of Philadelphia (IRB protocol # 13-010357). Informed
consent for the collection and use of human tissues was obtained from all donors, and parents or
legal guardian except for one piece of de-identified human colon.
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Statistics
All experiments employed a minimum of three biological replicates. Where relevant, the
exact number of independent replicates (n) and statistical tests used to calculate P values are
included in figures and/or legends.

P values were determined using GraphPad Prism 6, with the

exception of microbiome data that were analyzed with R.

4.4 Results
GDNF enemas rescue aganglionosis in three mouse models of S-HSCR
Using rectal enemas, we tested if early postnatal administration of GDNF could enhance
survival of four mouse models of S-HSCR: Holstein (HolTg/Tg; a fully-penetrant model for trisomy 21
[Collagen VI over-expression]-associated HSCR) (25), TashT (TashTTg/Tg; a partially-penetrant
model for male-biased HSCR) (26), Piebald-lethal (Ednrbs-l//s-l; a fully-penetrant model for EDNRB
mutation-associated HSCR) (27) and Ret9/- mutant mice (a hypomorphic model where
aganglionosis is induced by mycophenolic acid) (22). The enema volume necessary to fill whole
colon, GDNF concentration, treatment time window, as well as duration and frequency of therapy
were first empirically determined with HolTg/Tg pups (Supplementary Figure 4.1A-E). Remarkably,
our selected treatment (i.e., daily administration of 10 µg GDNF in PBS as 10 µl enemas for 5
consecutive days between postnatal day [P] 4 to P8) prevented death in about half of HolTg/Tg mice
at P28, the maximum age of survival for control HolTg/Tg mice (Figure 4.1A). Most animals surviving
to P28 reached adult age after GDNF treatment and mice evaluated could reproduce (two tested
breeding pairs were fertile). The few animals that were allowed to survive beyond P56 (our adult
reference age) eventually died from megacolon or dystocia between P68 and P250
(Supplementary Figure 4.1C). Importantly, the same GDNF enema treatment also prevented
premature death for more than 60% of Ednrbs-l//s-l mice (Figure 4.1B) and for all male TashTTg/Tg
pups (Figure 4.1C). Nine GDNF-treated male TashTTg/Tg mice kept for over a year looked healthy
without any sign of adverse effects. Enema treatment of HolTg/Tg mice using Noggin, endothelin-3,
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or the serotonin receptor (5-HT4R) agonist RS67506 (rationale provided in Supplementary Table
4.1) failed to increase life expectancy, suggesting specific benefit to GDNF (Supplementary
Figure 4.1F). We also failed to further increase the overall survival rate of GDNF-treated HolTg/Tg
animals either by replacing standard chow with a gel diet (Figure 4.1G) or by combining GDNF
with vitamin C, serotonin or endothelin-3 (Figure 4.1H).

Figure 4.1: GDNF enemas rescue aganglionic megacolon in HSCR mouse models
(A-C) Daily administration of GDNF enemas to HolTg/Tg (A), EdnrbS-l/s-l (B) and TashTTg/Tg (C) mice
between P4-P8 positively impacts both megacolon symptoms and survival rates (Mantel-Cox
statistical test, GDNF-treated vs PBS-treated groups).

Because modest reductions in RET function are common in people with HSCR, we wanted
to determine if GDNF enemas could work in RET hypomorphic mice. Unfortunately, there are no
good mouse models for RET mutation- associated HSCR. Ret-null mice have total intestinal
aganglionosis (28) whereas Ret heterozygotes are overtly normal (4). We therefore decided to use
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our established protocol to induce distal bowel aganglionosis in Ret9/- hypomorphic mice using
mycophenolate mofetil (22). Surprisingly, far less prenatal mycophenolate was needed to cause
dose-dependent aganglionosis in our novel experimental conditions (with Ret mutants rederived in
a new animal facility) (Supplementary Figure 4.2A) compared to our prior studies (22), and
postnatal GDNF enemas did not improve survival compared to PBS alone (Supplementary Figure
4.2B). Instead, many pups died with distended bowel before the end of GDNF treatment, even at
the lowest mycophenolate concentration (Supplementary Figure 4.2C). Moreover, many ill pups
had ganglia throughout the bowel (Supplementary Figure 4.2D), suggesting highly variable
efficiency of mycophenolate treatment and additional toxicity that complicates data interpretation.
To determine how GDNF enemas enhanced survival in the other three HSCR mouse
models, we tested the hypothesis that GDNF induced postnatal neurogenesis in aganglionic distal
colon. We focused on the Holstein line for practical reasons (fertility is low in Piebald-lethal and
megacolon incidence is lower in TashT), and analyzed P20 animals because HolTg/Tg mice
generally reach this stage even without enema treatment (Figure 4.1A). As we reported (25),
myenteric HuC/D+ neurons and SOX10+ glia were abundant in WT distal colon and absent from the
last cm of HolTg/Tg colon (Figure 4.2A). In contrast, in HolTg/Tg distal colon, SOX10+ cells were mainly
within thick extrinsic nerve fibers (Figure 4.2A) where Schwann cells reside (18). Remarkably,
distal colon from GDNF-treated HolTg/Tg animals had numerous HuC/D+ neurons and SOX10+ glia
organized into ganglia primarily adjacent to extrinsic nerves (Figure 4.2A). These GDNF-induced
ganglia formed Tuj1+ interconnected networks in both myenteric and submucosal plexuses (Figure
4.2B). Quantification of myenteric neuron density in whole colon of HolTg/Tg and male TashTTg/Tg
mice showed GDNF effects are most prominent in distal colon (i.e., final 3 cm), with minor effects
in proximal colon (Figure 4.2A and Supplementary Figure 4.3). In the mid-colon of GDNF-treated
HolTg/Tg mice, the increased neuron density (Figure 4.2A) was mainly due to an enlargement of
pre-existing myenteric ganglia (Supplementary Figure 4.3A). In the most distal colon, where
untreated HolTg/Tg mice are normally devoid of enteric neurons, GDNF-treated HolTg/Tg mice had an
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average neuron density that was about 40% that of WT mice (Figure 4.2A). When neuron density
in the distal colon was too low, GDNF-treated HolTg/Tg mice developed megacolon (Supplementary
Figure 4.1I). Remarkably, in GDNF-treated TashTTg/Tg males, neuron density in the most distal
colon was completely restored (Supplementary Figure 4.3B-C).
EdU incorporation assays confirmed that GDNF induced proliferation of neuron and glia
progenitors during the 5-day treatment from P4 to P8. Staining of P20 HolTg/Tg colon from mice that
received daily EdU injections during GDNF treatment revealed many EdU + HuC/D+ (presumptive
neurons) and EdU+ SOX10+ (presumptive glia or neuron/glia progenitors) in both myenteric and
submucosal ganglia (Figure 4.2C-D and Supplementary Figure 4.4). Yet, only a few, very small
ganglia (i.e., 3 neurons) were fully populated by EdU + neurons (Supplementary Figure 4.4C).
Collectively these data suggest that GDNF enemas induce proliferation and differentiation of ENS
progenitors in distal colon and that some of induced neurons and glia cluster into new ganglia.
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Figure 4.2: GDNF enemas induce a new ENS in the otherwise aganglionic region of P20
HolTg/Tg mice
(A) GDNF treatment induces myenteric ganglia containing HuC/D + neurons and SOX10+ glia. For
each colon subregion (cylinders), average neuronal density (color-coded) is expressed as the
percentage of area occupied by HuC/D+ cells in the myenteric plexus (n=6 mice per group; 3 fields
of view per subregion). (B) Immunofluorescence analysis of TuJ1+ neuronal structures in myenteric
and submucosal plexus, including GDNF-induced ganglia (arrows). Insets are zoomed-in views of
dashed boxes. (C-D) EdU incorporated in GDNF-induced myenteric neurons (arrowheads) and glia
(arrows) during the 5-day treatment. Quantitative results in D are expressed as the number of EdU+
cells per mm2 (n=3 WT and 3 GDNF-treated HolTg/Tg mice; 2-7 fields of view per animal; ***P<0.001;
****P<0.0001; one-way ANOVA with post-hoc Sidak’s test). All images show a z-stack projection
representative of observations made from 3 mice. Dashed outlines delineate extrinsic nerve fibers
(A) or a single ganglion (C). Scale bars, 100 µm (A, B) and 50 μm (B insets, C).

GDNF-induced ENS is morphologically and functionally similar to WT
Again focusing on the HolTg/Tg model, we next asked to what extent GDNF-induced ENS in
the distal colon resembles WT at P20. Average neuron-to-glia ratio within GDNF-induced myenteric
ganglia was statistically similar to WT (P=0.16) (Figure 4.3A). Relative proportions of major
myenteric neuron subtypes, including cholinergic (ChAT +) and nitrergic (nNOS+) neurons, were also
very similar to WT (Figure 4.3B-C). Moreover, many other neuronal subtypes were detected
including TH+ dopaminergic neurons, CalR+ excitatory motor neurons, VIP+ inhibitory motor
neurons, and SubP+ excitatory motor neurons (Figure 4.3C). Interestingly, in proximal and mid
colon of HolTg/Tg mice (Fig.S5), GDNF treatment also corrected the imbalance of nitrergic
(increased) and cholinergic (decreased) neuron subtypes that is observed proximal to the
aganglionic segment in both HSCR mouse models and human patients (29-32).
To evaluate function of P20 GDNF-induced myenteric ganglia, we analyzed colonic motility
in vivo, using the bead latency test. In contrast to untreated HolTg/Tg mice that never expelled a
rectally-inserted glass bead during our 30 minute observation period, a subset of GDNF-treated
HolTg/Tg expelled the bead in 10-21 min, a bit slower than WT mice (range of 2-8 min) (Figure 4.3D).
Analysis of neuron density in these GDNF-treated HolTg/Tg mice revealed a robust inverse
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correlation between time to expel the bead and neuron density in the distal colon (Supplementary
Figure 4.6A). We also evaluated motility ex vivo using muscle strips from P20 distal colons
attached to force transducers in organ baths. This system allows electric field stimulation-induced
contractions of WT colon muscles to be slightly increased by inhibition of nitric oxide synthase with
L-NAME, which can then be robustly counteracted by inhibition of cholinergic signaling with
atropine. Reminiscent of in vivo data, colon muscle strips from GDNF-treated HolTg/Tg mice
displayed one of two distinct response patterns (Figure 4.3E and Supplementary Figure 4.6B),
either similar to WT or similar to untreated HolTg/Tg. To indirectly test function of P20 GDNF-induced
submucosal ganglia, we analyzed epithelial permeability to small fluorescently labeled dextran
molecules (FD4) in Ussing chambers. Once more, distal colonic tissues from GDNF-treated HolTg/Tg
mice displayed two distinct response types, with mucosa either impermeable to FD4 like WT
tissues, or permeable to FD4 like control HolTg/Tg tissues from untreated mice (Figure 4.3F).
To complement ENS analyses, we evaluated other HSCR-associated bowel anomalies.
HolTg/Tg mouse colon had thicker smooth muscles and more neutrophils than WT mice, but GDNFtreated HolTg/Tg mouse colon was similar to WT (Figure 4.3G-I and Supplementary Figure 4.7).
Similarly, stool microbiome profiling demonstrated dysbiosis in P20 HolTg/Tg mouse colon, but
average abundance of several bacterial genera in HolTg/Tg mouse colon were indistinguishable from
WT after GDNF treatment (Figure 4.3J). A notable exception was Bacteroides abundance, which
was low in HolTg/Tg mice and even lower after GDNF treatment. Accordingly, beta diversity analysis
revealed distinct microbial communities among WT, HolTg/Tg and GDNF-treated HolTg/Tg mice
(Figure 4.3K).
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Figure 4.3: Phenotypic and functional characterization of the GDNF-induced ENS in P20
HolTg/Tg mice
(A-B) WT-like neuron (HuC/D+) to glia (SOX10+) ratio (A), and proportions of nitrergic and
cholinergic neurons (B) in GDNF-induced myenteric ganglia from distal colon of HolTg/Tg mice (n=6
mice per group; 3 fields of view per animal). (C) GDNF-induced myenteric ganglia include many
neuron subtypes (arrows; n=3 mice per marker). Scale bar, 20µm. (D) Bead latency test (n=8-9
mice per group, *P˂0.05; one-way ANOVA with post-hoc Sidak’s test). (E) Electric field-stimulated
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and drug-modulated patterns of longitudinal muscle contraction-relaxation (n=6 WT and HolTg/Tg,
n=7 HolTg/Tg + GDNF; **P˂0.01; ****P˂0.0001; two-way ANOVA with post-hoc Tukey’s test).
Contractile strength is expressed as the difference from baseline of the area under the curve (AUC)
values obtained after stimulation (see Fig.S6B). Muscle strips from GDNF-treated HolTg/Tg mice are
either unresponsive (i.e., like untreated HolTg/Tg mice; 3/7) or responsive (i.e., similar to WT; 3/7).
(F) Mucosal permeability to FD4 in Ussing chambers (n=6 mice per group; *P˂0.05; **P˂0.01; oneway ANOVA with post-hoc Sidak’s test). (G-I) H&E staining-based analysis of smooth muscle
thickness (brackets in G and quantification in H) and neutrophil invasion (asterisks in G and
quantification in I) in distal colon sections (n=6 mice per group; Scale bar, 150µm; *P˂0.05;
**P˂0.01; ***P˂0.001; one-way ANOVA with post-hoc Sidak’s test). (J-K) 16S rRNA sequencingbased microbiome profiling (n=5 mice per group). Bar histograms (J) display the average relative
abundance at the genera level (*P˂0.05; one-way ANOVA with post-hoc Tukey’s test). Betadiversity comparisons (K) with 95% confidence interval ellipses are based on non-metric
multidimensional scaling (NMDS) of Bray-Curtis dissimilarity of the relative abundance of
operational taxonomic units among samples (P<0.001; PERMANOVA).

Schwann cells within extrinsic nerves are a target of GDNF in aganglionic colon
To elucidate how GDNF induces enteric neurogenesis, we first evaluated GDNF
distribution in P8 bowel via Western blot, taking advantage of size differences between recombinant
(15 kDa) and endogenous (20 kDa, glycosylated) GDNF monomers. Recombinant GDNF was
detected in GDNF-treated HolTg/Tg distal colon but not in proximal colon (Figure 4.4A). Surprisingly,
while endogenous GDNF is normally only detected in ileum, recombinant GDNF enemas triggered
robust increases in endogenous GDNF throughout the colon (Figure 4.4A). Recombinant GDNF
was no longer detected in colon nor in any other tissue at P20, suggesting that administered GDNF
primarily acts during the treatment period (Supplementary Figure 4.8). To assess precise
locations of recombinant GDNF during treatment, we treated HolTg/Tg mice using a 6xHis-tagged
version of GDNF (HisGDNF) (23). Time-course analysis of distal colon 2h after GDNF treatment on
P4, P6 and P8 revealed

HisGDNF

accumulated over time in colon submucosa (Figure 4.4B),

smooth muscles, and subsets of enteric neurons (Figure 4.4C and Supplementary Figure 4.9) of
HolTg/Tg mice. Interestingly, RET levels also increased (Figure 4.4B and Supplementary Figure
4.9), supporting the hypothesis that GDNF-RET auto-regulatory loops are activated in GDNFtreated colon. Remarkably, both
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HisGDNF

and RET were detected in induced neurons close to

extrinsic nerves of

HisGDNF-treated

animals, not only in HolTg/Tg mice (Figure 4.4C) but also in

Ednrbs-l/s-l mice (Supplementary Figure 4.10A), and in both of our mouse facilities in Montreal and
Philadelphia (Supplementary Figure 4.10A-B).
Given that induced neurons and glia were often closely associated with extrinsic nerves,
we hypothesized that nerve-associated Schwann cells might be GDNF-targeted ENS progenitors.
We first assessed response of Schwann cells to GDNF using live explants of distal colon muscularis
externa from P4 HolTg/Tg;G4-RFP double transgenic pups. In these mice, neural crest derivatives
including Schwann cells are marked by RFP fluorescence (33). Time-lapse imaging of explants
after 72h of culture suggested GDNF (5 µg/ml) stimulates both migration and proliferation of
Schwann cells (Figure 4.4D). Impact of GDNF on proliferation of these Schwann cells was
confirmed via immunofluorescence after 96h of culture, which revealed a 3-fold increase in Ki67+
SOX10+ double positive cells upon exposure to GDNF (Figure 4.4E-F).
To more definitely demonstrate Schwann cells are GDNF targets, we used in vivo genetic
cell lineage tracing with the Schwann lineage-specific Dhh-Cre driver and the R26[Floxed Stop]YFP Cre
reporter allele in the Holstein [FVB/N] mutant background. Analysis of proximal and mid colons
from untreated Dhh-CreTg/+;R26YFP/+ and HolTg/Tg;Dhh-CreTg/+;R26YFP/+ animals at P20 showed that
the proportion of Schwann cell lineage-derived (YFP+) myenteric neurons increased from 5-7% in
a pure FVB/N genetic background to 10-11% in presence of homozygous Holstein mutation
(Supplementary Figure 4.11A-B). Remarkably, the Schwann cell lineage contribution further
increased to 34% of myenteric neurons in the distal colon of GDNF-treated HolTg/Tg;DhhCreTg/+;R26YFP/+ animals (Figure 4.4G-H). By daily EdU administration during GDNF treatment, we
identified four subgroups of induced myenteric neurons based on cellular origin (YFP fluorescence)
and/or EdU incorporation (Figure 4.4G-H and Supplementary Figure 4.11C). While this work
supports the hypothesis that Schwann cells are a source of GDNF-induced neurons and glia in
both myenteric (Figure 4.4G-H) and submucosal (Supplementary Figure 4.11C) plexus, it also
revealed that a majority of induced neurons (66%) were YFP-negative, suggesting a stronger
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contribution by non-Dhh-expressing cell type(s). Regardless of cellular origin, a majority of induced
neurons (62%) also did not incorporate EdU, raising the possibility that neurogenesis might result
from transdifferentiation (i.e., direct differentiation of a post-mitotic cell into another type of
specialized cell) instead of requiring proliferating precursor cells (Figure 4.4G-H).
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Figure 4.4: Extrinsic Schwann cells are a source of GDNF-induced neurons and glia in the
otherwise aganglionic colon
(A) Distribution of recombinant (r)GDNF (asterisks) and endogenous (e)GDNF (dashed boxes) in
different subregions of the GI tract from WT, HolTg/Tg and GDNF-treated HolTg/Tg mice at P8. (B-C)
Accumulation of 6xHis-tagged GDNF (HisGDNF) and RET during enema treatments of HolTg/Tg mice,
in the submucosa between P4-P8 (B) and in induced myenteric neurons at P8 (C). (D) 10-hour
long time-lapse recordings of GDNF-cultured aganglionic colon tissues from P4 HolTg/Tg;G4-RFP
mice showing dividing (arrows) and migrating (arrowheads) Schwann cells on extrinsic nerves (50
µm-thick z-stacks). (E-F) GDNF exposure for 96h increases Schwann cell proliferation (SOX10 +
Ki67+) in distal colon explants from P4 HolTg/Tg mice (**P˂0.01; two-tailed Student’s t-test). (G-H)
Myenteric ganglia from the distal colon of P20 HolTg/Tg;Dhh- CreTg/+;R26YFP/+ mice that were
administered GDNF and EdU between P4-P8. Four categories of induced neuron are detected: 1)
EdU-positive Schwann-derived (filled yellow arrowhead); 2) EdU-negative Schwann-derived
(empty yellow arrowhead); 3) EdU-positive unknown origin (filled white arrowhead); 4) EdUnegative unknown origin (empty white arrowhead). All blots/images are representative of
observations made from 3 mice. Quantifications were performed using 3 fields of view per mouse.
Dashed outlines delineate either an extrinsic nerve fiber (E), or an extrinsic nerve fiber and an
adjacent single ganglion (C and G). Scale bar, 20µm (B-C), 100µm (D), 50µm (E-F).

GDNF can induce new neurons in human aganglionic colon ex vivo
To test if GDNF could induce new enteric neurons in human tissue, we needed an ex vivo
model. We discovered that 96h of ex vivo GDNF treatment induced neurons in all HolTg/Tg distal
colon aganglionic tissues, but neurogenesis was much less efficient than in vivo (Figure 4.5A and
Supplementary Figure 4.12A). Induced neurons rarely clustered into ganglia and such ganglia
were always very small (Figure 4.5B). In marked contrast to widespread EdU incorporation into
Schwann cells (Figure 4.5C and Supplementary Figure 4.12B), EdU incorporation in induced
neurons was also minimal (Figure 4.5B-C). Although not perfect, we used this ex vivo system to
test if GDNF could induce neurogenesis in aganglionic human colon muscle from children who had
pull-through surgery to resect aganglionic distal bowel. Our cohort consisted of 12 children with
epidemiologic characteristics typical of HSCR (i.e., mostly sporadic, male-biased, short-segment)
(Table 4.1). Culturing small pieces of freshly- isolated muscularis externa with GDNF for 96h
markedly increased the proportion of EdU+ Schwann cells in 9/9 human tissues where EdU was
added to media (Figure 4.5D-E). Most importantly, we also detected new neurons expressing
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HuC/D, βIII-Tubulin (Tuj1), RET, PGP9.5 and PHOX2B in three HSCR explants (Figure 4.5F-G
and Supplementary Figure 13). These three explants were from the youngest children of our
cohort (28 to 44 days old) (Figure 4.5G and Table 4.1). Two of these young children had sporadic
HSCR with unknown genetic causes. The third child had a MEN2A syndrome- associated RET
mutation (Table 4.1). For older children (n=2; 86 and 1638 days old), we found that extending
GDNF treatment to 7 days could yield neurons that incorporated EdU (Figure 4.5H). Collectively
these data suggest our observations in mice may be extended to humans.
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Figure 4.5: Ex vivo preclinical testing of GDNF therapy on explants of aganglionic colon
from HolTg/Tg mice and human HSCR patients
(A-C) Distal colon explants from P4 HolTg/Tg mice cultured for 96h with GDNF and EdU (+GDNF)
or EdU alone (ctl). GDNF-induced HuC/D+ neurons (A) rarely form ganglia (B) and are less likely
to show EdU incorporation than SOX10+ Schwann cells (arrowhead in B and quantification in C)
(n=7 explants per condition; *P˂0.05; **P˂0.01; ***P˂0.001; two-tailed Mann-Whitney U test). (DG) Aganglionic colon explants from human HSCR patients cultured for 96h with GDNF and EdU
(+GDNF) or EdU alone (ctl). EdU incorporation was detected in SOX10 + Schwann cells but not in
HuC/D+ neurons (D-E). GDNF-induced HuC/D+ neurons were detected in a subset of explants (F),
all originating from patients less than 3 months of age at the time of surgery (G) (n=12 explants per
condition; *P˂0.05; two-tailed Mann-Whitney U test). (H) Extended culture in presence of GDNF
for 7 days yielded neurons in explants from older patients, including some that incorporated EdU
(arrowhead). All displayed images were taken at myenteric plexus level. Dashed outlines delineate
extrinsic nerve fibers. Scale bars, 50 µm (B and H) and 100 μm (D and F).

217

Table 4.1: Overview of HSCR colon samples used for ex vivo preclinical testing of GDNF
therapy
Age at
surgery
(days)

Genetic status

Sex

Clinical
Classification

Extent of
aganglion
-osis (cm)

Number
of
neurons

EdU+
Schwann
cells (%)

28

Sporadic,
unknown mutation
Sporadic,
unknown mutation
MEN2a syndrome,
RET mutation
Sporadic,
unknown mutation
Sporadic,
unknown mutation
Sporadic,
unknown mutation
Mowat-Wilson
syndrome,
ZFHX1B mutation
Data not available

M

Short segment
disease
Short segment
disease
Short segment
disease
Short segment
disease
Short segment
disease
Short segment
disease
Short segment
disease

5

31

38

25

27

33

6

15

44

7

3

34

6

1

32

7

0

46

30

0

32

M

Data not
available

Data not
available

0

Not
quantified

Sporadic,
unknown mutation

M

Short segment
disease

26

0

Not
quantified

Sporadic,
unknown mutation
1177
Bardet-Biedl
Syndrome, BBS1
mutation
1638
Sporadic,
unknown mutation
4.5 Discussion

M

Short segment
disease
Long segment
disease

9

0

43

40

0

Not
quantified

8

0

50

36
44
80
85
86
249

300

344

349

M
M
M
M
M
F

F

F

Short segment
disease

Here we report that GDNF enemas can regenerate a functional ENS in situ and prevent
death in three genetically- distinct mouse models of S-HSCR. Detailed mechanistic studies in
HolTg/Tg mice showed that exogenous GDNF can penetrate the permeable distal aganglionic colon,
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leading to increased levels of endogenous GDNF and RET in the whole colon. At least some of the
new neurons and glia appear to arise from extrinsic Dhh-Cre+ lineage Schwann cells, and newly
organized enteric ganglia appear to be self-sustaining until at least P56 (Supplementary Figure
4.14).
One concern for GDNF-based therapy is that RET signaling is often reduced in children
with HSCR, suggesting GDNF responsiveness would also be reduced. However, most children
with S-HSCR must have substantial RET activity in ENS precursors because complete RET
absence causes a much more severe phenotype (i.e., total intestinal aganglionosis) in mice and
humans (28, 34). Supporting this idea, recent whole genome sequencing studies of people with SHSCR found only 4.3% (out of 443 patients) (7) and 6.3% (out of 190 patients) (9) had RET rare
coding variants predicted to be damaging. Furthermore, rectal GDNF therapy increased levels of
RET and endogenous GDNF in mouse colon, suggesting positive feedback loops that could
enhance RET signaling even if initial RET levels were low. This could be particularly valuable since
RET provides trophic support to some enteric neurons in adults (4) and RET is expressed in a
subset of GDNF-induced neurons after rectal therapy (Figure 4.4C, Supplementary Figure 4.10AB and Supplementary Figure 4.11D). Finally, although some of the GDNF-induced neurons that
express RET are derived from Schwann cells (Supplementary Figure 4.11D), RET is most likely
not needed to activate these precursors in aganglionic bowel. GDNF signaling in Schwann cells is
instead mediated by NCAM (20), and our data show NCAM but not RET expression in Schwann
cells of extrinsic nerves in aganglionic mouse colon (Supplementary Figure 4.15). Nonetheless,
we tried to directly determine if reduced RET levels affected GDNF therapy using our previously
published model of Ret hypomorphic mice exposed to mycophenolate (22). However, several
problems complicated interpretation in our new experimental conditions, including the occurrence
of HSCR-like dilated bowel even in absence of aganglionosis (Supplementary Figure 4.2C-D).
Future studies would need to test GDNF enema effects in other models where reduced RET activity
is associated with short- segment aganglionosis, but the “ideal” model is not readily apparent.
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In contrast to Ret mutants, HolTg/Tg, TashTTg/Tg and Ednrbs-l//s-l mice are all reliable models
of S-HSCR (25-27), recapitulating key hallmarks of the human disease in both aganglionic segment
and proximal ENS-containing colonic regions (29-32). Although not all GDNF-treated mutant mice
have prolonged survival, the survival advantage after GDNF treatment in Montreal is dramatic and
the in situ generation of new enteric neurons in previously aganglionic bowel, which was observed
in both Montreal and Philadelphia (Supplementary Figure 4.10A-B), is unprecedented. The
reason why some mice responded better to GDNF than others might be due to the degree of
aganglionosis-associated inflammation (Figure 4.3G-I). Indeed, although GDNF is known to have
anti-inflammatory properties (35), the inflammatory microenvironment present in aganglionic bowel
before GDNF treatment might help trigger a neurogenic response as it does in the context of
inflammatory bowel disease (36). Unfortunately, the exact inflammatory mediators that enhance
enteric neurogenesis are not yet known, but once identified we could develop adjunct treatments
that enhance the effect of GDNF therapy.
Adjunct treatments might also be developed based on a serendipitous finding we made
when we tried to replicate our Montreal survival data (Figure 4.1A-C) using HolTg/Tg and Ednrbsl/sl
mice in Philadelphia. We unexpectedly discovered that these mouse lines live much longer in
Philadelphia than in Montreal without any specific treatment, even though all our mice originated
from the same colonies (Supplementary Figure 4.10C-D). The prolonged survival in Philadelphia
compared to Montreal was especially dramatic for untreated Ednrbs-l/s-l (Supplementary Figure
4.10C) that lived much longer than previously described in any other mouse facility (27, 30, 37).
Intriguingly, the survival advantage for untreated HSCR models in Philadelphia occurred despite
the confirmed presence of distal bowel aganglionosis and/or megacolon (Supplementary Figure
4.10C-D). In fact, Philadelphia-based untreated mice survived as long as GDNF-treated mice in
Montreal (Supplementary Figure 4.10E-F) and survival could not be further enhanced in
Philadelphia by GDNF treatment (Supplementary Figure 4.10E-F) even though GDNF-induced
neurogenesis was similar in both Montreal and Philadelphia (Supplementary Figure 4.10A-B).
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One especially attractive hypothesis for all these observations is that GDNF treatment in Montreal
and non-genetic factors in Philadelphia might both improve a critical pro-survival bowel function
(e.g., promoting enhanced epithelial barrier function or modulating mucosal immune responses),
either indirectly (via induced ENS ganglia) in Montreal or directly (bypassing the need for induced
ENS ganglia) in Philadelphia. Although we suspect that food- and/or microbiota-based mechanisms
underlie the survival advantage in Philadelphia, there are many variables so defining mechanisms
is complicated.
A potentially more straightforward approach to improve GDNF therapy would be to identify
GDNF-targeted ENS progenitors other than Dhh-lineage Schwann cells that appear to contribute
only about a third of GDNF-induced neurons. This could lead to an improved GDNF-based cocktail
that includes additional trophic factor(s) that bind receptors on these other cells. In this regard,
substantial literature suggests the existence of ENS “stem cells” in postnatal mouse and human
bowel38, 39, even in aganglionic regions (40, 41). Interestingly, extrinsic nerve fibers of aganglionic
regions were previously identified as a niche for these ENS stem cells (41). Our data confirm this
prior observation and further suggest that at least some of these stem cells are in fact Dhh-lineage
Schwann cells. It is possible that the other ENS progenitors are also Schwann cells that do not
express CRE in Dhh-Cre mice. In accordance with this possibility, we noted that some SOX10 +
Schwann cells are not YFP+ in extrinsic nerves from the aganglionic colon of HolTg/Tg;DhhCreTg/+;R26YFP/+ mice at P8 (Supplementary Figure 4.16). The strong contribution of non-Dhhexpressing cells combined with the location of some GDNF-induced ganglia away from extrinsic
nerves, however, also suggests the involvement of additional cell type(s), which might include
sacral neural crest-derived cells. Sacral-derived ENS progenitors can colonize the aganglionic
colon during prenatal development (42), and our SOX10 immunofluorescence data suggest that
some of these cells persist in postnatal aganglionic tissues as scattered progenitors and/or enteric
glia, also expressing the alternative GDNF receptor NCAM (Figure 4.2A and Supplementary
Figure 4.15). A contribution by differentiated enteric glia of sacral origin might also help explain the
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observation that many GDNF-induced neurons had not incorporated EdU suggesting they were
generated via transdifferentiation (Figure 4.4G-H).
In theory, GDNF-based rectal therapy would be easy to implement since normal saline
enemas are already commonly used in children with HSCR both before and after pull-through
surgery. If penetration of GDNF beyond the epithelium was limited, GDNF could be directly injected
into the colon wall with currently available endoscopes or via a specially designed delivery tool.
Ideally, GDNF-based rectal therapy would prevent the need for pull-through surgery. Even if GDNF
enemas did not work as primary HSCR treatment, GDNF therapy might nevertheless improve postsurgical outcomes by normalizing ENS structure in the retained distal bowel of the “transition zone”
(i.e., correcting hypoganglionosis and neuronal subtype imbalance). In addition, since ENS stem
cell-based therapies are being considered for the treatment of HSCR, GDNF might be a useful
adjunct to these therapies to promote engraftment. All these considerations make a human clinical
trial of GDNF-based rectal therapy in children with HSCR appealing.
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4.9 Supplementary Materials

Supplementary Methods
Mice
Holstein (Tg[Sox3-GFP,Tyr]HolNpln),

TashT

(Tg[SRY-YFP,Tyr]TashTNpln),

and

G4-RFP

(Gata4p[5kb]-RFP) lines were as previously described (all maintained on a FVB/N genetic
background) (25, 26, 33),

whereas Piebald-lethal (Ednrbs-l; JAX stock # 000308; C3H/HeJ-

C57BL/6 mixed background) and Dhh-Cre (Tg[Dhh-cre]1Mejr; JAX stock # 012929; FVB/N
background) were obtained from The Jackson Laboratory. Other mouse lines used were R26[Floxed
Stop]YFP

(Gt[ROSA]26Sortm1(EYFP)Cos; provided by F. Costantini (Columbia University, USA) and

maintained on a FVB/N background) (43),

RetTGM (here referred to as Ret-null; Rettm1Jmi;

maintained on a C57BL/6 background) (44), and Ret9 (Rettm2(RET)Jmi; provided by S. Jain
(Washington University School of Medicine, USA) and maintained on a 129X1/Sv1 background)
(45).
For mycophenolate mofetil treatments (22), timed pregnancies were set up by mating Ret+/with Ret9/+ or Ret9/9 mice, considering noon of the day of plug detection as E0.5. At E7.5, the drinking
water of pregnant dams was replaced with 0.25X PBS adjusted to pH3.6 with added prodrug
mycophenolate mofetil (Accord Healthcare, NDC Cat# 16729-094) at varying concentrations (250
µg/mL, 187.5 µg/mL, and 125 µg/mL). Dams remained on mycophenolate mofetil-supplemented
drinking water from E7.5 to E18.5.
Enemas were administered using a 24-gauge gavage needle (Fine Science Tools,
Canada) attached to a micropipette. The head of the gavage needle was introduced in the rectum
just beyond the anus, and enemas were injected over the course of a few seconds. Pups were then
placed back with their mother, and either sacrificed for tissue analysis (at age indicated in relevant
figure legends) or checked daily to track survival.
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Tissue labelling and imaging

For immunofluorescence staining, whole microdissected tissues were permeabilized for 2
hours in blocking solution (10% FBS and 1% Triton X-100, in PBS) before being sequentially
incubated with specific primary (at 4°C overnight) and relevant secondary (at room temperature for
2 hours) antibodies, both diluted in blocking solution that was also used to wash tissues between
all steps. All antibodies and dilution factors, are listed in Supplementary Table 4.2. EdU was
detected using the Invitrogen Click-iT EdU Imaging Kit (ThermoFisher Scientific, Cat# C10337) in
accordance with the manufacturer’s instructions. For histological analyses, cross-sections of fullthickness bowel tissues were stained with hematoxylin and eosin (H&E) as previously described
(46).
All immunofluorescence images were acquired with either a 20X or a 60X objective on a
confocal microscope (either Nikon A1R or Zeiss 710), with the exception of H&E-stained sections
that were imaged with a 10X objective using an Infinity-2 camera (Lumenera Corporation) mounted
on a Leica DM 2000 microscope (Leica Microsystems Canada). Image analysis was performed
with ImageJ, using the “Subtract background” function to decrease non-specific background signal,
the “Multi-point” function for cell counting, and the “Polygon selection” function for calculation of
surface area.

Western blot analysis
Organs dissolved in RIPA buffer (containing 1X Roche Complete protease inhibitors) were
sonicated on ice and centrifuged at 14,000 rpm for 15 minutes at 4°C, keeping the supernatants
for western blot analysis. Equal volumes of samples were electrophoretically separated in an 18%
sodium dodecyl sulfate-polyacrylamide gel (SDS-PAGE) and transferred to Immun-blot® PVDF
membranes (Bio-Rad, Cat# 1620177). Membranes were subsequently incubated in blocking
solution (5% skimmed milk and 0.1% Tween 20, in TBS), followed by incubation with either mouse
anti-GDNF (Santa Cruz Biotechnology, Cat# sc-13147; 1:500 dilution factor) or rabbit anti-βTubulin
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(Abcam, Cat# ab176560; 1:70 000 dilution factor) primary antibodies, and then relevant
horseradish peroxydase-conjugated secondary antibodies, all diluted in blocking solution. Each
incubation was for 60 min at room temperature, each time interspersed by 3 washes with blocking
solution. Proteins were finally visualized using Immobilon western chemiluminescent HRP
substrate (Millipore Sigma, Cat# WBKLS0050) and Fusion FX imaging system (Vilber).

Ex vivo culture for time-lapse imaging
Muscle strips were cultured in suspension as previously described for time-lapse imaging
of embryonic guts (25), in DMEM/F12 medium (Wisent, Cat# 319-085-CL) supplemented with 10%
FBS and 100IU/ml antibiotic-antimycotic with or without 5 µg/ml GDNF under standard culture
conditions (37°C, 5% CO2). After 72h of culture, each petri dish was placed in a microscope
incubation chamber (Okolab) for 10 hours under the same culture conditions, and image stacks
(250μm-thick) of RFP-labelled extrinsic nerves and Schwann cells were acquired every 10 min,
using a 20X objective on a Nikon A1R confocal unit as previously described (25).

In vivo and ex vivo analysis of colonic motility
For bead latency test, mice were anesthetized with 2% isoflurane and a 2mm glass bead
(Sigma, Cat# 1.04014) was inserted into the distal colon with a probe over a distance of 0.5 cm
from the anus. Each mouse was then isolated in its cage without access to food and water and
monitored for the time required to expel the glass bead. For ex vivo analysis of contractility, muscle
strips were initially stretched with a preload of 2 g of tension for 60 min, and contraction/relaxation
of longitudinal muscles was then continuously recorded with a myograph (Narco Biosystems Inc.,
Model F-60) coupled to a computer equipped with the BIOPAC student Lab 4.0.2 software
(BIOPAC Systems Inc.). Electrical field stimulation (EFS) was applied with a voltage stimulator
(BIOPAC Systems Inc., Model BSL MP36/35) connected to electrodes, using parameters that
activate enteric neurons without directly activating muscles (12 V, 20 Hz, 10s train duration, and
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300µs stimulus pulse duration). This procedure was repeated 3 times, with 10 min washout periods
between stimulations. To characterize the nitrergic and cholinergic components of EFS-induced
contractile responses, N-nitro-L-arginine methyl ester (L-NAME; Sigma, Cat# N5751) and atropine
(Sigma, Cat# A01132) were added to Krebs solution at a ﬁnal concentration of 0.5µM and 1µM,
respectively. The area under the curve (AUC) was measured during each EFS-induced response,
and data were expressed in ΔAUC (corresponding to the difference between the AUC measured
20s after stimulation minus the AUC measured 20s before stimulation).

Ex vivo analysis of paracellular permeability
Each Ussing chamber contained 5ml of DMEM/F12 medium (Wisent, Cat# 319-085-CL),
which was maintained at 37ºC and continuously oxygenated (95% O 2 / 5% CO2). After a 30 min
equilibration period, 200µl of apical medium was replaced with 200µl of a 1mg/ml solution of FITCconjugated dextran 4 kDa (FD4; Sigma, Cat# 60842-46-8). Fluorescence intensity of basolateral
aliquots of 150ul, reflecting paracellular transit from the luminal surface, was then measured every
30 min over a period of 3 hours, using a fluorimeter (TECAN, Model Infinite M1000). Fluorescence
intensity was finally converted in amount of FD4 by comparison to a standard curve, and the
average value for the 3 hour period was used to calculate paracellular permeability, which was
expressed in ng of FD4 per surface of mucosa area per min (ng/cm2/min).

Microbiome analysis
Mice were sacrificed at P20 and their feces were directly collected from the colon (3 fecal
pellets per mouse). Bacterial DNA was then extracted using the QIAamp® Fast DNA Stool Mini
Kit (QIAGEN, Cat# 51604), and the V5-V6 region of the 16S rRNA gene was PCR amplified with a
collection of previously described barcoded primers (47). Raw sequences generated with an
Illumina MiSeq sequencer were paired and processed using the MOTHUR pipeline (48), and the
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BIOM package (49) was subsequently used to transfer biom files into R (50) for generating graphs
of relative taxa abundance and beta diversity.

Supplementary Figures and Tables

Supplementary Figure 4.1: Set-up of GDNF therapy parameters in HolTg/Tg mice
(A-B) Distribution of 10µl methylene blue enemas in the colon of P4 (A) and P8 (B) HolTg/Tg pups.
(C) Impact of GDNF concentration on survival of HolTg/Tg pups that received 10µl enemas once
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daily between P4-P8. Indicated amounts correspond to the total quantity of GDNF that was
administered each day. (D) Impact of treatment time window (P4-P8 vs P8-P12), duration (1d, 5d
or 10d; starting at P4) and frequency (once or twice a day, for 5 days) on the survival of HolTg/Tg
pups treated with GDNF enemas (quantity of GDNF administered per single enema was kept
constant at 10µg in 10µl). (E) Survival rate of HolTg/Tg pups that were administered 10µl enemas
containing the indicated neurotrophic molecule (Noggin, Endothelin-3, or the serotonin receptor
agonist RS67506; all at 1µg/µl final concentration) once daily between P4-P8. (F) Impact of food
consistency (regular chow vs gel diet) on survival of HolTg/Tg pups that received GDNF enemas
(10µg in 10µl) on a daily basis between P4-P8. (G) Impact of co-administration of ascorbic acid
(Vit.C; 100µM final concentration), serotonin (5-HT; 1µg/µl final concentration) and Endothelin-3
(ET3; 1µg/µl final concentration) on survival of HolTg/Tg pups that received GDNF enemas (10µg in
10µl) once daily between P4-P8. (H) Neuron density in the colon (expressed in % of surface area)
and associated health status of P20 HolTg/Tg mice that received GDNF enemas (10µg in 10µl) on a
daily basis between P4-P8.
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Supplementary Figure 4.2: GDNF enemas do not rescue survival in RET hypomorph mouse
model of HSCR
(A) Treatment of pregnant dams with increasing doses of mycophenolate mofetil from E7.5 to E18.5
increases penetrance of HSCR-like aganglionosis and the length of aganglionic bowel in the
newborn Ret-/9 pups. A few Retwt/9 littermates (graphed as part of the control group) also exhibited
aganglionosis. (B) There is no survival difference for mice treated from P4-P8 with GDNF versus
PBS for all mycophenolate mofetil concentrations. (Log-rank test and Gehan-Breslow-Wilcoxon
test for all data sets P > 0.1). (C) Ret-/9 mice died during the P4-P8 treatment period with bowel
distention. (D) Representative image of the distal colon of 125µg/mL mycophenolate-treated Ret-/9
pups that died during the treatment period. This specific pup died at post-natal day 6 (as seen in
C) even though myenteric neurons (HuC/D+) completely colonized the bowel (anal skin marked
with *). Extrinsic nerve fibers are also visualized (TuJ1+). Scale bar, 250µm (D).
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Supplementary Figure 4.3: Analysis of myenteric ganglion size and neuronal density in the
colon of P20 HolTg/Tg and TashTTg/Tg mice that were treated or not with GDNF between P4-P8
(A) Analysis of myenteric ganglion size in HolTg/Tg mice. (B) Analysis of neuronal density in
TashTTg/Tg mice. The average neuronal density (color-coded) is indicated for each colon sub-region
(represented by cylinders) along the length of the colon. Neuronal density is expressed as the
percentage of area occupied by HuC/D+ cells in a single focal plane at the level of the myenteric
plexus within the bowel wall (n=6 mice per group; 3 fields of view per sub-region). For each distal
colon subregion, the neuronal density is also given as a numerical value. (C) Analysis of myenteric
ganglion size
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in TashTTg/Tg mice.

Supplementary Figure 4.4: Analysis of EdU incorporation in myenteric and submucosal
ganglia of the colon from P20 WT and GDNF-treated HolTg/Tg mice that were administered
EdU between P4-P8
(A) Example of EdU incorporation in a z-stack projection of submucosal neurons (arrowheads) and
glia (arrows) in the distal colon. Dashed outline marks area occupied by a single ganglion. Scale
bar, 50 µm. (B) Quantitative analysis of EdU incorporation in submucosal neurons (HuC/D+) and
glia (SOX10+) in mid and distal colon. Results are expressed as the number of EdU+ cells per mm2
(n=3 WT and 3 GDNF-treated HolTg/Tg mice; 2-7 fields of view per animal; *P<0.05; one-way
ANOVA with post-hoc Sidak’s test). (C) Quantitative analysis of EdU incorporation in myenteric (left
panel) and submucosal (right panel) neurons (HuC/D +) and glia (SOX10+) in distal colon. Results
are expressed in percentage of EdU+ cells per ganglion (n=3 WT and 3 GDNF-treated HolTg/Tg mice;
2-7 fields of view per animal; ***P<0.001; ****P<0.0001; one-way ANOVA with post-hoc Sidak’s
test). GDNF-treated mice received 10µg GDNF in 10µL enemas once daily between P4-P8.
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Supplementary Figure 4.5: Proportion of nitrergic and cholinergic myenteric neurons in the
proximal and mid colon of WT, untreated HolTg/Tg or GDNF-treated HolTg/Tg mice at P20
(A) Qualitative analysis of the proportion of nitrergic (left panel) and cholinergic (right panel)
neurons. Scale bar, 50 µm. (B) Quantitative analysis of the proportion of nitrergic (left panels) and
cholinergic (right panels) neurons (n=3 WT and 3 GDNF-treated HolTg/Tg mice; 3 fields of view per
animal; *P<0.05; **P<0.01; ***P<0.001; ****P<0.0001; one-way ANOVA with post-hoc Sidak’s test).
GDNF-treated mice received 10µg GDNF in 10µL enemas once daily between P4-P8.
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Supplementary Figure 4.6: Supporting information for in vivo and ex vivo analyses of
motility in the distal colon of WT, untreated HolTg/Tg or GDNF-treated HolTg/Tg mice at P20
(A) Correlation between neuron density in distal colon and time for bead expulsion in GDNF-treated
HolTg/Tg mice at P20 (in support of Figure 4.3D). (B) Examples of electric field-stimulated and drugmodulated patterns of longitudinal smooth muscle contraction-relaxation in an organ bath equipped
with a force transducer (in support of Figure 4.3E). In responsive tissues, electric field stimulation
(EFS) triggers contractions of colonic muscles that can be slightly increased by L-NAME-mediated
inhibition of nitrergic signaling, and robustly counteracted by atropine-mediated inhibition of
cholinergic signaling. GDNF-treated mice received 10µg GDNF in 10µL enemas once daily
between P4-P8.
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Supplementary Figure 4.7: Analysis of smooth muscle thickness in the distal colon of WT,
untreated HolTg/Tg or GDNF-treated HolTg/Tg mice at P20
(A) Representative H&E-stained cross-sections of different colon segments, with smooth muscle
thickness indicated by red brackets. Scale bar, 150 µm. (B) Average muscle thickness for each
colon segment (n=6 mice per group; **P<0.01; ***P<0.001; one-way ANOVA with post-hoc Tukey’s
test). GDNF-treated mice received 10µg GDNF in 10µL enemas once daily between P4-P8.
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Supplementary Figure 4.8: Analysis of GDNF distribution in multiple tissues of GDNFtreated HolTg/Tg mice at P20
Western bolt analysis of Tubulin-normalized levels of endogenous GDNF (eGDNF) and
recombinant GDNF (rGDNF) in different tissues of P20 HolTg/Tg mice that received 10µg GDNF in
10µL enemas once daily between P4-P8. The displayed blots are representative of observations
made from 3 mice.
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Supplementary Figure 4.9: Time-course analysis of HisGDNF distribution and RET
expression in colonic smooth muscles of P4-P8 HolTg/Tg mice treated with HisGDNF
Immunofluorescence analysis of HisGDNF distribution and RET expression in distal colon
muscularis of HisGDNF-treated HolTg/Tg mice. White arrowheads point to RET+ neurons that also
stain positive for HisGDNF. All images show a single focal plane representative of observations
made from 3 mice. Scale bar, 20µm.
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Supplementary Figure 4.10: GDNF enemas trigger enteric neurogenesis without prolonging
already extended survival of HSCR mouse models in Philadelphia
(A-B) In both Montreal and Philadelphia, daily administration of HisGDNF enemas (10µg HisGDNF
in 10µL of PBS) between P4-P8 trigger enteric neurogenesis in both Ednrbs-l/s-l (A) and HolTg/Tg (B)
mice (in support of Figure 4.4C). Upper panels are representative images of immunolabeled distal
colons (last cm) at P8 showing the presence of RET and HisGDNF double-positive myenteric
neurons close to an extrinsic nerve fiber (dashed outlines; Scale bar, 50µm). Lower panels are
quantitative analyses with results expressed in number of RET+ myenteric neurons per mm2. Each
dot corresponds to a field of view, with color code meaning that samples were from the same animal
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(n=3 for GDNF enemas; n=2 for untreated and PBS enemas; 4-8 fields of view per animal). (C-D)
Untreated Ednrbs-l/s-l (C) and HolTg/Tg (D) mice live longer in Philadelphia than in Montreal. For many
mice that were found dead, megacolon phenotype (distended feces-filled colon, as shown in insets)
was visually confirmed (marked by red dots). In addition, some moribund mice were euthanized in
order to prevent colon tissue alteration, thereby allowing to confirm distal aganglionosis by HuCTuJ1 double-immunofluorescence (marked by blue dots). (E-F) For both Ednrbs-l/s-l (E) and HolTg/Tg
(F) mice, GDNF treatment in Montreal increases survival to rates seen in untreated mice in
Philadelphia (P > 0.5 for GDNF-treated Ednrbs-l/s-l mice in Montreal versus untreated Ednrbs-l/s-l mice
in Philadelphia; P > 0.7 for GDNF-treated HolTg/Tg mice in Montreal versus untreated HolTg/Tg mice
in Philadelphia). GDNF treatment did not further enhance the survival advantage of Ednrbs-l/s-l and
HolTg/Tg mice in Philadelphia (P > 0.9 for untreated Ednrbs-l/s-l mice in Philadelphia versus GDNFtreated Ednrbs-l/s-l mice in Philadelphia; P > 0.5 for untreated HolTg/Tg mice in Philadelphia versus
GDNF-treated HolTg/Tg mice in Philadelphia). Log-rank (Mantel-Cox) and Gehan-Breslow-Wilcoxon
tests.
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Supplementary Figure 4.11: Analysis of Schwann cell lineage-derived neurogenesis in
myenteric and submucosal ganglia of Dhh-CreTg/+;R26YFP/+ and HolTg/Tg;Dhh-CreTg/+;R26YFP/+
mice at P20
(A) Analysis of myenteric neurons (HuC/D+) and YFP expression in the proximal colon of DhhCreTg/+;R26YFP/+ (Ctl) and HolTg/Tg;Dhh-CreTg/+;R26YFP/+ (HolTg/Tg) mice. Yellow arrowheads point to
Schwann lineage-derived neurons. (B) Quantitative analyses of myenteric neurons (HuC/D +) that
are YFP+ in the proximal and mid-colon of Dhh-CreTg/+;R26YFP/+ (Ctl) and HolTg/Tg;DhhCreTg/+;R26YFP/+ (HolTg/Tg) mice (n=3 Ctl and 3 HolTg/Tg mice; 3 fields of view per animal; *P<0.05;
one-way ANOVA with post-hoc Sidak’s test). (C) Analysis of submucosal neurons (HuC/D+) and
YFP expression in the distal colon of HolTg/Tg;Dhh-CreTg/+;R26YFP/+ (HolTg/Tg) mice that were treated
with GDNF between P4-P8. Neurons of either Schwann lineage (yellow arrowhead) or unknown
(white arrowhead) origin are detected. (D) Analysis of RET-expressing myenteric neurons (HuC/D+)
and YFP expression in the distal colon of HolTg/Tg;Dhh-CreTg/+;R26YFP/+ (HolTg/Tg) mice that were
treated with GDNF between P4-P8. RET is expressed in a subset of neurons, regardless of
Schwann lineage (RET+, filled yellow arrowhead; RET-, empty yellow arrowhead) or non-Schwann
lineage (white arrowhead) origin. All displayed images are z-stack projections representative of
observations made from 3 mice. Scale bar, 50µm. Dashed outline marks area occupied by a single
ganglion.
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Supplementary Figure 4.12: Analysis of neurogenesis and Schwann cell proliferation in
distal colon explants from P4 HolTg/Tg mice and cultured in the presence or absence of GDNF
for 96h
(A-B) Representative images of HuC/D+ neurons (A), and EdU+ SOX10+ proliferating Schwann
cells (arrows in B) in explants of distal colon from HolTg/Tg mice cultured in presence of GDNF and
EdU (+GDNF) or EdU alone (ctl). The displayed images are single focal planes representative of
observations made from 7 mice. Scale bar, 50µm. Dashed outline marks area occupied by extrinsic
nerve fibers.
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Supplementary Figure 4.13: Marker analysis of GDNF-induced neurons in sigmoid colon
explants prepared from HSCR patients and cultured in presence of GDNF for 96h
Immunofluorescence analysis showing that human GDNF-induced neurons are closely associated
with extrinsic nerves and express βIII-Tubulin (TuJ1), RET, PGP9.5 and PHOX2B (in support of
Figure 4.5F). Arrowheads in middle panels point to round/ovoid nuclei of PGP9.5 + neurons. The
displayed images are single focal planes representative of observations made from 3 human
samples. Scale bar, 100µm (upper panels), 50µm (middle panels) and 25µm (lower panels).

Supplementary Figure 4.14: GDNF-induced myenteric ganglia are self-sustaining until
adulthood
Immunofluorescence analysis of HuC/D and SOX10 expression in myenteric ganglia from distal
colon of GDNF-treated HolTg/Tg mice at P56. The displayed image is a single focal plane
representative of observations made from 3 mice. Scale bar, 50µm.
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Supplementary Figure 4.15: Schwann cells in the aganglionic distal colon of HolTg/Tg mice
express NCAM but not RET
Immunofluorescence analysis of NCAM and RET expression in extrinsic nerve fibers (delineated
by dashed lines) from distal colon of untreated HolTg/Tg mice at P20. NCAM but not RET is
expressed in SOX10+ Schwann cells and putative enteric glia/ENS progenitors (arrows). The
displayed images are single focal planes representative of observations made from 3 mice. Scale
bar, 50µm.
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Supplementary Figure 4.16: Schwann cells in the aganglionic distal colon of HolTg/Tg;DhhCreTg/+;R26YFP/+ mice are not all YFP-labeled
Immunofluorescence analysis of SOX10 and YFP expression in an extrinsic nerve fiber from distal
colon of untreated HolTg/Tg;Dhh-CreTg/+;R26YFP/+mice at P8. A subset of SOX10+ Schwann cells are
negative for YFP (arrows). The displayed images are single focal planes representative of
observations made from 3 mice. Scale bar, 50µm.

Supplementary Table 4.1. Rationale for selection of supplemental neurotrophic molecules
Molecule

Reason for selecting

Reference

Noggin

NSE promoter-driven Noggin overexpression
increases enteric neuron numbers in transgenic mice
Ex vivo culture of avian hindgut in presence of
endothelin-3 increases ENS density
Systemic administration of the serotonin receptor (5HT4R)
agonist
RS67506
triggers
enteric
neurogenesis in adult mice
Serotonin (5-HT) enhances in vitro neuronal
differentiation of murine enteric neural precursors
Ascorbic acid is needed for in vitro differentiation and
maturation of human enteric neural precursors

Chalazonitis et al., J
Neurosci 2004 (51)
Nagy and Goldstein,
Dev Biol 2006 (52)
Liu et al., J Neurosci
2009 (53)

Endothelin-3
RS67506

Serotonin
Vitamin C
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Fiorica-Howells et al., J
Neurosci 2000 (54)
Fattahi et al., Nature
2016 (55)

Supplementary Table 4.2. List of primary antibodies and dilution factors used for
immunofluorescence
Antibody
Source
Catalog number RRID reference
Dilution
6X His

R&D systems

MAB050

AB_357353

1:500

CalR

Swant,

CG1

AB_10000342

1:500

ChAT

Millipore

AB144P

AB_2079751

1:100

GFP

Abcam

Ab290

AB_303395

1:500

HuC/D

Molecular Probes

A-21271

AB_221448

1:500

HuC/D (ANNA-1)

---

AB_2313944

1:2000

Ki67

Gift from Vanda
Lennon
Abcam

ab15580

AB_443209

1:500

NCAM

Abcam

ab5032

AB_2291692

1:500

NOS1

sc-648

AB_630935

1:200

PHOX2B

Santa
Cruz
Biotechnology
R&D systems

AF4940

---

1:250

RET

R&D systems

MAB718

AB_2232594

1:500

SOX10

sc-17342

AB_2195374

1:200

SubP

Santa
Cruz
Biotechnology
Abcam

ab67006

AB_1143173

1:500

TH

Abcam

ab137869

---

1:500

TUJ1

Covance

MRB-435P

AB_663339

1:1000

VIP

Abcam

ab8556

AB_306628

1:500
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CHAPTER

5:

THE EPIGENETIC

REGULATOR

BAP1

IS

REQUIRED

FOR

MAINTENANCE OF POSTNATAL ENTERIC NERVOUS SYSTEM ANATOMY AND
FUNCTION BUT NOT EMBRYONIC ENTERIC NERVOUS SYSTEM FORMATION
This manuscript is being prepared for publication. In this chapter we present progress towards
understanding the role of epigenetic regulator Bap1 in murine enteric nervous system development
and postnatal function. Authors: Sabine Schneider, Jessica B. Anderson, Rebecca P. Bradley,
Christina M. Wright, J. William Harbour, Robert O. Heuckeroth

5.1 Abstract
Epigenetic regulatory mechanisms are underappreciated but likely critical for the development of
the enteric nervous system. We decided to explore the role of the epigenetic regulator Bap1 in ENS
development after a serendipitous discovery that embryonic Bap1 loss causes drastic bowel
dysfunction and early death. Bap1 has well-defined roles in cancer genesis, however, its role in
development is still barely understood. In this study, we report that deletion of Bap1 in enteric neural
precursors does not affect enteric neural precursor migration or neonatal proximal small intestine
motility and enteric neuron density. However, by postnatal day 15, in vitro and in vivo bowel motility
as well as myenteric and submucosal enteric neuron density is significantly reduced in both small
and large intestines. This loss of enteric neuron density can be partially explained by loss of
neurons derived from Bap1-/- enteric neuron precursors. However, tamoxifen-induced postnatal
deletion of Bap1 in most enteric neurons in either early life or adulthood does not cause obvious
morbidity. We are now working on elucidating the mechanism through which embryonic Bap1 loss
causes postnatal ENS dysfunction.

252

5.2 Introduction
The enteric nervous system (ENS) is a complex network of neurons and glia that resides
within the bowel wall. The ENS rivals the spinal cord in complexity, with more than 20 neuron
subtypes and at least four glial subtypes forming the basis of repeating neural circuits along the
length of the bowel (1–3). Enteric neural circuits regulate crucial bowel functions like fluid
homeostasis across the epithelium, epithelial homeostasis, blood flow within the bowel wall,
immune system activity, and coordinated smooth muscle contraction and relaxation (3–5). Due to
its vital role in bowel health, dysfunction of the ENS has devastating consequences. Congenital or
acquired defects in enteric nervous system function, also called enteric neuropathies, most notably
disrupt the propulsive gut smooth muscle contractions. This causes abdominal distention,
constipation, vomiting, pain, and in some cases sepsis and early death (6–8).
The most severe congenital ENS defect, Hirschsprung disease, is caused by incomplete
migration of enteric neuron precursors from the proximal to the distal end of the developing
embryonic bowel (6, 9). Hirschsprung disease is thus characterized by a complete lack of enteric
neurons at the distal end of the bowel. If the ENS forms along the entire length of the bowel, but
there are no or only subtle anatomic abnormalities, the enteric neuropathy is called chronic
intestinal pseudo-obstruction (CIPO). A number of causative gene mutations and genomic risk loci
for Hirschsprung disease have been identified over the past few decades (9–12). Two examples
that have been studied extensively are loss of EDNRB (13–18) and SOX10 (19–23), two
monogenic causes of Hirschsprung disease. However, only a few genetic causes of neuropathic
CIPO have been identified in humans (SOX10 (24), FLNA (25), SGOL1 (26), RAD21 (27), and
mitochondrial genes POLG and TYMP (28)). Cumulatively, these genes only explain a small
proportion of the total number of CIPO cases (29). A number of recent studies have advanced our
understanding of gene expression in enteric neuron subtypes at different stages of ENS
development ((22, 30–32) and Chapter 2) and greatly increased the number of possible candidate
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CIPO risk loci. A handful of genes are now also known to affect enteric neuron subtype
differentiation and function in mice (30, 31, 33–37).
Neural crest precursors undergo drastic changes in cell identity during their migration and
differentiation into the many cell types of the ENS. These changes include epithelial-tomesenchymal transition to become multipotent migratory neural crest precursors (38, 39), a
transition to migratory multipotent enteric neural crest precursors that gives rise to immature enteric
neurons and glia (40), and ultimately neural precursors make fate decisions to become specialized
enteric neuron subtypes (31, 40). All of these processes require epigenetic reorganization of the
chromatin landscape and coordinated transcriptional regulation of cell type and developmental
stage-specific gene sets (41, 42).
Epigenetic regulatory mechanisms are likely critical for the development of the ENS. For
example, loss of Aebp2 and Ezh2, subunits of the epigenetic regulator complex polycomb repressor
complex 2 (PRC2) in mouse enteric neuron precursors cause Hirschsprung Disease (43, 44). DNA
Methyltransferase 3b (Dnmt3b), an enzyme necessary for the generation of important epigenetic
marks, has also been implicated in ENS development (45). However, given the obvious importance
of epigenetic mechanisms in ENS development, the dearth of knowledge about specific epigenetic
mechanisms involved in ENS formation is surprising. We were thus intrigued by the serendipitous
discovery that deletion of the epigenetic regulator Bap1 in the ENS leads to bowel dysfunction and
early death in mice. Elucidating the role of Bap1 in enteric nervous system development and
function will add to the critical fund of ENS biology knowledge needed to ultimately develop curative
therapies for ENS-related human diseases like Hirschsprung disease and CIPO.
BAP1 is a deubiquitinase and well-known tumor suppressor gene with diverse nuclear and
cytoplasmic functions within the cell (46, 47). As a nuclear protein, BAP1 is involved in DNA
replication fork elongation (48) and double-stranded DNA damage repair (49, 50). BAP1 also
regulates gene expression. In association with other transcription factors, it can act as a
transcriptional activator or repressor itself (51, 52), it can change the activity of other transcription
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factors indirectly through its deubiquitinase activity (53, 54), and it can change gene expression
patterns at a larger scale as an epigenetic regulator (55–57). In the cytoplasm, BAP1 regulates
intrinsic apoptosis initiation through its deubiquitinase activity (46). However, BAP1’s role in
development is not well understood. Global knock-out of Bap1 leads to early embryonic lethality in
mice (52). In xenopus, Bap1 is required for lineage commitment of pluripotent cells to the germ
layers and neural crest lineages (55). Intriguingly, loss of Bap1 in uveal melanoma cells causes
downregulation of HSCR-associated genes Sox10 and Ednrb (58). Bap1 also has a role in
regulating retinoic acid-induced gene expression (57, 59). Reduced retinoic acid signaling is a
known cause of Hirschsprung disease (60–62). Therefore, we hypothesized that Bap1 knockout in
the enteric nervous system would lead to disrupted migration of enteric neuron precursors resulting
in Hirschsprung disease.
To investigate the role of Bap1 in enteric nervous system development, we used two Cre
recombinase driver mouse lines to conditionally delete Bap1 in different subsets of neural crest
derivatives. In Bap1;Wnt1-Cre mice, Cre expression is regulated by the Wnt1 promoter and Bap1
alleles are excised in all neural crest lineages early in neural crest development after embryonic
day 8.5 (E8.5) (63). In Bap1;Tyr-Cre mice, Cre recombinase is expressed under the control of the
tyrosinase promoter and Bap1 alleles are excised in the majority of migrating neural crest cells by
E 10.5. However, in the adult ENS, only a subset of enteric neurons are still derived from Tyr-Cre
lineage precursors (64). In this chapter, we present work towards anatomically and functionally
defining the ENS defect caused by Bap1 loss as well as preliminary work towards understanding
the underlying mechanisms.
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5.3 Methods
Study approval
Studies adhere to ARRIVE (Animals in Research: Reporting In Vivo Experiments)
guidelines (65). Mouse experiments were performed in accordance with Institutional Animal Care
and Use Committee (IACUC) approval from Children’s Hospital of Philadelphia (IACUC#19001041).

Animals

Bap1tm1.1Geno mice (referred to as Bap1; RRID:MGI:5439652, C57BL/6) (66) bred into
Tg(Tyr-cre)1Gfk mice (referred to as Tyr-Cre; RRID:MGI:3580524, C57BL/6) were a kind gift from
Dr. J. William Harbour at the University of Miami Miller School of Medicine. Hdac4tm2.1Eno mice
(referred to as Hdac4; RRID: MGI:4418117, C57BL/6) were a kind gift from Dr. Kelly A. Hyndman
at the University of Alabama at Birmingham. Rettm2(cre/ERT2)Ddg mice (referred to as RetCreERT2; RRID:MGI:4437245, C57BL/6) were a kind gift from Dr. Jeffrey Milbrandt, Washington
University. H2az2(Tg(Wnt1cre)11Rth mice (referred to as Wnt1-Cre; RRID:IMSR_JAX:003829,
(C57BL/6J x CBA/J)F1) and Gt(ROSA)26Sortm9(CAGtdTomato)Hze mice (referred to as R26RTdTomato; RRID:IMSR_JAX:007909, C57BL/6) were obtained from The Jackson Laboratory (Bar
Harbor, ME). Wnt1-Cre mice on a mixed background were bred into R26R-TdTomato mice on a
pure C57BL/6J background and maintained on a mixed (C57BL/6J x CBA/J)F1xC57BL/6
background. Wnt1-Cre mice were bred into Bap1 mice and maintained on a mixed (C57BL/6J x
CBA/J)F1xC57BL/6 background. Bap1 mice were bred into Tyr-Cre and maintained on a pure
C57BL/6 background. For specific experiments, Bap1;Tyr-Cre mice were bred into R26-TdTomato
mice and maintained in a pure C57BL/6 background. Lastly, Hdac4 mice were bred into Bap1;TyrCre;R26-TdTomato mice and maintained on a pure C57BL/6 background. Ret-CreERT2 mice were
bred to R26R-TdTomato and Bap1 mice and maintained on a pure C57BL/6 background. General
animal husbandry information can be found in Supplementary Table 1. Genotyping was performed
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with previously published and novel primers (Supplementary Table 3) and by Transnetyx
(Cordova, TN) using tail or ear biopsies. Vaginal plug day was considered day E0.5.

Tamoxifen treatment of Bap1;Ret-CreERT2;TdTomato mice

Tamoxifen (20 mg/mL; Sigma, Cat#:T5648) was prepared by first dissolving tamoxifen in
200 μL ethanol at 37°C and then adding 1800 μL sunflower oil (Sigma, Cat#:S5007). Adult
Bap1;Ret-CreERT2;TdTomato were gavaged with 200 mg/kg tamoxifen once daily on 4 days in a
5 day time window. Nursing dams (starting when litters are at postnatal day 1 to 3) were gavaged
with 200 mg/kg tamoxifen once daily on 4 days in a 5 day time window.

Whole Mount Immunofluorescence staining
P0 mice were euthanized by decapitation. P15 mice were euthanized by cervical
dislocation. Adult mice were euthanized with carbon dioxide (CO , 3 minutes) followed by cervical
2

dislocation. Full-length bowel was removed from the abdominal cavity, placed in 1x PBS, and
opened along the mesenteric border. Bowel borders were pinned out serosa-side up to a Sylgard
184 Elastomer (Ellsworth Adhesives, Cat#:184 SIL ELAST KIT 0.5KG) coated plate using insect
pins (Fine Science Tools, Cat#:26002-20) and fixed for 20 minutes at RT in 4% paraformaldehyde
(PFA; Thermo Fisher, Cat#:O4042-500). After fixation, the tissue was washed 3 times for 5 min
each with 1x PBS and stored in 50% glycerol (Sigma, Cat#:G9012-2L)/50% 1x PBS (Quality
Biological, Cat#:A611-E404-99) until use at 4°C (if up to a week) or -20°C (if stored longer than
one week). When tissue samples were ready to be stained, they were rinsed 3 times for 5 min each
in 1x PBS and blocked for 2 hours at RT in 5% normal donkey serum (Jackson ImmunoResearch
Laboratories, Cat#:017-000-121) in 0.1-0.5% Triton X-100 (Sigma, Cat#:T8787) in PBS (0.1-0.5%
PBST). HuC/D antibody (ANNA1) was incubated with tissue either for 3 hours at RT or overnight
at 4°C. The tissue was then transferred into primary antibody after a single 5 min wash in 1x PBS
at RT. Primary antibody (see Supplementary Table 2) in 5% normal donkey serum in 0.1-0.5%
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PBST was incubated with tissue either for 3 hours at RT or overnight at 4°C. The tissue was then
washed 3 times for 30min each in 1x PBS and transferred into secondary antibody (see
Supplementary Table 2) in 5% normal donkey serum in 0.1-0.5% PBST for incubation at RT for
60-90 min. The tissue was then washed 3 times for 30min each in 1x PBS and mounted in 50%
glycerol/ 50% 1x PBS on microscope slides (Fisherbrand, Cat#:1255015) using cover slips
(ThermoFisher, Cat#:125485P). All incubation and wash steps were performed on a benchtop
rocker (Speed 2-4, Cole-Parmer, Cat#:S2035-CP-A).

Immunohistochemistry for paraffin-embedded samples.
Bowel was removed from mice at postnatal day 15, opened at the mesenteric border, and
proximal small intestine, distal small intestine, and colon were stretched maximally and pinned out
with insect pins. The tissue was fixed in 4% PFA (20 min, RT). The tissue was prepared for paraffinembedding by briefly washing the tissue in 1x DPBS and then leaving the tissue in 70% Ethanol
for at least 3 hours at RT or overnight at 4°C. Pieces of 0.7 cm length were cut from the most
proximal and most distal ends of both small intestine and colon.
The tissue was dehydrated and pre-processed for paraffin-embedding using a Thermo
Scientific Excelsior Es Processor: 4 stages of graded ethanol 80%, 90%, 100%, 100% (30 min
each), then 3 stages of Xylene (30 min, 30 min, 45 min, Sigma, Cat#:EM-XX0060-4), then 3 stages
of paraffin (45 min, 30 min, 30 min). Care was taken to embed the tissue in paraffin with as little
horizontal or vertical curvature as possible. Tissue sections of 5μm were cut on a HM 355s Microm
microtome so that the full 0.7 cm proximo-distal length of the tissue piece is visible in a single
section. The tissue sections were then rehydrated (xylene - 3x 5 min, 100% ethanol - 5min, 5 min,
95% ethanol - 5 min, 80% ethanol - 5 min, 70% ethanol - 5 min, dH O - 5min) in preparation for
2

immunohistochemical staining.
For hematoxylin and eosin (H&E) staining, the tissue was first stained at hematoxylin
(Harris Modified Method Hematoxylin Stains, Fisher, Cat#:SH30-500D - 7 min), then rinsed in tap
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water for 5 min, differentiated in 1% acid alcohol (1% concentrated HCl (VWR, Cat# 470301-260)
in 70% ethanol, 23 sec), and blued in Scott’s tap water substitute concentrate (Scott’s tap water;
Sigma, Cat#:S5134) for 5 min. The slides were then washed with running tap water a couple of
times, dipped in 80% ethanol and directly afterwards transferred into alcoholic Eosin Y Solution
(Sigma, Cat#:HT110116) for 60-90s. To finish, the slides were rinsed in fresh dH O a couple of
2

times, and then dehydrated (95% Ethanol > 1 min, 95% Ethanol - 2 min, 100% Ethanol - 2 min,
Xylene - 2x 2 min) and mounted (Richard-Allan Scientific Cytoseal XYL, ThermoFisher, Cat#:83124).
For periodic acid-Schiff/Alcian blue (PAS/AB) staining, the sections were incubated with
Alcian blue (pH2.5, RT, 6 min, Sigma, Cat#A5268), then washed in running tap water (2 min),
rinsed in dH O, treated with 0.5% periodic acid solution (RT, 5 min, Fisher, Cat#:A223-25), and
2

again washed with dH O. The slides were subsequently incubated with Schiff’s reagent (RT, 15
2

min, Sigma, Cat#:3952016), washed with running tap water (5min), stained with hematoxylin (45
sec - 1 min), washed again in running tap water (2 min), differentiated with acid alcohol (1%
concentrated HCl in 70% ethanol; 22sec), then blued in Scott’s tap water (1min), and rinsed in
running tap water a couple of times before dehydration (95% Ethanol - 2x 2 min, 100% Ethanol 2 min, Xylene - 2x 2 min) and mounting (Richard-Allan Scientific Cytoseal XYL, ThermoFisher,
Cat#:8312-4).

Colon Bead Expulsion

Adult mice (P95-P210) were anesthetized with 2 L/min carbogen with 2.5% (v/v) isoflurane
for 1.5 minutes before start of the experiment, anesthesia was continued until completed bead
insertion. A glass bead (3 mm, Sigma, Cat#:Z143928) lubricated with sunflower seed oil (Sigma,
Cat#:S5007) was inserted 2 cm into the colon using a custom-made 3-mm rounded glass rod. Mice
were placed in empty cages, and time to bead expulsion was recorded. Assay was repeated 3
times per mouse with at least 48 hours between procedures. If a mouse regained consciousness
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before bead insertion, mice were anesthetized for an additional 2-4min. If the bead insertion was
met with increased resistance due to the presence of feces in the colon, the experiment was halted
to allow the mouse to regain consciousness. After 10 minutes the bead insertion was attempted a
second time. If there was still resistance, the experiment was not continued on that day and a new
attempt was made 48 hours later. Mice were allowed to eat ad libitum before testing.

FITC-Dextran small intestinal transit assay
P15 Tyr-Cre;Bap1 mice were gavaged with 70-100 μL of 10 mg/mL FITC-Dextran, MW
70,000, (Sigma, Cat#:FD70S) dissolved in 2% methylcellulose (Sigma, Cat:#274429). Mice were
kept in a normal cage environment for 90 min post gavage, but without access to their mother or
food and water. The mice were then euthanized and the small intestine was cut into 12 segments
of equal length. Colon was cut into 5 segments of equal length. The segments were each placed
into individually labeled Eppendorf tubes containing 400 μL 1xPBS. Bowel segments in PBS were
first minced with scissors and then vortexed for 40 sec until FITC was fully released from tissue.
The samples were centrifuged (4000 xg, 10 min) and 100 μL of supernatant from each sample
was transferred into a 96 well plate. Absolute fluorescence intensity in each well was measured
with a Modulus II microplate Multimode Reader and a filter Cube with Excitation 490 nm and
Emission 510-570 nm. Data is presented as percent fluorescence intensity ([fluorescence
intensity measured in a specific bowel segment]/[sum of fluorescence intensities measured for all
bowel segments] x100). Geometric mean is calculated as follows: i=119ixi. Where “i” refers to
each of the 19 bowel segments (ordered from most proximal (stomach; segment 1) to most distal
segment (distal colon; segment 19) and “x” refers to the measured fluorescence intensity in the
corresponding segment.

In vivo colon transit assay

P15 Tyr-Cre;Bap1 mice were separated into individual opaque holding containers and
placed in a dark, undisturbed location. The welfare of the mice was confirmed every hour. The
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number of stool pellets in the container at the end of an 8 hour time period was counted and the
presence of liquid diarrhea or feces-matted perianal fur was noted.

In Vitro Organ Bath Experiments

For Tyr-Cre;Bap1 mice at postnatal day 15 (P15), full-length colon was removed from the
abdomen and immediately placed in a dish with warm (37°C), oxygenated (95% O and 5% CO )
2

2

Krebs-Ringers solution (118 mM NaCl (Sigma, Cat#:S6191), 4.6 mM KCl (Thermo Fisher Scientific,
Cat#:BP366-500), 2.5 mM CaCl (Sigma, Cat#:C-7902), 1.2 mM MgSO (Sigma, Cat#:M-7506), 1
2

4

mM NaH PO (Sigma, Cat#:S0751), 25 mM NaHCO (Sigma, Cat#:BP328-500), 11 mM D-glucose
2

4

3

(Sigma, Cat#:G7021, pH 7.4). To remove stool from the bowel lumen, Krebs-Ringers solution was
pushed into the bowel lumen through a 21-gauge needle (BD Biosciences, Cat#:BD305167). Care
was taken to touch the epithelium as little as possible. After flushing, the entire colon was
transferred to the organ bath (Hugo Sachs Elektronik - Harvard Apparatus, Cat#:D-79232) which
was pre-filled with warm, oxygenated Krebs-Ringers solution flowing through the chamber at a rate
of 9.189 mL/min. The colon was cannulated on both ends (Hugo Sachs Elektronik - Harvard
Apparatus, Cat#:S#16105) and the tissue was secured to the cannula with thread. Intraluminal
pressure was created and maintained with a liquid reservoir suspended level to the water surface
in the bath. The height of the water column in the reservoir was maintained at 2cm above the
surface of the water bath. The fluid reservoir was connected to the proximal colon and the distal
colon was connected to an outflow tube that opened 1 cm above the fluid level in the chamber to
facilitate continuous flow of the oxygenated Krebs-Ringers solution through the colon.

For newborn (P0) Wnt1-Cre;Bap1 mice, the most proximal 3 cm of small bowel from P0
Wnt1-Cre;Bap1 mice was removed from the mice and immediately placed in warm Krebs-Ringers
solution. The small bowel was then transferred to the organ bath (Hugo Sachs Elektronik Harvard
Apparatus, Cat#:D-79232) which was pre-filled with warm, oxygenated Krebs-Ringers solution
flowing through the chamber at a rate of 9.189 mL/min. P0 proximal small bowel was cannulated
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on the proximal end using a 10 μL pipette tip as a cannula (Fisher Scientific, Cat#:21-277-2A) and
secured to the cannula using string. The distal end of the small bowel segment was pinned to
sylgard through the mesentery. The cannula was connected to a 3 mL syringe via a 2 mm diameter
plastic, L-shaped tube. Intraluminal pressure was created and maintained with a liquid reservoir
suspended level to the height of the water in the bath with fluid levels maintained 1 cm above the
surface level of the water bath. The fluid reservoir was connected only to the proximal bowel and
allowed to freely flow out of the distal bowel, facilitating continuous flow of the warm, oxygenated
Krebs-Ringers solution through the bowel.

The bowel was equilibrated for 30 minutes. Video was recorded for 20 minutes.
Tetrodotoxin (Abcam, Cat#:ab120054; 1mM stock in sodium citrate buffer [40mM citric acid
monohydrate (EMD Millipore, Cat#:CX1725-1) and 60mM trisodium citrate dihydrate (Sigma,
Cat#:C3434), pH 4.8]) was then added to the warm, oxygenated Krebs-Ringers solution at a final
concentration of 1 μM. Video was recorded 20 minutes immediately following application.

Video Imaging and data processing

An E-PM1 Olympus digital camera was mounted on a dissecting microscope to video the
bowel at 15 frames per second, 1,920 × 1,080 pixel resolution. The organ bath chamber was
illuminated using the dissecting microscope’s light source, and contrast was provided between the
bath and the bottom of the chamber by securing a piece of black paper to the bottom of the chamber
(in the case of the P0 small bowel organ baths, beneath the sylgard). The files were converted from
.MTS to .mp4 using VLC Media Player and spatiotemporal information was converted to matrices
using

a

MATLab

script

created

by

Dr.

Christina

M.

Wright

(https://github.com/christinawright100/BowelSegmentation/commit/095850905504f6ac29c7311f5
6fd9bf089ad4574, commit ID 958509). The script first thresholds the image, then separates and
distinguishes the bowel from the background. The thresholded image was used to determine bowel
width across the bowel for the duration of the video to create a graph depicting bowel width over
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time for each location along the proximo-distal axis of the bowel segment in question. CMCs
(defined as a neurogenic contraction characterized by being repetitive and containing a defined
peak point of contraction) were quantified by blinded trained laboratory personnel.

Microscopy
Images of whole mount immunofluorescence staining were acquired with a Zeiss LSM 710
confocal microscope with a x20 (20x/0.8 air) Plan-Apochromat objective and Zeiss Zen software
version 2.3 14.0.14.201 (Zeiss, Oberkochen, Germany). Images of Hematoxylin and Eosin as well
as Periodic Acid-Schiff/Alcian Blue staining were acquired with a Leica DMC 2900 camera attached
to a Leica DM 6000B epifluorescence microscope with an x20 (20x/0.7 air) HC Plan-Apochromat
objective and Leica Application Suite X version 2.0.0.14332.2 (Leica Microsystems, Wetzlar,
Germany). Confocal images show either single optical slices or maximum intensity z-projections
as indicated in the figure legends. ImageJ (NIH) was used to color-adjust images. ImageJ or
Inkscape (67); http://www.inkscape.org/) were used to crop images.

Biological sample size and technical replicates.
For H&E and PAS/AB immunohistochemistry, five slides per mouse for each bowel region were
stained. Each slide held 3-5 consecutive sections separated by a minimum distance of 200 μm.
Only one section was imaged per slide: the section with the highest number of “intact” villi or crypts
(full-length epithelial crypts and/or villi with an uninterrupted epithelial monolayer). For proximal
small intestine and distal colon, only fields of view containing at least one “intact” villus and/or crypt
were imaged. For distal small intestine and proximal colon, the entire section was imaged and
analyzed.
For whole mount immunofluorescence staining of P0 and P15 mouse bowel, at least 4x
randomly chosen full-thickness confocal Z-stacks at 20x magnification were acquired and
analyzed as technical replicates for each individual bowel region. For P15 ENS quantifications,
cells in the entire field of view were counted. For P0 ENS quantifications, cells in two randomly
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chosen quadrants of the imaged field of view were counted. Quadrant choice was adjusted if
tissue damage was identified.

Statistics
We used Prism 7.03 - 8 (GraphPad Software, San Diego, CA) for statistical analysis. A
cutoff of p < 0.05 was considered significant. All data was tested for normality and appropriate tests
were chosen. Statistical analysis was only attempted if the sample number in all comparison groups
exceeded n=3.

5.4 Results

Loss of Bap1 in the enteric nervous system causes failure to thrive
Bap1 fl/fl;Tyr-Cre+ (Tyr-Cre cKO) mice failed to thrive and died prematurely with a median
survival of only 18 days (Figure 5.1A). A few Tyr-Cre cKO pups were able to live beyond day 40,
however, only when they were left with parents and in the presence of soft, moist food. At birth,
Tyr-Cre cKO pups could not be differentiated from their littermates (data not shown). However, TyrCre cKO pups gained weight more slowly (Figure 5.1B), stayed smaller than their littermates, and
developed visibly distended abdomens towards the end of their lives (Figure 5.1C). At death, TyrCre cKO colon and distal small intestine were distended with accumulated feces (Figure 5.1D).
This distention and accumulated feces developed with increasing age. At postnatal day 15 (P15),
rare Tyr-Cre cKO pups still had a normal-appearing bowel with well-formed fecal pellets in the distal
colon, but for most pups the proximal colon was already distended by accumulated feces (Figure
5.1E-E’’). The colon of some Tyr-Cre cKO mice even became deformed by the accumulated feces
within (Figure 5.1E-E’). By P20 and beyond, the vast majority of Tyr-Cre cKO mice presented with
a deformed colon and accumulated feces throughout the colon (Figure 5.1E-E’). Accumulation of
feces in the distal small intestine also increased with age. At P15, we observed distal small intestine
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fecal aggregation and distention for 30.4% of Tyr-Cre cKO mice, but that percentage increased to
89.9% beyond postnatal day 20 (Figure 5.1F). We also noticed white patches of abdominal fur for
most Tyr-Cre cKO pups, indicating incomplete embryonic melanocyte migration (Figure 5.1G-H).

Figure 5.1: Bap1 fl/fl; Tyr-Cre+ mice failed to thrive and died with massively dilated bowel.
(A) Bap1 fl/fl;Tyr-Cre + (cKO) mice died early in life (median survival 20 days, n=30). Only mice left
with parents and in the presence of softened, moist food lived beyond postnatal day 25 (P25). (B)
cKO mice (n=111 measurements across all ages, 6.76 +/- 10.25 measurements per time point,
R =0.4861) gained weight more slowly than their heterozygous (Het, n=177 measurements across
all ages, 10.50 +/- 15.58 measurements per time point, R =0.8334) and wild-type (WT, n=168
measurements across all ages, 11.06 +/- 15.49 measurements per time point, R =0.8873)
littermates. Graph shows simple regression with 95% confidence interval of mean weight per time
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point with standard error of the mean (p = 0.001, Repeated Measures One-way ANOVA mixed
effects model). (C) cKO mice (right) were smaller than their unaffected littermates (left). At P20, the
representative cKO mouse also had a visibly distended abdomen (white arrows). (D) The colon
and distal small intestine of cKO mice became severely distended due to aggregated feces later in
life. The representative image of a cKO bowel was taken at P27. (E) cKO mice presented with
abnormal colon phenotype beyond P15 (p<0.0001 comparing Het to cKO for both P15 and beyond
P20, Binomial test). The severity of the observed bowel phenotype increased with age for cKO
mice. At P15, the colons of the majority of cKO mice had a range of abnormal appearances (cKO:
n=23, Het: n=19, WT: n=15), however, beyond P20 (>P20; cKO: n=9, Het: n=17, WT: n=20) most
of the cKO mice presented with the most severe abnormal phenotype of aggregated feces with a
deformed colon and a lack of formed fecal pellets (p=0.0142, Binomial test comparing P15 and
>P20 cKO). (E’) An example of an unusual deformation (black arrowhead) in the mid-colon and
accumulated, unformed feces in the proximal colon (white arrowhead) as well as distal small
intestine (no arrow) in a P15. (E’’) A normal-appearing colon of a P15 WT pup shows well-formed
stool pellets starting at the distal end of the proximal colon. (F) Feces also aggregated in the distal
small intestine of cKO mice (P<0.0001 for both P15 and >P20, Binomial test) and distal small
intestine involvement increased with age from 30.4% at P15 to 88.9% for cKO mice >P20.
(P<0.0001, Binomial test). Sample size at P15: cKO: n=23, Het: n=19, WT: n=15. Sample size for
ages >P20: cKO: n=9, Het: n=17, WT: n=20. (G) Example of a spot of white fur on the abdomen of
a P10 cKO pup (white arrow). This indicates incomplete melanocyte migration. (H) Melanocyte
migration was incomplete for the majority of cKO mice as compared to WT mice (cKO: n=33, WT:
n=76, Binomial test, P<0.00001). (A-H) cKO refers to Bap1 fl/fl;Tyr-Cre + genotype. (B,E-F) Het
refers to Bap1 fl/wt; Tyr-Cre + genotype. (E,H) WT refers to Bap1 wt/wt;Tyr-Cre + genotype. (B)
WT includes the genotypes Bap1 wt/wt; Tyr-Cre + genotype plus any mice not carrying a Cre allele.
Data not significant unless otherwise indicated. ****p<0.0001
Bowel motility is reduced in Bap1 conditional knockout mice

To better understand the fecal stasis phenotype observed in the Tyr-Cre cKO mice, we
decided to assess bowel motility in vivo and in vitro. We decided to focus our analysis on P15 mice.
This is a time point where 83.3% of the Tyr-Cre cKO pups are still alive, but where a clearly
abnormal bowel phenotype can already be observed in the vast majority of Tyr-Cre cKO pups
(Figure 5.1A and E-F). We never observed gross abnormalities in the proximal small intestine like
gas or fecal accumulation. However, in vivo bowel motility was significantly reduced in this part of
the bowel based on slower transit of FITC Dextran dye along the proximal small intestine (Figure
5.2A-B). Since fecal accumulation was most severe in the colon and was also first observed there,
we assessed in vivo colon motility. We quantified the number of fecal pellets expelled within an 8
hour time window by P15 Tyr-Cre cKO pups and control littermates. Unlike their littermates, all but
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one Tyr-Cre cKO pup did not pass any fecal pellets in the 8 hour time window and if any feces were
evident, it was watery diarrhea (Fig. 5.2C-D). The inability to pass stool could be explained by
either a complete lack of colonic bowel motility or uncoordinated motility, where contractions can
be observed but are unable to productively move stool pellets towards the anus. To differentiate
between these possibilities, we took full-length colons from P15 mice, subjected them to constant
intraluminal pressure in oxygenated Krebs-Ringers solution and recorded spontaneous contractility
patterns. We observed repetitive contractions involving the whole colon with a defined peak point
of contraction in all wild-type mice (Figure 5.2E). These contraction patterns matched the definition
of “colonic motor complexes” (CMC) as proposed by Corsetti et al. (68). As expected for neurogenic
contractions, these colonic motor complexes disappeared in the presence of the voltage-gated
sodium channel inhibitor tetrodotoxin which blocks all neurotransmission (Supplementary Figure
5.1A-B). In contrast, the majority of Tyr-Cre cKO mice had no neurogenic contractions (5/10,
Figure 5.2F, Supplementary Figure 5.1C-D,F). We observed abnormal neurogenic contractions
in three Tyr-Cre cKO mice (e.g. only retrograde propulsive contractions or very slow contractions
involving only part of the colon, Supplementary Figure 5.1E-F). A single Tyr-Cre cKO colon
exhibited both abnormal contractions as well as a single CMC. However, we also noted exclusively
normal neurogenic motility for two of the Tyr-Cre cKO mice (Figure 5.2F). This is consistent with
the observation that the bowel of some P15 mice still looks grossly normal and that a small number
of cKO mice can still pass stool pellets. Overall, significantly fewer neurogenic colonic motility
patterns were observed for Tyr-Cre cKO mice in vitro (Figure 5.2G). Dysfunction or loss of specific
neuron subtypes could cause bowel dysmotility by causing imbalances in inhibitory and excitatory
neuroeffector signaling to gut smooth muscle. This would result in tonic contraction or relaxation
and abnormal motility of the affected gut segment (34). To assess this possibility, we assessed
colon diameter before and after the addition of tetrodotoxin but could not detect a difference in
either absolute colon diameter or percent change in bowel diameter before and after tetrodotoxin
between Bap1 wild-type and cKO colons. (Supplementary Figure 5.1G-H).
267

Figure 5.2: Proximal small intestine and colon motility were significantly reduced in Bap1
fl/fl; Tyr-Cre+ mice at postnatal day 15.
(A) Mean FITC fluorescence intensity (+/- standard error of the mean) measured along the full
length of the bowel indicates that FITC-conjugated Dextrans traveled more slowly through the cKO
(n=6, sex unknown) proximal small intestine as compared to Het (n=5, sex unknown) and WT (n=4,
sex unknown) bowels at postnatal day 15 (P15). (B) The geometric center of measured FITC
fluorescence was more proximal for cKO mice than for Het and WT mice (P=0.0017, Kruskal-Wallis
Test with Dunn’s Multiple Comparisons Test, cKO vs Het: P=0.0086, cKO vs WT: P=0.0452, cKO:
n=6, 5.48 ± 1.21; Het: n=5, 8.47 ± 1.35; WT: n=4, 8.26 ± 0.33 (mean ± stdev)). (C) P15 cKO mice
passed fewer stool pellets in an 8 hour time window than Het and WT mice (P=0.0001, KruskalWallis Test with Dunn’s Multiple Comparisons Test, cKO vs Het: P=0.0016, cKO vs WT: P=0.0004,
cKO: n=9 (4F/3M/2 unknown), 0.11 ± 0.33; Het: n=9 (4F/5M), 3.33 ± 1.66; WT: n=10 (6F/4M), 3.90
± 1.97 (mean ± stdev)). (D) The majority of P15 cKO mice had abnormal stool (diarrhea or no feces
at all, P<0.0001, Binomial test comparing cKO and WT). (E-F) Representative kymographs
depicting bowel width as a function of time and distance along the proximo-distal axis of the
cannulated colon for P15 WT (E) and cKO (F) mice. (G) Fewer colonic motor complexes (CMC)
were recorded for cKO as compared to Het and WT colons (P=0.0003, Kruskal-Wallis Test with
Dunn’s Multiple Comparisons Test, Het vs cKO: P = 0.0065, WT vs. cKO: P=0.0003, cKO: n=10 (4
females/ 6 males), 0.05 ± 0.10 CMC/min; Het: n=9 (6 females/ 3 males), 0.28 ± 0.12 CMC/min;
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WT: n=9 (6 females/ 3 males), 0.34 ± 0.10 CMC/min (mean ± stdev)). (A-G) cKO refers to Bap1
fl/fl;Tyr-Cre+ genotype and Het refers to Bap1 fl/wt; Tyr-Cre+ genotype. (A-B) WT includes Bap1
wt/wt; Tyr-Cre + genotype plus any mice not carrying a Cre allele. (C-G) WT refers to Bap1
wt/wt;Tyr-Cre + genotype. (B,C,G) Graphs show mean +/- standard deviation. Data not significant
unless otherwise indicated. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001
Loss of Bap1 in the enteric nervous system alters bowel epithelium

The deformed colon shape commonly observed in cTyr-Cre cKO mice beyond P15 (Figure
5.1E-E’) led us to ask if the normally soft and flexible distal bowel wall had stiffened due to fibrosis
and/or inflammatory infiltrates. Increased stiffness of the bowel wall also could directly affect bowel
motility. To address this question, we first stained cross-sections of proximal and distal small
intestine as well as proximal and distal colon with trichrome stain to visualize collagen-I deposition
within the bowel wall. We did not observe any differences in Tyr-Cre cKO versus control bowels
(Supplementary Figure 5.2A-H). We also did not see any inflammatory infiltrates within the bowel
wall (Supplementary Figure 5.2A-H, I-J, O-R, A’-D’, and I’-J’). However, we noticed a possible
reduction in goblet cells in Tyr-Cre cKO distal small intestine and proximal colon epithelium as
compared to control epithelium (Supplementary Figure 5.2B-C versus F-G). Goblet cells produce
mucus which lubricates stool and facilitates movement of the stool along the bowel. Mucus also
forms an important protective layer between luminal contents and the epithelial layer and prevents
access of potentially pathogenic bacteria to the epithelium (69). Thus, loss of goblet cells could
increase susceptibility to sepsis and death. However, these preliminary observations were not
confirmed. Proximal small intestine epithelium appeared grossly normal (Supplementary Figure
5.2I-N), whereas distal small intestine epithelium was normal except for a significantly increased
presence of relatively more immature goblet cells in Tyr-Cre cKO epithelial crypts that was no
longer apparent in epithelial villi where mature epithelial cells are located (Supplementary Figure
5.2O-Z). Tyr-Cre cKO epithelial crypts in proximal colon were deeper than in control mice and
contained proportionally more goblet cells (Supplementary Figure 5.2A’-H’). No obvious
differences in Tyr-Cre cKO versus control distal colon epithelium could be detected
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(Supplementary Figure 5.2I’-L’). Overall, we were able to detect small differences in Tyr-Cre cKO
epithelium in the distal bowel, however, the significance of these changes is unclear.

Enteric neuron density along the length of the bowel is normal at birth but significantly
reduced by postnatal day 15 in Bap1 conditional knock-out mice

Bap1 is an epigenetic regulator with known roles in differentiation (55) and regulation of
genes important for ENS precursor migration (58). Loss of Bap1 also affects fetal migration of
melanocytes, another neural crest derivative (Figure 5.1G-H). Therefore, we hypothesized that
loss of Bap1 in the ENS causes abnormal ENS anatomy. At P15, total myenteric and submucosal
neuron density were significantly reduced throughout the bowel, including proximal small intestine,
distal small intestine, proximal colon, and distal colon (Figure 5.3A-D, and Supplementary
Figures 5.3, 5.4A-B). Since imbalance in enteric neuron subtypes can lead to abnormal enteric
neural circuits and dysmotility, we also looked at the density of nitrergic neurons. Nitrergic neurons
are an abundant and functionally important category of enteric neurons and include interneurons
and inhibitory motor neurons (1). We found no difference in overall density of NOS1+ neurons in
myenteric and submucosal plexi (Figure 5.3A-B,E-F, Supplementary Figures 5.3, 5.4C-D).
However, nitrergic neuron numbers varied greatly between fields of view for both Tyr-Cre cKO and
control mice. Thus we also assessed the ratio of nitrergic neurons to total neurons in each field of
view and preliminary results suggest that nitrergic neurons are reduced proportionally to total
neurons in both myenteric and submucosal plexi in all bowel regions assessed (Figure 5.3G-H and
Supplementary Figure 5.4E-F). In Bap1;Tyr-Cre mice, only ~80% of migrating ENS precursor
cells at day 11.5 of embryonic development (E11.5) are derived from Tyr-Cre lineage cells (64) and
carry homozygous Bap1 null alleles. We thus hypothesized that ENS abnormalities would be much
more severe in Bap1;Wnt1-Cre mice, a mouse model where 100% of the neonatal ENS is derived
from ENS precursors carrying Bap1 knock-out alleles (70).
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Figure 5.3: Preliminary analysis suggested that Bap1 fl/fl; Tyr-Cre+ mice at postnatal day 15
had decreased total enteric neuron density and proportionally decreased nitrergic neuron
density along the bowel. However, neonatal enteric neuron density was unaffected by Bap1
loss.
(A-B) Representative images of myenteric plexus showing enteric neurons (HUC/D+, green) and
nitrergic neurons (NOS1+, magenta) in proximal small intestine for Control (A) and Bap1 fl/fl; TyrCre + (cKO; B) mice at postnatal day 15 (P15). (A) Single confocal optical slice. (B) Maximum
intensity z-projection. (C-D) Quantification of total neuron density in Bap1;Tyr-Cre mice at postnatal
day 15 showed decreased neuron density for cKO mice in both myenteric (A) and submucosal
plexus (B) as compared to Control mice in all regions of the bowel (Student’s t-test; myenteric PSI:
p < 0.0001, myenteric DSI: p= 0.0130, myenteric PCO: p = 0.0006, myenteric DCO: p = 0.0001,
submucosal PSI: p < 0.0001, submucosal DSI: p = 0.0003, submucosal PCO: p = 0.0002, and
submucosal DCO: p = 0.0003). (E-F) Preliminary analysis of nitrergic neuron (NOS1+) density in
Bap1;Tyr-Cre mice at P15 suggests no significant decrease in NOS1+ neuron density in myenteric
(E) and submucosal plexus (F) except for distal colon (DSI; Student’s t-test; myenteric PSI: p =
0.02829, myenteric DSI: p= 0.6083, myenteric PCO: p = 0.8402, myenteric DCO: p = 0.0.0357,
submucosal PSI: p = 0.0793, submucosal DSI: p = 0.2791, submucosal PCO: p = 0.0856, and
submucosal DCO: p = 0.0011). (G-H) However, preliminary analysis of the proportion of nitrergic
neurons in Bap1;Tyr-Cre mice at P15 suggests a proportional decrease of NOS1+ neuron density
in myenteric plexus (G) in all bowel regions and submucosal plexus (H) in proximal small intestine
(PSI; Student’s t-test; p = 0.1608). No conclusions can be drawn about submucosal plexus (H) in
other bowel regions at this time. (I) Representative images of myenteric plexus showing myenteric
enteric neurons (HUC/D+, magenta) and myenteric neurite network (TUJ1+, green) for neonatal
(P0) Control and cKO Bap1;Wnt1-Cre mice along the bowel. All images are maximum intensity zprojections. (J-K) Preliminary analysis of enteric neuron density in P0 Bap1;Wnt1-Cre mice
indicates that there is no significant difference between Control and cKO mice in myenteric (G) and
submucosal plexus (H; Student’s t-test; myenteric PSI: p = 0.2976, myenteric DSI: p= 0.6707,
myenteric PCO: p = 0.2313, myenteric DCO: p = 0.3779, submucosal PSI: p = 0.1070, submucosal
DSI: p = 0.2032, submucosal PCO: n too small for statistical analysis, and submucosal DCO: p =
0.3877). (A) Control genotype is Bap1 wt/wt; Tyr-Cre + . (C-K) Control encompasses genotypes
Bap1 wt/wt;Cre+ or any genotype without Cre allele plus Bap1 fl/wt;Cre +. cKO genotype is Bap1
fl/fl;Cre +. (C-H,J-K) All data derived from mice with the following genotypes are visualized with
green data points: Bap1 wt/wt;Cre + genotype or any genotype without Cre allele. PSI = proximal
small intestine, DSI = distal small intestine, PCO = proximal colon, DCO = distal colon. (A-B) Scale
bar = 50 μm. (I) Scale bar = 20 μm. All data represented as mean +/- standard deviation. *p<0.05,
**p0.01, ***p<0.001, ****p<0.0001
Surprisingly, when we compared the ENS of neonatal Bap1 fl/fl; Wnt1-Cre+ (Wnt1-Cre
cKO) pups to that of control littermates, the ENS of cKO mice appeared unremarkable (Figure
5.3I). When we quantified the density of enteric neurons in proximal small intestine, distal small
intestine, proximal colon, and distal colon, we found no differences between Wnt1-Cre cKO and
control ENS (Figure 5.3J-K). This suggests that embryonic loss of Bap1 in the ENS does not affect
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the development of a structurally normal way until birth. We hypothesized that enteric neurons
without functional BAP1 are possibly lost postnatally. Unfortunately, Wnt1-Cre cKO mice did not
live beyond the first day of life due to cardiac abnormalities (data not shown), so we turned back to
the Bap1;Tyr-Cre mouse model to interrogate this hypothesis. We noticed no obvious difference in
the percentage of Tyr-Cre lineage (TDTOMATO fluorescent reporter- expressing) enteric neurons
in P0 Tyr-Cre cKO mice as compared to control pups (Figure 5.4A-B, quantifications are ongoing).
However, by P15, the percentage of Tyr-Cre lineage neurons was significantly lower in Tyr-Cre
cKO myenteric plexus throughout the bowel as compared to wild-type myenteric plexus (Figure
5.4C-E and Supplementary Figure 5.5). In the submucosal plexus, a significant reduction in
TdTomato+ neurons could only be verified in distal colon (Figure 5.4F and Supplementary Figure
5.5) where the overall number of enteric neuron numbers is also most severely reduced (Figure
5.3D). This data supports the hypothesis that conditional loss of Bap1 allows the development of a
normal ENS, but that enteric neurons are either lost postnatally or that there is significantly reduced
postnatal proliferation of persistent ENS precursors.
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Figure 5.4: Neonatal Bap1 fl/fl; Tyr-Cre+ mice appeared to have a normal complement of TyrCre lineage neurons, but lost neurons of the Tyr-Cre lineage by postnatal day 15.
(A-B) The vast majority of enteric neurons (HUC/D+, green) of both Bap1 wt/wt; Tyr-Cre + (Control,
A) and Bap1 fl/fl; Tyr-Cre + (cKO, B) mice at birth were derived from enteric neuron precursors of
the Tyr-Cre lineage (TDTOMATO+, magenta). Images are representative confocal optical slices of
distal small intestine myenteric plexus. (C-F) cKO mice preferentially lose Tyr-Cre lineage neurons
by postnatal day 15 (P15). (C-D) Representative confocal optical slices of proximal colon myenteric
plexus for Control (C) and cKO (D) mice. White arrows point to neurons (HUC/D+, green) that do
not express TDTOMATO (magenta). (E) Quantification of the proportion of Tyr-Cre lineage neurons
in the myenteric plexus of P15 Control and cKO mice showed a significant decrease in
TDTOMATO+/ Tyr-Cre lineage neurons in all bowel regions (PSI: p = 0.013, DSI: p = 0.021, PCO:
p = 0.028, DCO: p = 0.006; Student’s t-tests; Control = 2 females/ 2 males, cKO = 3 females/
1male). (F) Quantification of the proportion of Tyr-Cre lineage neurons in the submucosal plexus
of P15 Control and cKO mice showed a significant decrease in TDTOMATO+/ Tyr-Cre lineage
neurons in proximal small intestine only (PSI: p = 0.035, DSI: p = 0.263, PCO: 0.635, DCO: 0.362,
Student’s t-tests). Control = Bap1 wt/wt; Tyr-Cre+ and cKO = Bap1 fl/fl; Tyr-Cre+. Scale bar = 25
μm.
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Neonatal bowel motility is unchanged in Bap1 conditional knock-out mice

We observed a progressive worsening of the bowel phenotype overall (Figure 5.1E-F and
Figure 5.2) and some P15 mice were still gaining weight at a rate similar to their littermates (Figure
5.1B) and had normal bowel motility (Figure 5.2C-D,G and Supplementary Figure 3F). Therefore,
we wondered if the normal-appearing neonatal ENS is able to induce neurogenic motility patterns
or if the neurons that are present are already functionally abnormal. We chose the Bap1;Wnt1-Cre
mouse model to assess neonatal bowel motility since 100% of enteric neurons and glia carry the
Bap1 null allele and any functional deficit should be more noticeable in these mice. We compared
in vitro proximal small intestine motility in P0 Wnt1-Cre cKO mice with that of control littermates at
birth and were unable to find a difference. As expected (71), we observed CMCs (low
frequency/neurogenic contractions) in about half of both Wnt1-Cre cKO and control pups (Figure
5.5A-E and Supplementary Figure 5.6A-D) and there was no difference in the frequency of
observed CMCs (Figure 5.6F). We also assessed myogenic, high frequency contractions and
again found no differences for P0 Wnt1-Cre cKO and control mice (Supplementary Figure 5.6EF).
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Figure 5.5: Neonatal proximal small bowel motility in Bap1 fl/fl; Wnt1-Cre+ mice was normal.
(A-D) Representative kymographs depicting bowel width as a function of time and distance along
the proximo-distal axis of the cannulated proximal small intestine for Control (Ctrl; A-B) and cKO
(C-D) neonatal (P0) mice. Low frequency (L.F.) contractions could be recorded for a subset of P0
Ctrl and cKO pups (A and C; white arrows) while no L.F. contractions were detected for other Ctrl
and cKO pups (B and D; Ctrl: n=10 [WT: 5 males/2 females and Het: 1 male/ 2 unknown], cKO: 6
females/ 1 male/ 2 unknown). (E) The proportion of bowels where any L.F. contractions were
recorded did not differ for P0 Ctrl (WT: contractions - 3 mice, no contractions - 4 mice, Het:
contractions - 2 mice, no contractions - 1 mouse) and P0 cKO mice (contractions - 4 mice, no
contractions - 5 mice). (F) The frequency of L.F. contractions did not differ for Ctrl and cKO
neonates for which any L.F. contractions could be recorded (p=0.3368, Student’s t-test, Ctrl: : 0.18
± 0.13, cKO: 0.11 ± 0.07 (mean ± stdev)). Data points derived from Het mice are marked by blue
color. (A-F) WT refers to Bap1 wt/wt; Wnt1-Cre + or any genotype without the Wnt1-Cre transgene,
Het refers to Bap1 fl/wt; Wnt1-Cre + genotype. cKO refers to Bap1 fl/fl; Wnt1-Cre + genotype. Data
not significant unless otherwise indicated.
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Postnatal loss of Bap1 in the ENS does not affect survival, weight gain or colon motility

The ENS in Bap1 conditional knock-out mice appears to be structurally and functionally
normal at birth, but enteric neurons, specifically of the Tyr-cre lineage are lost postnatally. These
observations led us to ask if Bap1 has a primary role in the postnatal ENS maintenance with limited
effects on prenatal ENS development. We thus deleted Bap1 in the postnatal ENS either at 8 weeks
of age (adult) or between P1 and P7 (early life) in a Bap1;Ret-CreERT2 mouse model. Deletion of
Bap1 in Bap1 fl/fl; Ret-CreERT2 + (Ret-CreERT2 cKO) adult mice or in early life did not affect
overall survival of Ret-CreERT2 cKO mice, despite some toxicity-related lethality across genotypes
due to the tamoxifen treatment early in life (Figure 5.6A-B). Loss of Bap1 caused a small increase
in percent weight gain in Ret-CreERT2 cKO treated with tamoxifen in adulthood, but this increase
in weight gain did not translate to a clear biologically meaningful increase in raw body weight (the
weights of individual adult mice varied greatly at the beginning and end of experimental observation
period. cKO: from 23.48g ± 2.96g to 24.49g ± 1.01g, Het: from 23.72g ± 3.41g to 24.77g ± 0.78g,
and WT: from 20.73g ± 1.36g to 21.13g ± 0.74g). Weight gain of Ret-CreERT2 cKO mice was not
affected by loss of Bap1 in early postnatal life (Figure 5.6C-D). Preliminary quantification of the
proportion of TDTOMATO-expressing neurons in adult mice 1-12 weeks after tamoxifen treatment
shows that most enteric neurons (myenteric plexus: 87.02 ± 6.15 across genotypes and
submucosal plexus: 96.14 ± 4.62 across genotypes) have undergone Cre-mediated recombination
and lost functional Bap1 alleles (Figure 6E-G). However, colon motility appears to be unaffected
by postnatal loss of Bap1 irrespective of the timing of tamoxifen treatment (Figure 6H). These
observations indicate either that prenatal Bap1 loss is required for the postnatal dysmotility
phenotype and decrease in enteric neuron density, despite a functional, normal-appearing ENS at
birth, or that loss of Bap1 in a small percentage of enteric neurons (1%-20%) is responsible for the
observed phenotypes.
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Figure 5.6: Tamoxifen-induced postnatal loss of Bap1 in the ENS did not affect survival,
bowel motility, and possibly post-treatment weight gain.
(A) CRE-mediated excision of Bap1 allele in Bap1 fl/fl; Ret-CreERT2 + (cKO) mice at 8 weeks of
age did not cause early lethality. Mice were followed for at least 90 days after tamoxifen treatment
(cKO: 8 females/ 5 males, Het: 3 females/ 3 males, Control: 4F/1M). (B) Tamoxifen treatment
between postnatal day 1 and day 7 (P1-P7) was lethal for a subset of mice, however, no meaningful
difference in survival was observed for tamoxifen-treated cKO mice (cKO: 5 females/ 3 males/ 1
not known, Het: 5 females/ 2 males, Control: 11 females/ 11 males/ 4 not known). (C) Tamoxifentreated adult cKO mice gained and maintained slightly more weight than Control and Het mice
between 1 to 10 weeks after tamoxifen treatment with unclear biological significance (p=0.001,
Repeated Measures One-way ANOVA mixed effects model with multiple comparisons, p = 0.025;
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Control vs. cKO p = 0.016; Het vs. cKO, cKO: 3 females/ 5 males [112.2 ± 3.45], Het: 2 females/ 3
males [109.3 ± 3.14], Control: 3 females [107.8 ± 3.64]). (D) cKO mice treated with tamoxifen
between P1-P7 gained weight at the same rate as their Het and Control littermates (p=0.2076,
Repeated Measures One-way ANOVA mixed effects model with multiple comparisons, cKO: 5
females/ 2 males, Het: 3 females/ 2 males, Control: 6 females/ 10 males). (E) Proximal colon
myenteric plexus in a cKO mouse 1 week after tamoxifen treatment contained some neurons that
did not express TDTOMATO (white arrowheads). cKO mouse treated at 8 weeks of age. (F)
Proximal colon submucosal plexus in a cKO mouse 1 week after tamoxifen treatment contained
some neurons that did not express TDTOMATO (white arrowheads). cKO mouse treated at 8
weeks of age. (G) Preliminary quantification of the proportion of TDTOMATO+ (magenta) enteric
neurons (green) shows that tamoxifen treatment at 8 weeks of age led to CRE-mediated
recombination in the vast majority of myenteric and submucosal neurons (Control: 2 males (1 week
and 12 weeks after treatment), Het: 1 female (12 weeks after treatment), cKO: 1 male (1 week after
treatment)) and that the proportion of Ret-CreERT2 lineage neurons remained constant. (H) Colon
bead expulsion latency was normal for cKO mice that were treated with tamoxifen at 8 weeks of
age (p = 0.8116, One-way ANOVA, cKO: 4 females/ 1 males, Het: 1 female/ 2 males, Control: 3
females/ 1 males) and colon bead expulsion latency in cKO mice was likely unaffected by tamoxifen
treatment between P1-P7 (cKO: 1 female, Het: 2 females, Control: 4 females, 2M). (E-F) Single
confocal optical slice. (A-D, G) WT refers to Bap1 wt/wt; Ret wt/CreERT2 or any genotype without
the CreERT2 knock-in allele. (A-H) Het refers to Bap1 fl/wt; Ret wt/CreERT2 genotype. cKO refers
to Bap1 fl/fl; Ret wt/CreERT2 genotype. PSI = Proximal Small Intestine, DSI = Distal Small Intestine,
PCO = Proximal Colon, and DCO = Distal Colon. (E-F) Scale bar = 20 μm.
Summary

Loss of Bap1 in enteric neural precursors did not affect neonatal enteric nervous system
anatomy and function. However, density of Tyr-Cre lineage neurons and total neuron density were
decreased by P15 in Tyr-Cre cKO mice along the entire length of the bowel. By P15, proximal small
intestine and colon motility were decreased and Tyr-cre cKO mice failed to thrive and died early
with greatly distended bowels due to accumulated feces. Postnatal loss of Bap1 in the vast majority
of enteric neurons did not cause motility defects, affect weight gain or survival of RetCreERT2 cKO
mice, indicating that prenatal loss of Bap1 in enteric neural precursors is required for postnatal
neuron loss and bowel dysmotility or that postnatal loss of Bap1 in very specific neuron
subpopulations is responsible for the majority of the observed motility and survival phenotype.
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5.5 Discussion and Future Directions
Loss of Bap1 does not cause Hirschsprung disease

We initially expected that loss of Bap1 would lead to Hirschsprung disease. This hypothesis
was supported by previous studies showing that Bap1 regulates neural crest lineage differentiation
(55) and expression of genes important for enteric neural crest migration (58). We also observed
early in this study that the majority of Tyr-Cre cKO mice had a patch of white abdominal fur,
indicating incomplete embryonic melanocyte migration. Melanocytes are also a neural crest
derivative and melanocyte migration defects are associated with Hirschsprung disease
(Waardenburg-Shah syndrome (13, 17)). Hirschsprung disease can be caused by disruption of a
number of processes, including enteric neural precursor proliferation, survival, and migration (9).
Bap1’s role as a transcriptional and epigenetic regulator could affect all of these processes. Bap1
loss could further impair enteric neural precursors differentiation into a full complement of neurons
and glia. This could cause ENS structural abnormalities at birth even in the parts of the bowel
colonized by enteric neural precursors (36, 72, 73).

To our surprise, the ENS in Wnt1-Cre cKO mice appeared anatomically and functionally
normal at birth. In neonatal Wnt1-Cre cKO mice, overall enteric neuron density was normal along
the length of the bowel in both myenteric and submucosal plexi. Additionally, enteric neurons were
arranged into enteric ganglia connected by Tuj1+ neurites. Despite the unexpected nature of this
observation, the lack of an enteric neural precursor migration defect still needs to be interpreted
with caution. Previous studies have shown that Cre-mediated recombination takes place at around
E8.5-E9 in the Bap1;Wnt1-Cre mouse model (63) and before E10.5 for the Bap1;Tyr-cre mouse
model (64). However, we do not know how long functional BAP1 protein is retained in migrating
enteric neural precursors. It seems unlikely that the functionally and anatomically normal P0 ENS
can be solely explained by lingering BAP1 protein that is still able to affect cell signaling until close
to birth (more than 9 days after Cre excision in the case of Bap1;Tyr-Cre and more than 10 days
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later in the case of Bap1;Wnt1-Cre). However, ENS migration is completed around E13.5 and the
lack of an ENS migration defect could be due to BAP1 protein activity beyond the time point of Cre
mediated recombination. We are currently staining embryonic bowel during enteric neuron
precursor migration with BAP1 antibodies to visualize whether loss of BAP1 protein was already
complete at this stage of development.

Wnt1-Cre cKO in vitro proximal small intestine motility also seemed unaffected. Both the
proportion of mice for which any neurally mediated contractions could be observed during the
observation window and the frequency of recorded contractions was unchanged. These
observations support the conclusion that Bap1 loss does not affect the intrauterine formation of the
ENS. It should be noted, however, that assessing bowel motility in neonatal mice is complicated by
the relative immaturity of the ENS at that age. Neurologically mediated neurogenic contractions
can be observed in proximal small intestine as early as E18.5 (71), but at that same age, neurally
mediated contractions are not yet present in the colon (74). The presence of a CMC with a “defined
peak of contraction” in vitro cannot be directly equated with normal motility patterns that
productively propagate a bolus of food towards the anus. To complete the characterization of
neonatal bowel motility in cKO pups, we are currently assessing in vivo neonatal Wnt1-Cre cKO
proximal small intestine motility with a FITC Dextran transit assay (analogous to Figure 5.2A-B).

The ENS at P15 is abnormal in Bap1;Tyr-Cre mice

At P15, Tyr-Cre cKO myenteric and submucosal enteric neuron density was reduced along
the length of the bowel. This decrease in enteric neuron numbers could be due to a reduction of all
ENS neuron subtypes proportional to normal ENS subtype composition or a lack of specific cell
populations with complete sparing of other cell types. The change in Tyr-Cre cKO enteric neuron
density was also accompanied by in vivo and in vitro bowel dysmotility. Since loss of specific neuron
subtypes in particular has been shown to cause dysmotility (30, 34), we decided to evaluate
nitrergic (NOS1+) neuron density. Myenteric nitrergic neurons are functionally important since they
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include interneurons and inhibitory motor neurons and, in combination with cholinergic enteric
neurons, make up >95% of mouse myenteric plexus neurons (1). The data presented here is
preliminary and only limited statistical conclusions could be reached, however, it appears that
nitrergic neuron density was unchanged despite an overall decrease in neuron density. High
variability in NOS1+ neuron numbers in individual fields of view across all genotypes was apparent.
This variability made the proportion of NOS1+ neurons to total neurons easier to interpret than
nitrergic neuron density since nitrergic neurons could be matched to total neuron numbers for each
field of view. We are currently completing the quantification of nitrergic neuron density for the
remainder of our P15 sample set.

As a next step, we will assess cholinergic enteric neuron density in P15 Tyr-Cre cKO mice.
Cholinergic neurons comprise a large subset of submucosal neurons ~41% (75) and a subset of
myenteric neurons that is mostly non-overlapping with nitrergic neurons (~70%) (76, 77). So far,
we have focused exclusively on enteric neuron density at P0 and P15. However, neonatal enteric
glial density as well as postnatal glial survival could also be affected by loss of Bap1. Loss or
dysfunction of glia could even contribute to the observed functional deficit at P15 (78–80), albeit
more subtly than enteric neuron dysfunction.

Loss of Bap1 may lead to postnatal neuron loss

A postnatal loss of enteric neurons could explain the observed anatomic and functional
differences in neonatal versus P15 cKO mice. We observed a worsening of Tyr-Cre cKO mouse
health over time. At birth, Tyr-Cre cKO mice were indistinguishable from their littermates in size
and weight and then progressively fell behind their littermates in development and bowel motility
defects could be detected in most cKO mice by P15. Interestingly, the rate of phenotype worsening
was not uniform. Some Tyr-Cre cKO pups stopped gaining weight by P5 and died before P15. In
contrast, some P15 Tyr-Cre cKO mice exhibited normal colon motility both in vivo and in vitro and
rare Tyr-Cre cKO bowels were still free of aggregated feces as late as P20.
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Loss of only Tyr-Cre lineage neurons in cKO mice would be sufficient to explain the overall
loss of myenteric neurons in the myenteric plexus. However, the drastic loss of enteric neurons in
the submucosal plexus does not correlate with the modest loss of Tyr-cre lineage neurons in
proximal small intestine and a lack of statistically significant Tyr-Cre lineage neuron loss in all other
bowel regions. This implies that the presence of Tyr-Cre lineage cells also affects the survival of
other enteric neurons in the submucosa.

Epithelial changes caused by loss of Bap1 are of unclear significance

Loss of Bap1 caused subtle changes in distal small intestine and proximal colon epithelium.
We decided to look at the epithelium after we noticed apparent qualitative changes in goblet cell
density in Tyr-Cre cKO mice (see Supplementary Figure 5.1A-H). Assessing epithelial changes
also made sense in the context of other observations: Tyr-Cre cKO mice sometimes started losing
weight and developed diarrhea before any feces had started to accumulate in the distal bowel,
which hinted at a possible loss of absorptive capacity for nutrients and water along the bowel.
Enteric neurons and glia regulate epithelial turnover and epithelial barrier function (reviewed in
Chapter 1) and loss of enteric neuron subtype signaling can affect epithelial wound healing
capacity (81). The subtle changes we quantified in P15 Tyr-Cre cKO pups (e.g. deeper crypts with
a proportional increase in goblet cells in proximal colon and a higher density of goblet cells in distal
small intestinal crypts but not villi) could be caused directly by altered enteric neuron signaling to
epithelial stem cells (82–85), but more likely, the epithelial changes were secondary to prolonged
exposure to aggregated feces.

Postnatal loss of Bap1 in most ENS cells does not cause obvious pathology

Tamoxifen-induced Bap1 loss in most of the ENS does not seem to affect survival, bowel
motility or biologically significant weight change. This could mean that prenatal Bap1 loss is
necessary for the postnatal dysmotility phenotype and decrease in enteric neuron density, despite
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a functional, normal-appearing ENS at birth. An alternative possibility is that the observed functional
deficits in Bap1;Tyr-Cre mice are caused by loss of Bap1 in a small number of enteric neurons that
do not express Ret (1-20% of total ENS neurons, see Figure 5.6G). We are currently in the process
of completing in vivo small intestine and colon motility assays for Bap1;Ret-CreERT2 mice treated
with tamoxifen in early life and adulthood to back up our preliminary observations. We are also
quantifying enteric neuron density and Ret-CreERT2 lineage neuron density in Bap1;Ret-CreERT2
mice treated with tamoxifen at early and later time points to see if enteric neuron survival is affected
by postnatal loss of Bap1. If we can observe a decrease in enteric neuron density in Ret-CreERT2
cKO mice compared to wild-type mice after tamoxifen treatment , this would indicate the fascinating
possibility that the ENS can buffer a statistically significant loss of enteric neurons without any
obvious morbidity and that the functional deficits observed in Tyr-Cre cKO mice are caused by
dysfunction in a relatively small subset of neurons.

Next steps - towards defining a mechanism

Our next steps will focus on better understanding how Bap1 is causing postnatal enteric
nervous system dysfunction. As a first step, we will look for apoptosis (cleaved caspase 3 staining)
and evidence of double-stranded DNA breaks (stain tissue for phosphorylated histone 2AX) (86) in
the ENS between P5 and P10. One of Bap1’s nuclear roles is facilitating double-stranded DNA
break repair (49, 50). Therefore, loss of Bap1 could cause accumulation of DNA damage resulting
in ENS dysfunction and eventually loss of neurons. For example, ENS loss of Ercc1, an
endonuclease complex subunit required for nucleotide excision repair, causes hypersensitivity to
UV irradiation. In this mouse model, the ENS accumulates DNA damage, degenerates after 1
month of age, and animals experience massive colonic distention and death around 4-6 months
of age (87). However, the timeline for ENS degeneration and survival in the Ercc1 cKO mouse
model is very different from that in our mice (2-4 weeks for Bap1 versus 4-6 months for Ercc1), and
Ercc1 loss only leads to this drastic phenotype when combined with UV radiation exposure. This
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makes accumulation of DNA damage a less likely possibility, yet a possibility we need to exclude.
It should also be noted that a lack of apoptotic markers in the postnatal Bap1;Tyr-Cre ENS would
have to be interpreted with care and cannot exclude cell death since enteric neurons can employ
cell death pathways that do not depend on effector caspase activation (88).

We are also evaluating whether histone deacetylase 4 (Hdac4) regulation by Bap1
contributes to the observed postnatal phenotype in the Bap1;Tyr-Cre cKO ENS. We were intrigued
by the prominent regulatory interaction between Bap1 and Hdac4 in early xenopus development.
Loss of both bap1 and hdac4 was able to rescue the prominent gastrulation and neurulation defects
caused by bap1 loss alone. Deletion of other epigenetic regulators like the polycomb repressor
complex 2 subunit ezh2 did not have any effect (55). We are currently in the process of breeding
floxed Hdac4 alleles into the Bap1;Tyr-Cre mouse model to assess the effect of loss of both alleles
on survival and bowel phenotype. Preliminary results suggest that Hdac4 loss by itself is insufficient
to correct Bap1-induced postnatal ENS dysfunction (data not shown).

Lastly, we are planning to compare single cell ENS transcriptomes from Bap1;Tyr-Cre cKO
and wild-type mice at P5. We are planning to isolate Tyr-Cre lineage/TDTOMATO+ neurons and
glia by FACS and assess changes in RNA expression due to Bap1 loss in comparable ENS cell
types (89). This type of analysis can provide indirect evidence of epigenetic dysregulation through
large numbers of dysregulated transcripts (56, 57) and may allow us to detect if any specific ENS
cell types are most severely affected.
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5.8 Supplementary Figures and Tables

Supplementary Figure 5.1: Motility patterns observed at postnatal day 15 were neurogenic
and often abnormal or absent in Bap1 fl/fl;Tyr-Cre+ mice.
(A-D) Representative kymographs depicting bowel width as a function of time and distance along
the proximo-distal axis of the cannulated colon for WT (Bap1 wt/wt; Tyr-cre+; A-B) and cKO (Bap1
fl/fl; Tyr-Cre+; C-D) mice at postnatal day 15 (P15). (A-B) Colonic motor complexes (CMC) recorded
for P15 WT mice (A; white arrows) disappeared in the presence of tetrodotoxin (TTX, B). (C-D) For
some P15 cKO mice, no CMC was recorded (C) and this was also true in the presence of TTX (D).
(E) Example kymograph for P15 cKO mouse shows regular but abnormal neurogenic propagating
motility patterns. (F) Breakdown of the types of motility patterns observed for P15 cKO mice (n=10).
(G) Colon width did not change significantly in the presence of TTX for either P15 WT or cKO mice
(cKO: 2 males/1 female, WT: 2 females/1 male). (H) Percent change in colon width as compared
to baseline also did not differ significantly for P15 WT and cKO mice (cKO: 2 males/ 1 females,
WT: 2 females/ 1 male). (A-E) TTX = tetrodotoxin. (F-G) Graphs show mean +/- standard deviation.
Data not significant unless otherwise indicated.
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Supplementary Figure 5.2: Bap1 fl/fl; Tyr-Cre+ mice at postnatal day 15 had altered bowel
epithelium.
(A-H) Similar amounts of collagen in the bowel wall were observed in control (A-D) and cKO (E-H)
proximal small intestine (A,E), distal small intestine (B,F), proximal colon (C,G), and distal colon
(D,H). White arrows indicate trichrome stained collagen in submucosa (blue). Representative
images shown. (I-J) Representative images of haematoxylin and eosin-stained proximal small
intestine of control (I) and cKO (J) mice. Black arrowheads indicate villi that were included in the
quantification. (K-O) No differences could be detected between control and cKO mice in proximal
small intestine when comparing villus length (K), number of epithelial cells per villus (L), crypt length
(M), and the number of epithelial cells per crypt (N). (O-P) Representative images of haematoxylin
and eosin-stained distal small intestine of control (O) and cKO (P) mice. Black arrowheads indicate
villi that were included in the quantification. (Q-R) Alcian Blue/Periodic Acid-Schiff staining was
used to visualize goblet cells (dark purple spots within epithelium) in distal small intestine of control
(Q) and cKO (R) mice. Black arrowheads indicate villi that were included in the quantification. (SV) No differences in villus length (S), number of epithelial cells per villus (T), crypt depth (U), and
number of epithelial cells/crypt (V) could be verified when distal colon epithelium of control and cKO
mice was compared. Comparison of average villus length trended towards shorter villi in cKO mice
(S, p=0.0533). (W-X) No difference in goblet cell number per villus (W) or per villus epithelial cell
number (X) could be found in control versus cKO mice. (Y-Z) cKO distal small intestinal crypts
contain a significantly greater number of goblet cells, both when normalizing to crypt depth (Y,
p=0.0317) or to crypt epithelial cell numbers (Z, p=0.0315). (A’-B’) Representative images of
haematoxylin and eosin-stained proximal colon of control (A’) and cKO (B’) mice. Black arrowheads
indicate villi that were included in the quantification. (C’-D’) Alcian Blue/Periodic Acid-Schiff staining
visualized goblet cells (dark purple spots within epithelium) in proximal colon of control (C’) and
cKO (D’) mice. Black arrowheads point towards villi that were included in the quantification. (E’)
Proximal colon epithelial crypts were significantly deeper for cKO mice than control mice. (F’)
However, epithelial cell number per crypt was not significantly different for control and cKO mice
(p=0.0675). (G’) cKO mice had significantly greater numbers of goblet cells in proximal colon crypts
(p=0.035). (H’) This increase in goblet cell number disappeared when normalized to the number of
epithelial cells per crypt. (I’-J’) Representative images of haematoxylin and eosin-stained distal
colon of control (I’) and cKO (J’) mice. Black arrowheads indicate villi that were included in the
quantification. (K’-L’) Distal colon crypt depth (K’) and number of epithelial cells per crypt (L’) were
not significantly different for control and cKO mice. (A-D) Control refers to Bap1 wt/wt;Tyr-Cre+
genotype (n=1, 1 male) or Bap1 fl/wt; Tyr-Cre+ (n=4, 3 females/ 1 male). (E-H) cKO refers to Bap1
fl/fl;Tyr-Cre+ genotype (n=4, 3 females/ 1 males). (I-O’) Control refers to Bap1 wt/wt;Tyr-Cre+
genotype (n=3, 2 females/ 1 male). (I-O’) cKO refers to Bap1fl/fl;Tyr-Cre + genotype (n=3, 2
females/ 1 male). Data is presented as mean ± stdev. Unpaired t test was performed on all data
sets to determine significance. Data not significant unless indicated otherwise. *p<0.05. (A-H) Scale
bar = 200 μm. (I-M’) Scale bar = 50 μm.
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Supplementary Figure 5.3: Bap1 fl/fl; Tyr-Cre + mice at postnatal day 15 had decreased total
enteric neuron density along the bowel and nitrergic enteric neuron density appears
proportionally decreased.
(A-X) Representative images of myenteric plexus along the bowel for Bap1 wt/wt; Tyr-Cre+
(Control; A-C, G-I, M-O, S-U) and Bap1 fl/fl; Tyr-Cre + (cKO; D-F, J-L, P-R, V-X) mice at postnatal
day 15. (D-F, J-L, P-R) Maximum intensity z-projections. All other images are single confocal optical
slices. PSI = proximal small intestine, DSI = distal small intestine, PCO = proximal colon, DCO =
distal colon. Scale bar = 50 μm.
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Supplementary Figure 5.4: Preliminary analysis suggests Bap1 fl/fl; Tyr-Cre + mice had
decreased total enteric neuron density along the bowel by postnatal day 15, but are born
with normal neuron density. Nitrergic neurons may decrease proportionally to total neuron
numbers.
(A-B) Preliminary analysis of total neuron density in Bap1;Tyr-Cre mice at postnatal day 15 (P15)
suggests decreased neuron density for cKO mice in both myenteric (A) and submucosal plexus (B)
in all regions of the bowel (One-Way ANOVA with Tukey’s Multiple Comparisons Test; myenteric
PSI: n too small for statistics, myenteric DSI: p= 0.0489, myenteric PCO: p = 0.0005, myenteric
DCO: p = 0.0007; submucosal PSI/PCO/DCO: n too small for statistical analysis, submucosal DSI:
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p = 0.0011). (C-D) Preliminary analysis of nitrergic neuron density (NOS1+) in P15 Bap1;Tyr-Cre
mice indicates that there is no difference in NOS1+ neuron density between WT, Het, and cKO
bowel in myenteric (C) and submucosal plexus (D) (all n too small for statistical analysis). (E-F)
However, preliminary analysis of the proportion of nitrergic neurons in P15 Bap1;Tyr-Cre mice
suggests a proportional decrease of NOS1+ neuron density in myenteric plexus (E) in all bowel
regions (all n too small for statistical analysis). No conclusions can be drawn about submucosal
plexus (H) at this time. (G-H) Preliminary analysis of total neuron density in Bap1;Wnt1-Cre mice
at birth suggests no significant difference between WT, Het, and cKO mice in myenteric (G) and
submucosal plexus (H; (all n too small for statistical analysis). (A-G) WT refers to Bap1 wt/wt; TyrCre + or any genotype without Cre allele, Het refers to Bap1 fl/wt; Tyr-Cre +, and cKO refers to
Bap1 fl/fl; Tyr-Cre +. All data represented as mean +/- standard deviation. *p<0.05, **p0.01,
***p<0.001, ****p<0.0001.
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Supplementary Figure 5.5: Bap1 fl/fl; Tyr-Cre+ mice lose neurons of the Tyr-Cre lineage by
postnatal day 15.
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(A-V’) Representative images showing enteric neurons (HUC/D+, green) and neurons of the TyrCre lineage (TDTOMATO+, magenta) in different bowel regions for Control (Bap1 wt/wt; Tyr-Cre+;
D-F, J-L, P-R, V-X, B’-D’, H’-J’, N’-P’, and T’-V’) and cKO (Bap1 fl/fl; Tyr-Cre+; A-C, G-I, M-O, S-U,
Y-A’, E’-G’, K’-M’, and Q’-S’) mice at postnatal day 15. (D-F, B’-D’, K’-P’) Maximum intensity zprojections. All other images are single confocal optical slices. PSI= proximal small intestine, DSI
= distal small intestine, PCO = proximal colon, and DCO = distal colon. Scale bar = 25 μm.
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Supplementary Figure 5.6: Neonatal proximal small intestine motility patterns observed in
vitro are neurogenic and Bap1 fl/fl; Wnt1-Cre+ mice exhibited normal myogenic contraction
frequency at birth.
(A-D) Representative kymographs depicting bowel width as a function of time and distance along
the proximo-distal axis of the cannulated proximal small intestine for neonatal control (Ctrl; A-B)
and cKO (C-D) mice. (A-B) Low frequency (L.F.) contractions could be recorded for a subset of
control mice (A; white arrows) and these L.F. contractions disappeared in the presence of
tetrodotoxin (TTX, B). (C-D) Low frequency (L.F.) contractions could also be recorded for a subset
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of cKO mice (C; white arrows) and these contractions also disappeared in the presence of
tetrodotoxin (TTX, D). (E) Example Fourier transform of the recorded contractions that allows the
identification of regularly-occurring myogenic higher frequency contractions (H.F. contractions;
white arrow). (F) There was no difference in the frequency of myogenic H.F. contractions recorded
for control and cKO neonates and the frequency of contractions was also unaffected by the
presence of tetrodotoxin ([No TTX: Ctrl: WT 5 males/ 2 females and Het 1 male/2 unknown (11.38
± 4.62), cKO: 6 females/ 1 male/ 2 unknown (19.97 ± 7.4)]. [+TTX: Ctrl: 2 male/ 1 unknown (13.30
± 1.65), KO: 5 females (19.72 ± 8.74)]). Data points derived from Hets are marked by blue color.
(A-F) WT refers to Bap1 wt/wt; Wnt1-Cre+ or any genotype without the Wnt1-Cre transgene. Het
refers to Bap1 fl/wt; Wnt1-Cre+ genotype. cKO refers to Bap1 fl/fl; Wnt1-Cre+ genotype. (F) Data
represented as mean ± standard deviation. Data not significant unless otherwise indicated.

Supplementary Table 5.1: ARRIVE Guidelines - General animal husbandry information
Childrens’ Hospital of Philadelphia

Location of Animal facility
(types of experiments)
Facility Type

Conventional: cages are opened at room air, face masks are
not required when handling mice

Facility Type

Specific pathogen free, Pathogens detected in room within
the past 2 years: MNV (mouse norovirus), Helicobacter not
tested but likely present

Bedding

¼ inch corncob (The Andersons, Product 4B)

Cage type

Lab Products (Seaford, DE) 75 sq. in. Ventilated.

Cage cleaning/sterilization

Standard tunnel washer

Mouse diet

Mouse Diet 5015 (Lab Diet), direct from manufacturer: not
autoclaved, not irradiated

Light-dark cycle

12/12
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Childrens’ Hospital of Philadelphia

Location of Animal facility
(types of experiments)

Temperature

72°F +/- 2°F

Humidity

30-70% depending on the day/season

Water pH and quality

Reverse Osmosis, pH~7, Edstrom automatic watering system

Number of mice per cage

1-5 (20-30g)

Cage Enrichment

house/dome (Bioserve, S3174) and nestlet (Ancare)

Mating strategy

Continuous

Age at weaning

19-20 days

Access to food and water

Continuous

Animal welfare assessment

Daily

Cage changes

1x/week
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Supplementary Table 5.2: List of antibodies
Antibody

Concentration

Rabbit anti-NOS1
ANNA-1 (HuC/D)

1:200
N/A

Catalog
number
AB5380
N/A

Chicken anti-GFP
Goat anti-SOX10
Rabbit anti-Cleaved
Caspase 3
Rabbit anti-H2AX

1:500
1:100
1:150

GFP-1020
AF2864
9661S

1:300

A300-081A

Alexa Fluor goat antihuman 647
AlexaFluor donkey antirabbit 488
AlexaFluor donkey antirabbit 594
AlexaFluor donkey antirabbit 647
AlexaFluor donkey antigoat 594
AlexaFluor goat antichicken 488
AlexaFluor donkey antigoat 647
AlexaFluor donkey antigoat 488
AlexaFluor goat antirabbit 488
DyLight donkey antihuman 488
DyLight donkey antihuman 650

1:400

A21445

1:400

A21206

1:400

A21207

1:400

A31573

1:400

A11058

1:400

A11039

1:400

A21447

1:400

A11055

1:400

A31556

1:200

ab102424

Bethyl Laboratories,
RRID:AB_203288
Thermo Fisher Scientific;
RRID:AB_2535862
Thermo Fisher Scientific;
RRID:AB_2535792
Thermo Fisher Scientific;
RRID:AB_141637
Thermo Fisher Scientific;
RRID:AB_2536183
Thermo Fisher Scientific;
RRID:AB_2534105
Thermo Fisher Scientific;
RRID:AB_142924
Thermo Fisher Scientific;
RRID:AB_141844
Thermo Fisher Scientific;
RRID:AB_2534102
Thermo Fisher Scientific;
RRID:AB_221605
Abcam; RRID:AB_10710634

1:200

ab102427

Abcam; RRID:AB_10711474
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Source
Sigma; RRID:AB_91824
Kind gift from Dr. V. Lennon,
Mayo Clinic
Aves Labs, RRID:AB_10000240
R&D Systems, RRID:AB_442208
Cell Signaling, RRID:AB_2341188

Supplementary Table 5.3: List of PCR primers for mouse genotyping
Gene
(Strain)

Primer Sequence

Band size

Genotyping
solution

Reference

Bap1

F: 5'-AGC GTG CTT CTG
AAC TGC AGC AAT GTG
GAT-3’
R: 5’-TTC TGA AAG GGC
AGT GGT GGC AAA TGA
GAC-3’

Mut: 520bp Taq (NEB,
Personal
WT: 423bp Cat#:M0271L) communication with
Dr. J. William Harbour

Gfp (ChATEGFPL10a)

F: 5'-TCA TAG AGG CGC
AGA GTT CC-3'
R: 5'-CTG AAC TTG TGG
CCG TTT AC-3'

Mut: 250bp KAPA (KAPA JAX genotyping
Biosystems,
protocol (Stock No:
Cat#:KK7352) 030250)

Cre (Wnt1Cre and
Tyr-Cre)

F: 5’-GCA TTA CCG GTC
GAT GCA ACG AGT GAT
GAG-3’
R: 5’-GAG TGA ACG AAC
CTG GTC GAA ATC AGT
GCG-3’

408bp

KAPA (KAPA https://mgc.wustl.edu/
Biosystems,
protocols/pcr_genotypi
Cat #KK7352), ng_primer_pairs
Taq (NEB,
Cat#:M0271L)

R26RTdTomato

Common F: 5'-AAA GTC
GCT CTG AGT TGT TAT-3'
Tg R: 5’-GCG AAG AGT
TTG TCC TCA ACC-3’
WT R:
5'-GGA GCG GGA GAA
ATG GAT ATG-3'

Mut:
~350bp
WT:
~600bp

KAPA (KAPA JAX genotyping
Biosystems,
protocol (Stock No:
Cat #KK7352), 007909)
Taq (NEB,
Cat#:M0271L)

Hdac4

F: 5’-ATC TGC CCA CCA
GAG TAT GTG-3’
R: 5’-CTT GTT GAG AAC
AAA CTC CTG CAG CT-3’

Mut: 620bp Taq (NEB,
Personal
WT: 480bp Cat#:M0271L) communication with
Dr. Kelly A. Hyndman
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6.1 Abstract
BACKGROUND & AIMS: Small, 2-dimensional sections routinely used for human pathology
analysis provide limited information about bowel innervation. We developed a technique to image
human enteric nervous system (ENS) and other intramural cells in 3 dimensions.
METHODS: Using mouse and human colon tissues, we developed a method that combines tissue
clearing, immunohistochemistry, confocal microscopy, and quantitative analysis of full-thickness
bowel without sectioning to quantify ENS and other intramural cells in 3 dimensions.
RESULTS: We provided 280 adult human colon confocal Z-stacks from persons without known
bowel motility disorders. Most of our images were of myenteric ganglia, captured using a 20x
objective lens. Full-thickness colon images, viewed with a 10x objective lens, were as large as 4 x
5 mm2. Colon from 2 pediatric patients with Hirschsprung disease was used to show distal colon
without enteric ganglia, as well as a transition zone and proximal pull-through resection margin
where ENS was present. After testing a panel of antibodies with our method, we identified 16
antibodies that bind to molecules in neurons, glia, interstitial cells of Cajal, and muscularis
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macrophages. Quantitative analyses demonstrated myenteric plexus in 24.5% ± 2.4% of flattened
colon Z-stack area. Myenteric ganglia occupied 34% ± 4% of myenteric plexus. Single myenteric
ganglion volume averaged 3,527,678 ± 573,832 mm3 with 38,706 ± 5763 neuron/mm3 and 129,321
± 25,356 glia/mm3. Images of large areas provided insight into why published values of ENS density
vary up to 150- fold—ENS density varies greatly, across millimeters, so analyses of small numbers
of thin sections from the same bowel region can produce varying results. Neuron subtype analysis
revealed that approximately 56% of myenteric neurons stained with neuronal nitric oxide synthase
antibody and approximately 33% of neurons produce and store acetylcholine. Transition zone
regions from colon tissues of patients with Hirschsprung disease had ganglia in multiple layers and
thick nerve fiber bundles without neurons. Submucosal neuron distribution varied among imaged
colon regions.
CONCLUSIONS: We developed a 3-dimensional imaging method for colon that provides more
information about ENS structure than tissue sectioning. This approach could improve diagnosis for
human bowel motility disorders and may be useful for other bowel diseases as well.

6.2 Introduction
The enteric nervous system (ENS) controls most aspects of bowel function and is thought
to contain as many neurons as the spinal cord, with approximately 20 neuron and 4–7 glial cell
types (1–4). ENS defects can cause debilitating or life-threatening bowel dysfunction, including
diverse motility disorders. In many cases, human diseases are well-modeled by mouse mutations
that cause striking changes in ENS anatomy (5,6). ENS structural defects are readily visualized in
mice via whole-mount staining because murine bowel is thin. In contrast, human ENS is buried in
opaque tissue, making visualization challenging, especially because ENS accounts for < 1:10,000
cells in colon wall (our estimate). For this reason, human clinical pathology relies primarily on
formalin-fixed paraffin-embedded thin sections to visualize ENS. However, even major ENS defects
are difficult to appreciate in sectioned bowel (Supplementary Figure 6.1) and human quantitative
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analyses provide highly variable results for “normal” colon neuron density (7–9). This variability in
“normal” makes structural defects causing bowel motility disorders difficult to define. A few
approaches demonstrated elaborate ENS structures in human bowel (10–17), but methods were
not reproducible in our hands, technically challenging and time consuming, or failed to demonstrate
ENS in large intact regions. We therefore sought to develop robust, highly reproducible methods to
visualize cells controlling human colon motility. Our new approach provides 3-dimensional ENS
views in large colon regions without sectioning, preserving associations with other bowel cells. This
is important because bowel motility requires coordinated muscle contraction and relaxation18
organized by enteric sensory neurons, interneurons, excitatory and inhibitory motor neuron
(1,3,19,20), interstitial cells of Cajal (21), enteric glia, muscularis macrophages, platelet-derived
growth factor receptor a-immunoreactive cells (or “fibroblast-like cells”), and enteroendocrine cells
(1,3). Defining cell type–specific defects that affect bowel motility is most important for lifethreatening diseases like Hirschsprung disease (22,23), achalasia (24), gastroparesis (25), and
chronic intestinal pseudo-obstruction (26), where improved imaging could provide new ideas about
disease pathogenesis or treatment. First, however, we aimed to quantitatively define “normal” ENS
anatomy. Here we provide 280 confocal Z-stacks and quantitative data from 14 human adult colons.
We also visualized colon ENS from children with Hirschsprung disease, a birth defect where ENS
is absent from distal bowel and a hypoganglionic “transition zone” separates aganglionic from
proximal ENS-containing colon.

6.3 Methods
Mice
Studies adhere to ARRIVE (Animals in Research: Reporting In Vivo Experiments) guidelines (27)
and Institutional Animal Care and Use Committee at Children’s Hospital of Philadelphia (16001041). P0 Gfrα1 (MGI cat no. 3715269, RRID:MGI:3715269) (28) and wild-type littermate
(C57BL/6) were analyzed (9–12 AM). Dam was fed Mouse Diet 5015* (LabDiet, St Louis, MO), not
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fasted, housed on corncob (Product 4B; The Andersons, Maumee, OH) in Lab Products (Seaford,
DE) caging. Human Tissue Colon was acquired with Children’s Hospital of Philadelphia Institutional
Review Board (IRB 13-010357) and Perelman School of Medicine at University of Pennsylvania
approval (IRB 804376) using Abramson Cancer Center Tumor Tissue Bank or pathology deidentified tissue, providing limited clinical data. Jejunum and pancreas were from the Human
Pancreas Analysis Program (IRB exempt).

Human Colon Staining
Detailed protocol is at protocols.io (dx.doi.org/10.17504/ protocols.io.wyeffte).

Tissue Processing
Adult colons remained at ambient temperature until arrival in pathology after routine
hospital procedures. Transfer to sterile icecold 1X phosphate-buffered saline (PBS) occurred 61–
112 minutes after resection. Staff pathologists provided regions without recognized abnormalities.
The laboratory received coded specimens in PBS on ice. While in PBS, fat was removed and tissue
was pinned along edges (serosa up) to Sylgard 184 Silicone Elastomer (Dow, Midland, MI) using
insect pins. We stretched while pinning, making the colon thin, flat, and uniform thickness. Pins
were repositioned several times to stretch colon as muscles relaxed, increasing area 2.6-fold (N =
3, SEM = 0.15) compared to unstretched colon. Pinned tissue was fixed (4% paraformaldehyde,
4C overnight), transferred to PBS, and the edges with pin holes were trimmed. Full-thickness colon
was cut with scissors. Most specimens were 1 x 1 cm2. Larger colonic specimens also stained
adequately using this method (eg, 2 x 3 cm2 ). Stored tissue (4C, 50% PBS/50% glycerol/0.05%
sodium azide) could be stained months later without obvious tissue degradation. Human jejunum,
pancreas, and Hirschsprung colon were processed similar to adult colons. Hirschsprung colon was
in ice-cold PBS 20–60 minutes after resection. Jejunum and pancreas from transplant donors were
in Belzer UW solution (29) (NC0410019; Fisher Scientific, Waltham, MA) immediately after
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resection and stored approximately 8 hours before fixation.

Immunohistochemistry
The 1 x 1 cm2 fixed colons were processed in 24-well VWR Culture Plates (nontreated), 2cm diameter (cat no. 10861-558). Reagent volumes were 500–1000 µL/well (enough to cover
tissue). After washing (PBS, 3 x 5 minutes, room temperature), incubating to permeabilize and
remove lipids (100% methanol, 1 hour, on ice), and treating with Dent’s bleach (5 mL 30% hydrogen
peroxide, 5 mL dimethylsulfoxide, 20 mL 100% methanol) (30) (2 hours, room temperature) to
permeabilize and quench auto-fluorescence, colon was washed (PBS, 3 x 5 minutes, room
temperature), transferred to 2- mL Eppendorf tubes containing blocking solution (4% normal
donkey serum, 0.5% Triton X-100, and 0.05% sodium azide/PBS) and incubated (3 days, 37 0C,
New Brunswick Scientific I24 Incubator Shaker, 40–100 rpm). Then we incubated with 1–3 primary
antibodies (Supplementary Table 6.1) in blocking solution on shaker (14 days, 370C, 40–100 rpm)
using Parafilm-sealed tubes. Unbound primary antibody was removed (PBS/0.05% sodium azide,
3 washes, 2 hours/wash, plus an overnight wash, on rocker). Secondary antibodies were in
PBS/0.05% sodium azide (3 days, 370C, on rocker). Excess secondary was removed with
PBS/0.05% sodium azide (3 washes, 2 hours/wash, plus additional wash overnight, room
temperature, on rocker). Some tested antibodies did not work (Supplementary Table 6.2).

Dehydration, Clearing, and Mounting After Immunohistochemistry
Colon was dehydrated in 24-well dishes in graded methanol/PBS (approximately 500
µL/well, extra if needed to cover, 30 minutes/wash: 50% methanol, 70% methanol, 80% methanol,
95% methanol, 100% methanol x3, room temperature, on rocker). Dehydrated colon incubated in
Murray’s Clear (2:1 benzyl benzoate: benzyl alcohol) (31) until completely translucent (15–30
minutes, room temperature) was mounted on glass slides in Murray’s Clear and imaged within 48
hours.
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Imaging
Zeiss LSM 710 confocal microscope (10x and 20x PlanApochromat objectives, Zeiss Zen
software, version 2.3 14.0.14.201; Zeiss, Oberkochen, Germany) Z-axis increments were 4 mm
(10x objective) or 1 mm (20x objective). Each image slice was 900 x 900 (10x) or 1200 x 1200
pixels (20x). The 10x Z-stacks were stitched to cover large regions. Laserscanning operated under
multitrack to sequentially acquire multichannel images. Each channel used 100% laser power.
Excitation/long-pass emission filters were Alexa Fluor 647 (excitation: 633 nm, emission: 656- to
755-nm filter), Alexa Fluor 594 (excitation: 561 nm, emission: 588- to 656-nm filter), and Alexa Fluor
488 (excitation: 488 nm, emission: 493- to 584-nm filter). Tile scan and Zen stitching were used to
assemble multifield images. ImageJ (Java 1.8), Imaris 9.0.2 (Bitplane AG, Zurich Switzerland),
Adobe Photoshop CS6, and Inkscape (0.92.3) manipulation was limited to uniform contrast
adjustment, cropping, rotating, stitching, assembling Z-stacks, and generating 3-dimensional
projections and videos.

Quantitative Analyses Employed Manual and Automated Features
Imaris modules were Crop 3D, Image Processing, Thresholding, Background Subtraction,
Surface, Manual Contour, Click Drawing Mode, and Detailed Statistics. ImageJ features were
regions of interest, Polygon selection, Straight line tool, Measurements, Scale bar, Z-Project, Split
channels, Merge channels, and Duplicate.

Myenteric plexus
Neurons (HuC/D+PHOX2B+) and glia (S100B+) were manually counted in ganglia using
39 randomly selected colon regions (4 right, 5 fields/subject; 3 left, 5 fields/subject; 1 left, 4 fields).
Two-dimensional ganglion areas were manually outlined in flattened Z-stacks (4 right, 4 left colon).
Using similar manual outlining, we determined percent colon containing myenteric plexus (defined
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as ganglia plus thick nerve fiber bundles connecting ganglia), and percent plexus occupied by
ganglia (defined as regions with >2 myenteric neurons separated by < 1 cell diameter). For 3dimensional analyses, individual ganglion volumes were determined by manually outlining at 5- to
7-µm increments within 20x Z-stacks using Click Drawing mode (Surface Contour module; Imaris).
Cell density within ganglia was determined by manually counting within defined volumes.

Neuron subtypes
Myenteric neurons (HuC/D+) expressing neuronal nitric oxide synthase (nNOS), choline
acetyltransferase (ChAT), or vesicular acetylcholine transporter (VAChT) identified by triple-label
immunohistochemistry were manually counted within Z-stacks (5 random fields/subject, 4 right, 4
left, 40 total regions). Maximum neuron diameter was determined manually using ImageJ (6
nNOS+/image, 6 ChAT+/image, five 20x images/subject; 4 right, 4 left; forty 20x images total, 240
nNOS neurons, and 240 ChAT neurons).

Submucosal plexus
Ganglia location was defined in Z-stacks using ImageJ.

Statistics
We used Prism 7 (GraphPad Software, San Diego, CA), D’Agostino & Pearson, and
Shapiro-Wilk normality tests with unpaired t tests to compare means. Volumes of manually
contoured ganglia used Detailed Statistical Analysis (Imaris). Data are presented as mean ± SEM.
Degrees of freedom were 6 for analyses.
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6.4 Results
Our goal was to establish highly reproducible, inexpensive, simple techniques to visualize
human ENS in 3 dimensions to advance understanding of bowel motility disorders. We tried many
published approaches to visualize human ENS (10–13,16,17,32–35), but human colon was
incompletely penetrated by antibody, not transparent after clearing, or methods provided only
limited views of ENS anatomy after meticulous challenging microdissection. Optimal Clearing,
Staining, and Imaging To image ENS in full-thickness colon without perturbing cellular associations,
we modified published methods (32,34) to enhance staining and translucency. Our approach
worked routinely with 1 x 1 cm2 colon and can work with larger regions. We reasoned antibodies
and light would penetrate better if colon was thin. We therefore pinned and repeatedly stretched
colon before fixation to average thickness 800– 1000 µm (Figure 6.1A). We kept colon as flat and
uniform as possible and avoided drying. We tried staining tissue that had not been stretched before
fixation, but reagent penetration was poor, and folded tissue made image interpretation difficult.
Methanol, Dent’s bleach, prolonged 370C incubation and shaking enhanced staining, but took 23
days (Supplementary Figure 6.2). Murray’s Clear made tissue translucent, but fluorescence in
Murray’s Clear declined over time so we imaged within 48 hours of immersion. Tissue area
underwent shrinkage to 66.9% ± 6.6% of original area measured after fixation (Supplementary
Figure 6.3), partially reversing stretching

Imaging and Antibody Testing
Colon was easily imaged to a depth of 1000 µm, allowing full-thickness reconstructions of
stretched preparations. We identified antibodies binding nerve cell bodies (HuC/D), neuronal and
some glial nuclei (PHOX2B), nerve fibers (TuJ1), nerve cell bodies and fibers (PGP9.5), enteric
glia (S100β, SOX10), interstitial cells of Cajal (cKIT), muscularis macrophages (Iba1), and enteric
neuron subsets (CHAT, VAChT, nNOS, neurofilament 200, neurofilament M, peripherin, calretinin,
and somatostatin) (Figure 6.1B–Q). We generated 3-dimensional images of many cell types
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thought to influence human colon motility and provide 280 adult colon Z-stacks (available at
Blackfynn DOI:10.26275/pzek91wx). Our method also worked for human jejunum and pancreas
(Supplementary Figure 6.4, Supplementary Videos 1 and 2). Quantitative analyses focused on
adult human colon.

Figure 6.1: Imaging cells controlling human colon motility
(A) Strategy to image without sectioning. (B–G, J–Q) Human colon myenteric plexus visualized
with 14 antibodies. (H, I) Longitudinal muscle interstitial cells of Cajal and muscularis macrophages
visualized with cKIT (H) and Iba-1 (I) antibodies. Scale bars: 200 µm.
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Human Colon Enteric Nervous System in 3 Dimensions
To examine normal human colon ENS structure, we analyzed specimens resected for varied clinical
indications; all lacked identified motility disorders (Supplementary Table 4.3) and adult colon
lacked obvious pathology. Three- dimensional imaging of HuC/D, PHOX2B, and S100β stained
colon showed enteric neurons clustered into submucosal and myenteric ganglia connected by thick
nerve fiber bundles (Supplementary Video 3). Myenteric ganglia appeared larger on average than
submucosal ganglia. A few individual neuron cell bodies were within thick circular muscle of all
colons (Supplementary Video 3). A rich network of fine nerve fibers and closely associated glia
(S100β) was present within circular and longitudinal muscle, with neurites largely parallel to smooth
muscle (Supplementary Video 3). Glia were also closely associated with neuronal soma in ganglia
(Supplementary Video 4, Supplementary Figure 6.5) and nerve fibers were dense near bowel
mucosa (Supplementary Video 3).

Human Colon Myenteric Plexus
To establish normal indices, full-thickness colon stained for HuC/D, PHOX2B, and S100β was
imaged parallel to bowel surface (Figure 6.2A). Confocal Z-stacks were stitched to evaluate large
regions (Figure 6.2A is 4 x 5 mm2 ). For quantitative analyses, we defined “myenteric plexus” as
nerve fiber bundles (containing S100β+ glia) and embedded nerve soma (HuC/D+PHOX2B+). We
defined “myenteric plexus ganglia” as regions within fiber bundles containing >2 adjacent neuron
cell bodies. Using flattened Z-stacks, we determined percent colon containing myenteric plexus or
ganglia (Figure 6.2B). Although myenteric plexus area was similar in left and right colon (left 26.5%
± 2.5%, right 22.5% ± 4%; P = .4514), more myenteric plexus (left 43% ± 3.2%, right 26% ± 3.7%;
P = .0113), and more image area (left 11.6%% ± 1.7%, right 5.3%% ± 0.1%; P = .0116) was
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occupied by ganglia in left colon. Two-fold differences in density between left and right colon
suggest region-specific normal ranges.

Figure 6.2: Human colon myenteric plexus 2-dimensional analyses
(A) Flattened Z-stack through myenteric plexus (10x objective, stitched fields, 4 x 5 mm 2 ). Small
clustered ganglia have HuC/D+ (green) and PHOX2B+ (blue) neurons. Nerve fibers are visualized
via glial S100β (red). Myenteric plexus and ganglia within plexus were outlined manually (thin
yellow lines). (B) Quantitative data from 4 x 5 mm2 images like (A). (C, D) Flattened Z-stack from
colon myenteric ganglia (left [C] or right [D]) stained for HuC/D (green), S100β (red), and PHOX2B
(blue) imaged with 20x objective. Table to right of each image shows quantitative data from that
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specific Z-stack. (E) Quantitative data from 4 right colon, 5 fields/subject; 3 left colon, 5 fields/
subject; 1 left colon, 4 fields; total neurons counted: 1953 right colon, 2603 left colon; Total glia
counted: 8021 right colon, 6423 left colon. Single ganglion areas are from 24 right and 19 left colon
ganglia. Cells/mm2 within these ganglia are based on 5261 neurons and 16,915 glia. (F, G, H)
Colon stained with HuC/D (green), S100β (red), and PHOX2B (blue) antibodies. PHOX2B+ nuclei
include all myenteric neurons and glia within myenteric ganglia (G). Glia in longitudinal (F) and
circular muscle (H) were not PHOX2B immunoreactive. (A) Scale bar: 1000 µm. (C, D) Scale bar:
350 µm. (F–H) Scale bar: 50 µm.

We next determined colon myenteric plexus neuronal and glial density by counting
HuC/D+, PHOX2B+, and S100β+ cells (Figure 6.2C–E). We discovered all neurons and glia within
myenteric ganglia or thick nerve fiber bundles had nuclear PHOX2B immunoreactivity (Figure
6.2G). In contrast, glia in thin nerve fibers throughout muscle were not PHOX2B-immunoreactive
(Figure 6.2F and H). Using 20X Z-stacks, we counted all stained cells in each image. Data are first
presented based on 2-dimensional areas, ignoring Z-depth. Quantitative data adjacent to each
image were from that specific Z-stack (Figure 6.2C-D). Areas containing neurons were considered
“ganglia” and outlined (see thin yellow lines, Figure 6.2A). Mean density data are in Figure 6.2E.
Although neuron density within myenteric ganglia was similar in left and right colon, neurons/mm2
bowel was greater on left because ganglia occupy a larger percentage of bowel wall (left = 135 ±
22, right 56 ± 8; P = .0179). In contrast, glial density was not statistically different in right vs left
colon (glia/mm2 : left = 323 ± 68, right = 226 ± 28; P = .2329) or within myenteric ganglia (left =
2875 ± 513, right = 4242 ± 536; P = .1151). Interestingly, within ganglia, ratio of glia to neurons was
lower in left than right colon (left = 2.5 ± 0.2 glia/neuron, right = 4.2 ± 0.2; P = .0013). To define cell
density within myenteric ganglia in 3 dimensions, we manually outlined and counted cells in Zstacks
(Figure 6.3A-B). Quantitative data for 2 individual images are provided (Figure 6.3A-B). Pooled
data indicate normal ranges for adult humans without known bowel motility disorders (Figure 6.3C).
Estimates for large areas were generated by multiplying cell numbers within ganglia
(counted at high magnification in 3-dimensional Z-stacks) by percent colon containing ganglia
(measured at low magnification, Figure 6.2A). Using 5 regions/individual, cell density estimates
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clustered within tight ranges (Figure 6.3N-O). Variation was greater between subjects with more
variation in left vs right colon.

Figure 6.3: Human colon myenteric plexus 2- and 3-dimensional analyses
(A, B) Three-dimensional ganglia volumes (yellow regions) (Supplementary Videos 5 and 6 are
from these regions). To right of each image are quantitative data from that specific region. (C) Cell
density based on five 20x fields/subject, 8 subjects (4 left, 4 right colon)), 24 right and 19 left colon
ganglia volumes, 5261 neurons and 16,915 glial cells. (D–M) Manual neuron and glia counts were
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obtained after HuC/D (blue), S100β (green), and PHOX2B (red) staining. (D, I) Flattened Z-stacks.
(E–H, J–M) Single slices and channels from Z-stack. (N, O) To estimate cell density over large
regions we multiplied density within small regions (like Figure 6.2C) by percentage of bowel with
myenteric plexus (using images like Figure 6.2A). We found little variability in cell density within
ganglia, indicated by tight data clusters in individuals. Inter-individual differences primarily reflect
percentage of bowel occupied by ganglia in each individual. (A, B, D, I) Scale bars: 100 µm. (E, F,
G, H, J, K, L, M) Use (E) scale bar: 25 µm.

We next asked how biopsy size impacts neuron density estimates, recognizing ENS is not
uniformly distributed. To do this we divided a single 4 x 5 mm 2 region into 20 x 1 mm2 zones and
analyzed ganglion density in each zone (Figure 6.4A-B). If 1 mm2 is evaluated, widely divergent
estimates of ganglion density (0–17%) occur, depending on zone evaluated. Using 4 mm2 areas,
ganglion density estimates were more tightly clustered, but still ranged 3.5%– 11.4%. In contrast,
narrow ranges were generated analyzing 9 mm2 regions. Thus, limited sampling causes diverse
enteric neuron density estimates, with greater precision as area evaluated increases.

Figure 6.4: Size of region evaluated affects estimated myenteric plexus neuron density
(A) Flattened Z-stack (Figure 6.2A) was divided into 20 squares (1 mm2 each). We determined
percentage of each square occupied by ganglia (regions with nerve cell bodies). (B) Estimates of
percent colon occupied by ganglia using 1 x 1 mm 2 , 2 x 2 mm2 , or 3 x 3 mm2 regions. Some 1 x
1 mm2 regions have no myenteric plexus; others have up to 17% occupied by ganglia. As size of
region evaluated increases, estimates of percent area occupied by ganglia become more uniform.
Scale bar: 1000 µm.
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Neuron Subtype Ratios
Because most myenteric neurons express either nNOS or ChAT and VAChT (1,2,36–39),
we defined ratios of these markers in human colon myenteric plexus using ChAT/nNOS/HuC/D
(Figure 6.5A–H) or ChAT/VAChT/HuC/D staining (Figure 6.5K–Q). Using Z-stacks to
unambiguously distinguish cytoplasmic staining from overlying neurites, we determined percent
neurons (HuC/D+) expressing nNOS, ChAT, both or neither (40 samples, 3359 total neurons
evaluated, Supplementary Table 6.4). In parallel, we compared ChAT to VAChT staining because
murine data suggested ChAT staining is often weak. VAChT was considered “positive” in 1.62-fold
more neurons than ChAT, but many VAChT+ cells had faint ChAT staining or high background
(Figure 6.5O–Q, N = 1902 cells). We hypothesize ChAT alone (at least with this antibody) led to
systematic cholinergic neuron undercounting. Supplementary Table 6.4 explains how we adjusted
ChAT+ counts based on VAChT/ChAT data to establish “cholinergic” neuron counts (Figure 6.5IJ). We scored approximately 50% of myenteric neurons as nNOS+/noncholinergic (Figure 6.5I-J),
approximately 28% as cholinergic/nNOS negative, approximately 5% nNOS+/cholinergic, and
approximately 16% as nNOS-/noncholinergic. Figure 6.5I shows inter-individual variability.
Supplementary Figure 6.6 shows ChAT+ neuron diameters were 32% larger than nNOS+
neurons diameters.
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Figure 6.5: Cholinergic/ nitrergic neuron ratios
(A) Flattened Z-stack, human colon myenteric ganglion stained for HuC/D (red), nNOS (green),
and ChAT (blue). (B–D) Channels for (A). (E–H) Sample neurons from (A): (E) ChAT+/ nNOS+,
(F) ChAT+/ nNOS–, (G) ChAT+/ nNOS+, (H) neither ChAT nor nNOS positive. (I) Proportion of
neuron classes (8 individuals). (J) Average neuron percentages in each class. (I, J) We initially
evaluated 3360 HuC/D+ cells with ChAT and nNOS antibodies. Subsequent analysis of
VAChT/ChAT/ HuC/D staining showed 1.62-fold more neurons would be identified as cholinergic
using combined VAChT/ChAT staining compared to ChAT alone (N = 1902 HuC/D+ cells).
“Cholinergic numbers” = “ChAT+ numbers” x 1.62. (K) Flattened Z-stack, human colon myenteric
ganglion stained for ChAT (green), VAChT (red), and HuC/D (blue). (L–N) Channels for (K). (O–
Q) High magnification single confocal slice of neuron from box in (K). We scored this neuron as
VAChT+. ChAT immunoreactivity alone was not well localized and ChAT background too high to
score this cell as ChAT+ without VAChT staining. (A) Scale bar: 100 µm. (B–H, O–Q) Scale bars:
25 µm. (K–N) Scale bars: 200 µm. Cell numbers evaluated are in Supplementary Table 6.4.
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Submucosal Ganglion Location
Additional parameters could be defined via 3-dimensional imaging. For example, human
colon submucosal plexus was reported to be in 3 distinct layers (40), but our data suggest ganglia
are scattered throughout submucosa, with considerable variability in patterns between evaluated
specimens (Supplementary Figure 6.7). A subset may have ganglia in definable layers.

Hirschsprung Disease
To highlight clinical utility, we stained colon from children with Hirschsprung disease, a
problem where enteric neurons are absent from distal bowel. Resected bowel from pull-through
surgery should contain the entire distal aganglionic region, a hypoganglionic transition zone, and
ideally normal ENS at proximal margins. This anatomy is difficult to appreciate in paraffin sections
(Figure 6.6A). In contrast, our 3-dimensional method showed proximal resection margin had a rich
ENS network (Figure 6.6C–H). Transition zone was relatively hypoganglionic, with unusual
features like rows of neurons along nerve fibers (Figure 6.6B), myenteric ganglia in more than 1
layer (Figure 6.7, slices 23, 29, 42, Supplementary Video 7), thick nerve fiber bundles without
neurons (slice 50), and areas without ganglia (slice 144). As expected, distal aganglionic zone was
devoid of nerve cell bodies but had extrinsic nerve fibers (Figure 6.7, Supplementary Videos 8 and
9).
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Figure 6.6: Whole mount staining in Hirschsprung disease
(A) Full-thickness colon approximately 4.5 mm from distal resection margin (H&E stained). (B– H)
Two-month-old Hirschsprung colon stained for nNOS (green) and HuC/D (red). (B) Magnified
region from transition zone with enteric neurons along nerve fibers. (C–H) Most proximal resection
margin for Hirschsprung colon. (D–H) Z-stacks slices: (D) 49–97, (E) 95–96, (F) 118– 145, (G)
165–176, (H) 208– 209. Scale bars: 500 µm. Supplementary Video 7 provides additional images
from colon region used to generate Figure 6.6C–H).

Figure 6.7: Transition zone and distal aganglionic region of Hirschsprung pull through
resections
Full-thickness Z-stacks stained with HuC/D (red) and nNOS (green) antibodies. Identified single
slices from Z-stacks in transition zone (left panel) and aganglionic region (right panel). Higher
numbers are closer to mucosa. Scale bars: 500 µm.
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6.5 Discussion
Human bowel was estimated to have approximately 500 million enteric neurons controlling
most aspects of bowel function (2,3). Our data suggest colon alone has approximately 37 million
enteric neurons (approximately 100 neurons/ mm2 x 1.4 m colon length x 0.15 m circumference
(41) x 1,000,000 mm2 /m2 x 2.6-fold (stretching) x 0.67-fold (shrinkage with processing)). When
ENS is missing or defective, profound bowel dysfunction may occur causing life-threatening
problems like Hirschsprung disease (22) and neuropathic chronic intestinal pseudo-obstruction
(26). ENS defects may also underlie achalasia (24) and gastroparesis (42), where selective nNOS
neuron loss was reported. Furthermore, ENS can be damaged by toxins (eg, chemotherapy) (43–
45), systemic disease (diabetes, Parkinson disease) (46–49), inflammation due to infection (50,51),
inflammatory bowel disease (52) or necrotizing enterocolitis (53), causing long-term dysmotility and
visceral hypersensitivity (54). Unfortunately, until now it has been difficult to visualize human ENS
in 3 dimensions. This technical problem limits our understanding of disease mechanisms because
full-thickness tissue sections often appear “normal” unless changes are dramatic (eg, complete
enteric neuron loss).
Not surprisingly, most of what we know about ENS comes from animal models, in which
bowel is thin and muscle is easily dissected from submucosa (5,6,55). In contrast, human bowel is
thick (approximately 1000 µm in maximally stretched colon) and muscle layers are difficult to
separate from submucosa or each other. For this reason, most human ENS analyses use thin
cross-sections (eg, 5 µm), yielding limited data. We hypothesize this problem led to wide variation
for “ganglia per 10 mm” (13.5-fold range in rectum) and neurons per ganglia (9-fold range in colon)
previously reported (7). Swaminathan and Kapur (9) further identified an approximately 150-fold
range for “mean number of ganglion cells per cm” in normal colon (9) and determined reproducible
enteric neuron counts require >5 full-circumference sections (estimated at 1.25 mm2 = 5 sections x
approximately 0.005-mm thick section x approximately 50 mm circumference in 8-week-old). Our
data suggest 1 mm2 still yields quite variable neuron density estimates in adult colon and that >9
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mm2 provides more reliable data. Additional problems arise when evaluating human ENS anatomy
using thin sections. ENS organization is difficult to appreciate, so dramatic changes can be missed.
Nerve fiber bundle orientation is impossible to discern in sections and small nerve fibers are difficult
to see, so changes in neurite density or organization are not appreciated. Decades of mouse work
suggest 3-dimensional imaging provides much greater insight into disease mechanisms and is
essential to see many ENS defects (eg, Supplementary Figure 6.1). Thus, robust 3-dimensional
methods to visualize human ENS may provide new insight into bowel motility disorders. A few prior
studies demonstrated human ENS in 3 dimensions. Myenteric plexus has been visualized by
meticulous “fiber by fiber” removal of longitudinal muscle to expose ENS (13,39,56). We tried this,
but found it difficult to uncover even small regions, and only cells exposed by dissection could be
imaged. Three-dimensional human ENS images were also generated by optical clearing and
immunohistochemistry using 300-µm sections (10–12), but we had difficulty replicating this
approach, even with significant effort, and few quantitative data were provided from those images.
To overcome these problems, we spent years optimizing clearing and antibody staining for
human colon. Our goal was to establish methods that worked well, were easy, and did not require
special skill (like microdissection). In addition, we wanted to visualize cells that control bowel
motility in 3 dimensions without sectioning that disrupts cellular connections. For this approach to
be useful, we need a large library of publicly available images from people without known bowel
motility disorders and we need rigorous quantitative data for “normal” ENS anatomy. Our strategy
accomplished many of these goals.
Our approach makes colon completely translucent. Large bowel pieces were stained and
imaged without sectioning. Confocal imaging permitted visualization of stained cells from serosa to
mucosa. Identified antibodies stain neurons, glia, interstitial cells of Cajal, muscularis
macrophages, neuron subtypes, and nerve fibers. As expected, some antibodies did not work with
our method. We provide 280 three-dimensional Z-stacks of stained adult human colon, highlighting
how much we miss with traditional tissue sectioning. We performed substantial quantitative
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analyses to define “normal” adult human colon ENS anatomy. Finally, we show images of
Hirschsprung disease colon. This is clinically relevant because “transition zone pull through” is
thought to commonly cause Hirschsprung disease postoperative morbidity (22), although
prolonged processing needed with our approach means it cannot be used for intraoperative
decision making. Methods are also applicable to human jejunum and pancreas.
Several observations are worth highlighting. We estimate enteric neurons are < 0.01% of
total human colon cells. Myenteric and submucosal plexus resembles ENS in other species, but
differences in ENS anatomy between species (57,58) means we need human ENS normal values.
Irregular ganglia spacing probably explains dramatic variability in reported enteric neuron densities
(7,9) because some thin sections include large ganglia and others lack neurons. Within myenteric
ganglia, neuron density was fairly uniform (SEM < 25% of mean neurons/mm 3 ) and adult human
colon had on average 137 ± 20 neurons/myenteric ganglion (Figure 6.3C: 38,706 neurons/mm3 x
0.0035278 mm3 / ganglion = 137 neurons/ganglion). Uniformity of neuron density within myenteric
ganglia contrasts with the 1.65-fold difference in ganglion density within myenteric plexus of right
vs left colon (P = .0113). These differences highlight the need to establish region-specific normal
ranges for most parameters, although variable ganglion density might simply reflect differences in
proximal vs distal colon distensibility.
Enteric glia are much more abundant than neurons, even within myenteric ganglia. Our
estimates of glial index (glia to neuron ratio) within ganglia (2.5 left; 4.2 right colon) are lower than
prior estimates (5.9–7) (56), but S100β does not label all glia (59,60). Furthermore, 3 left colons
were from people with diverticulitis where S100β-labeled enteric glia loss was reported (61). One
novel observation was that PHOX2B-immunoreactive nuclei included S100β+ glia and HuC/D+
neurons, but PHOX2B was not detected in enteric glia outside ganglia. Murine data also showed
PHOX2B in adult enteric neurons and glia, although mouse images suggest PHOX2B in glia within
and outside ganglia (62). These data suggest PHOX2B, a gene mutated in some people with
Hirschsprung disease (22), might influence human enteric glial diversity.
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We began to define neuron subtype ratios in human colon myenteric plexus because
human intestinal motility disorders may result from quantitative or qualitative ENS defects
(5,8,22,26,63,64) and nitric oxide–producing enteric neurons are particularly susceptible to injury
(65). Because most myenteric neurons produce either nitric oxide or acetylcholine (2), we focused
on these subgroups. We found little between-subject variability in noncholinergic nNOS+ neuron
prevalence (approximately 50% of myenteric neurons) similar to prior reports indicating 43%–54%
of human myenteric neurons were ChAT–/nNOS+ (Supplementary Table 6.5) (36–39,66–69).
Also consistent with past studies reporting 3%–10% of human colon myenteric neurons produce
nNOS and ChAT, we scored 4%–6% of myenteric neurons as nNOS+/cholinergic. We differed
substantially from prior studies reporting 36%–56% of human colon myenteric neurons were
ChAT+/nNOS– and 2%–7% ChAT–/nNOS– (37–39). Despite using ChAT and VAChT, we scored
fewer myenteric neurons as cholinergic/ nNOS– (approximately 28%) and more as noncholinergic/
nNOS– (14%–19%). We suspect the differences are technical (eg, less robust staining with this
ChAT antibody using our method). We note, however, that neuron subtype ratios vary between
mouse strains and are influenced by diet (70–75) and human subtype ratios are impacted by age
(66), diabetes (67), and inflammation (69), so biological variability between subjects is plausible.
Clearly, more remains to be done to define human enteric neuron subtype ratios.
Finally, we include many images from distal Hirschsprung disease colon. Although
additional studies are needed to define transition zone and “normal” infant ENS, 3-dimensional
imaging should facilitate development of intraoperative strategies to avoid transition zone pull
through. For example, once transition zone characteristics are well-defined, methods like confocal
laser endomicroscopy (76) could be used in the operating room to visualize ENS anatomy. Biopsies
could also be evaluated 3-dimensionally in children treated initially by ostomy because they
undergo pull-through surgery months later.
Our study has limitations. Subjects were 28–80 years old, with the exception of 2 infants
with Hirschsprung disease. Colons were resected for clinical indications. Although we tried to
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evaluate only pathology-free regions, diverticulitis-associated inflammation could affect ENS. Exact
colon regions are not known (ie, “left” might mean splenic flexure or sigmoid). Specimens were
randomly oriented so we cannot distinguish proximal from distal and do not know location along
the circumferential colon axis.
Finally, technical obstacles should be noted. Staining takes several weeks, so our method
cannot be used intraoperatively. Fluorophores fade after immersion in Murray’s Clear, so efficient
confocal imaging is required. Threedimensional imaging takes hours without light sheet
microscopy, limiting size of samples that can be imaged. Tissues may dry during prolonged imaging
and Murray’s Clear dissolves some plastics. Finally, not all tested antibodies worked well.
Nonetheless, our work lays the foundation for future research and suggests new directions for
human ENS analyses. We can now visualize human ENS in 3 dimensions in large colon areas with
minimal dissection and no sectioning. Our images make it easy to understand why previously
reported enteric neuron density estimates vary up to 150-fold. We hope this method will be widely
adopted for defining ENS anatomy in adults and children with life-threatening bowel motility
disorders where current diagnostic strategies seem most inadequate. We invite others to help us
perform quantitative analysis using our images.
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6.9 Supplementary Figures and Tables

Supplementary Figure 6.1: ENS is difficult to appreciate in bowel sections
(A) Full-thickness human colon. H&E-stained (5-mm paraffin) section, the most common method
to evaluate bowel pathology. (B, F, J) Rich ENS networks in P0 wild-type mouse stomach (B),
small bowel (F), and colon (J) are easily seen after TuJ1 (blue)/PHOX2B (green) whole-mount
immunohistochemistry. (E, I, M) P0 GFRα1–/– mice have few enteric neurons in stomach (E) and
only extrinsic nerve fibers in small bowel (I) and colon (M) seen by whole-mount TuJ1
(blue)/PHOX2B (green) immunohistochemistry. (C, D, G, H, K, L) ENS is difficult to appreciate in
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H&E-stained 5-mm sections from P0 wild-type stomach (C Q14 ), small bowel (G), or colon (K).
ENS loss is difficult to appreciate in P0 GFRα1–/– stomach (D), small bowel (H), or colon (L) 5-mm
sections even though magnification is approximately 5–7x higher in sections than whole mounts.
(A, C, D, G, H, K, L) Scale bar: 100 µm. (B, E, F, I, J, M) Scale bar: 1000 µm.

Supplementary Figure 6.2: Tissue processing
A single fixed piece of full-thickness human colon on selected days: tissue is opaque on day 1, but
translucent on day 23 when imaging is performed.
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Supplementary Figure 6.3: Change in tissue area during processing
(A) Before images show fixed stretched colon. After images show tissue ready for imaging. (B)
Quantitative analysis shows tissue area after processing is 0.67-fold smaller area compared to
fixed tissue before processing. The reduction in tissue area during processing partially
compensates for the increase in tissue area as we stretch colon before fixation. Because colon
stretches and contracts in vivo, images are likely to reflect physiologically relevant dimensions.
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Supplementary Figure 6.4: Human jejunum and human pancreas tissue clearing,
immunohistochemistry, and 3-dimensional imaging
Using our method optimized for colon, we stained 1 piece of human jejunum (top panels) and 1
piece of human pancreas (bottom). Images show single panels from Z-stacks that are available as
Supplementary Data.
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Supplementary Figure 6.5
Large (5.5 x 2.5 mm2 ) confocal images. (A, B) Flattened Z-stacks of human colon myenteric (A)
and submucosal plexus (B) stained with HuC/D (green), PHOX2B (blue), and S100β (red)
antibodies were acquired with 10x objective and stitched. Scale bar: 1000 µm.
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Supplementary Figure 6.6: Largest neuron soma diameter
(A, J) Flattened Z-stack, single human myenteric ganglion from left (A) or right colon (J) stained
for HuC/D (red), nNOS (green), and ChAT (blue). (B–I, K–R) Higher magnification images. (B–E)
nNOS+/ChAT– neurons from dotted line boxed region in (A). (F–I) ChAT+/nNOS– neuron from
solid line boxed region in (A). (K–N) nNOS+/ChAT– neurons from dotted line boxed region in (J).
(O–R) ChAT+/nNOS– neuron from solid line boxed region in (J). (S) Longest neuron diameter (N
= 240 nNOS+ and 240 ChAT+ neurons (A, J). (A) Scale bar: 100 µm. (B–I, K–R) Scale bar: 25
µm.

Supplementary Figure 6.7: Quantitative analysis of relative location for ganglia within
submucosa
Analysis is based on fullthickness 10X Z-stacks from 6 human colon specimens (A–C right colon;
D–F left colon) stained with antibodies to HuC/D, PHOX2B, and S100b. Because submucosal
thickness varied between specimens, we set inner margin of circular smooth muscle (CSM) at 0%
and crypt base to 100%. Each dot shows the relative location of a single submucosal ganglion.
Bars show positions of all Z-stack slices where submucosal ganglia were present (defined as >2
neuron cell bodies). Area analyzed = 3.6 mm2 per sample.
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Supplementary Table 6.1: Antibodies
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Supplementary Table 6.2: Antibodies that did not work well with our tissue clearing 3dimensional imaging method

Supplementary Table 6.3: Demographics
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Supplementary Table 6.4: Myenteric neuron subtypes in human colon based on 3359 cells
counted in full confocal Z-stacks after ChAT, nNOS and HuC/D antibody staining

344

Supplemental Table 6.5. Previously published data about human colon myenteric neuron
subtypes

Neuron subtype percentages
ChAT +/nNOSnNOS +/ChATNeither nNOS nor ChAT
ChAT+/nNOS+
nNOS/VIP
nNOS without VIP

52%
43%
4%
6%
19%
29%

ChAT+/nNOSnNOS+ /ChATChAT+/nNOS+
Neither nNOS nor ChAT

48%
43%
4%
5%

Control
ChAT+/nNOS- (ascending)
(transverse)
(descending)
nNOS+/ChAT- (ascending)
(transverse)
(descending)
ChAT+/nNOS+
ChAT-/nNOSSlow transit constipation
ChAT+/nNOS- (ascending)
(transverse)
(descending)
nNOS+/ChAT- (ascending)
(transverse)
(descending)
ChAT+/nNOS+
ChAT-/nNOS345

41%
51%
48%
51%
43%
44%
3-4%
2-4%
36%
38 %
42%
54%
52%
49%
3-5%
4-5%

Demographics
and colon region
-Ascending colon
-5 male/8 female
-Cancer surgery
-Median age 76
years
-Age range 55-86
years
--Excluded IBS
and slow transit
constipation
-3 transverse
colon
-5 descending
colon
-2 sigmoid colon
-5 male/5 female
-Cancer surgery
-Median age 68
years
-Age range 52-83
years
-Control
Colon cancer
surgery
7 male/5
female
Median age 64
years
Age range 4982 years
-Colon resection
for slow transit
constipation (4
females)
-Median age 37
years
-Ascending,
transverse and
descending colon

Comment

Ref

Myenteric neurons

36

Manuscript also
includes data for DiI
labeled circular muscle
projecting neuron
subtypes

Myenteric neurons
triple labeled for
nNOS/ChAT and
HuC/D

37

Analysis of ENS in slow
transit constipation

38

Triple labeling
ChAT/nNOS/HuC/D

Neuron subtype percentages
ChAT+
nNOS+

71%
42%

-1.3 HuC/D+ neurons/mm/10 years
Starting at about 10 neuron/mm
for youngest
-1.1 ChAT+ neurons/mm/10 years
Starting at about 7 neurons/mm
for youngest
-No change in nNOS+ neurons relate to
age
Neuron counts not reported
ChAT immunoreactive area is about 50%
lower in diabetic than in control
nNOS immunoreactive area is about 80%
lower in diabetic than in control

Distal colon, < 1 year old
NADPH diaphorase+
39%
Proximal and distal colon, > 70 year old
NADPH diaphorase+
25%

Control:
ChAT+
Ulcerative colitis
ChAT+

346

35%
33%

Demographics
and colon region
-Descending and
sigmoid colon
-9 male/7 female
-Cancer surgery
-33 to 99 years
old

Comment

Ref

ChAT+ myenteric
neurons density
declined by >50% over
interval evaluated, but
no change in nNOS+
neuron density

66

Double labeling
nNOS/HuC/D or
ChAT/HuC/D

-Colon region not
specified
-24 male/18
female control
-11 male/11
female diabetic
-Cancer or polyp
surgery
-Mean age 62 to
65 years
-Age distribution
not clear. SEM (?)
~ 2 for ages
-3 male/1 female
(4-12 months)
-1 male/3 female
(48-58 years)
-4 male/7 female
(70-95 years)
-Cancer,
diverticulitis, anal
atresia, polyp
anus praeter
-2 male/6 female
control
-Control age 43
to 82 years
-3 male/7 female
UC

9% of control and 18%
of diabetics had
constipation

67

Comparing control to
ulcerative colitis (UC)
ENS
-NSE to label neurons

69

Neuron subtype percentages

Demographics
and colon region
-UC age 22 to 68
years
-8 males/7
females
-Cancer surgery
-Rectum or
descending colon
-Median age 63
years
-Age range 51-86
years

Comment

Ref

Descending colon
Whole mount
39
ChAT+
56%
immunohistochemistry
nNOS+
43%
ChAT+/nNOS+
9%
ChAT-/nNOS7%
Rectum
ChAT+
55%
nNOS+
48%
ChAT+/nNOS+
10%
ChAT-/nNOS6%
Notes:
DiI = (1,1¢- didodecyl 3,3,3¢,3¢-indocarbocyanine perchlorate), a lipophilic dye for membrane
tracing.
IBS = Irritable bowel syndrome
NADPH-diaphorase stains nitric oxide producing neurons

Supplementary Videos 1-9 can be viewed at https://www.gastrojournal.org/article/S00165085(20)30262-6/fulltext#supplementaryMaterial .
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